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Chapter 1 
 
General Introduction 
 
 
1.1 Neuropeptide Y 
 
Neuropeptide Y (NPY), a 36 amino acid peptide, is one of the most abundant neuropeptides in 
the central and peripheral nervous system.1 NPY was first isolated by Tatemoto and co-workers 
from porcine brain in 1982.2 Together with the homologous 36 amino acid peptides pancreatic 
polypeptide (PP) and peptide YY (PYY), NPY belongs to the pancreatic polypeptide (or NPY) 
family. For all these peptides C-terminal amidation is essential for biological activity.3 The 
sequence of NPY is highly conserved in various species.4 
The three-dimensional structure of NPY has been subject of numerous studies. One of the first 
models was based on the x-ray structure of avian pancreatic polypeptide (aPP).5 In the aPP 
structure, amino acid residues 1 – 8 form a polyproline-like helix, which is linked through a turn 
(amino acids 9 – 13) with an anti-parallel -helix (amino acids 14 – 31). The C-terminal 
pentapeptide is in flexible loop conformation. This hairpin-like structure, the so called PP-fold 
(cf. Figure 1), which brings N- and C-terminus into close proximity, was also proposed for NPY 
due to its high sequence homology to PP (50 %).6  
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Figure 1. Tertiary structure of porcine NPY (according to Allen, 19876). 
 
The tertiary structure of NPY in solution was intensively investigated over two decades using 
NMR and CD spectroscopy as well as FRET based approaches. Some of these studies 
confirmed the PP-fold structure7, 8, others reported contradictory findings, e.g. dimeric structures 
through -helical contacts and conformations with non-helical and flexible N-termini.9-12 Major 
drawbacks of NMR studies are physiologically non-relevant concentrations of the peptides and 
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pH values considerably lower than pH 7.4 (required to increase the solubility of NPY). However, 
CD spectroscopic measurements revealed that, depending on the concentration of NPY and the 
pH, different conformations of NPY co-exist in a dynamic equilibrium, and the PP-fold 
conformation is probably favored under physiological conditions.13 Also interactions of NPY with 
the cell membrane, supporting the formation of the active conformation, were discussed.14, 15 
In the periphery NPY is abundant in sympathetic neurons, where it is co-stored and co-released 
with noradrenaline, and it was also found in the parasympathetic nervous system16, 17. In the 
central nervous system (CNS) NPY was found in numerous brain regions including basal 
ganglia, hypothalamus, amygdala, hippoampus, locus coeruleus, nucleus accumbens, and the 
cerebral cortex.18-20 
 
Five mammalian NPY receptors have been cloned so far, the Y1, Y2, Y4, Y5, and y6 receptor.21-28 
The y6 receptor was found to be functional in mice, but is non-functional as a pseudogene in 
most mammalian species, and in the rat genome it is missing at all.29 NPY receptors belong to 
the superfamily of heptahelical G-protein coupled receptors. Their main signal transduction 
pathway is the coupling to pertussis toxin sensitive Gi/o proteins, resulting in an inhibition of 
forskolin stimulated cAMP accumulation.30, 31 Besides the inhibition of adenylyl cyclase, 
elevation of the intracellular calcium concentration after NPY receptor stimulation was reported 
for subtypes Y1, Y2, Y4 and Y5,32-39 but the magnitude of the calcium response depends on the 
cell type.30 
NPY binds strongly to the Y1, Y2 and Y5 receptor, but exhibits low affinity for the Y4 receptor. 
The latter is nearly exclusively addressed by pancreatic polypeptide. 
 
NPY is involved in the regulation of numerous physiological processes, and was therefore 
referred to as a “universal soldier”.40 Important biological functions, which are regulated or co-
regulated by NPY, are summarized in Table 1. 
 
Table 1. Overview of biological effects mediated by NPY and its receptors in humans. 
Y1 
blood pressure (peripheral effect: ↑, due to vasoconstriction; via 
central effects: ↓), food intake (↑), anxiolysis, sedation, hormone 
release, pain sensitivity, depression, angiogenesis, ethanol 
consumption 
Y2 
blood pressure, seizures and food intake (↓), anxiety, pain sensitivity, 
depression, angiogenesis, gastrointestinal motility, NPY release (↓, 
presynaptic autoreceptor), circadian rhythms, bone formation, effects 
on vasculature  
Y4 food intake, gastrointestinal motility 
Y5 
food intake (↑), seizure, anxiety, luteinizing hormone release (↓), 
circadian rhythms 
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Recently, the Y1 and Y2 receptor were found to be expressed in different tumors such as breast 
cancer41 (Y1 > Y2), prostate cancer42 (Y1 ≈ Y2), adrenal cortical tumors43 (Y1), ovarian tumors44 
(Y1 ≈ Y2) and distinct gliomas45 (Y2). For some of these malignancies NPY production was 
detected in the tumor cells (e.g. neuroblastoma, paraganglioma), in some cases NPY was found 
in nerve fibres contacting the tumor cells (e.g. adrenal cortical tumors, nephroblastoma) and 
others showed no intratumoral NPY (e.g. mammary carcinomas). Thus, NPY is supposed to 
exert autocrine and paracrine effects on tumor cell metabolism and tumoral blood supply. The 
peptide was reported to inhibit tumor growth, and conversely to stimulate tumor growth in vitro.46 
Although the role of NPY in tumor biology is unclear in vivo, Y1 and Y2 receptors have been 
proposed as potential tumor markers.46  
 
 
 
1.2  NPY Receptor Ligands 
 
1.2.1  NPY Y1 Receptor Ligands 
 
Approaches to develop Y1 receptor (Y1R) selective agonists by truncation and modification of 
physiological NPY were more or less successful. In the early 1990th Pro34-substituted analogs of 
neuropeptide Y and peptide YY were reported to have selectivity for Y1 over Y2 receptors. An 
iodine-125 labeled analog of the most established one, [Leu31, Pro34]peptide YY, was used for 
numerous autoradiographic binding studies of Y receptor expressing tissues.47, 48 Later binding 
studies at the Y4 receptor revealed that this PYY analog shows also high affinity to NPY Y4 
receptors49 (cloned in 199524).  
Several selective NPY Y1R agonists were described by Mullins et al in 2001.50 The success was 
based on the introduction of D-amino acids (e.g. [D-Arg25]NPY) as well as on truncation and 
cyclization (e.g. Des-AA11-18[Cys7,21, D-Lys9(Ac), D-His26, Pro34]NPY). Other NPY analogs with a 
preference for the Y1 receptor, namely [Phe7, Pro34]NPY and the cyclic peptide c[D-Cys29-L-
Cys34]NPY Ac29-36 (YM-42454) were described by Söll et al and Takebayashi et al, 
respectively.51, 52 Also N-terminally shortened peptides, containing -aminocyclopropane-
carboxylic acids (-ACCs) as unnatural amino acids stabilizing the secondary structure, were 
reported to be potent and selective Y1R ligands.53 
 
The first non-peptidic Y1R antagonist described in literature was the arpromidine-type histamine 
H2 receptor agonist BU-E-76 (HE 90481)54 with a pA2 value of 4.4 in human erythroleukemia 
cells55. In the last two decades a multitude of highly potent and selective non-peptidic Y1R 
antagonists with affinities in the nanomolar and subnanomolar range have been developed. A 
selection is shown in Figure 2 (for a review see Brennauer et al56). 
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Figure 2. Selection of non-peptide selective Y1R antagonists. aRudolf at al 57, bWieland et al 58, cSlit et al 
59, dZarrinmayeh et al 60, eKanatani et al 61, fLeslie et al 62, gHipskind et al 63. 
 
 
1.2.2  BIBP 3226 
 
In 1994 the (R)-argininamide BIBP 3226 (cf. Figure 2 and 3) was described as the first highly 
potent and selective Y1R antagonist.57 In literature Y1R binding data of BIBP 3226 ranging from 
0.5 to 10 nM are reported.31, 64 As an alanin scan of NPY revealed that the C-terminal part of the 
peptide, especially Arg35 and Tyr36, are of major importance for the interaction with the Y1R and 
the Y2 receptor (Y2R),65 several hundred low molecular weight analogs mimicking the C-
terminus of NPY were synthesized and characterized at Boehringer Ingelheim Pharma. 
Structure optimization with respect to Y1R affinity including a replacement of L-arginine by the 
D-enantiomer resulted in the identification of the first highly selective and potent non-peptidic 
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Y1R antagonist BIBP 3226 (Scheme 3). The corresponding (S)-enantiomer, BIBP 3435, was 
reported to be at least 1000 times less potent.57 The replacement of the phenolic OH group by 
an ureidomethyl entity yielded another selective Y1R antagonist, BIBO 3304, which is more 
potent than BIBP 3226 by a factor of about ten (Ki = 0.4 nM, cf. Figure 2).58, 66  
BIBP 3226 has not been considered as an appropriate drug candidate due to lack oral 
bioavailability and inability to penetrate across the blood brain barrier, but it has been very 
useful as a pharmacological tool for the characterization of NPY Y1 receptors located in the 
periphery as well as in the CNS.  
 
(R)
H
N N
H
O
OHO
NH
NHH2N
(S)
H
N N
H
O
O
NH
NHH2N
CONH2
OH
Arg35
Tyr36
BIBP 3226  
Figure 3. Structural similarity between the C-terminus of NPY and the selective Y1R antagonist BIBP 
3226. 
 
 
Based on results using [125I]NPY and [3H]BIBP 3226 and several hY1R mutants Sautel et al 
proposed a model for the binding of BIBP 3226 and NPY to the human Y1R, disclosing an 
overlapping binding site of the two ligands.67, 68 Recently, a new model of BIBP 3226 binding to 
the Y1R was generated on the basis of the crystal structure of bovine rhodopsin, confirming the 
binding mode derived from the formerly reported receptor mutants (Sautel et al68). This topic 
was discussed in detail by Brennauer et al56.  
In these models the strongly basic guanidine group interacts with an aspartate residue (Asp287) 
at the top of transmembrane domain six. Therefore, it has been assumed that substituents 
attached to the N guanidine nitrogen, and, upon binding to the receptor, pointing to the 
extracellular loop region, could be tolerated in terms of Y1R affinity. A recently prepared series 
of Nsubstituted BIBP 3226 derivatives revealed that especially electron-withdrawing 
substituents such as acyl, alkoxycarbonyl and carbamoyl are indeed tolerated, and therefore, a 
bioisosterism of guanidines and acylguanidines was suggested for this class of compounds.56, 69, 
70  
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1.2.3  Y2, Y4 and Y5 Receptor Antagonists 
 
In 1997, a peptidic Y2R antagonist, T4[NPY(33-36)]4, consisting of four C-terminal NPY 
fragments attached to a cyclic template molecule, was reported to bind selectively to the Y2 
receptor with considerable affinity71, 72. To date, only the (S)-argininamide BIIE 0246 and some 
N-substituted derivatives are known as selective non-peptidic Y2R antagonists with affinities in 
the low nanomolar range (Figure 4).70, 73, 74 Other Y2R antagonists with affinities around and 
higher than 100 nM were described, e.g. the Johnson & Johnson compound JNJ-5207787 
(Figure 4).75 
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Figure 4. Structures of the most potent non-peptide Y2R antagonists described in literature to date. 
aDoods at al 73, bBonaventure et al 75. 
 
Recently, an analog of the C-terminus of NPY, the peptide VD-11, which is structurally closely 
related to the peptidic Y4R agonist and Y1R antagonist GW1229 (1229U91)76, 77, was shown to 
have Y4R antagonistic characteristics.78 High affinity non-peptide Y4R ligands are not known so 
far. However, very recently some acylguanidine derivatives synthesized in the laboratory of 
Prof. Dr. A. Buschauer (University of Regensburg) as histamine receptor ligands proved to be 
weak Y4R antagonists (most potent compound: IC50 ≈ 5 µM) in a functional assay performed 
with genetically engineered CHO cells, expressing the hY4R, the chimeric G protein Gqi5 and 
mitochondrially targeted apoaequorin79. The structure of one of these compounds is shown in 
Figure 5.    
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Figure 5. Example of an acylguanidine derivative with moderate Y4R antagonistic activity. aInhibition of 
PP induced luminescence in CHO cells expressing the hY4R, the chimeric G protein Gqi5 and 
mitochondrially targeted apoaequorin79. 
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In case of the Y5 receptor the situation is similar as for the Y1 receptor: the search for new anti-
obesity drugs led to numerous highly potent and selective non-peptidic antagonists with broad 
structural diversity. The Novartis compound CGP 71683A37, 80, a naphthylsulfonamide, linked 
through cyclohexane with a 2,4-diaminoquinazoline moiety, was the first selective Y5R 
antagonist with nanomolar affinity (IC50 = 2.9 nM) (Figure 6).  
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Figure 6. Exemplary structures of selective non-peptide Y5R antagonists. aCriscione at al 37, bBlum et al 
81, cItani et al 82, dConnell et al 83, eKawanishi et al 84, fSato et al 85, gFukami et al 86, hNorman et al 87, 
iBlock et al 88.  
 
 
In the last decade numerous arylsulfonamides were reported to be highly potent Y5R 
antagonists, and many other Y5R ligands comprising a broad variety of heteroaryl cycles were 
described. A selection of Y5R antagonists with affinities in the low nanomolar range is given in 
Figure 6. A more detailed overview on Y5R ligands is included in a review by A. Brennauer et 
al.56  
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1.3  Scope of the Thesis 
 
Fluorescent and radiolabeled peptides such as Cy5-pNPY and [125I]PYY are the preferred tools 
for the pharmacological evaluation of NPY receptor subtypes and their ligands since labeled 
small molecules are not available for routine use up to date. As an exception [3H]BIBP 3226 
was formerly commercially available, but at present this compound can only be obtained on 
special orders at high costs. The use of peptide tracers is often compromised, especially in 
studies on living cells due to intrinsic properties of these compounds such as limited selectivity 
and stability (enzymatic degradation). In addition, their applicability as pharmacological tools 
may be hampered by long incubation periods accompanied by receptor desensitization due to 
the slow binding kinetics of peptides acting as agonists. Thus, there is a demand for 
fluorescence and radiolabeled NPY receptor subtype selective low molecular weight 
antagonists.  
The attachment of acyl, alkoxycarbonyl and carbamoyl substituents to the guanidine group of 
the highly potent, Y1R-antagonistic argininamide BIBP 3226 resulted in analogs with moderately 
decreased, retained or even increased affinity.56, 69, 70, suggesting a strategy for the synthesis of 
potent radio- and fluorescence labeled Y1R selective antagonists. The aim of this thesis was the 
development of such functionalized non-peptidic ligands for the Y1R. The design strategy is 
based on the hypothesis that a fluorescent or radioactive label can be attached by an acyl linker 
to the guanidine group in argininamide-type Y1R antagonists such as BIBP 3226 or BIBO 3304. 
-Amino acyl linkers were considered most promising, since the majority of fluorophores and 
radionuclide containing entities is usually provided with electrophilic groups (e.g. activated 
carboxylic acids, isothiocyanates, etc.) requiring nucleophilic labeling precursors. 
Very recently, first attempts by A. Brennauer70, 89 and E. Schneider90 to prepare N(-amino-
alkanoyl)argininamides were affected by the extreme instability of the primarily chosen amino-
precursor N5-aminopentanoyl-BIBP 3226. At pH > 8 this compound is very rapidly cleaved to 
BIBP 3226 and valerolactame.70, 89 Nevertheless, the outlined strategy is considered promising. 
Therefore, the present work was focused on the identification and optimization of more stable 
amino-functionalized acyl linkers to pave the way for Y1R selective fluorescent and radioactive 
tracers.    
With respect to the preparation of radioligands for routine use, tritiated antagonists are preferred 
in our laboratory, and the synthetic pathway should take into account the commercial availability 
of appropriate tritiated reagents, in particular [3H]-propionic acid succinimidyl ester. Such a Y1R 
selective radioligand is anticipated to serve as a pharmacological tool for the detection of Y1 
receptors on cells and tissues, as well as for autoradiographic studies and for the determination 
of binding constants at native receptors or receptor mutants.  
Beside tritiated compounds the synthesis of fluorine-18 labeled Y1R antagonists as PET ligands 
was planned for the in vivo imaging of Y1 receptors. Y1R PET ligands are of potential value as 
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diagnostic radiopharmaceuticals, since the Y1R was recently reported to be expressed in 
several tumors.46, 91 In order to explore the structure-activity relationships of potential PET 
ligands, a series of “cold” fluorinated compounds had to be synthesized and characterized. 
Thereafter, the most promising candidates had to be radioactively labeled to explore the 
suitability of argininamide-type Y1R antagonists as PET ligands in vivo using human tumor 
xenograft models in nude mice.  
By analogy with this approach, fluorescent Y1R antagonists had to be designed, synthesized 
and characterized, since fluorescence labeled compounds, compared to radioligands, offer 
advantages with respect to safety precautions, waste disposal and applicability to the powerful 
techniques flow cytometry and fluorescence microscopy. A major challenge in this field was the 
preservation of the receptor affinity which is usually considerably affected when large 
fluorophoric entities are bound to small receptor ligands.  
As ligands containing two pharmacophoric entities are discussed to be of potential value as 
tools for the investigation of GPCR homodimerization,92 the feasibility of the bivalent ligand 
approach to argininamide-type Y1R ligands was intended to be evaluated by linking of two BIBP 
3226 moieties through dicarboxylic acids of different structure and length. 
Finally, with respect to a broader application of the guanidine-acylguanidine bioisosteric 
approach in combination with labeling strategies, the preparation and the synthetic use of N-
Fmoc protected arginine building blocks, containing amino-functionalized N-acyl substituents, 
was planned to explore. The replacement of arginine with such building blocks harbors the 
potential for the preparation of versatile imaging probes derived from biologically relevant 
oligopeptides, in particular, if the N-acylated arginine building blocks are suitable for solid 
phase peptide synthesis. 
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Chapter 2 
 
Guanidine - Acylguanidine Bioisosteric Approach 
in the Design of Radioligands: Synthesis of a 
Tritium-Labeled N-Propionylargininamide  
([3H]-UR-MK114) as a Highly Potent and Selective 
Neuropeptide Y Y1 Receptor Antagonist 
 
 
 
 
2.1  Introduction 
 
The (R)-configured argininamide BIBP 3226 (2.14, Chart 1), the first highly potent and selective 
nonpeptide Y1 receptor antagonist,1 has been commonly used as a pharmacological tool for 
studying the physiological role of the Y1 receptor (Y1R). The compound is considered a mimic of 
the C-terminus, i. e. Arg35 and Tyr36, in NPY.2 On one hand the guanidino group in 2.14 has 
been considered important for the biological activity due to interaction with Asp287 of the human 
Y1R, on the other hand the strongly basic group is a major drawback with respect to oral 
availability and brain penetration. Recently, we prepared a series of N-substituted derivatives 
of 2.14, which revealed a preference for electron-withdrawing substituents in terms of retaining 
or even increasing the Y1R affinity regardless of the by 4-5 orders of magnitude reduced 
basicity3 (selection shown in Chart 1). Especially the introduction of carbamoyl residues into the 
N-position yielded Y1R antagonists with considerably increased affinity (Chart 1),3, 4 These 
findings support the concept that the acylguanidines are bioisosteres of guanidines. The high 
affinities and selectivities achieved with this class of compounds prompted us to develop a Y1R 
selective antagonistic radioligand. 
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Chart 1. Structures and Y1R affinities of BIBP 3226 (2.14) and selected N-substituted derivatives, 
arranged according to increasing size of the substituent “R”. 
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aDetermined on SK-N-MC cells with [3H]-propionyl-pNPY as radioligand (1 nM).3 bDetermined on SK-N-
MC cells with [3H]-UR-MK114 (2.8b) as radioligand (1.5 nM). The subnanomolar affinities of the 
carbamoylated argininamides 2.19 and 2.20 were confirmed using 2.8b (1.5 nM) as radioligand. 
 
 
 
2.2  Results and Discussion 
 
N-acetyl (2.15), N-methoxycarbonyl (2.16) and N-propyl (2.17) substituted argininamides 
(Chart 1) exhibit lower Y1R affinities (two-digit nM-range) than the parent compound BIBP 3226 
(2.14), whereas the N-propionyl derivative 2.8a turned out to be a highly potent Y1 antagonist 
with a KB value of 0.8 nM (cf. Figure 2). Obviously, the extension of the acyl substituent by one 
methylene group enables an additional hydrophobic interaction, which compensates for the 
moderate acylation-induced decrease in affinity observed for the lower homolog 2.15. This was 
also true for the methoxycarbonyl derivative 2.16 (Ki = 33 nM) compared to the ethoxycarbonyl 
homolog 2.18 (Ki = 4.5 nM). Acylation was superior to alkylation at the N-position (2.8a vs. 
2.17, Chart 1), but an exchange of the -CH2 group by an oxygen atom, resulting in an ester 
group, was again less favorable (2.16, 2.8a, Chart 1). Surprisingly, the corresponding N-
carbamoyl substituted analogs (2.19, 2.20), containing a -NH group, showed significantly 
higher affinities. Presumably, the presence of this H-donor group enables additional affinity-
enhancing interactions resulting in a different favorable orientation of the flexible amide 
substituent in 2.19, 2.20 compared to the acyl residues in 2.8a,b.    
Considering Y1R affinity and selectivity as well as synthetic feasibility, the N-[2,3-3H]propionyl-
substituted argininamide 2.8b ([3H]-UR-MK114), the “hot” form of 2.8a, was considered most 
attractive, particularly, since tritiated propionic acid succinimidyl ester is commercially available 
as a radiolabeling reagent. In principle, this labeling strategy can be transferred to other classes 
of compounds containing guanidine as a pharmacophoric group. 
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2.2.1  Chemistry 
 
Alkylguanidines are conventionally prepared from amines and bis-urethane (Boc, Cbz) 
protected guanidinylation reagents, for example S-methyl isothioureas5, pyrazol-1-
carboxamidines6, 7, or triflylguanidines8. Alternatively, guanidine derivatives can be N-alkylated 
with alcohols under Mitsunobu conditions.9 Acyl-substituted alkylguanidines are accessible, if 
one of the protecting groups of the guanidinylation reagent is replaced with the pertinent acyl 
residue.4 However, such a synthetic route is not well suited for the preparation of a tritiated 
propionylguanidine, since the radiolabel is preferably introduced in a final one-pot reaction. 
Therefore, direct attachment of the acyl substituent to the guanidine group in 2.14 (Chart 1) was 
performed using the N-Boc, O-tert-butyl protected analog 2.7 as a precursor (Scheme 1). 
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Scheme 1. Synthetic route for the preparation of the N-propanoyl argininamides 2.8a,b. 
Reagent and conditions: Reagents and conditions: (a) (1) Cbz-Cl (45 % in toluene), NaOH 0.5 N, K2CO3, 
CuSO4, 20 h, 4 °C to rt; (2) titriplex III, H2O, 60 min, 100 °C, 83 %; (b) FmocOSu, H2O/dioxane, 20 h, rt, 
96 %; (c) CDI, THF, 20 h, rt, 62 %; (d) diethylamine, DCM, 4 h, rt, 76 %; (e) NEt3, 1,2-dimethoxyethane, 
20 h, 35 °C, 84 %; (f) Pd/C, ammonium formate, MeOH, 20 h, rt, 85 %; (g) (1) NEt3, CH2Cl2, 20 h, rt; (2) 
Pd/C, H2, MeOH, 3.5 h, rt, 84 %; (h) (1) NEt3, MeCN, 20 h, rt; (2) TFA, MeCN, 3 h, 50 °C, 70 % (2.8a), 34 
% (2.8b). 
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This method afforded the target compounds in good (up to 80 %) yields and has been 
frequently used in our laboratory to synthesize N-acylated arginine derivatives. Carboxylic 
acids can be attached to the NG-Boc-alkylguanidine scaffold with the aid of coupling reagents 
from peptide chemistry (EDAC, CDI) or using anhydrides, chlorides and active esters. However, 
the reaction rate is noticeably slower compared to the coupling with amines. 
The precursor 2.7 can be obtained from amine 2.6 by reaction with a guanidinylation reagent 
containing a Boc and a Cbz protecting group (2.13), followed by hydrogenolytic Cbz 
deprotection. For the preparation of amine 2.6, starting from D-ornithine, the -amino group was 
protected with Fmoc, orthogonally to Cbz and the tert-butyl phenyl ether.4 A conversion of the 
alcohol corresponding to amine 2.6 (obtained via reduction of D-glutamate) into acylated 
guanidines under Mitsunobu condition was reported not to give the desired argininamides10, and 
was therefore not explored any longer as an alternative synthetic route. The guanidinylation 
reagent 2.13 was prepared from aminoguanidine carbonate following reported protocols 
(Scheme 3).6 The other required compounds (2.9, 2.10, 2.11) were prepared according to 
standard procedures (Scheme 2). 
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Scheme 2. (a) (1) LiAlH4, diethyl ether, 4 h, reflux; (2) H2O, 15 % aq. NaOH, 3 h, 0 °C, 98 %; (b) N-
hydroxysuccinimide, DCC, THF, 20 h, rt; 94 % (2.10), 60 % (2.11a). 
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Scheme 3. (a) (1) conc. HCl, 1,1,3,3-tetramethoxypropane, H2O, 1.5 h, 45 °C; (2) Cbz-Cl, CH2Cl2, MeOH, 
NEt3, 20 h, 0 °C to rt, 25 %; (b) (1) Boc2O, DMAP, CHCl3, 20 h, rt; (2) Mg(ClO4)2, THF, 3 h, 55 °C, 53 %. 
 
 
Depending on the source of succinimidyl [2,3-3H]-propionate, GE Healthcare (Amersham) and 
ARC (American Radiolabeled Chemicals, Inc.), the tritiated compound 2.8b was obtained with 
specific activities of 97 Ci/mmol and 51 Ci/mmol, respectively. The radioligand 2.8b was isolated 
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by HPLC with a radiochemical purity of 99 % (Figure 1, dashed line) and showed a high long-
term stability when stored in ethanol at -20 °C over a period of 1.5 years (Figure 1, solid line). 
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Figure 1. HPLC purity control of the freshly synthesized (I, dashed line) and long-term (18 months) 
stability control (II, solid line) of the tritiated Y1R antagonist 2.8b with radiometric detection. Conditions: I, 
purity control: eluent: mixtures of acetonitrile + 0.05 % TFA (A) and 0.05 % aq. TFA (B), gradient: 0 to 30 
min: A/B 20/80 to 90/10, 30 to 38 min: 90/10, tR = 16.7 min; II, long term stability control: eluent: mixtures 
of acetonitrile (A) and 0.05 % aq. TFA (B), gradient: 0 to 30 min: A/B 20/80 to 50/50, 30 to 35 min: 50/50 
to 90/10, 35 to 45 min: 90/10, tR = 26.5 min. The identity of 2.8b was confirmed by co-injection of larger 
amounts of the “cold” analog 2.8a, which allowed UV detection. 
 
 
 
2.2.2  Pharmacology: Selectivity, Schild Analysis, Kinetics and Saturation Experiments  
 
The selectivity of the new Y1R antagonist 2.8a for human NPY Y1 over Y2, Y4 and Y5 receptors 
was proven by flow cytometric binding assays based on fluorescence-labeled pNPY (Y2R, Y5R) 
or [K4]-hPP (Y4R) according to previously described methods.11-13 As also reported for the 
parent compound BIBP 3226, the N-propionylated derivative (2.8a) shows a clear binding 
preference for the Y1R (Table 1).  
 
Table 1. NPY receptor subtype selectivity of 2.8a. 
Y1 Ki [nM]a Y2 Ki [nM]b Y4 Ki [nM]c Y5 Ki [nM]b 
1.0 > 10,000 > 10,000 > 2,000 
aDissociation constant from radioligand competition assay with 2.8b on SK-N-MC 
neuroblastoma cells. bFlow cytometric binding assay on CHO-Y2 and HEC-1B-Y5
cells using Dy-635-pNPY or Cy5-pNPY as labeled ligands (10 nM). cFlow cytometric 
binding assay on CHO-Y4 cells with Cy5-[K4]-hPP (5 nM) as fluorescent ligand. 
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The Y1R antagonism of 2.8a was investigated in a fura-2-based Ca2+-assay on HEL cells14. 
Concentration-response curves of pNPY were constructed in the absence and presence of 2.8a 
at different concentrations (Figure 2A) and the data were subjected to Schild analysis15 (Figure 
2B). Since the slope in this linear plot nearly equals unity a competitive antagonism of 2.8a is 
very likely. The pKB (in this case identical to pA2) reflects the affinity of the antagonist and the 
resulting KB value (0.8 nM) is in very good agreement with the KD value (1.2 nM) from saturation 
binding experiments (Figure 3). A plausible reason for the depressed maxima of the 
concentration effect curves (Figure 2A) is hemi-equilibrium.15 Due to the rapid onset of the 
calcium response in the functional assay, the time window is too narrow to enable an 
equilibrium among the receptors, the agonist pNPY (slow binding kinetics16) and the antagonist 
2.8a (high on- and off-rate, Figure 3).  
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Figure 2. A: Concentration-response curves (CRCs) of pNPY from a fura-2 assay on HEL cells. The 
presence of 2.8a led to a parallel rightward shift of the curves. B: Schild regression: log(r-1) plotted 
against log[antagonist]; the concentration ratios r (r = 10pEC50) were calculated from the rightward shifts 
(pEC50) of the CRCs in the presence of 2.8a as shown in Fig. 2A. The slope of the line equals unity, 
therefore the pA2 value corresponds to pKB: pA2 ≈ pKB = 9.1 (slope forced to unity), KB = 0.8 nM. (mean 
values ± SEM or propagated error, n = 2) 
 
 
 
The results of kinetic studies of 2.8b at 24 °C are presented in Figure 3. Association and 
dissociation at the Y1R were in the range of minutes (kon = 0.19 min-1 · nM-1, koff = 0.22 min-1) 
which is typical for small ligands acting as antagonists. The kinetically derived KD (koff/kon = 1.1 
nM) is in excellent agreement with the KD from saturation binding experiments (1.2 nM). 
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Figure 3. Association and dissociation kinetics for the specific Y1R binding of 2.8b on SK-N-MC cells (65th 
passage) at 24 °C. A: Radioligand (c = 3 nM) association as a function of time, Inset: ln[Beq/(Beq-B)] 
versus time, slope = kob = 0.79 min-1, kon = (kob - koff)/[L] = 0.19 min-1 · nM-1. B: Radioligand (pre-
incubation: 6 nM) dissociation as a function of time, monophasic exponential decay, t1/2 = 2.2 min, Inset: 
ln(B/B0) versus time, slope·(-1) = koff = 0.22 min-1. (mean values ± SEM, n = 3)  
 
 
Saturation analysis of radioligands provides dual information, the equilibrium dissociation 
constant KD and the maximum number of binding sites (Bmax). Multiple saturation experiments 
with 2.8b on SK-N-MC neuroblastoma cells and MCF-7-Y1 breast cancer cells afforded KD 
values of 1.2 nM and 2.9 nM, respectively (Figure 4). The Bmax value for SK-N-MC cells of about 
50,000 sites per cell fit well with data from literature.17 The breast cancer cells express about 
100,000 to 150,000 sites/cell (fluctuations are probably caused by a slightly varying estrogen 
stimulus provided by the fetal calf serum supplement of the culture medium). Estrogen 
stimulation of MCF-7-Y1 cells leads to Y1R up-regulation up to 300,000 sites/cell. Y1R up-
regulation has been already reported on the mRNA level18 and could be confirmed on intact 
cells at the protein level using the radioligand 2.8b as an NPY Y1R probe. Based on these 
results an assay has been developed for the functional characterization of estrogens and 
antiestrogens (to be reported elsewhere). Binding and functional Y1R data of 2.8a/2.8b are 
summarized in Table 2. 
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Figure 4. A: Saturation curves for binding of 2.8b to MCF-7-Y1 (176th passage) and SK-N-MC (67th 
passage) cells revealing KD values of 2.2 nM and 0.85 nM, respectively. Estimated Bmax (sites/cella): 
120,000 (MCF-7-Y1) and 52,000 (SK-N-MC). aThe cell number was determined in at least 4-6 wells. B: 
Scatchard plot for the binding of 2.8b to MCF-7-Y1 cells, KD = -1/slope = 1.7 nM. C: Scatchard plot for the 
binding to SK-N-MC cells, KD = -1/slope = 1.1 nM. (mean values ± SEM or propagated error, n = 3) 
 
 
 
Table 2. Y1R binding and functional characteristics of 2.8a/2.8b. 
KD [nM]a KD [nM]b KB [nM]c KD [nM]d kon [min-1 · nM-1]e koff [min-1]f 
2.9 ± 0.4 1.2 ± 0.1 0.8 ± 0.1 1.1 ± 0.1 0.19 ± 0.01 0.22 ± 0.01 
aEquilibrium dissociation constant determined on MCF-7-Y1 cells, mean value ± SEM from 5 
independent experiments, each in triplicate. bEquilibrium dissociation constant determined on SK-N-
MC cells, mean value ± SEM from 6 independent experiments, each in triplicate. cSchild analysis 
derived dissociation constant of 2.8a, mean value ± SEM from 2 independent experiments (calcium
assay using HEL cells). dKinetically derived dissociation constant ± propagated error. eAssociation 
rate constant ± standard error from linear regression. fDissociation rate constant ± standard error from 
linear regression. 
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2.2.3  Competition Binding Experiments and Autoradiography 
 
Competition binding experiments of 2.8b with the antagonist BIBP 3226 and the agonist pNPY 
yielded Ki values (1.5 ± 0.2 nM and 0.5 ± 0.02 nM, resp.) consistent with reported data (Figure 
5).17, 19 In theory the dissociation constant of 2.8a derived from a competition binding experiment 
with its hot analog 2.8b has to be identical with the KD value of 2.8b. The experimental data (Ki 
of 2.8a = 1.0 nM (Figure 5); KD of 2.8b = 1.2 nM and 1.1 nM, resp.) are in good agreement with 
this requirement. 
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Figure 5. Displacement of the tritiated Y1R antagonist 2.8b (c = 1.5 nM) by the agonist pNPY, the 
antagonist BIBP 3226 and the non-labeled analog 2.8a. The competition assay was performed on SK-N-
MC cells at 24 °C with incubation periods of 20 min (BIBP 3226, 2.8a) and 120 min (pNPY). BIBP 3226: 
pIC50 = 8.44, Ki = 1.5 nM, pNPY: pIC50 = 9.01, Ki = 0.5 nM, 2.8a: pIC50 = 8.65, Ki = 1.0 nM. (mean values 
± SEM, n = 3)  
 
 
To explore the applicability of 2.8b to autoradiographic binding studies cryosections of a human 
MCF-7-Y1 tumor, subcutaneously grown in a nude mouse, and of a rat brain were incubated 
with the new radioligand. In rat brain Y1R binding sites were clearly detected in the cerebral 
cortex in layers I-III (I: molecular layer, II: external granular layer, III: layer of medium-sized 
pyramidal cells), in the thalamus and in the hippocampus (Figure 6, A and B) as reported from 
binding studies with [125I][Leu31,Pro34]PYY and [3H]BIBP 3226.20, 21 The results indicate a very 
high Y1R expression in the tumor as there is a strong difference between total and non-specific 
binding (Figure 6C). 
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Figure 6. A: Total and non-specific binding of the tritiated Y1R antagonist 2.8b to adjacent coronal 
sections of rat brain (male Wistar rat, 10 month old). B: H & E stained adjacent section, a: cerebral cortex, 
b: third ventricle, c: hippocampus, d: thalamus. C: Total and non-specific binding of 2.8b to adjacent 
tumor sections (s.c. human MCF-7 mammary carcinoma from a NMRI (nu/nu) mouse). D: Masson-
Goldner (Jerusalem’s modification) stained adjacent tumor section, e: connective and adipose tissue, f: 
necrotic regions.  
 
 
 
2.2.4  Conclusion 
 
N-propionylation of BIBP 3226 leads to a highly potent (Ki = 1 nM) and selective Y1R 
antagonist (2.8a). Direct N-acylation of N-Boc, O-tert-butyl protected BIBP 3226 (2.7) allows a 
convenient preparation of a tritium-labeled radioligand from succinimidyl [2,3-3H]-propionate 
with specific activities of up to 100 Ci/mmol. Due to practicability and low costs of this labeling 
strategy, 2.8b ([3H]-UR-MK114) is a highly attractive alternative to (the formerly commercially 
available) [3H]-BIBP 3226. 2.8b has also advantages over radiolabeled peptides addressing the 
Y1R due to stability, selectivity, mode of action (antagonist) and costs. [3H]-UR-MK114 can be 
used for the quantification of Y1R binding sites as well as for autoradiography experiments on 
tissues. Because of the attenuated basicity (pKa = 7 - 8) of the acyl-guanidine moiety 2.8a is 
supposed to exhibit an improved pharmacokinetic profile over the strongly basic BIBP 3226 (pKa 
≈ 13). Generally, radioligands capable of penetrating into the brain would provide interesting 
tools for the study of Y1R binding by ex vivo (autoradiography) and in vivo (PET) experiments. 
Recent findings in the NPY Y2R10 as well as in the histamine H2R and H4R field22 support the 
hypothesis that the concept of guanidine-acylguanidine bioisosterism may be of general interest 
to design receptor ligands including radiotracers with high affinity, reduced basicity and 
improved pharmacokinetic properties. 
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2.3  Experimental Section 
 
2.3.1  General Experimental Conditions 
 
Chemicals and solvents were purchased from commercial suppliers (Merck, Darmstadt, 
Germany; Sigma, München, Germany) and used without further purification unless otherwise 
stated. D-ornithine hydrochloride was purchased from Iris Biotech GmbH (Marktredwitz, 
Germany). Petroleum ether (40-60 °C) was distilled before use. DMF was stored over 3 Å 
molecular sieves. Anhydrous reactions were run under an atmosphere of dry nitrogen or argon. 
Thin layer chromatography was performed on Merck silica gel 60 F254 TLC aluminum plates. For 
column chromatography silica gel Geduran 60 (Merck, 0.063-0.200 mm) was used. NMR 
spectra were recorded on an Avance 300 (1H: 300 MHz) and an Avance 600 (1H: 600 MHz, 13C: 
150.9 MHz) (Bruker, Karlsruhe, Germany) with TMS as external standard. Elemental analysis 
(C, H, N) was performed in-house on a Heraeus Elementar Vario EL III. Mass spectrometry 
analysis (MS) was performed on a Finnigan ThermoQuest TSQ 7000 (ES-MS), a Finnigan SSQ 
710A (EI-MS 70 eV, CI-MS) and Finnigan MAT 95 (LSIMS, HRMS). Melting points were 
determined with a Büchi 510 melting point apparatus and are uncorrected. Lyophilization was 
done with a Christ alpha 2-4 LD equipped with a vacuubrand RZ 6 rotary vane vacuum pump. 
Preparative HPLC was performed with a system from Knauer (Berlin, Germany) consisting of 
two K-1800 pumps, a K-2001 detector and a RP-column (Eurospher-100 C18, 250 × 32 mm, 5 
µm; Knauer, Berlin, Germany) at a flow rate of 38 mL/min. Analytical HPLC analysis of non-
labeled compounds was performed on a system from Thermo Separation Products composed 
of a SN400 controller, a P4000 pump, an AS3000 autosampler, a Spectra Focus UV-VIS 
detector and a RP-column (Eurospher-100 C18, 250 × 4.0 mm, 5 µm; Knauer, Berlin, Germany) 
at a flow rate of 0.8 mL/min. Tritiated compounds were chromatographically analyzed and 
purified on a RP-column (Agilent Scalar C18, 250 × 4.6 mm, 5 µm) either with a Shimadzu 
system C-R4A (pump LC-6A, UV-VIS-spectrophotometric detector SPD-6AV, system controller 
SCL-6A, Chromatopac C-R4AX) or on a Waters system (two pumps 510, pump control module, 
486 UV detector, Packard Radiomatic Flow-1 beta Series A-500 detector, flow rate of liquid 
szintillator (Quickszint 212; Zinsser Analytic, Frankfurt, Germany): 4 mL/min).  
 
 
2.3.2 Chemistry: Experimental Protocols and Analytical Data 
 
(R)-N-Benzyloxycarbonylornithine (2.1).23, 24 Benzyloxycarbonyl chloride (45 % in toluene, 
48.5 mL, 130.46 mmol, 1.1 eq) was added to an ice-cold solution of D-ornithine hydrochloride 
(20 g, 118.6 mmol, 1 eq), potassium carbonate (16.4 g, 118.6 mmol, 1 eq) and copper(II)sulfate 
pentahydrate (14.8 g, 59.3 mmol, 0.5 eq) in aqueous NaOH (0.5 N, 237 mL, 118.6 mmol, 1 eq) 
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over a period of 15 min. The ice-bath was removed and the reaction was left under stirring at rt 
overnight. The resulting solid was filtered off, washed twice with ice-cold water (50 mL), ice-cold 
MeOH (50 mL) and water (50 mL). Lyophilization yielded a blue-violet powder which was 
suspended together with Titriplex III (22.1 g, 59.3 mmol, 0.5 eq) in water (200 mL) under 
vigorous stirring and heated to 100 °C for 60 min. After cooling to 4 °C the solid was separated, 
washed with ice-cold water (3 × 40 mL) and dried (white solid, 26.8 g, 83 %). 1H-NMR (300 
MHz, DMSO-d6):  (ppm) 1.35-1.61 (m, 3H, CH-CH2-CH2), 1.69 (m, 1H, CH-CH2-CH2), 2.97 (m, 
2H, CH2-NH), 3.09 (m, 1H, CH), 5.0 (s, 2H, CH2-Ph), 7.3-7.4 (m, 5H, Ph); MS (ES, H2O/MeOH 
+ 10 mM NH4OAc): m/z 267 [M + H]+; C13H18N2O4 (266.3) 
 
(R)-N-Benzyloxycarbonyl-N-(9-fluorenylmethoxycarbonyl)ornithine (2.2).25 A solution of 
9-fluorenylmethyl succinimidyl carbonate (FmocOSu) (26.35 g, 78.1 mmol, 1 eq) in 1,4-dioxane 
(200 mL) was added to a solution of 2.1 (20.8 g, 78.1 mmol, 1 eq) and sodium carbonate (8.3 g, 
78.1 mmol, 1 eq) in a mixture of water and 1,4-dioxane (2.5/1 v/v, 350 mL) over a period of 60 
min and the mixture was stirred at rt overnight. About 50 % (volume) of the solvent was 
evaporated under reduced pressure, the product was precipitated by the addition of 1 M aq. 
hydrochloric acid (160 mL) and filtered off. Washing with hydrochloric acid (0.1 %, 50 mL) and 
ice-cold water (50 mL) afforded the product as a white solid (36.6 g, 75 mmol, 96 %). 1H-NMR 
(300 MHz, DMSO-d6):  (ppm) 1.4-1.68 (m, 3H, CH-CH2-CH2), 1.73 (m, 1H, CH-CH2-CH2), 3.0 
(m, 2H, CH2-NH), 3.91 (m, 1H, CH), 4.17-4.31 (m, 3H, CH-CH2 from Fmoc), 5.01 (s, 2H, CH2-
Ph), 7.26-7.45 (m, 10H, Ph, Fmoc, CH2-NH), 7.60 (d, 1H, 3J = 7.95 Hz, CO-NH-CH), 7.73 (d, 
2H, 3J = 7.37 Hz, Fmoc), 7.89 (d, 2H, 3J = 7.45 Hz, Fmoc), 12.76 (bs, 1H, COOH); MS (ES, 
H2O/MeOH + 10 mM NH4OAc): m/z 506 [M + NH4]+, 489 [M + H]+; C28H28N2O6 (488.5) 
 
(R)-N-Benzyloxycarbonyl-N-(4-tert-butoxybenzyl)-N-(9-fluorenylmethoxycarbonyl)-
ornithinamide (2.3). The carboxylic acid 2.2 (37 g, 75.7 mmol, 1 eq) was activated with 
carbonyldiimidazole (15.4 g, 94.7 mmol, 1.3 eq) in THF (650 mL) for 60 min followed by the 
addition of 2.9 (13.6 g, 75.7 mmol, 1 eq) in THF (100 mL). Stirring was continued under argon at 
rt for 20 h. The reaction mixture was concentrated under reduced pressure and the residue was 
dissolved in ethyl acetate (1000 mL) under warming. The solution was washed with 0.1 M aq. 
KHSO4/brine 8/1 (180 mL), water/brine 8/1 (180 mL), 5 % aq. Na2CO3/brine 15/1 (160 mL), 
water/brine 3/1 (200 mL) and brine (150 mL). The solvent was removed under reduced pressure 
after drying over Na2SO4 and filtration. Subsequent purification with column chromatography 
(eluent: EtOAc/PE 1/1 to EtOAc) afforded the product as a white solid (30.6 g, 47.2 mmol, 62 
%). 1H-NMR (300 MHz, DMSO-d6):  (ppm) 1.24 (s, 9H, t-Bu), 1.34-1.74 (m, 4H, CH-CH2-CH2), 
3.0 (m, 2H, CH2-NH), 4.05 (m, 1H, CH), 4.17-4.32 (m, 5H, CH-CH2 from Fmoc, CH2-Ar-O-t-Bu), 
5.01 (s, 2H, CH2-Ph), 6.88 (d, 2H, 3J = 8.30 Hz, AA’BB’), 7.14 (d, 2H, 3J = 8.42 Hz, AA’BB’), 
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7.26-7.45 (m, 10H, Ph, Fmoc, CH2-CH2-NH), 7.56 (d, 1H, 3J = 8.18 Hz, CO-NH-CH), 7.74 (d, 
2H, 3J = 7.24 Hz, Fmoc), 7.89 (d, 2H, 3J = 7.45 Hz, Fmoc), 8.36 (t, 1H, 3J = 5.66, CH-CO-NH-
CH2); MS (ES, CH2Cl2/MeOH + 10 mM NH4OAc): m/z 650 [M + H]+, 667 [M + NH4]+; C39H43N3O6 
(649.8) 
 
(R)-N-Benzyloxycarbonyl-N-(4-tert-butoxybenzyl)ornithinamide (2.4). A solution of 2.3 
(30.6 g, 47.1 mmol,) in CH2Cl2 (1200 mL), DMF (100 mL) and diethylamine (150 mL) was stirred 
at rt for 4 h. The volatiles were removed under reduced pressure and the residue was taken up 
in CH2Cl2 (400 mL). The solution was filtered from a quite small amount of insoluble material 
and the filtrate was subjected to column chromatography (eluent: EtOAc to EtOAc/MeOH 5/1). 
The product was obtained as a yellow oil (15.3 g, 35.8 mmol, 76 %). 1H-NMR (300 MHz, 
DMSO-d6):  (ppm) 1.26 (s, 9H, t-Bu), 1.3-1.63 (m, 4H, CH-CH2-CH2), 2.98 (m, 2H, CH2-CH2-
NH), 3.15 (m, 1H, CH), 4.23 (d, 2H, 3J = 5.87 Hz, CH2-C6H4-O-t-Bu), 5.01 (s, 2H, CH2-Ph), 6.9 
(d, 2H, 3J = 8.45 Hz, AA’BB’), 7.02 (bs, 2H, NH2), 7.15 (d, 2H, 3J = 8.47 Hz, AA’BB’), 7.25-7.4 
(m, 5H, Ph), 7.64 (t, 1H, CH2-CH2-NH), 8.26 (t, 1H, 3J = 5.93, CH-CO-NH-CH2); MS (ES, 
CH2Cl2/MeOH + 10 mM NH4OAc): m/z 428 [M + H]+, 855 [2M + H]+; C24H33N3O4 (427.5) 
 
(R)-N-Benzyloxycarbonyl-N-(4-tert-butoxybenzyl)-N-(2,2-diphenylacetyl)ornithinamide 
(2.5). A solution of 2.10 (14.4 g, 46.5 mmol, 1.3 eq) in 1,2-dimethoxyethane (100 mL) and THF 
(40 mL) was added to a solution of 2.4 (15.3 g, 35.8 mmol, 1 eq) and NEt3 (3.6 g, 35.8 mmol, 1 
eq) in 1,2-dimethoxyethane (130 mL). The reaction mixture was concentrated under reduced 
pressure to give a volume of about 80 mL after stirring at 35 °C for 20 h. Water was added (220 
mL) and the pH was adjusted to 2.5-3 with KHSO4. The precipitate was separated by filtration, 
washed with water (60 mL), dried in vacuo, dissolved in CH2Cl2/EtOAc 3/1 (150 mL) and purified 
by column chromatography (eluent: CH2Cl2/EtOAc 3/1 to EtOAc) affording 2.5 as a white solid 
(18.8 g, 30.3 mmol, 84 %). 1H-NMR (300 MHz, DMSO-d6):  (ppm) 1.27 (s, 9H, t-Bu), 1.38 (m, 
2H, CH2-CH2-CH2), 1.5-1.76 (m, 2H, CH-CH2), 2.98 (m, 2H, CH2-CH2-NH), 4.24 (m, 2H, CH2-
C6H4-O-t-Bu), 4.34 (m, 1H, CH), 5.02 (s, 2H, CH2-Ph), 5.08 (s, 1H, CH-(Ph)2), 6.87, (d, 2H, 3J = 
8.45 Hz, AA’BB’), 7.12 (d, 2H, 3J = 8.48 Hz, AA’BB’), 7.1-7.4 (m, 15H, Ph), 8.43 (t, 1H, 3J = 
5.78, CH-CO-NH-CH2), 8.49 (d, 1H, 3J = 8.03, CO-NH-CH); MS (ES, CH2Cl2/MeOH + 10 mM 
NH4OAc): m/z 622 [M + H]+, 639 [M + NH4]+, 660 [M + K]+; C38H43N3O5 (621.8) 
 
(R)-N-(4-tert-Butoxybenzyl)-N-(2,2-diphenylacetyl)ornithinamide (2.6).26 To a suspension 
of 2.5 (18.5 g, 29.75 mmol, 1 eq) in MeOH (400 mL) were added ammonium formate (22.5 g, 
357 mmol, 12 eq) and 10 % Pd/C catalyst (2.7 g). The evolution of gas was monitored with a 
bubble counter. Compound 5 had been completely dissolved after 4 h. The reaction mixture 
was left under stirring at rt overnight. The catalyst was removed by filtration, the filtrate was 
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concentrated under reduced pressure and the residue was taken up in CHCl3 (600 mL). The 
organic solution was treated with saturated aq. Na2CO3 (150 mL, 100 mL) and brine (100 mL), 
then dried over Na2SO4 and filtered. Removal of the solvent yielded an oil which turned to a 
hardned foam during drying in vacuo (12.3 g, 25.2 mmol, 85 %). 1H-NMR (300 MHz, DMSO-d6): 
 (ppm) 1.27 (s, 9H, t-Bu), 1.21-1.36 (m, 2H, CH2-CH2-CH2), 1.48-1.77 (m, 2H, CH-CH2), 3.29 
(m, 2H, CH2-CH2-NH2), 4.21 (m, 2H, CH2-C6H4-O-t-Bu), 4.3 (m, 1H, CH), 5.12 (s, 1H, CH-
(Ph)2), 6.86 (d, 2H, 3J = 8.49 Hz, AA’BB’), 7.09 (d, 2H, 3J = 8.48 Hz, AA’BB’), 7.16-7.34 (m, 10H, 
Ph), 8.47 (m, 1H, CO-NH-CH2), 8.55 (d, 1H, 3J = 8.03, CO-NH-CH); MS (ES, CH2Cl2/MeOH + 
10 mM NH4OAc): m/z 488 [M + H]+; C30H37N3O3 (487.6) 
 
(R)-N-(4-tert-Butoxybenzyl)-N-tert-butoxycarbonyl-N-(2,2-diphenylacetyl)argininamide 
(2.7). Compound 2.6 (3.5 g, 7.18 mmol, 1 eq) and N-tert-butoxycarbonyl-N'-benzyloxycarbonyl-
1H-pyrazol-1-carboxamidine (2.13) (2.97 g, 8.6 mmol, 1.2 eq) were dissolved in CH2Cl2 (50 mL) 
and NEt3 (0.36 g, 0.5 ml, 3.59 mmol, 0.5 eq) was added. The reaction mixture was stirred at rt 
overnight and then subjected to column chromatography (eluent: CH2Cl2/EtOAc 20/1 to 3/1, 
column was packed with 0.5 % NEt3). The eluate was evaporated to dryness in vacuo yielding a 
hardened foam which was dissolved in MeOH (HPLC grade, 65 mL) in a two-necked round 
bottom flask equipped with a three-way valve (N2, H2). A 10 % palladium-on-charcoal catalyst 
(0.4 g) was added and a slow stream of hydrogen was led through a glass tube into the 
vigorously stirred suspension. After depletion of the starting material (3.5 h; control by TLC) the 
catalyst was removed using a PTFE-filter (25 mm, 0.2 µm). The filtrate was concentrated to give 
an oil and water (50 mL) was added. Lyophilization afforded the product as a white solid (3.83 
g, 6.08 mmol, 84 %). Mp > 85 °C (decomp.); 1H-NMR (600 MHz, DMSO-d6, COSY, HSQC):  
(ppm) 1.27 (s, 9H, t-Bu), 1.36 (s, 9H, t-Bu), 1.4 (m, 2H, CH2-CH2-CH2), 1.55 (m, 1H, CH-CH2), 
1.68 (m, 1H, CH-CH2), 3.06 (m, 2H, CH2-CH2-NH), 4.21 (dd, 1H, 2J = 15.28 Hz, 3J = 5.96 Hz, 
CH2-C6H4-O-t-Bu), 4.25 (dd, 1H, 2J = 15.28 Hz, 3J = 5.96 Hz, CH2-C6H4-O-t-Bu), 4.34 (m, 1H, 
CH), 5.13 (s, 1H, CH-(Ph)2), 6.87 (d, 2H, 3J = 8.48 Hz, AA’BB’), 7.1 (d, 2H, 3J = 8.49 Hz, 
AA’BB’), 7.2 (m, 2H, Ph), 7.25-7.32 (m, 8H, Ph), 8.43 (t, 1H, 3J = 5.65 Hz, CO-NH-CH2), 8.49 (d, 
1H, 3J = 8.03, CO-NH-CH); 13C-NMR (150 MHz, DMSO-d6, HSQC, HMBC):  (ppm) 25.4 (CH2-
CH2-CH2), 28.3 (C-(CH3)3), 28.5 (C-(CH3)3), 29.6 (CH-CH2), 39.6 (CH2-CH2-NH), 41.5 (CH2-
C6H4-O-t-Bu), 52.5 (CH), 55.9 (CH-(Ph)2), 75.9 (C-(CH3)3), 77.7 (C-(CH3)3), 123.5 (aryl, 
AA’BB’), 126.48 (Ph), 126.52 (Ph), 127.6 (Ar AA’BB’), 128.1 (Ph), 128.2 (Ph), 128.4 (Ph), 128.6 
(Ph), 133.7 (CH2-CC4H4C-O-t-Bu), 140.3 (CH-(CC5H5)2), 140.5 (CH-(CC5H5)2), 153.8 (CH2-
CC4H4C-O-t-Bu), 161.1 (CO-O-t-Bu), 163.1 (guanidine), 170.9 (CO-NH-CH), 171.3 (CO-NH-
CH2); Anal. (C36H47N5O5) calcd. C 68.66, H 7.52, N 11.12, found C 68.41, H 7.74, N 11.05; 
HRMS: (FAB+, MeOH/Glycerin): m/z calcd. for [C36H47N5O5 + H]+ 630.3655, found: 630.3646; 
C36H47N5O5 (629.8); C36H47N5O5 (629.8) 
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(R)-N-(2,2-Diphenylacetyl)-N-(4-hydroxybenzyl)-N-propanoylargininamide (2.8a).  
Compounds 2.7 (100 mg, 159 µmol, 1 eq) and 2.11a (32.5 mg, 191 µmol, 1.2 eq) were 
dissolved in anhydrous acetonitrile (4 mL), NEt3 (8 mg, 11 µL, 79 mmol, 0.5 eq) was added and 
the reaction mixture was stirred under argon at rt overnight. TFA (2 mL) and two drops of water 
were added and stirring was continued for 4 h. CH2Cl2 (20 mL) was added and the solution was 
concentrated under reduced pressure. Addition of CH2Cl2 (30 mL) and evaporation under 
reduced pressure was repeated twice. The residue (yellow oil) was taken up in a mixture of 
acetonitrile and 0.1 % aq. TFA (1/1 v/v, 5 mL), filtered (0.2 µm) and injected into the preparative 
HPLC system (6 injections). Eluent: mixtures of acetonitrile (A) and 0.1 % aq. TFA (B). Gradient: 
A/B 20/80 to 50/50 in 30 min. Acetonitrile was removed under reduced pressure from the eluate 
containing the product (tR ≈ 24 min). After lyophilization of the remaining aqueous solution the 
product was obtained as TFA salt as a white fluffy solid (71.6 mg, 111 µmol, 70 %). Mp 166-168 
°C; 1H-NMR (600 MHz, DMSO-d6, 1H-COSY, HSQC):  (ppm) 1.04 (t, 3H, CH3, 3J = 7.42 Hz), 
1.39-1.48 (m, 2H, CH2-CH2-CH2), 1.54 (m, 1H, CH-CH2), 1.67 (m, 1H, CH-CH2), 2.43 (q, 2H, 
CH2-CH3, 3J = 7.40 Hz), 3.22 (m, 2H, CH2-CH2-NH), 4.12 (dd, 1H, 2J = 14.82 Hz, 3J = 5.78 Hz, 
CH2-C6H4-OH), 4.16 (dd, 1H, 2J = 14.81 Hz, 3J = 5.85 Hz, CH2-C6H4-OH), 4.33 (m, 1H, CH), 
5.12 (s, 1H, CH(Ph)2), 6.6 (d, 2H, 3J = 8.49 Hz, AA’BB’), 6.99 (d, 2H, 3J = 8.49 Hz, AA’BB’), 7.21 
(m, 2H, Ph), 7.26-7.30 (m, 8H, Ph), 8.34 (t, 1H, 3J = 5.81 Hz, CO-NH-CH2), 8.46 (d, 1H, 3J = 
8.10, CO-NH-CH), 8.67 (bs, 2H, NH2), 9.16 (t, 1H, CH2-CH2-NH), 9.28 (s, 1H, NH-CO-CH2-
CH3), 11.7 (s, 1H, ArOH); 13C-NMR (150 MHz, DMSO-d6, HSQC, HMBC):  (ppm) 8.2 (CH3), 
24.3 (CH2-CH2-CH2), 29.3 (CH-CH2), 29.5 (CH2-CH3), 40.4 (CH2-CH2-NH), 41.6 (CH2-C6H4-OH), 
52.3 (CH), 55.9 (CH-(Ph)2), 115.0 (Ar AA’BB’), 126.5 (Ph), 126.6 (Ph), 128.1 (Ph), 128.2 (Ph), 
128.4 (Ar AA’BB’), 128.46 (Ph), 128.48 (Ph), 129.1 (CH2-CC4H4C-OH), 140.3 (CH-(CC5H5)2), 
140.5 (CH-(CC5H5)2), 152.9 (guanidine), 156.2 (CH2-CC4H4C-OH), 170.9 (CO-NH), 171.0 (CO-
NH), 175.9 (COCH2CH3); HPLC purity (210 nm): > 99 % (cf. Figure 7); HRMS: (FAB+, 
MeOH/glycerol): m/z calcd. for [C30H35N5O4 + H]+ 530.2767, found: 530.2774; C30H35N5O4 × 
C2F3HO2 (643.6) 
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Figure 7. HPLC purity control of 2.8a. Eluent: mixtures of acetonitrile (A) and 0.05 % aq. TFA (B), 
gradient: 0 to 30 min: A/B 20/80 to 95/5, 30 to 40 min: 95/5, detection: 210 nm, injection: 100 µL of a 50 
µM solution of 2.8a in a mixture of acetonitrile and 0.05 % aq. TFA (20/80) prepared from a 5 mM solution 
in acetonitrile, tR = 14.0 min, k = 4.2. 
 
 
4-tert-Butoxybenzylamine (2.9).27 A solution of 4-tert-butoxybenzonitrile (50 g, 285.4 mmol, 1 
eq) in anhydrous diethyl ether (200 mL) was dropped to a mechanically stirred suspension of 
LiAlH4 (25 g, 658.8 mmol, 2.3 eq) in anhydrous diethyl ether (400 mL) over a period of 3 h. The 
reaction mixture was refluxed for additional 60 min, cooled to 0 °C and carefully quenched by 
the dropwise addition of water (20 mL), 15 % aq. NaOH (17 mL) and again water (50 mL). 
Inorganic material was filtered off and washed twice with diethyl ether. The combined filtrate 
and washings were concentrated to about 150 mL followed by the addition of water (850 mL) 
and 1 M aq. KHSO4 (about 300 mL) to adjust the pH to 2-3. The aqueous phase was separated, 
washed with diethyl ether (180 mL) and alkalified with 2 N aq. NaOH (200 mL). The product was 
extracted with CH2Cl2 (three times 450 mL). The extracts were pooled, washed with brine (300 
mL) and dried over Na2SO4. After filtration and removal of the solvent in high vacuo the product 
was obtained as a yellowish oil (50.1 g, 299.2 mmol, 98 %). 1H-NMR (300 MHz, CDCl3):  (ppm) 
1.31 (s, 9H, t-Bu), 2.03 (s, 2H, NH2), 3.8 (s, 2H, CH2), 6.93 (d, 2H, 3J = 8.51, AA’BB’), 7.18 (d, 
2H, 3J = 8.64, AA’BB’); MS (EI): m/z 122.0 [M - C(CH3)3]+, 123.0 [M - ·C(CH3)3 + H]·+, 164 [M - 
·CH3]+, 179 (M·+); C11H17NO (179.3) 
 
Succinimidyl 2,2-diphenylacetate (2.10).28, 29 DCC (40.8 g, 197.9 mmol, 1.05 eq) was added 
to a stirred solution of diphenylacetic acid (40 g, 188.5 mmol, 1 eq) and N-hydroxysuccinimide 
(22.8 g, 197.9 mmol, 1.05 eq) in anhydrous THF (800 mL). After stirring at rt overnight the white 
solid (DCU) was removed by filtration and the solvent was removed under reduced pressure. 
Purification with column chromatography (eluent: PE/EtOAc 2/1 to 1/2) yielded the product as a 
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white semi-crystalline solid (54.8 g, 177.2 mmol, 94 %). 1H-NMR (300 MHz, CDCl3):  (ppm) 
2.79 (s, 4H, CH2), 5.36 (s, 1H, CH), 7.26-7.4 (m, 10H, Ph); MS (CI, NH3): m/z 327 [M + NH4]+; 
C18H15NO4 (309.3) 
 
Succinimidyl propanoate (2.11a).30 DCC (3 g, 14.85 mmol, 1.1 eq) was added to a stirred ice-
cold solution of propanoic acid (1 g, 1 mL, 13.5 mmol, 1 eq) and N-hydroxysuccinimide (1.71 g, 
14.85 mmol, 1.1 eq) in anhydrous THF (30 mL). The ice-bath was removed after 2 h and stirring 
was continued at rt overnight. The white solid (DCU) was removed by filtration and the solvent 
was removed under reduced pressure. Purification with column chromatography (eluent: 
PE/EtOAc 3/1 to 1/1) yielded the product as a white solid (1.4 g, 8.2 mmol, 60 %). 1H-NMR (300 
MHz, CDCl3):  (ppm) 1.27 (t, 3H, 3J = 7.51, CH3), 2.63 (q, 2H, 3J = 7.52, CH2-CH3), 2.82 (s, 4H, 
CH2-CH2); MS (CI, NH3): m/z 189 [M + NH4]+; C7H9NO4 (171.2) 
 
N-Benzyloxycarbonyl-1H-pyrazole-1-carboxamidine (2.12).26, 31 Concentrated hydrochloric 
acid (76 mL) was added dropwise to a stirred suspension of aminoguanidine carbonate (80 g, 
587.8 mmol, 1.05 eq) in water (120 mL) resulting in a clear solution of aminoguanidine 
hydrochloride which was added to a gently warmed (45 °C) suspension of 1,1,3,3-
tetramethoxypropane (91.9 g, 559.8 mmol, 1 eq) in water (120 mL) over a period of 60 min. The 
obtained darkly colored solution was stirred for additional 30 min. Since crystallization of 1H-
pyrazole-1-carboxamidine hydrochloride could not be initiated by the treatment with acetone (as 
described26, 31) or acetonitrile, all solvents were removed by evaporation under reduced 
pressure and drying in vacuo. The darkly colored residue (only soluble in water under warming) 
was suspended in MeOH/CH2Cl2 1/1 (1000 mL) and NEt3 (178 mg, 244 µL, 1763 mmol, 3 eq) 
was added. The mixture was cooled to 0 °C, benzyloxycarbonyl chloride (45 % in toluene, 559.8 
mmol, 218.5 mL, 1.0 eq) was added over a period of 2.5 h and the reaction was left under 
stirrung at rt overnight. All volatiles were removed under reduced pressure. To the residue ethyl 
acetate (1300 mL) and water (400 mL) were added. The two phases were mixed vigorously and 
then separated. The darkly colored aqueous phase was treated with ethyl acetate (200 mL), the 
organic layers were combined and washed with saturated aqueous NaHCO3 solution (300 mL), 
water (300 mL) and brine (300 mL). After drying over Na2SO4 and filtration the solvent was 
removed under reduced pressure and the product was roughly purified by column 
chromatography (eluent: CH2Cl2/EA 3/1). The product was crystallized from CH2Cl2 (35.8 g, 
146.7 mmol, 25 %). 1H-NMR (300 MHz, DMSO-d6):  (ppm) 5.13 (s, 2H, CH2-Ph), 6.58 (dd, 1H, 
3J = 1.61 Hz, 2.76 Hz, pyrazole), 7.32-7.42 (m, 5H, Ph), 7.92 (dd, 1H, 3J = 1.52 Hz, 4J = 0.60 
Hz, pyrazole), 8.45 (dd, 1H, 3J = 2.75 Hz, 4J = 0.48 Hz, pyrazole), 8.97 (bs, 2H, NH2); MS (CI, 
NH3): m/z 245 [M + H]+; C12H12N4O2 (244.2) 
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N-Benzyloxycarbonyl-N’-tert-butoxycarbonyl-1H-pyrazole-1-carboxamidine (2.13).32, 33 A 
solution of 2.12 (35.5 g, 145.3 mmol, 1 eq) and di-tert-butyl dicarbonate (76 g, 348 mmol, 2.4 
eq) in chloroform (150 mL) was treated with DMAP (3.6 g, 29.1 mmol, 0.2 eq) and stirred 
overnight. Chloroform (250 mL) was added and the reaction mixture was washed with 0.5 M aq. 
KHSO4 (100 mL), water (100 mL) and brine (100 mL). The solution was dried over Na2SO4, 
filtered, and the volume was reduced to about 100 mL under reduced pressure. The residue 
was subjected to column chromatography (eluent: CH2Cl2/EtOAc 20/1 to 5/1) to isolate the 
twofold Boc-protected intermediate as a yellow oil which was treated with Mg(ClO4)2 (6.2 g, 27.8 
mmol, 0.2 eq) in THF (500 mL) at 55 °C for 3 h. The solvent was removed under reduced 
pressure and the residue was dissolved in CH2Cl2 (1000 mL). The organic solution was washed 
with water (200 mL) and brine (200 mL), then dried over Na2SO4 and filtered. The filtrate was 
concentrated. Purification with column chromatography (eluent: PE/EtOAc 5/1 to 1/1, column 
packed with 0.5 % NEt3) afforded the product as a highly viscous yellow oil (26.7 g, 77.5 mmol, 
53 %). 1H-NMR (300 MHz, DMSO-d6):  (ppm) 1.44 (s, 9H, t-Bu) 5.14 (s, 2H, CH2-Ph), 6.60 (dd, 
1H, 3J = 1.61 Hz, 2.76 Hz, pyrazole), 7.32-7.44 (m, 5H, Ph), 7.88 (dd, 1H, 3J = 1.58 Hz, 4J = 
0.53 Hz, pyrazole), 8.37 (dd, 1H, 3J = 2.79 Hz, 4J = 0.53 Hz, pyrazole); MS (CI, NH3): m/z 345 
[M + H]+, 245 [M - Boc + H]+; C17H20N4O4 (344.4) 
 
 
2.3.3  Synthesis of N-([2,3-3H]-Propionyl)-BIBP 3226 ([3H]-UR-MK114, 2.8b) 
 
2.8b was prepared from two different batches of succinimidyl [2,3-3H]-propionate (2.11b), one 
from GE Healthcare (München, Germany, formerly Amersham Biosciences) provided in toluene 
(185 MBq/5 mL, as = 3.48 TBq/mmol), and a second one from American Radiolabeled 
Chemicals Inc. (St. Louis, MO, USA) provided in ethyl acetate (185 MBq/1 mL, as = 2.22 
TBq/mmol). The labeling reaction was performed in a 1.5-mL Eppendorf reaction vessel (screw 
top) in acetonitrile using 40 eq of the labeling precursor 2.7. 
 
(R)-N-(2,2-Diphenylacetyl)-N-(4-hydroxybenzyl)-N-([2,3-3H]propanoyl)argininamide 
(2.8b).  
(1) Synthesis of 2.8b from 185 MBq of succinimidyl [2,3-3H]-propanoate (2.11b) (as = 3.48 
TBq/mmol, GE Healthcare). Compound 2.7 (1.34 mg, 2.13 µmol, 40 eq) was dissolved in 
anhydrous acetonitrile (30 µL) yielding a concentration of 70.9 mM, and NEt3 was diluted in 
acetonitrile to a concentration of 0.55 µL NEt3/22.5 µL. Compound 2.7 (70.9 mM in acetonitrile, 
15 µL, 1.064 µmol, 20 eq) and NEt3 (7.5 µL of the obove described solution in acetonitrile, 1.33 
µmol, 25 eq) were added to 2.11b (9.3 µg, 0.053 µmol, 1 eq) in toluene (5 mL), and the solvent 
was removed with a slight stream of nitrogen (blown through a PTFE filter, 13 mm, 0.2 µm, 
nylon) over a period of 2 h. The 5-mL glas vial was rinsed three times with acetonitrile (100 µL 
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each), the washings were combined in a 1.5-mL Eppendorf reaction vessel (screw top) and 2.7 
(70.9 mM in acetonitrile, 15 µL, 1.064 µmol, 20 eq) as well as NEt3 (15 µL of the above 
described solution in acetonitrile, 2.66 µmol, 50 eq) were added. The reaction mixture was 
concentrated to about 80 µL in a vacuum concentrator and stirred with a magnetic micro stirrer 
at 35 °C overnight. TFA (100 µL) was added and the reaction mixture was allowed to stand 
under stirring at 60 °C for 2 h. MeOH (400 µL) was added and the volume was reduced to about 
20 µL in a vacuum concentrator (at 40 °C). The residue was diluted with a mixture of acetonitrile 
and 0.05 % aq. TFA (25/75 v/v, 300 µL) and the product was isolated with a Shimadzu HPLC 
system (4 injections). Eluent: mixtures of acetonitrile plus 0.04 % TFA (A) and 0.05 % aq. TFA 
(B), gradient: 0 to 22 min: A/B 25/75 to 53/47, 22 to 24 min: 53/47 to 95/5, 24 to 29 min: 95/5. 
The product was eluted at 18.9 min and collected in a 1.5-mL Eppendorf reaction vessel (screw 
top), which was put into the vacuum concentrator between the injections. The combined product 
fractions were evaporated to dryness in a vacuum concentrator (about 5 h), the residue was 
dissolved in ethanol (500 µL), transferred into the clean 5-mL Amersham glass vial and 
combined with the washings (160 µL and 140 µL). 
Quantification: A five point calibration was performed with 2.8a (0.5, 0.75, 1.0, 1.25 and 1.5 µM, 
inj. vol.: 100 µL). Eluent: mixtures of acetonitrile plus 0.04 % TFA (A) and 0.05 % aq. TFA (B), 
gradient: 0 to 17 min: A/B 20/80 to 50/50, 17 to 19 min: 50/50 to 90/10, 19 to 24 min: 90/10 (tR = 
18.7 min). The solutions for injection were prepared in a mixture of acetonitrile and 0.05 % aq. 
TFA (20/80) less than 3 min prior to the injection. All standard solutions were prepared 
separately from a 100 µM solution of 2.8a in a mixture of acetonitrile and 0.05 % aq. TFA 
(20/80), which was freshly prepared for each standard from a 10 mM solution of 2.8a in DMSO. 
6.6 µL of the ethanolic solution (total volume: 800 µL) were diluted with 103.4 µL of a mixture of 
acetonitrile and 0.05 % aq. TFA (20/80) in duplicate and 100 µL of each solution were analyzed 
by HPLC. The molarity of the ethanolic solution of 2.8b was calculated from the mean of the 
peak areas and the linear calibration curve obtained from the peak areas of the standards. 
Yield: 9.6 µg (0.018 µmol, 34 %a). 
Determination of the specific activity: four aliquots (1 µL) of the ethanolic solution were diluted 
with 499 µL of acetonitrile and 10 µL of the 1:500-dilutions were counted in 3 mL of Rothiszint 
eco plus (Roth, Karlsruhe, Germany) in a LS 6500 liquid scintillation counter (Beckmann-
Coulter, München; Germany). Calculated specific activity: 3.6 TBq/mmol (97.3 Ci/mmol). The 
activity concentration was adjusted to 18.5 MBq/mL (0.5 mCi/mL) by the addition of ethanol 
(3311 µL) with a TFA additive (100 µM) to the remaining solution yielding a concentration of 4.4 
µM. The radioligand 2.8b was stored at –20 °C.  
(aThe actual efficiency of the labeling reaction was about 60 % related to the amount of activity 
which was available after the toluene removal.) 
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(2) Synthesis of 2.8b from 74 MBq of succinimidyl [2,3-3H]-propanoate (2.11b) (as = 2.22 
TBq/mmol, American Radiolabeled Chemicals). Compound 2.7 (0.84 mg, 1.33 µmol, 40 eq) was 
dissolved in anhydrous acetonitrile (60 µL) yielding a concentration of 22.2 mM, and NEt3 was 
diluted in acetonitrile to a concentration of 0.18 µL NEt3/10 µL. Compound 2.7 (22.2 mM in 
acetonitrile, 20 µL, 0.44 µmol, 13.3 eq) was added to 2.11b (5.84 µg, 0.033 µmol, 1 eq, 74 MBq) 
in ethyl acetate (0.4 mL) in a 1.5-mL Eppendorf reaction vessel (screw top). The solvent was 
removed in a vacuum concentrator (40 °C) over a period of 50 min. 2.7 (22.2 mM in acetonitrile, 
40 µL, 0.89 µmol, 26.7 eq) and NEt3 (10 µL of the above described solution in acetonitrile, 1.33 
µmol, 40 eq) were added. The reaction mixture was vigorously blended (vortexer) for 1 min, 
briefly centrifuged and stirred with a magnetic micro stirrer at rt overnight. For deprotection TFA 
(60 µL) was added and stirring was continued for 3 h at 40 °C. For HPLC analysis 2 µL of the 
“deprotection mixture” were diluted (1:20) with 38 µL of acetonitrile/0.05 % aq. TFA (50/50), and 
2 µL of this solution were diluted (1:50) with 98 µL of acetonitrile/0.05 % aq. TFA (20/80). This 
solution was completely injected into the Waters HPLC-system and analyzed with UV- and 
radiometric detection (radiometric: see Figure 8B). The residual “deprotection mixture” (≈ 98 µL) 
was diluted with acetonitrile/0.05 % aq. TFA (10/90, 260 µL) and combined with the remaining 
1:20-diluted “deprotection mixture” (≈ 38 µL). The product was isolated with a Waters HPLC 
system (3 injections) using the conditions specified for the analysis of the “deprotection 
mixture”. For this purpose radiometric detection was not performed (Figure 8A). The product 
was eluted at 25.4 to 26.1 min and collected in a 1.5-mL Eppendorf reaction vessel (screw top), 
which was put into the vacuum concentrator between the injections. The combined product 
fractions were evaporated to dryness in a vacuum concentrator (about 5 h), the residue was 
dissolved in 200 µL of ethanol containing TFA (100 µM) and transferred to a clean 5-mL 
Amersham glass vial together with the washings (3 × 100 µL).  
Quantification: A five point calibration was performed with 2.8a (0.3, 0.5, 0.75, 1.0 and 1.5 µM, 
inj. vol.: 100 µL). Eluent: mixtures of acetonitrile + 0.05 % TFA (A) and 0.05 % aq. TFA (B), 
gradient for the 1.5 µM standard: 0 to 30 min: A/B 20/80 to 90/10, 30 to 38 min: 90/10 (retention 
time of 2.8a: 16.7 min), gradient for the other standards: 0 to 12 min: A/B 30/70 to 50/50, 12 to 
12.5 min: 50/50 to 90/10, 12.5 to 18 min: 90/10 (retention time of 2.8a: 12.85 min). The 
solutions for injection were prepared in acetonitrile/0.05 % aq. TFA (20/80) less than 3 min prior 
to the injection. All standard solutions were prepared from a 40 µM solution of 2.8a (in 
acetonitrile/0.05 % aq. TFA 20/80), which was freshly made for each standard solution from a 2 
mM stock solution of 2.8a in acetonitrile/water 80/20. Two aliquots (4.0 µL) of the ethanolic 
solution (total volume: 500 µL) of the product were diluted with 100 µL of acetonitrile/0.05 % aq. 
TFA (20/80), and 100 µL were analyzed by HPLC. Whereas one sample was only used for 
quantification of the product by UV detection the second sample was additionally monitored 
radiometrically to determine radiochemical purity (Figure 1). The molarity of the ethanolic 
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solution of 2.8b was calculated from the mean of the peak areas and the linear calibration curve 
obtained from the peak areas of the standards. Yield: 5.86 µg (0.011 µmol, 33 %). 
Determination of the specific activity: 1.5 µL of the ethanolic solution were diluted with 448.5 µL 
of a mixture of acetonitrile and water (65/35) in triplicate, and 9 µL of the 1:300-dilutions were 
counted in RothiszintTM eco plus (3 mL). Calculated specific activity: 1.9 TBq/mmol (51 
Ci/mmol). The activity concentration was adjusted to 9.25 MBq/mL (0.25 mCi/mL) by addition of 
ethanol (1696.5 µL) containing TFA (100 µM) to the residual solution yielding a molarity of 4.9 
µM. The radioligand 2.8b was stored at –20 °C.  
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Figure 8. A: Analytical HPLC run for isolation of radioligand 2.8b; detection: UV (220 nm); tR = 25.8 min. 
B: HPLC analysis of the “deprotection mixture” containing the non-purified radioligand 2.8b; radiometric 
detection, tR = 26.4 min. Eluent (for A and B): mixtures of acetonitrile + 0.05 % TFA (A) and 0.05 % aq. 
TFA (B); gradient (for A and B): 0 to 26 min: A/B 20/80 to 47/53, 26 to 27 min: 47/53 to 90/10, 27 to 35 
min: 90/10. 
 
 
2.3.4 Pharmacology: Experimental Protocols 
 
General. Unless otherwise noted, all chemicals (analytical grade) were obtained from 
commercial suppliers. Millipore water was used throughout. Dy-635-pNPY was synthesized as 
described previously.34 [K4]-hPP was synthesized in the laboratory of Prof. Beck-Sickinger 
(University of Leipzig, Germany) and labeled with the cyanine dye Cy5 in our laboratory.35 
Porcine NPY (pNPY) was prepared in-house in the laboratory of Dr. C. Cabrele. The fura-2 AM 
(Calbiochem/Merck Biosciences, Beeston, UK) stock solution (1 mM) was prepared in 
anhydrous DMSO. Pluronic F-127 (Calbiochem/Merck Biosciences, Beeston, UK) was dissolved 
in DMSO to a concentration of 20 %. The buffer for the Y1R binding studies of 2.8b on SK-N-MC 
cells, MCF-7 cells and tissue sections was prepared by the addition of BSA (1 % for binding on 
cells, 0.2 % for binding on tissue sections) and bacitracin (50 µg/mL) to a buffer (pH 7.4) 
consisting of HEPES (10 mM), NaCl (150 mM), KCl (5 mM), CaCl2·2H2O (2.5 mM), KH2PO4 (1.2 
mM), Mg2SO4·7H2O (1.2 mM), and NaHCO3 (25 mM). This HEPES buffer without the additives 
was used to wash the cells and tissue sections previous to and after radioligand binding. The 
loading buffer (pH 7.4) for the determination of intracellular Ca2+ mobilization in HEL cells was 
Chapter 2 38 
prepared by dissolving NaCl (120 mM), KCl (5 mM), MgCl2·6H2O (2 mM), CaCl2·2H2O (1.5 mM), 
HEPES (25 mM), and glucose (10 mM). The lysis solution for the radioligand binding assays 
consisted of urea (8 M), acetic acid (3 M) and Triton-X-100 (1 %) in water. Stock solutions of 
2.8a (10 mM in DMSO, 2 mM in acetonitrile/water 80/20), BIBP 3226 (10 mM in DMSO) and 
pNPY (1 mM in DMSO) were stored at –20 °C. Tritium counting was done in 3 mL of Rothiszint 
eco plus with a Beckman LS 6500 beta-counter. Animals were taken from the livestock breeding 
of the University of Regensburg. 
 
Cell culture. HEL and SK-N-MC cells were cultured as described elsewhere.36, 37 HEL cells 
were subcultured by 1:6-dilution with fresh culture medium 24 h prior to the fura Ca2+-assay. 
MCF-7-Y1a cells were maintained in MEM (Sigma), supplemented with 5 % FCS (Biochrom AG, 
Berlin, Germany). The CHO cells transfected with the Y2R, Gqi5 and aequorin were cultured as 
previously described.34 CHO cells transfected with the Y4R, Gqi5 and aequorin were cultured 
under the same conditions. HEC-1B-Y5 cells were cultured as previously described.38 
(aThis cell line originated from MCF-7 cells in the 157th passage and shows a higher Y1R 
expression (factor 2 – 3) over the original MCF-7 cells.) 
 
Radioligand binding assay. The radioligand binding assay was essentially performed as 
described36. Cells were seeded in 24-well plates 2 or 3 days prior to the experiment. On the day 
of the experiment confluency of the cells was at least 70 %. The culture medium was removed, 
the cells were washed once with buffer (500 µL), and covered with binding buffer (200 µL). 
Binding buffer (25 µL) and binding buffer (25 µL) with 2.8b (10-fold concentrated) was added for 
total binding. For non-specific binding and displacement of 2.8b binding buffer (25 µL) with the 
competing agent (pNPY, 2.14 (BIBP 3226) or 2.8a, 10-fold concentrated) and binding buffer (25 
µL) with 2.8b (10-fold concentrated) was added. During incubation at room temperature (22 – 
25 °C) the plates were gently shaken. After incubation (saturation experiments and competition 
with 2.14 or 2.8a: 20 min; competition with pNPY: 2 h) the binding buffer was removed, the cells 
were washed twice with buffer (500 µL, 4 °C, ≤ 30 s), covered with lysis solution (200 µL) and 
the plates were gently shaken for at least 30 min. The lysis solution was transferred into 6-mL 
scintillation vials filled with scintillator (3 mL) and the dishes were washed once with lysis 
solution (100 µL). In case of the investigation of the dissociation kinetics the cells were 
incubated with binding buffer (250 µL) containing BIBP 3226 (100-fold higher concentrated than 
the previously used radioligand) after the incubation with radioligand (6 nM) and subsequent 
washing (twice 500 µL, 4 °C). After different periods of time the cells were washed again twice 
with buffer (500 µL, 4 °C) followed by the addition of lysis solution. Assays were performed in 
triplicate.  
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Fura-2 assay on HEL cells (Schild analysis). The fura assay was performed with HEL cells as 
previously described39 using an LS50 B spectrofluorimeter (Perkin Elmer, Überlingen, 
Germany). Concentration-response curves of pNPY were constructed in the presence of 2.8a at 
different concentrations. The signal intensities were related to the maximal intensity obtained 
from a pNPY effect curve in the absence of 2.8a. 
 
Autoradiography. Subcutaneous MCF-7-Y1 tumors were established in female NMRI (nu/nu) 
mice bearing an estrogen depot40 by subcutaneous injection of a cell suspension in culture 
medium without FCS (4 Mio cells/50 µL, 171st in vitro passage). The tumor and the rat brain 
(male Wistar rat, 10 month) were taken from the animals (brain: 24 h prior to experiment, tumor: 
48 h prior to experiment), immediately frozen in Tissue-Tek with the help of dry ice, and stored 
at -18 °C (brain) and at -78 °C (tumor). Cryosections (12 µm) were obtained at -16 °C with a 
2800 Frigocut E freezing microtome (Reichert-Jung/Leica, Germany). Two adjacent sections 
were mounted on a microscopic slide (Superfrost Plus, 75 × 25 × 1 mm), put 1 min into a 
chamber of 100 % humidity and then carefully covered with binding buffer or fixed for 20 s in an 
alcoholic formaldehyde fixative (40 mL of 37 % formaldehyde, 360 mL of 95 % ethanol and 0.2 
g calcium acetate41). The binding buffer was removed (after a period of less than 60 min under 
cooling) by putting the slides uprightly on a paper towel (≈ 1 min). For total binding the sections 
were covered with binding buffer (about 800 to 1000 µL for one slide) containing 2.8b (3 nM) 
and for non-specific binding with binding buffer containing 2.8b (3 nM), 2.8a (30 nM) and pNPY 
(300 nM)a. The sections were incubated at room temperature (22 - 25 °C) for a period of 8 min 
(tumor) or 30 min (brain). After incubation the binding buffer was removed, the slides were 
immerged three times into buffer split to 3 vessels (4 °C, 10 s) and finally rinsed with distilled 
water (4 °C, 3 s). The slides were put uprightly on a paper towel for 1 min and then dried in 
horizontal position in a desiccator over P4O10. The slides were set in close contact with a tritium 
sensitive screen (PerkinElmer, 192 × 125 mm) using an X-ray film cassette and stored in a dark 
room for 10 d. The autoradiographic image was generated from the tritium screen using a 
phosphorimager (Cyclone Storage Phosphor System, Packard).  
The fixed sections were stained with haematoxylin and eosin (brain) or using the Masson-
Goldner (Jerusalem’s modification) staining procedure (tumor): H & E: rinsing (demineralized 
H2O), Mayer’s haemalum solution (Merck) 1:3 diluted in water (11 min), rinsing (tap water), 1 % 
aq. acetic acid (3 × immersion), running tap water (10 min), rinsing (H2Odemin), eosin standard 
solution (2 min), running H2Odemin (5 min); Masson-Goldner (Jerusalem’s modification): Weigert’s 
iron-haematein (45 s), rinsing (H2Odemin), running tap water (10 min), differentiation with 200 mL 
of H2Odemin + 20 mL of 2 M aq. hydrochloric acid (15 s), running tap water (10 min), rinsing 
(H2Odemin), 0.5 % aq. phosphotungstic acid (15 s), running H2Odemin (10 min), acid fuchsine-
Ponceau (30 s), 1 % aq. acetic acid (3 × immersion), phosphoric acid-Orange G (10 s), 1 % aq. 
acetic acid (3 × immersion), 0.2 % light green (3.5 min), 1 % aq. acetic acid (3 × immersion), 96 
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% aq. ethanol (2 × 3 min), 100 % ethanol (2 × 3 min), 100 % xylene (3 min). Entellan (Merck) 
was used for covering.  
(a2.8b was displaced with pNPY in combination with 2.8a to determine non-specific binding in 
tissue structures inaccessible to pNPY.) 
 
Flow cytometric binding assays. Flow cytometric binding studies at the Y2R (CHO cells 
transfected with the Y2R, Gqi5 and aequorin)42 and at the Y5R (expressed by HEC-1B cells 
transfected with the Y5R)34, 43 were performed as previously described. The cell density in 
loading buffer was 1 Mio/mL (Y2R) or 0.5 Mio/mL (Y5R). For Y2R binding studies Dy-635-pNPY 
(10 nM) was used instead of Cy5-pNPY (10 nM).  
Flow cytometric binding studies at the Y4R (expressed by CHO cells transfected with the Y4R, 
Gqi5 and aequorin)35 were performed as reported44 with the following variations: Cy5-[K4]-hPP35 
(5 nM) was used instead of S0586-[K4]-hPP (10 nM). The cell density in loading buffer was 
106/mL. Non-specific binding was determined in the presence of hPP (100 nM). The stock 
solution of Cy5-[K4]-hPP was prepared in 10 mM HCl + 0.1 % BSA (500 nM). 
All flow cytometric assays were performed in triplicate on a FACSCaliburTM flow cytometer 
(Becton Dickinson, Heidelberg, Germany), equipped with an argon laser (488 nm) and a red 
diode laser (635 nm). 2.8a was tested at a concentration of 1 µM and 10 µM (for Y2R binding 
also 30 µM). Whereas no displacement of the fluorescent ligands was observed in case of the 
Y2R and Y4R by 2.8a (10 µM), displacement at the Y5R was around 50 %.  
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Chapter 3 
 
Bivalent Argininamide-Type NPY Y1 Receptor 
Antagonists 
 
 
3.1 Introduction 
 
Today, a large number of G-protein coupled receptors (GPCRs), for instance adrenergic 
receptors, GABAB receptors, dopamine receptors, opioid receptors, adenosine receptors, 
neuropeptide Y receptors, etc.1, 2 are supposed to form homo- or hetero-oligomers, and there is 
growing evidence that particularly GPCR hetero-oligomerization is implicated in the modulation 
of physiological responses. Various methods were developed to study the existence of GPCR 
dimers and higher oligomers. Co-immunoprecipitation allows the detection of GPCR dimers in 
cell lysates after co-expression of differentially epitope-tagged forms of a GPCR.3, 4 Distinct 
pairs of individually non-functional receptor mutants showed reconstituted function when co-
expressed.5-7 Resonance energy transfer techniques (FRET, BRET) are frequently used to 
study GPCR oligomerization, but they are compromised by a low signal-to-noise ratio due to an 
overlap of the emission spectra with cellular auto-fluorescence. Another limitation is the 
occurrence of intracellular FRET additional to FRET on the cell surface, which is of interest. 
These problems could be overcome with time-resolved FRET (TR-FRET)8, a technology, where 
epitope tagged receptors are labeled with an antibody, carrying a long-lived fluorescence donor 
such as europium cryptate and an appropriate acceptor, respectively.9 Recently, this technique 
has been improved by the fusion of the N-terminal receptor domain with a snap protein. The 
snap protein, exerting O6-guanine nucleotide alkyltransferase activity, serves for a covalent 
attachment of TR-FRET-compatible fluorophores to the receptor.10 These techniques require 
the expression of GPCRs which are either epitope-tagged or fused to a protein. 
The use of bivalent ligands as an alternative to the afore-mentioned methods offers the 
possibility to investigate native GPCRs expressed endogenously by normal wild-type cells. 
Such compounds, defined as two pharmacophoric entities linked through a spacer, are 
anticipated to bring more insight into the phenomenon of GPCR dimerization. Addressing 
GPCR dimers by homo or hetero bivalent ligands is challanging because the bivalent ligands 
have to fulfill numerous special requirements. One prerequisite is the appropriate length of the 
linker, which should be at least as long as the distance between the binding sites. For instance, 
Portoghese proposed a distance of 22 to 32 Å (corresponding to 15-22 atoms) for the opioid 
receptor family.11, 12 This value is a rule of thumb as on one hand, the distance between the 
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binding sites of a GPCR dimer depends on the orientation of the two receptor monomers 
contacting each other, on the other hand the linker may span the transmembrane domains, the 
shortest distance between the binding sites, or it may form an extracellular loop requiring 
remarkably longer spacers.  
Another critical issue is the binding behavior of bivalent ligands, which can occupy both binding 
sites of two receptor monomers simultaneously. Do we stringently have to expect a dramatic 
increase in affinity (factor of 50 and more) over mono-site binding? Such observations are 
limited to a few cases.13, 14 This leads to a key question, the thermodynamic profile of a bivalent 
ligand, which addresses two binding sites simultaneously. The binding affinity, reflected by the 
dissociation constant Ki, is related to the Gibbs free energy (G = RTlnKi). The released Gibbs 
free energy upon complex formation (ligand binding) results from entropic and enthalpic 
contributions (G = H - TS). In favorable cases the overall binding enthalpy (Htotal) of a 
polyvalent ligand can be more negative than the sum of the enthalpies, which result from a 
single docking of pharmacophoric moieties.15 Since a simultaneous binding of two 
pharmacophoric entities of a bivalent ligand is entropically disfavored, the loss of entropy will 
more or less compensate the gain in enthalpy. Particularly for very flexible linkers (high number 
of freely rotatable single bonds), the binding will be remarkably diminished due to considerable 
vibrational and rotational restrictions.15, 16 Positive entropic contributions arising from the release 
of water molecules are assumed to be less important for these considerations since such 
entropic terms were reported to have usually similar values in monovalent and polyvalent 
systems.15 This argumentation can be subjected to the potential case that one pharmacophoric 
entity of a bivalent ligand binds orthosterically and the second simultaneously to an allosteric 
site. The observed affinity in the latter constellation is supposed to be comparatively lower since 
it is likely that the binding to the allosteric site is less strong compared to the orthosteric 
docking. Nevertheless, ligand binding can be favorably altered through allosteric interactions of 
the second pharmacophoric entity as becomes obvious, e.g. from twin drug approaches. In 
close relation to bivalent ligands twin drugs are composed of two drug entities (different or 
identical) combined by a linker, no linker or in overlap mode. Twin drugs were developed, e.g. 
for adrenergic, muscarinic, opioid and serotonergic receptors.17-21 In most cases they do not 
intend to address two binding sites simultaneously, but in numerous cases twin drugs proved to 
be more potent and differentially profiled in their pharmacological properties. Therefore, these 
twin drug approaches give evidence that interaction of the second, not specifically bound 
pharmacophoric moiety with allosteric sites can considerably trigger the pharmacological profile. 
In close connection to allosteric modulation cooperativity effects are usually discussed. For 
instance, the phenomenon that binding of one pharmacophoric moiety facilitates the binding of 
the second pharmacophore is termed positive cooperativity. 
Also critical is the chemical nature of the spacers. Most bivalent ligand approaches are based 
on the use of linkers with well-balanced hydrophilic and lipophilic properties which are attained, 
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e.g. by the implication of ethylene glycol and amide moieties. Purely aliphatic spacers would 
lead to solubility problems and strong membrane binding. The connection of the linker and the 
recognition unit is also important. The spacer has to be attached in a manner that binding 
affinity is affected as little as possible. On one hand the linker should be sufficiently flexible for 
sterical adaption, but on the other hand a too flexible linker is entropically disfavored. 
To explore if bivalent ligans can contribute to bring more insight into the presumed association 
of GPCRs, a series of bivalent neuropeptide Y (NPY) Y1 receptor antagonists with spacer 
lengths between 8 and 36 atoms were synthesized. The Y1 receptor, belonging to the 
superfamily of G-protein coupled receptors, was recently proposed to dimerize2 and a twin drug, 
the irreversible alpha-adrenoceptor antagonist benextramine, was reported previously to 
interact with NPY binding sites.22, 23 
 
 
3.2 Results and Discussion 
 
The presented bivalent Y1R antagonists are derived from the (R)-argininamide BIBP 3226, the 
first highly potent and selective Y1R antagonist.24 Advantage was taken of the experience in the 
synthesis and pharmacological characterization of N-substituted BIBP 3226 analogs. Among 
them, acylated and carbamoylated derivatives turned out to be more favorable in terms of 
retaining binding affinity. In some cases the affinity could be increased over that of the parent 
argininamide.25 The distomer of BIBP 3226, the (S)-enantiomer (referred to as BIBP 3435), was 
reported to be more than 1000 times less potent than the eutomer.24 Therefore, sets of (R,R)-, 
(R,S)- and (S,S)-configured bivalent ligands with identical physicochemical properties were 
prepared (Scheme 2) in order to facilitate conclusions from binding data. This approach was 
considered advantageous compared to strategies, where analogs of monovalent ligands with 
bisected or capped linkers are used as reference compounds, as any additional structural 
element (the linker and the second pharmacophore, if it does not bind specifically to a second 
site), which is attached to the orthosterically bound pharmacophoric entity, will undergo non-
specific interactions with the receptor protein or parts of the cell membrane. 
 
 
3.2.1  Chemistry 
 
Synthetic strategies aimed at compounds of maximal purity on the low mg scale rather than at 
the optimization of yields and synthetic routes. The bivalent ligands (3.8, 3.22 – 3.25, 3.29, 3.37 
– 3.41) were prepared in a straightforward manner using standard protecting group chemistry 
as depicted in Schemes 2 - 5. A synthesis focused, click chemistry and BIBP 3226 based 
approach for the preparation of bivalent Y1R antagonists has already been reported.26 The 
linkers between the two BIBP 3226 moieties are composed of aliphatic dicarboxylic acids and 
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3,6-dioxa-octane-1,8-diamine as well as N,N’-bis(2-aminoethyl)-ethane-1,2-diamine (branched 
linkers) providing a hydrophilic-lipophilic balance. A linkage to the -nitrogen of the Y1R 
antagonist BIBP 3226 and its less active S-enantiomer BIBP 3435 via carboxylic groups yielding 
N-acylated BIBP 3226 and BIBP 3435 derivatives, respectively, was chosen. The synthesis of 
the guanidinylating reagent 2.13 as well as the N-Boc, O-tert-butyl protected BIBP 3226 
building block (R)-3.6 (cp. to 2.7) was described in chapter 2, and the respective S-enantiomer 
(S)-3.6 was prepared following this protocol (Scheme 1). The non-protected terminal guanidine 
nitrogen (N’) of this building block reacts similar to amines, but at lower reaction rates. N-
acylation can be achieved by the aid of coupling reagents from peptide chemistry (EDAC, CDI) 
or using anhydrides, chlorides and active esters. Final deprotection with TFA and purification 
with preparative HPLC yielded the bivalent ligands with purities > 90 %. Mono-Boc protected 
N,N’-bis(2-aminoethyl)ethane-1,2-diamine (3.30) was successfully prepared according to a 
published protocol (Scheme 5).27 
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Scheme 1. Synthesis of the BIBP 3435 building block (S)-3.6. 
Reagents and conditions: (a) (1) Cbz-Cl (45 % in toluol), NaOH 0.5 N, K2CO3, CuSO4, 4 °C to rt, 20 h; (2) 
Titriplex III, H2O, 100 °C, 60 min; (b) FmocOSu, H2O/Dioxan, rt, 20 h, 85 %; (c) 4-tert-butoxybenzylamine, 
CDI, THF, rt, 20 h, 60 %; (d) diethylamine, DCM, rt, 4 h, 76 %; (e) (1) diphenylacetic acid succinimidyl 
ester, NEt3, 1,2-dimethoxyethane, 35 °C, 20 h; (2) Pd/C, ammonium formate, MeOH, rt, 20 h, 82 %; (f) (1) 
NEt3, CH2Cl2, rt, 20 h; (2) Pd/C, H2, MeOH, rt, 3.5 h, 87 %. 
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Scheme 2. Synthesis of the bivalent ligand 3.8. 
Reagents and conditions: (a) NHS, DCC, THF, 0 °C to rt, 20 h, 42 %; (b) (1) NEt3, MeCN, rt, 20 h; (2) 
MeCN/TFA 1/1 (v/v), H2O, rt, 4 h, 57 %. 
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Scheme 3. Synthesis of the bivalent ligands 3.22 - 3.25. 
Reagents and conditions: (a) (1) alkanedioic acid, acetic anhydride, m-xylene, reflux, 2 h; (2) BnOH, 60 
°C, 20 h, 30-77 %; (b) (1) 3.9 - 3.12, oxalyl chloride, DMF, CH2Cl2, reflux, 2 h; (2) 3.6, NEt3, CH2Cl2, rt, 20 
h; (3) Pd/C, H2, MeOH, rt, 20 h, 55-65 %; (c) (1) 3.13 - 3.16 (only R-configuration), EDAC, CH2Cl2, rt, 20 
h; (2) Pd/C, H2, MeOH, rt, 20 h, 45-55 %; (d) (1) EDAC, CH2Cl2, rt, 20 h; (2) CH2Cl2/TFA 1/1 (v/v), H2O, rt, 
2.5 h, 19-26 %; (e) (1) 3,6-dioxaoctane-1,8-diamine, EDAC, CH2Cl2, rt, 20 h; (2) CH2Cl2/TFA 1/1 (v/v), 
H2O, rt, 2.5 h, 14-32 %. 
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Scheme 4. Synthesis of the bivalent ligand 3.29. 
Reagents and conditions: (a) (1) EDAC, CH2Cl2, rt, 20 h; (2) CH2Cl2/TFA 1/1 (v/v), rt, 3 h, 55 %; (b) (1) 
NEt3, CH2Cl2, rt, 20 h; (2) Pd/C, H2, MeOH, rt, 84 %; (c) (1) CDI, DMF, rt, 20 h; (2) CH2Cl2/TFA 1/1 (v/v), 
rt, 2.5 h, 21 %. 
Chapter 3 
 
50 
H2N
N NH2
3.30
N
H
N N
H
O
OH
OO
HO
O
nn
3.31   n = 1  
3.32   n = 2
3.33   n = 4
NHBoc
N
H
N N
H
O
NH2
O
H2N
3.35   n = 1  
3.36   n = 2
NHBoc
NHBoc
3.34
N
H
N N
H
O H
N
OH
N
NHBoc
O
HO
O
OH 3.40   n = 1  3.41   n = 2
3.37   n = 1  
3.38   n = 2
3.39   n = 4(R)-3.6
a
b
c
d
        3.9 
    3.10 
3.12
O O
n n
        3.9 
    3.10
(R)-3.6
d
 
Scheme 5. Synthesis of the bivalent ligands 3.37 - 3.41. 
Reagents and conditions: (a) (1) EDAC, CH2Cl2, rt, 20 h; (2) Pd/C, H2, MeOH, rt, 58-75 %; (b) (1) N-
benzyloxycarbonyl--aminobutyric acid, EDAC, CH2Cl2, rt, 20 h; (2) Pd/C, H2, MeOH, rt, 89 %; (c) (1) 
EDAC, CH2Cl2, rt, 20 h; (2) Pd/C, H2, MeOH, rt, 53-60 %; (d) (1) CDI, DMF, rt, 20 h; (2) CH2Cl2/TFA 1/1 
(v/v), rt, 2.5 h, 12-37 %. 
 
The potential bivalent radioligands 3.42 - 3.44 were synthesized from the fully deprotected 
amine precursors 3.38 and 3.40 using NHS esters of the pertinent carboxylic acids, which are 
standard reagents for a tritium or fluorine-18 labeling (Scheme 6). Usually, the most profitable 
strategy for the preparation of radioligands is a labeling at the final step.  
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Scheme 6. Synthesis of the potential bivalent tritium ligands 3.42 and 3.43 as well as the potential 
bivalent PET ligand 3.44. 
Reagents and conditions: (a) DMF, NEt3, 3 h, rt, 55-68 %. 
 
The fluorescence labeling of the bivalent amine precursors 3.38 - 3.40 yielding the fluorescent 
ligands 4.45 – 4.47 is described in chapter 4. 
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3.2.2  Pharmacology: Y1R Antagonism and Binding 
 
The Y1R antagonistic activity of the bivalent Y1R antagonists was determined by inhibition of the 
neuropeptide Y induced mobilization of intracellular Ca2+ in human erythroleukemia (HEL) 
cells.28 [3H]-UR-MK114 (cf. chapter 2) served as radioligand for binding studies on SK-N-MC 
cells (ca. 50,000 sites/cell) as well as MCF-7-Y1 cells (ca. 250,000 sites/cell, when stimulated 
with 1 nM -estradiol for 48 h, cf. chapter 2). Data for Y1R antagonism and binding are 
summarized in Table 1. Except from the (S,S)-enantiomers all bivalent ligands proved to be 
potent Y1R antagonists with affinities in the nM range, whereas Y1R affinities at SK-N-MC cells 
were slightly higher (factor 2 - 3) than at MCF-7-Y1 cells as was also observed for other BIBP 
3226 analogs (cf. chapters 2, 4 and 5). Among the four sets of (R,R)-, (R,S)- and (S,S)-
configured bivalent Y1R antagonists the triplet with the shortest spacer length (20 atoms) 
revealed a moderate difference (factor 4 - 6) in binding affinity between the (R,R)- and (R,S)-
diastereomer ((R,R)-3.22 vs. (R,S)-3.22: 8/34 nM on SK-N-MC cells and 22/150 nM on MCF-7-
Y1 cells). The other (R,R)- and (R,S)-isomer pairs showed almost no difference between 
affinities (factor 1 - 2, cf. Table 1). The preferential binding of (R,R)-3.22 may be a hint to a 
bridging of two Y1R monomers. However, this finding must not be over-interpreted as the 
competition curves were not bi-phasic and no statistically significant difference in the Hill-slope 
from one was observed (Figure 1). Nevertheless, this gives reason to prepare further sets of 
(R,R)- and (R,S)-stereoisomers with structurally modified linkers (i.e. more rigid linkers) around 
20 atoms of length and to conduct supporting investigations, e.g. with the help of bivalent 
radioligands as discussed below. A successive truncation of compound (R,R)-3.22 to 
monovalent ligands containing the whole linker and fragments of the linker, would be an 
approach to study the impact of the nature of the linker on affinity. 
Surprisingly there was only a small fluctuation in binding affinity (9 to 63 nM on SK-N-MC cells) 
among the (R,R)-configured ligands over the wide span in spacer length, ranging from 8 to 36 
atoms. The bivalent ligand with the longest linker of 36 atoms even proved to be one of the 
most potent compound (Ki = 16 nM). Thus, linker length and structural diversity seem to be less 
decisive for binding affinity, and it is difficult to evaluate the effect of the second pharmacophoric 
moiety. Does it enhance binding while interacting with allosteric sites? As quite long and flexible 
linkers were used, a potential increase in affinity due to the simultaneous occupation of an 
allosteric pocket could be entropically balanced or even over-compensated (discussed in the 
introduction). On the contrary, unfavorable allosteric interactions, which hinder the specific 
binding of the orthosterically bound pharmacophoric entitiy are less probable due to the long 
distance between both pharmacophoric moieties, which are linked through quite long flexible 
spacers. To some extend this could be the case for compound 3.8 with a short linker of eight 
atoms having the lowest affinity in this series (Table 1). 
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Table 1. Structures, Y1R antagonistic activities (IC50) and affinities (Ki) of the bivalent Y1R antagonists. 

H
N
NH
N
H
O
NH2N
O OH
R =
 
No. Config. X n Spacera IC50 [nM]b Ki [nM]c Ki [nM]d 
R-CO-CH2-CH2-CH2-CH2-CH2-CH2-CO-R 
3.8 R,R   - 8 23±6 63±13 -- 
H
N O O N
H
O
R
O
O
R
O
nn
3.22 
 
R,R 
R,S 
S,S 
 
1 
1 
1 
20 
20 
20 
15±2 
40±15 
1500±470 
9±3* 
34±2 
1800±300 
22±4 
150±22 
-- 
3.23 R,R 
R,S 
S,S 
 
2 
2 
2 
22 
22 
22 
31±9 
65±10 
890±70 
23±5 
26±3 
1300±70 
62±15 
96±7 
-- 
3.24 R,R 
R,S 
S,S 
 
3 
3 
3 
24 
24 
24 
18±4 
20±3 
1600±100 
15±2 
19±3 
2600±800 
42±3 
52±14 
-- 
3.25 R,R 
R,S 
S,S 
 
4 
4 
4 
26 
26 
26 
10±3 
13±2 
1440±170 
41±5 
65±7 
2500±90 
95±24 
280±96 
-- 
O
O
N
H HN O O N
H
R
OOO
H
N
O
OR
O
n
n
3.29 R,R  3 36 97±3 16±4 31±6
N
H
N N
H
O
R
OO
R
O
nn
X
3.37 R,R  NH2 1 17 28±3 30±4 34±8
3.38 R,R  NH2 2 19 15±3 16±1 43±3
3.42 R,R  NHCO-CH2CH3 2 19 23±3 49±4 -- 
3.39 R,R  NH2 4 23 20±5 34±5 47±1
N
H
N N
H
O H
N
OH
N
O
R
O O
R
O
nn
X
 
3.40 R,R NH2 1 27 20±4 17±2 29±5
3.43 R,R NHCO-CH2CH3 1 27 41±3 18±3 -- 
3.44 R,R NH-4-F-benzoyl 1 27 21±1 34±1 -- 
3.41 R,R NH2 2 29 19±5 11±3 27±3
H R (BIBP3226/3435)  
BIBP 3226 R - -- 10±1 1.3±0.2 -- 
BIBP 3435 (3.45) S - -- 3400±120 200±47 -- 
aNumber of atoms which contribute to spacer length. bInhibition of 10 nM NPY induced [Ca2+]i mobilization in 
HEL cells; mean values ± SEM from two independent experiments. CDissociation constant from the 
displacement of [3H]-UR-MK114 (KD = 1.2 nM, c = 1.5 nM) on SK-N-MC cells; mean values ± SEM from two 
independent experiments performed in triplicate. dDissociation constant from the displacement of [3H]-UR-
MK114 (KD = 2.9 nM, c = 2 nM) on MCF-7 cells; mean values ± SEM from two independent experiments
performed in duplicate. *mean value ± SEM from four independent experiments performed in triplicate using 
three independently prepared stock solutions. 
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Figure 1. Displacement of [3H]-UR-MK114 (SK-N-MC cellsa: KD = 1.2 nM, c = 1.5 nM; MCF-7-Y1 cellsb: 
KD = 2.9 nM, c = 2 nM) by BIBP 3226 as well as the bivalent ligands (R,R)-3.22 and 3.40 on SK-N-MCa 
cells and MCF-7-Y1b cells. 
 
It is very likely that simply the attachment of the linkers to BIBP 3226 leads to a decrease in 
affinity as it was e.g. observed, for N-acetylated BIBP 3226 (Ki = 12 nM).25 Moreover, the 
attachment of fluorescent dyes through a linker to BIBP 3226 can lead to a considerable 
decrease in affinity (Ki > 100 nM), indicating unfavorable allosteric interactions of the bulky 
fluorophore.29 Therefore, with respect to the observed affinity range of 9 – 63 nM (Ki) a nearly 
neutral behavior of the second pharmacophoric entity with respect to enhancement or mitigation 
of binding affinity is assumed. 
All (S,S)-enantiomers exhibited significantly lower Y1R antagonistic acitivities, but not as low as 
reported24 due to the presence of an impurity of 2.7 % of the eutomer BIBP 3226 as determined 
by capillary electrophoresis (using -cyclodextrin) for BIBP 3435 (3.45). 3.45 was obtained by 
N- and O-tert-butyl deprotection of the building block (S)-3.6 and revealed a remarkable activity 
(Ki = 200 nM, Table 1). D-ornithine, the starting material for the synthesis of (S)-3.6 (Scheme 1), 
was determined to be enantiomerically pure (investigated by HPLC after derivatization with 
ortho-phthalaldehyde and N-acetyl-L-cysteine30). Consequently, racemization occurred during 
the synthesis of BIBP 3435 (3.45).  
Selectivity data were not determined for two reasons. Firstly, there was no bivalent Y1R 
antagonist with outstanding characteristics, and secondly the selectivity was already confirmed 
for monovalent fluorescence labeled BIBP 3226 derivatives, where the fluorophore is attached 
to the guanidine in the same way through alkanoyl linkers.29 Nevertheless, the selectivity profile 
of fluorescence labeled or radiolabeled bivalent Y1R antagonists such as the potential 
radioligand 3.43 has to be determined if such ligands are used as pharmacological tools. 
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With the intension to extend the experimental applicability of the bivalent ligands as 
pharmacological tools, branched linkers, bearing a primary amino group for radio- and 
fluorescence labeling, were introduced. The bivalent Y1R antagonist 3.43, one of the most 
potent bivalent compounds (Ki = 18 nM), can be easily prepared as a tritiated ligand from 3.40 
and commercially available [2,3-3H]-propanoic acid succinimidyl ester. Complementary to 
binding experiments with the monovalent Y1R antagonist [3H]-UR-MK114, such a radiolabeled 
bivalent ligand should be a valuable tool for investigations on the stoichiometry of Y1R binding 
sites. 
The fluorescence labeling of amine precursors 3.38 – 3.40 resulted only in a moderate 
decrease in affinity, and two bivalent fluorescent ligands proved to be well suited for an imaging 
of Y1 receptors on MCF-7-Y1 cells using confocal microscopy (cf. chapter 4). 
 
 
3.2.3 Summary and Conclusion 
 
A wide range of linker lengths (shortest: 8-membered chain, longest: 36-membered chain) was 
chosen for the preparation of bivalent Y1R antagonists derived from the highly potent and 
selective Y1R antagonist BIBP 3226. The most potent bivalent ligand, consisting of a 20-atom 
spacer, revealed a moderately lower Y1R affinity for the (R,S)-stereoisomer than for the (R,R)-
enantiomer (factor of 4-6), which was not observed for other pairs of (R,R)- and (R,S)-
configured bivalent ligands (Table 1). This can be interpreted as hint to the bridging of two Y1 
receptor monomers, but further investigations based on complementary tools are needed. Since 
quite flexible linkers were used in this work, it is possible that the enhanced binding of the (R,R)-
enantiomer ((R,R)-3.22) is mitigated by negative entropic effects. However, the preparation of 
further sets of (R,R)- and (R,S)-stereoisomers with more rigid linkers comprising around 20 
atoms could be promising.  
Interestingly, among the (R,R)-configured antagonists only minor differences in affinities (9 to 63 
nM) with respect to spacer length and chemical diversity were observed (Table 1). The 
successful preparation of bivalent Y1R antagonists with branched linkers, where radio- and 
fluorescence labels can be attached, is especially worth mentioning. Such a potential bivalent 
radioligand had an affinity of 18 nM (Ki), which is probably high enough to perform investigations 
on the stoichiometry of binding sites in combination with monovalent radioligands. 
Notwithstanding the presented work paved the way for the future development of high affiniy 
bivalent ligands with improved structure of the linker entitiy (length, rigidity). 
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3.3 Experimental Section 
 
3.3.1 General Experimental Conditions 
 
Unless otherwise stated, chemicals and solvents were purchased from commercial suppliers 
and used without further purification. L-Ornithine hydrochloride was obtained from Merck 
(Darmstadt, Germany). Millipore water was used throughout for the preparation of buffers and 
HPLC eluents. Petroleum ether (40-60 °C) was distilled before use. DMF was stored over a 
molecular sieve (3 Å). Anhydrous reactions were run under an atmosphere of dry nitrogen or 
argon. Thin layer chromatography was performed on Merck silica gel 60 F254 TLC aluminum 
plates. For column chromatography silica gel Geduran 60 (Merck, 0.063-0.200 mm) was used. 
NMR spectra were recorded on a Bruker Avance 300 (1H: 300 MHz) and a Bruker Avance 600 
(1H: 600 MHz, 13C: 150.9 MHz) (Bruker, Karlsruhe, Germany) with TMS as external standard. 
Low resolution mass spectrometry analysis (MS) was performed in-house on a Finnigan 
ThermoQuest TSQ 7000 (ES-MS) and a Finnigan SSQ 710A (EI-MS 70 eV, CI-MS). High 
resolution mass spectrometry for compound 3.8 was performed on a LTQ Orbitrap Discovery 
(Thermo Fisher Scientific, Waltham, MA, USA). Other high resolution mass spectra were 
acquired with an Ultraflex III MALDI-TOF/TOF 200 systen mass spectrometer (2007, 
BrukerDaltonics) equipped with a nitrogen laser emitting at 337 nm. The spectra were calibrated 
using an external calibration with Peptide Calibration Standard II (BrukerDaltonics). 
Melting points were determined with a Büchi 510 melting point apparatus and are uncorrected. 
Lyophilisation was done with a Christ alpha 2-4 LD equipped with a vacuubrand RZ 6 rotary 
vane vacuum pump. Fluorescence spectra were recorded with a Cary Eclipse 
spectrofluorimeter (Varian Inc., Mulgrave, Victoria, Australia).  
Preparative HPLC was performed with a system from Knauer (Berlin, Germany) consisting of 
two K-1800 pumps, a K-2001 detector and a RP-column (Eurospher-100 C18, 250 × 32 mm, 5 
µm) at a flow rate of 38 mL/min. Mixtures of acetonitrile and 0.1 % aq. TFA were used as mobile 
phase. Acetonitrile was removed from the eluates under reduced pressure (final pressure: 60 
mbar) at 40 °C prior to lyophilization. Analytical HPLC analysis was performed on three different 
systems (Waters, Merck, Thermo Separation Products) which are listed in detail below. Mixtures 
of acetonitrile (A) and 0.05 % aq. TFA (B) were used as mobile phase. Helium degassing was 
used throughout.  
The buffer for the Y1R binding studies on SK-N-MC cells and MCF-7-Y1 cells was prepared by 
the addition of BSA (1 %) and bacitracin (50 µg · L-1) to a buffer (pH 7.4) consisting of HEPES 
(10 mM), NaCl (150 mM), KCl (5 mM), CaCl2·2H2O (2.5 mm), KH2PO4 (1.2 mM), Mg2SO4·7H2O 
(1.2 mM), and NaHCO3 (25 mM). HEPES buffer without additives was used to wash the cells 
prior to and after radioligand binding. The loading buffer (pH 7.4) for the determination of the 
mobilization of intracellular Ca2+ in HEL cells was prepared by dissolving NaCl (120 mM), KCl (5 
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mM), MgCl2·6H2O (2 mM), CaCl2·2H2O (1.5 mM), HEPES (25 mM), and glucose (10 mM). The 
lysis solution for the radioligand binding assays consisted of urea (8 M), acetic acid (3 M) and 
Triton-X-100 (1 %) in water. Stock solutions of all compounds were prepared in DMSO at 
concentrations of 5 or 10 mM and stored at –20 °C. Tritium counting was done in 3 mL of a 
liquid scintillator (RothiszintTM eco plus) with a Beckman LS 6500 beta-counter. 
 
Analytical HPLC systems: 
System 1: Waters; composed of a 600S controller and pump, a Waters degasser, a temperature 
control module, a 717 plus autosampler and a 2487 UV-detector; flow rate: 0.7 mL/min 
System 2: Merck; composed of a L-5000 controller, a 655A-12 pump, a 655A-40 autosampler 
and a L-4250 UV-VIS detector; flow rate: 0.7 mL/min 
System 3: Thermo Separation Products; composed of a SN400 controller, a P4000 pump, a 
degasser (Degassex DG-4400, phenomenex), an AS3000 autosampler and a Spectra Focus 
UV-VIS detector; flow rate: 0.8 mL/min 
 
Applied gradients:  
Gradient 1: 0 to 25 min: A/B 25/75 to 65/35, 25 to 27 min: 65/35 to 95/5, 27 to 33 min: 95/5 
Gradient 2: 0 to 30 min: A/B 20/80 to 95/5, 30 to 40 min: 95/5 
With the exception of compound 3.8 all bivalent Y1R antagonists were analyzed with gradient 2 
on a Eurospher-100 C18 (250 × 4 mm, 5 µm, Knauer, Berlin, Dueren, Germany). In case of 
compound 3.8 a Nucleodur 100-5 C18 ec (250 × 4 mm, 5 µm, Macherey-Nagel, Germany) 
served as reversed-phase column. 
 
 
3.3.2 Chemistry: Experimental Protocols and Analytical Data 
 
For synthesis of compounds 3.1 – 3.6 the experimental protocols as for the preparation of 2.1 – 
2.7 (chapter 2) were used.  
 
(S)-N-Benzyloxycarbonyl-N-(9-fluorenylmethoxycarbonyl)ornithine (3.1). White solid, 85 
% (74 g); 1H-NMR (300 MHz, DMSO-d6):  (ppm) 1.4-1.69 (m, 3H, CH-CH2-CH2), 1.75 (m, 1H, 
CH-CH2-CH2), 3.02 (m, 2H, CH2-NH), 3.92 (m, 1H, CH), 4.16-4.31 (m, 3H, CH-CH2 Fmoc), 
5.01 (s, 2H, CH2-Ph), 7.25-7.45 (m, 10H, Ph, Fmoc, CH2-NH), 7.60 (d, 1H, 3J = 7.94 Hz, CO-
NH-CH), 7.73 (d, 2H, 3J = 7.38 Hz, Fmoc), 7.89 (d, 2H, 3J = 7.45 Hz, Fmoc), 12.76 (bs, 1H, 
COOH); MS (ES, CH2Cl2/MeOH + 10 mM NH4OAc): m/z 489 [M + H]+; C28H28N2O6 (488.5) 
 
 
 
Bivalent Argininamide-Type NPY Y1 Receptor Antagonists 
 
57
(S)-N-Benzyloxycarbonyl-N-(4-tert-butoxybenzyl)-N-(9-fluorenylmethoxycarbonyl)-
ornithinamide (3.2). White solid, 60 % (50 g); 1H-NMR (300 MHz, DMSO-d6):  (ppm) 1.24 (s, 
9H, t-Bu), 1.34-1.74 (m, 4H, CH-CH2-CH2), 3.0 (m, 2H, CH2-NH), 4.05 (m, 1H, CH), 4.17-4.32 
(m, 5H, CH-CH2 Fmoc, CH2-C6H4-O-t-Bu), 5.01 (s, 2H, CH2-Ph), 6.88 (d, 2H, 3J = 8.30 Hz, 
AA’BB’), 7.14 (d, 2H, 3J = 8.42 Hz, AA’BB’), 7.26-7.45 (m, 10H, Ph, Fmoc, CH2-CH2-NH), 7.56 
(d, 1H, 3J = 8.18 Hz, CO-NH-CH), 7.74 (d, 2H, 3J = 7.24 Hz, Fmoc), 7.89 (d, 2H, 3J = 7.45 Hz, 
Fmoc), 8.36 (t, 1H, 3J = 5.66, CH-CO-NH-CH2); MS (ES, CH2Cl2/MeOH + 10 mM NH4OAc): m/z 
650 [M + H]+; C39H43N3O6 (649.8) 
 
(S)-N-Benzyloxycarbonyl-N-(4-tert-butoxybenzyl)ornithinamide (3.3). Yellow oil, 76 % (25 
g); 1H-NMR (300 MHz, CDCl3):  (ppm) 1.32 (s, 9H, t-Bu), 1.6 (m, 3H, CH-CH2-CH2), 1.85 (m, 
1H, CH-CH2-CH2), 3.21 (m, 2H, CH2-CH2-NH), 3.43 (m, 1H, CH), 4.37 (d, 2H, 3J = 5.86 Hz, 
CH2- C6H4-O-t-Bu), 5.06 (s, 2H, CH2-Ph), 6.93 (d, 2H, 3J = 8.51 Hz, AA’BB’), 7.15 (d, 2H, 3J = 
8.53 Hz, AA’BB’), 7.28-7.37 (m, 5H, Ph); MS (ES, CH2Cl2/MeOH + 10 mM NH4OAc): m/z 428 [M 
+ H]+; C24H33N3O4 (427.5) 
 
(S)-N-(4-tert-Butoxybenzyl)-N-(2,2-diphenylacetyl)ornithinamide (3.4). White solid, 82 % 
(5.6 g); 1H-NMR (300 MHz, CDCl3):  (ppm) 1.31 (s, 9H, t-Bu), 1.48-1.78 (m, 4H, CH-CH2-CH2), 
2.9 (m, 2H, CH2-CH2-NH2), 4.32 (m, 2H, CH2-C6H4-O-t-Bu), 4.54 (m, 1H, CH), 4.97 (s, 1H, CH-
(Ph)2), 6.89 (d, 2H, 3J = 8.52 Hz, AA’BB’), 7.1 (d, 2H, 3J = 8.49 Hz, AA’BB’), 7.18-7.37 (m, 10H, 
Ph); MS (ES, CH2Cl2/MeOH + 10 mM NH4OAc): m/z 488 [M + H]+; C30H37N3O3 (487.6) 
 
(S)-N-(4-tert-Butoxybenzyl)-N-(4-tert-butoxycarbonyl)-N-(2,2-diphenylacetyl)arginin-
amide (3.6). White solid, 87 % (6.2 g); mp > 85 °C (decomp.); 1H-NMR (300 MHz, CDCl3):  
(ppm) 1.32 (s, 9H, t-Bu), 1.37-1.54 (m, 11H, t-Bu, CH2-CH2-CH2), 1.64 (m, 1H, CH-CH2), 1.74 
(m, 1H, CH-CH2), 3.09 (m, 2H, CH2-CH2-NH), 4.19 (dd, 1H, 2J = 14.92 Hz, 3J = 4.3 Hz, CH2-
C6H4-O-t-Bu), 4.31 (dd, 1H, 2J = 14.71 Hz, 3J = 4.52 Hz, CH2-C6H4-O-t-Bu), 4.52 (m, 1H, CH), 
4.97 (s, 1H, CH-(Ph)2), 6.88 (d, 2H, 3J = 8.52 Hz, AA’BB’), 7.02 (d, 2H, 3J = 8.53 Hz, AA’BB’), 
7.18-7.34 (m, 10H, Ph); MS (ES, CH2Cl2/MeOH + 10 mM NH4OAc): m/z 630 [M + H]+; 
C36H47N5O5 (629.8) 
 
Octanedioic acid disuccinimidylester (3.7). DCC (2.81 g, 13.64 mmol, 2.2 eq) was added to 
an ice-cold, stirred solution of octanedioic acid (1.08 g, 6.2 mmol, 1 eq) and N-
hydroxysuccinimide (1.57 g, 13.64 mmol, 2.2 eq) in anhydrous THF (45 mL). The mixture was 
stirred under cooling for 60 min. The ice-bath was removed and stirring was continued at rt 
overnight. The white solid (DCU) was separated by filtration and the solvent was removed under 
reduced pressure. Purification with column chromatography (eluent: PE/EtOAc) yielded the 
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product as a white solid (0.95 g, 2.59 mmol, 42 %). 1H-NMR (300 MHz, CDCl3):  (ppm) 1.46 
(m, 4H, CH2-CH2-CH2-CH2-CH2-CH2), 1.76 (m, 4H, CH2-CH2-CH2-CH2-CH2-CH2), 2.61 (t, 4H, 3J 
= 7.37, CH2-CH2-CH2-CH2-CH2-CH2), 2.83 (s, 8H, CO-CH2-CH2-CO); MS (CI, NH3): m/z 386 [M 
+ NH4]+; C16H20N2O8 (368.3) 
 
(R,R)-N,N'-Bis{[4-diphenylacetamido-4-(4-hydroxybenzylaminocarbonyl)butyl]-
amino(amino)methylene}octandiamide (3.8). (R)-3.6 (100 mg, 159 µmol, 2.5 eq) and 3.7 
(23.4 mg, 63.5 µmol, 1 eq) were dissolved in anhydrous acetonitrile (5 mL). NEt3 (19.3 mg, 26.4 
µL, 190.6 µmol, 3 eq) was added and the reaction mixture was stirred under argon at rt 
overnight. TFA (5 mL) and 4 drops of water were added and stirring was continued for 4 h. The 
mixture was concentrated under reduced pressure and MeOH (20 mL) was added twice, each 
time followed by evaporation. The residue (colorless oil) was taken up in a mixture of 
acetonitrile and 0.1 % aq. TFA (1/1, 4 mL), filtered (0.2 µm) and injected into the preparative 
HPLC system (4 injections). Acetonitrile was removed under reduced pressure prior to 
lyophilization. White fluffy solid (47.8 mg, 36.4 µmol, 57 %); mp 148-151 °C; 1H-NMR (600 MHz, 
DMSO-d6, COSY, HSQC):  (ppm) 1.3 (bs, 4H, CH2-CH2-CH2-CH2-CH2-CH2), 1.44 (m, 4H, CH2-
CH2-CH2-CH2-CH2-CH2), 1.56 (m, 6H, CH-CH2-CH2), 1.68 (m, 2H, CH-CH2-CH2), 2.41 (t, 4H, 3J 
= 7.22 Hz, CH2-CO), 3.22 (m, 4H, CH2-CH2-CH2-NH), 4.12 (dd, 2H, 2J = 14.78 Hz, 3J = 5.68 Hz, 
CH2-ArOH), 4.17 (dd, 2H, 2J = 14.79 Hz, 3J = 5.83 Hz, CH2-ArOH), 4.33 (m, 2H, CH), 5.12 (s, 
2H, CH-(Ph)2), 6.67 (d, 4H, 3J = 8.43 Hz, AA’BB’), 7.0 (d, 4H, 3J = 8.41 Hz, AA’BB’), 7.22 (m, 
4H, Ph), 7.28 (m, 16H, Ph), 8.35 (t, 2H, 3J = 5.76 Hz, CO-NH-CH2), 8.47 (d, 2H, 3J = 8.06 Hz, 
CO-NH-CH), 8.57 (bd, 4H, NH2), 9.22 (s, 2H, NH), 9.31 (s, 2H, NH), 11.83 (s, 2H, ArOH); RP-
HPLC (210 nm, system 3): 100 % (tR = 15.3 min, k = 5.6); HRMS: (ES): m/z calcd. for 
[C62H73N10O8 + H]+ 1085.5613, found: 1085.5604; C62H72N10O8 × C4H2F6O4 (1313.3) 
 
Glutaric acid monobenzylester (3.9). Glutaric anhydride (10 g, 87.6 mmol, 1 eq) was treated 
with benzyl alcohole (11.4 g, 105 mmol, 1.2 eq) at 60 °C overnight. Column chromatography 
afforded the product as a white solid (15 g, 67.6 mmol, 77 %). 1H-NMR (300 MHz, CDCl3):  
(ppm) 1.78 (m, 2H, CH2-CH2-CH2), 2.41 (m, 4H, CH2-CH2-CH2), 5.12 (s, 2H, CH2-Ph), 7.32-7.37 
(m, 5H, Ph); C12H14O4 (222.2) 
 
General procedure for the synthesis of mono-Cbz-protected alkanedioic acids 3.10 - 3.12 
 
The pertinent alkanedioic acid (1 eq) and acetic anhydride (4 eq) were heated under reflux in 
xylene (40 mL for 0.5 mmol of dioic acid) for 2 h. All volatiles were removed under reduced 
pressure and the pale yellow solid was treated with benzyl alcohole (1.2 eq) at 60 °C overnight. 
Column chromatography afforded the product as a white solid. 
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Hexanedioic monobenzylester (3.10). 62 % (10 g); 1H-NMR (300 MHz, CDCl3):  (ppm) 1.69 
(m, 4H, CH2-CH2-CH2-CH2), 2.39 (m, 4H, CH2-CH2-CH2-CH2), 5.12 (s, 2H, CH2-Ph), 7.33-7.38 
(m, 5H, Ph); MS (EI): m/z 236 (M·+); C13H16O4 (236.3) 
 
Heptanedioic acid monobenzylester (3.11). 51 % (4 g); 1H-NMR (300 MHz, CDCl3):  (ppm) 
1.37 (m, 2H, CH2-CH2-CH2-CH2-CH2), 1.65 (m, 4H, CH2-CH2-CH2-CH2-CH2), 2.35 (m, 4H, CH2-
CH2-CH2-CH2-CH2), 5.12 (s, 2H, CH2-Ph), 7.33-7.38 (m, 5H, Ph); MS (EI): m/z 250 (M·+)·; 
C14H18O4 (250.3) 
 
Octanedioic acid monobenzylester (3.12). 30 % (2.7 g); 1H-NMR (300 MHz, CDCl3):  (ppm) 
1.34 (m, 4H, CH2-CH2-CH2-CH2-CH2-CH2), 1.64 (m, 4H, CH2-CH2-CH2-CH2-CH2-CH2), 2.34 (m, 
4H, CH2-CH2-CH2-CH2-CH2-CH2), 5.11 (s, 2H, CH2-Ph), 7.31-7.37 (m, 5H, Ph); MS (ES, 
CH2Cl2/MeOH + 10 mM NH4OAc): m/z 265 [M + H]+; C15H20O4 (264.3) 
 
General procedure for the synthesis of carboxylic acids 3.13 - 3.16 
 
The benzyl ester 3.9-3.12 (1 eq) was dissolved in CH2Cl2. DMF (1 drop) and oxalyl chloride (1.3 
eq) were added, the mixture was refluxed for 2 h and the volatiles were removed under reduced 
pressure. The residue was taken up in CH2Cl2 and 3.6 as well as NEt3 (3 eq) were added. The 
mixture was allowed to stand at rt overnight. The intermediate was purified by column 
chromatography (CH2Cl2/EtOAc) prior to hydrogenation at rt and atmospheric pressure in MeOH 
using hydrogen and a 10 % Pd/C catalyst. 
 
(R)- and (S)-N-(4-tert-Butoxybenzyl)-N-(4-tert-butoxycarbonyl)-N-(4-carboxybutanoyl)-
N-(2,2-diphenylacetyl)argininamide ((R)-3.13, (S)-3.13). 60-65 % (≈ 200 mg); 1H-NMR (300 
MHz, CDCl3):  (ppm) 1.31 (s, 9H, t-Bu), 1.4-1.95 (bm, 15H, t-Bu, CH-CH2-CH2, CH2-CH2-CH2-
COOH), 2.15-2.45 (m, 4H, CH2-CO), 2.4 (m, 2H, CH2-CO), 3.24 (m, 2H, CH2-CH2-CH2-NH), 
4.29 (m, 2H, CH2-ArOH), 4.52 (m, 1H, CH), 4.98 (s, 1H, CH-(Ph)2), 6.9 (d, 2H, 3J = 8.48 Hz, 
AA’BB’), 7.05 (d, 2H, 3J = 8.48 Hz, AA’BB’), 7.16-7.32 (m, 10H, Ph); MS (ES, CH2Cl2/MeOH + 
10 mM NH4OAc): m/z 744 [M + H]+; C41H53N5O8 (743.9)  
 
(R)- and (S)-N-(4-tert-Butoxybenzyl)-N-(4-tert-butoxycarbonyl)-N-(5-carboxyheptanoyl)-
N-(2,2-diphenylacetyl)argininamide ((R)-3.14, (S)-3.14). 55-60 % (≈ 120 mg); 1H-NMR (300 
MHz, MeOH-d4):  (ppm) 1.33 (s, 9H, t-Bu), 1.4-1.75 (bm, 16H, t-Bu, CH-CH2-CH2, CH2-CH2-
CH2-CH2), 1.82 (m, 1H, CH-CH2-CH2), 2.2 (m, 2H, CH2-CO), 2.4 (m, 2H, CH2-CO), 3.3 (m, 2H, 
CH2-CH2-CH2-NH), 4.32 (m, 2H, CH2-ArOH), 4.42 (m, 1H, CH), 5.05 (s, 1H, CH-(Ph)2), 6.9 (d, 
2H, 3J = 8.12 Hz, AA’BB’), 7.12 (d, 2H, 3J = 8.12 Hz, AA’BB’), 7.2-7.35 (m, 10H, Ph); MS (ES, 
CH2Cl2/MeOH + 10 mM NH4OAc): m/z 758 [M + H]+; C42H55N5O8 (757.9)  
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(R)- and (S)-N-(4-tert-Butoxybenzyl)-N-(4-tert-butoxycarbonyl)-N-(6-carboxyhexanoyl)-
N-(2,2-diphenylacetyl)argininamide ((R)-3.15, (S)-3.15). 55-60 % (≈ 120 mg); 1H-NMR (300 
MHz, CDCl3):  (ppm) 1.2-1.7 (m, 27H, 2 × t-Bu, CH-CH2-CH2, CH2-CH2-CH2-CH2-CH2), 1.77 
(m, 1H, CH-CH2-CH2), 2.1-2.4 (m, 4H, CH2-CO), 3.24 (m, 2H, CH2-CH2-CH2-NH), 4.24 (m, 2H, 
CH2-ArOH), 4.6 (m, 1H, CH), 4.97 (s, 1H, CH-(Ph)2), 6.86 (d, 2H, 3J = 8.39 Hz, AA’BB’), 7.03 
(d, 2H, 3J = 8.28 Hz, AA’BB’), 7.1-7.3 (m, 10H, Ph); MS (ES, CH2Cl2/MeOH + 10 mM NH4OAc): 
m/z 772 [M + H]+; C43H57N5O8 (771.9) 
 
(R)- and (S)-N-(4-tert-Butoxybenzyl)-N-(4-tert-butoxycarbonyl)-N-(7-carboxyheptanoyl)-
N-(2,2-diphenylacetyl)argininamide ((R)-3.16, (S)-3.16). 55-65 % (≈ 150 mg); 1H-NMR (300 
MHz, CDCl3):  (ppm) 1.24-1.43 (m, 22H, 2 × t-Bu, CH2-CH2-CH2-CH2-CH2-CH2), 1.52-1.73 (m, 
7H, CH-CH2-CH2, CH2-CH2-CH2-CH2-CH2-CH2), 1.8 (m, 1H, CH-CH2-CH2), 2.24-2.35 (m, 4H, 
CH2-CO), 3.25 (m, 2H, CH2-CH2-CH2-NH), 4.3 (m, 2H, CH2-ArOH), 4.6 (m, 1H, CH), 4.98 (s, 
1H, CH-(Ph)2), 6.89 (d, 2H, 3J = 8.45 Hz, AA’BB’), 7.08 (d, 2H, 3J = 8.47 Hz, AA’BB’), 7.18-7.33 
(m, 10H, Ph); MS (ES, CH2Cl2/MeOH + 10 mM NH4OAc): m/z 786 [M + H]+; C44H59N5O8 (786.0)  
 
N-Cbz-3,6-dioxaoctane-1,8-diamine (3.17). 3,6-dioxa-octane-1,8-diamine (3 g, 20.2 mmol, 1 
eq) and Na2CO3 (10.7 g, 101 mmol, 5 eq) were dissolved in water (450 mL) and acetonitrile 
(150 mL). A solution of benzyl chloroformate (3.45 g, 20.2 mmol, 1 eq) in acetonitrile (150 mL) 
was added dropwise over a period of 3 h. Acetonitrile was removed under reduced pressure, 
the product was extracted with CH2Cl2 and purified by column chromatography 
(CH2Cl2/MeOH/NH4OH). 47 % (2.7 g, 9.6 mmol); 1H-NMR (300 MHz, CDCl3):  (ppm) 2.03 (s, 
2H, NH2), 2.83 (s, 2H, O-CH2-CH2-NH2), 3.36 (m, 2H, CH2), 3.47 (t, 2H, 3J = 5.16 Hz, CH2), 3.5-
3.63 (m, 6H, 6 × CH2), 5.07 (s, 2H, CH2-Ph), 7.27-7.35 (m, 5H, Ph); MS (CI, NH3): m/z 283 [M + 
H]+; C14H22N2O4 (282.3) 
 
General procedure for the synthesis of amines 3.18 - 3.21 
 
The carboxylic acids (R)-3.13 - (R)-3.16 (1 eq) and 3.17 were dissolved in CH2Cl2, EDAC (1.3 
eq) was added and the mixture was kept under stirring at rt for 20 h. The intermediate was 
purified by column chromatography (EtOAc/MeOH) prior to hydrogenation at rt and atmospheric 
pressure in MeOH using hydrogen and a 10 % Pd/C catalyst. 
 
(R)-N-[5-(8-Amino-3,6-dioxaoctyl)amino-5-oxo-pentanoyl]-N-(4-tert-Butoxybenzyl)-N-(4-
tert-butoxycarbonyl)-N-(2,2-diphenylacetyl)argininamide (3.18). Light brown resin; 50 % 
(130 mg); 1H-NMR (300 MHz, MeOH-d4):  (ppm) 1.31 (s, 9H, t-Bu), 1.44 (s, 9H, t-Bu), 1.52 (m, 
3H, CH-CH2-CH2), 1.6-1.95 (bm, 3H, CH-CH2-CH2, CO-CH2-CH2-CH2-CO), 2.23 (m, 4H, CH2-
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CO), 3.13 (t, 2H, 3J = 6.89 Hz, CH2-NH2), 3.36 (m, 4H, CH2-CH2-CH2-NH, NH-CH2-CH2-O), 3.5-
3.67 (m, 8H, CH2-O-CH2-CH2-O-CH2-), 4.32 (s, 2H, CH2-ArOH), 4.41 (m, 1H, CH), 5.08 (s, 1H, 
CH-(Ph)2), 6.9 (d, 2H, 3J = 8.54 Hz, AA’BB’), 7.15 (d, 2H, 3J = 8.59 Hz, AA’BB’), 7.2-7.33 (m, 
10H, Ph); C47H67N7O9 (874.1) 
 
(R)-N-[6-(8-Amino-3,6-dioxaoctyl)amino-6-oxo-hexanoyl]-N-(4-tert-Butoxybenzyl)-N-(4-
tert-butoxycarbonyl)-N-(2,2-diphenylacetyl)argininamide (3.19). Light brown resin; 55 % 
(64 mg); 1H-NMR (300 MHz, CDCl3):  (ppm) 1.3 (s, 9H, t-Bu), 1.42 (s, 9H, t-Bu), 1.51 (m, 3H, 
CH-CH2-CH2), 1.65 (m, 4H, CH2-CH2-CH2-CH2), 1.83 (m, 1H, CH-CH2-CH2), 2.26 (m, 2H, CH2-
CO), 2.37 (m, 2H, CH2-CO), 2.98 (t, 2H, CH2-NH2), 3.2-3.44 (m, 4H, CH2-CH2-CH2-NH, NH-
CH2-CH2-O), 3.47-3.65 (m, 8H, CH2-O-CH2-CH2-O-CH2), 4.3 (m, 2H, CH2-ArOH), 4.58 (m, 1H, 
CH), 5.07 (s, 1H, CH-(Ph)2), 6.87 (d, 2H, 3J = 8.52 Hz, AA’BB’), 7.08 (d, 2H, 3J = 8.51 Hz, 
AA’BB’), 7.18-7.31 (m, 10H, Ph); C48H69N7O9 (888.1)  
 
(R)-N-[7-(8-Amino-3,6-dioxaoctyl)amino-7-oxo-heptanoyl]-N-(4-tert-Butoxybenzyl)-N-(4-
tert-butoxycarbonyl)-N-(2,2-diphenylacetyl)argininamide (3.20). Light brown resin; 45 % 
(83 mg); 1H-NMR (300 MHz, CDCl3):  (ppm) 1.23-1.55 (m, 23H, 2 × t-Bu, CH-CH2-CH2, CH2-
CH2-CH2-CH2-CH2), 1.56-1.73 (m, 4H, CH2-CH2-CH2-CH2-CH2), 1.81 (m, 1H, CH-CH2-CH2), 2.1 
(t, 2H, CH2-CO), 2.37 (t, 2H, CH2-CO), 2.97 (t, 2H, CH2-NH2), 3.2-3.43 (m, 4H, CH2-CH2-CH2-
NH, NH-CH2-CH2-O), 3.46-6.0 (m, 8H, CH2-O-CH2-CH2-O-CH2), 4.29 (m, 2H, CH2-ArOH), 4.57 
(m, 1H, CH), 5.06 (s, 1H, CH-(Ph)2), 6.85 (d, 2H, 3J = 8.54 Hz, AA’BB’), 7.07 (d, 2H, 3J = 8.53 
Hz, AA’BB’), 7.16-7.32 (m, 10H, Ph); C49H71N7O9 (902.1) 
 
(R)-N-[8-(8-Amino-3,6-dioxaoctyl)amino-8-oxo-octanoyl]-N-(4-tert-Butoxybenzyl)-N-(4-
tert-butoxycarbonyl)-N-(2,2-diphenylacetyl)argininamide (3.21). Light brown resin; 45 % 
(60 mg); 1H-NMR (300 MHz, CDCl3):  (ppm) 1.24-1.42 (m, 22H, 2 × t-Bu, CH2-CH2-CH2-CH2-
CH2-CH2), 1.48-1.73 (m, 7H, CH-CH2-CH2, CH2-CH2-CH2-CH2-CH2-CH2), 1.83 (m, 1H, CH-CH2-
CH2), 2.2 (t, 2H, CH2-CO), 2.37 (t, 2H, CH2-CO), 2.72 (t, 2H, CH2-NH2), 3.23 (m, 2H, CH2-CH2-
CH2-NH), 3.41 (m, 2H, CH2), 3.53 (m, 2H, CH2), 3.58 (s, 4H, O-CH2-CH2-O), 3.57 (t, 2H, CH2), 
4.32 (m, 2H, CH2-ArOH), 4.57 (m, 1H, CH), 4.99 (s, 1H, CH-(Ph)2), 6.8 (d, 2H, 3J = 8.5 Hz, 
AA’BB’), 7.07 (d, 2H, 3J = 8.5 Hz, AA’BB’), 7.17-7.32 (m, 10H, Ph); MS (ES, CH2Cl2/MeOH + 10 
mM NH4OAc): m/z 458.5 [M + 2H]2+, 917 [M + H]+; C50H73N7O9 (916.2) 
 
General procedure for the synthesis of bivalent ligands 3.22 - 3.25 (meso forms) 
 
The carboxylic acids (S)-3.13 - (S)-3.16 (1 eq) and amine 3.18 - 3.21 (1.1 eq) were dissolved in 
CH2Cl2. EDAC (1.5 eq) was added and the mixture was kept under stirring at rt for 20 h. TFA (1 
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volume equivalent) and water (3 drops) were added, the mixture was allowed to stand for 2.5 h 
and then it was concentrated under reduced pressure. CH2Cl2 was added three times, each 
time followed by evaporation under reduced pressure. The product was purified using 
preparative HPLC. 
 
(R,S)-5,5'-Bis({[4-diphenylacetamido-4-(4-hydroxybenzylaminocarbonyl)butyl]amino-
(amino)methylene}amino)-5,5'-dioxo-N,N'-(ethylenedioxydiethylenediyl)dipentanamide 
((R,S)-3.22). White solid; 23 % (8 mg); mp > 94 °C (decomp.); 1H-NMR (300 MHz, MeOH-d4):  
(ppm) 1.48-2.0 (bm, 12H, CH-CH2-CH2, CO-CH2-CH2-CH2-CO), 2.27 (t, 4H, 3J = 7.24 Hz, CH2-
CO), 2.49 (t, 4H, 3J = 7.34 Hz, CH2-CO), 3.25 (m, 4H, CH2-CH2-CH2-NH), 3.35 (t, 4H, 3J = 5.32 
Hz, CH2 from O-CH2-CH2-NH), 3.53 (t, 4H, 3J = 5.46 Hz, CH2 from O-CH2-CH2-NH), 3.60 (s, 4H, 
O-CH2-CH2-O), 4.21 (d, 2H, 2J = 14.72 Hz, CH2-ArOH), 4.27 (d, 2H, 2J = 14.78 Hz, CH2-ArOH), 
4.42 (m, 2H, CH), 5.07 (s, 2H, CH-(Ph)2), 6.7 (d, 4H, 3J = 8.54 Hz, AA’BB’), 7.05 (d, 4H, 3J = 
8.45 Hz, AA’BB’), 7.20-7.33 (m, 20H, Ph); RP-HPLC (220 nm, system 1): 97 % (tR = 20.1 min, k 
= 6.1); HRMS: (MALDI): m/z calcd. for [C70H87N12O12 + H]+ 1287.6566, found: 1287.6585; 
C70H86N12O12 × C4H2F6O4 (1515.6) 
 
(R,S)-6,6'-Bis({[4-diphenylacetamido-4-(4-hydroxybenzylaminocarbonyl)butyl]amino-
(amino)methylene}amino)-6,6'-dioxo-N,N'-(ethylenedioxydiethylenediyl)dihexanamide 
((R,S)-3.23). White solid; 26 % (13.5 mg); mp 77-79 °C; 1H-NMR (300 MHz, MeOH-d4):  (ppm) 
1.48-1.91 (bm, 16H, CH-CH2-CH2, CO-CH2-CH2-CH2-CH2-CO), 2.23 (t, 4H, 3J = 6.74 Hz, CH2-
CO), 2.47 (t, 4H, 3J = 6.61 Hz, CH2-CO), 3.25 (m, 4H, CH2-CH2-CH2-NH), 3.35 (t, 4H, 3J = 5.56 
Hz, CH2 from O-CH2-CH2-NH), 3.53 (t, 4H, 3J = 5.42 Hz, CH2 from O-CH2-CH2-NH), 3.59 (s, 4H, 
O-CH2-CH2-O), 4.20 (d, 2H, 2J = 14.64 Hz, CH2-ArOH), 4.27 (d, 2H, 2J = 14.76 Hz, CH2-ArOH), 
4.42 (m, 2H, CH), 5.07 (s, 2H, CH-(Ph)2), 6.7 (d, 4H, 3J = 8.56 Hz, AA’BB’), 7.05 (d, 4H, 3J = 
8.57 Hz, AA’BB’), 7.21-7.33 (m, 20H, Ph); RP-HPLC (220 nm, system 2): 99 % (tR = 17.1 min, k 
= 4.9); HRMS: (MALDI): m/z calcd. for [C72H91N12O12 + H]+ 1315.6879, found: 1315.6879; 
C72H90N12O12 × C4H2F6O4 (1543.6)          
 
(R,S)-7,7'-Bis({[4-diphenylacetamido-4-(4-hydroxybenzylaminocarbonyl)butyl]amino-
(amino)methylene}amino)-7,7'-dioxo-N,N'-(ethylenedioxydiethylenediyl)diheptanamide 
((R,S)-3.24). White solid; 24 % (14 mg); mp > 77 °C (decomp.); 1H-NMR (300 MHz, MeOH-d4): 
 (ppm) 1.28-1.44 (m, 4H, CO-CH2-CH2-CH2-CH2-CH2-CO), 1.47-1.9 (bm, 16H, CH-CH2-CH2, 
CO-CH2-CH2-CH2-CH2-CH2-CO), 2.20 (t, 4H, 3J = 7.31 Hz, CH2-CO), 2.45 (t, 4H, 3J = 7.22 Hz, 
CH2-CO), 3.25 (m, 4H, CH2-CH2-CH2-NH), 3.34 (t, 4H, 3J = 5.35 Hz, CH2 from O-CH2-CH2-NH), 
3.52 (t, 4H, 3J = 5.36 Hz, CH2 from O-CH2-CH2-NH), 3.59 (s, 4H, O-CH2-CH2-O), 4.21 (d, 2H, 2J 
= 14.92 Hz, CH2-ArOH), 4.27 (d, 2H, 2J = 14.87 Hz, CH2-ArOH), 4.42 (m, 2H, CH), 5.07 (s, 2H, 
CH-(Ph)2), 6.7 (d, 4H, 3J = 8.53 Hz, AA’BB’), 7.05 (d, 4H, 3J = 8.46 Hz, AA’BB’), 7.19-7.34 (m, 
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20H, Ph); RP-HPLC (220 nm, system 1): 95 % (tR = 20.8 min, k = 6.4); HRMS: (MALDI): m/z 
calcd. for [C74H95N12O12 + H]+ 1343.7192, found: 1343.7204; C74H94N12O12 × C4H2F6O4 (1571.7) 
        
(R,S)-8,8'-Bis({[4-diphenylacetamido-4-(4-hydroxybenzylaminocarbonyl)butyl]amino-
(amino)methylene}amino)-8,8'-dioxo-N,N'-(ethylenedioxydiethylenediyl)dioctanamide 
((R,S)-3.25). White solid; 19 % (12 mg); mp 78-80 °C; 1H-NMR (300 MHz, MeOH-d4):  (ppm) 
1.27-1.44 (m, 8H, CO-CH2-CH2-CH2-CH2-CH2-CH2-CO), 1.49-1.9 (bm, 16H, CH-CH2-CH2, CO-
CH2-CH2-CH2-CH2-CH2-CH2-CO), 2.19 (t, 4H, 3J = 7.48 Hz, CH2-CO), 2.44 (t, 4H, 3J = 7.25 Hz, 
CH2-CO), 3.26 (m, 4H, CH2-CH2-CH2-NH), 3.34 (t, 4H, 3J = 5.79 Hz, CH2 from O-CH2-CH2-NH), 
3.53 (t, 4H, 3J = 5.65 Hz, CH2 from O-CH2-CH2-NH), 3.6 (s, 4H, O-CH2-CH2-O), 4.21 (d, 2H, 2J = 
14.87 Hz, CH2-ArOH), 4.27 (d, 2H, 2J = 14.77 Hz, CH2-ArOH), 4.42 (m, 2H, CH), 5.07 (s, 2H, 
CH-(Ph)2), 6.7 (d, 4H, 3J = 8.57 Hz, AA’BB’), 7.05 (d, 4H, 3J = 8.56 Hz, AA’BB’), 7.21-7.32 (m, 
20H, Ph); RP-HPLC (220 nm, system 1): 98 % (tR = 21.6 min, k = 6.7); HRMS: (MALDI): m/z 
calcd. for [C76H99N12O12 + H]+ 1371.7505, found: 1371.7490; C76H98N12O12 × C4H2F6O4 (1599.7) 
 
General procedure for the synthesis of bivalent ligands 3.22 - 3.25 (R,R- and S,S-
configuration) 
 
The carboxylic acid (S)-3.13 - (S)-3.16 or (R)-3.13 - (R)-3.16 (2 eq) and 3,6-dioxa-octane-1,8-
diamine (1 eq) were dissolved in CH2Cl2. EDAC (2.5 eq) was added and the mixture was kept 
under stirring at rt for 20 h. TFA (1 volume equivalent) and water (3 drops) were added, the 
mixture was allowed to stand for 2.5 h and then it was concentrated under reduced pressure. 
CH2Cl2 was added three times, each time followed by evaporation under reduced pressure. The 
product was purified using preparative HPLC. 
 
(R,R)-5,5'-Bis({[4-diphenylacetamido-4-(4-hydroxybenzylaminocarbonyl)butyl]amino-
(amino)methylene}amino)-5,5'-dioxo-N,N'-(ethylenedioxydiethylenediyl)dipentanamide 
((R,R)-3.22). White solid; 26 % (19.9 mg); mp > 94 °C (decomp.); 1H-NMR (300 MHz, 
MeOH-d4):  (ppm) 1.48-1.98 (bm, 12H, CH-CH2-CH2, CO-CH2-CH2-CH2-CO), 2.26 (t, 4H, 3J = 
7.36 Hz, CH2-CO), 2.49 (t, 4H, 3J = 7.31 Hz, CH2-CO), 3.24 (m, 4H, CH2-CH2-CH2-NH), 3.34 (t, 
4H, 3J = 5.41 Hz, CH2 from O-CH2-CH2-NH), 3.52 (t, 4H, 3J = 5.51 Hz, CH2 from O-CH2-CH2-
NH), 3.59 (s, 4H, O-CH2-CH2-O), 4.19 (d, 2H, 2J = 14.62 Hz, CH2-ArOH), 4.26 (d, 2H, 2J = 14.64 
Hz, CH2-ArOH), 4.42 (m, 2H, CH), 5.07 (s, 2H, CH-(Ph)2), 6.7 (d, 4H, 3J = 8.54 Hz, AA’BB’), 
7.04 (d, 4H, 3J = 8.53 Hz, AA’BB’), 7.21-7.30 (m, 20H, Ph); RP-HPLC (220 nm, system 2): 99 % 
(tR = 17.4 min, k = 5.0); HRMS: (MALDI): m/z calcd. for [C70H87N12O12 + H]+ 1287.6566, found: 
1287.6561; C70H86N12O12 × C4H2F6O4 (1515.6) 
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(S,S)-5,5'-Bis({[4-diphenylacetamido-4-(4-hydroxybenzylaminocarbonyl)butyl]amino-
(amino)methylene}amino)-5,5'-dioxo-N,N'-(ethylenedioxydiethylenediyl)dipentanamide 
((S,S)-3.22). White solid; 22 % (16 mg); mp > 94 °C (decomp.); 1H-NMR (300 MHz, MeOH-d4): 
 (ppm) 1.48-1.98 (bm, 12H, CH-CH2-CH2, CO-CH2-CH2-CH2-CO), 2.27 (t, 4H, 3J = 7.31 Hz, 
CH2-CO), 2.49 (t, 4H, 3J = 7.26 Hz, CH2-CO), 3.24 (m, 4H, CH2-CH2-CH2-NH), 3.34 (t, 4H, 3J = 
5.58 Hz, CH2 from O-CH2-CH2-NH), 3.52 (t, 4H, 3J = 5.52 Hz, CH2 from O-CH2-CH2-NH), 3.59 
(s, 4H, O-CH2-CH2-O), 4.19 (d, 2H, 2J = 14.58 Hz, CH2-ArOH), 4.26 (d, 2H, 2J = 14.60 Hz, CH2-
ArOH), 4.42 (m, 2H, CH), 5.07 (s, 2H, CH-(Ph)2), 6.7 (d, 4H, 3J = 8.55 Hz, AA’BB’), 7.05 (d, 4H, 
3J = 8.53 Hz, AA’BB’), 7.20-7.31 (m, 20H, Ph); RP-HPLC (220 nm, system 2): 96 % (tR = 17.2 
min, k = 4.9); HRMS: (MALDI): m/z calcd. for [C70H87N12O12 + H]+ 1287.6566, found: 1287.6552; 
C70H86N12O12 × C4H2F6O4 (1515.6) 
 
(R,R)-6,6'-Bis({[4-diphenylacetamido-4-(4-hydroxybenzylaminocarbonyl)butyl]amino-
(amino)methylene}amino)-6,6'-dioxo-N,N'-(ethylenedioxydiethylenediyl)dihexanamide 
((R,R)-3.23). White solid; 25 % (20 mg); mp 77-79 °C; 1H-NMR (300 MHz, MeOH-d4):  (ppm) 
1.46-1.91 (bm, 16H, CH-CH2-CH2, CO-CH2-CH2-CH2-CH2-CO), 2.23 (t, 4H, 3J = 6.63 Hz, CH2-
CO), 2.47 (t, 4H, 3J = 6.42 Hz, CH2-CO), 3.25 (m, 4H, CH2-CH2-CH2-NH), 3.35 (t, 4H, 3J = 5.54 
Hz, CH2 from O-CH2-CH2-NH), 3.52 (t, 4H, 3J = 5.52 Hz, CH2 from O-CH2-CH2-NH), 3.59 (s, 4H, 
O-CH2-CH2-O), 4.21 (d, 2H, 2J = 14.58 Hz, CH2-ArOH), 4.27 (d, 2H, 2J = 14.52 Hz, CH2-ArOH), 
4.42 (m, 2H, CH), 5.07 (s, 2H, CH-(Ph)2), 6.69 (d, 4H, 3J = 8.56 Hz, AA’BB’), 7.05 (d, 4H, 3J = 
8.55 Hz, AA’BB’), 7.21-7.32 (m, 20H, Ph); RP-HPLC (220 nm, system 1): 97 % (tR = 20.3 min, k 
= 6.2); HRMS: (MALDI): m/z calcd. for [C72H91N12O12 + H]+ 1315.6879, found: 1315.6867; 
C72H90N12O12 × C4H2F6O4 (1543.6) 
 
(S,S)-6,6'-Bis({[4-diphenylacetamido-4-(4-hydroxybenzylaminocarbonyl)butyl]amino-
(amino)methylene}amino)-6,6'-dioxo-N,N'-(ethylenedioxydiethylenediyl)dihexanamide 
((S,S)-3.23). White solid; 27 % (23.7 mg); mp 77-79 °C; 1H-NMR (300 MHz, MeOH-d4):  (ppm) 
1.47-1.9 (bm, 16H, CH-CH2-CH2, CO-CH2-CH2-CH2-CH2-CO), 2.23 (t, 4H, 3J = 6.41 Hz, CH2-
CO), 2.47 (t, 4H, 3J = 6.52 Hz, CH2-CO), 3.25 (m, 4H, CH2-CH2-CH2-NH), 3.35 (t, 4H, 3J = 5.48 
Hz, CH2 from O-CH2-CH2-NH), 3.52 (t, 4H, 3J = 5.49 Hz, CH2 from O-CH2-CH2-NH), 3.59 (s, 4H, 
O-CH2-CH2-O), 4.20 (d, 2H, 2J = 14.61 Hz, CH2-ArOH), 4.27 (d, 2H, 2J = 14.59 Hz, CH2-ArOH), 
4.42 (m, 2H, CH), 5.07 (s, 2H, CH-(Ph)2), 6.7 (d, 4H, 3J = 8.55 Hz, AA’BB’), 7.05 (d, 4H, 3J = 
8.53 Hz, AA’BB’), 7.18-7.32 (m, 20H, Ph); RP-HPLC (220 nm, system 1): 94 % (tR = 20.4 min, k 
= 6.2); HRMS: (MALDI): m/z calcd. for [C72H91N12O12 + H]+ 1315.6879, found: 1315.6878; 
C72H90N12O12 × C4H2F6O4 (1543.6) 
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(R,R)-7,7'-Bis({[4-diphenylacetamido-4-(4-hydroxybenzylaminocarbonyl)butyl]amino-
(amino)methylene}amino)-7,7'-dioxo-N,N'-(ethylenedioxydiethylenediyl)diheptanamide 
((R,R)-3.24). White solid; 32 % (34.6 mg); mp > 77 °C (decomp.); 1H-NMR (300 MHz, 
MeOH-d4):  (ppm) 1.31-1.42 (m, 4H, CO-CH2-CH2-CH2-CH2-CH2-CO), 1.47-1.9 (bm, 16H, CH-
CH2-CH2, CO-CH2-CH2-CH2-CH2-CH2-CO), 2.20 (t, 4H, 3J = 7.39 Hz, CH2-CO), 2.45 (t, 4H, 3J = 
7.35 Hz, CH2-CO), 3.25 (m, 4H, CH2-CH2-CH2-NH), 3.34 (t, 4H, 3J = 5.72 Hz, CH2 from O-CH2-
CH2-NH), 3.52 (t, 4H, 3J = 5.55 Hz, CH2 from O-CH2-CH2-NH), 3.59 (s, 4H, O-CH2-CH2-O), 4.20 
(d, 2H, 2J = 14.61 Hz, CH2-ArOH), 4.27 (d, 2H, 2J = 14.56 Hz, CH2-ArOH), 4.42 (m, 2H, CH), 
5.07 (s, 2H, CH-(Ph)2), 6.7 (d, 4H, 3J = 8.55 Hz, AA’BB’), 7.05 (d, 4H, 3J = 8.55 Hz, AA’BB’), 
7.19-7.32 (m, 20H, Ph); RP-HPLC (220 nm, system 2): 99 % (tR = 18.1 min, k = 5.2); HRMS: 
(MALDI): m/z calcd. for [C74H95N12O12 + H]+ 1343.7192, found: 1343.7176; C74H94N12O12 × 
C4H2F6O4 (1571.7) 
 
(S,S)-7,7'-Bis({[4-diphenylacetamido-4-(4-hydroxybenzylaminocarbonyl)butyl]amino-
(amino)methylene}amino)-7,7'-dioxo-N,N'-(ethylenedioxydiethylenediyl)diheptanamide 
((S,S)-3.24). White solid; 24 % (22 mg); mp > 77 °C (decomp.); 1H-NMR (300 MHz, MeOH-d4): 
 (ppm) 1.28-1.43 (m, 4H, CO-CH2-CH2-CH2-CH2-CH2-CO), 1.46-1.9 (bm, 16H, CH-CH2-CH2, 
CO-CH2-CH2-CH2-CH2-CH2-CO), 2.20 (t, 4H, 3J = 7.38 Hz, CH2-CO), 2.45 (t, 4H, 3J = 7.32 Hz, 
CH2-CO), 3.24 (m, 4H, CH2-CH2-CH2-NH), 3.34 (t, 4H, 3J = 5.66 Hz, CH2 from O-CH2-CH2-NH), 
3.52 (t, 4H, 3J = 5.55 Hz, CH2 from O-CH2-CH2-NH), 3.59 (s, 4H, O-CH2-CH2-O), 4.20 (d, 2H, 2J 
= 14.60 Hz, CH2-ArOH), 4.27 (d, 2H, 2J = 14.65 Hz, CH2-ArOH), 4.42 (m, 2H, CH), 5.08 (s, 2H, 
CH-(Ph)2), 6.7 (d, 4H, 3J = 8.56 Hz, AA’BB’), 7.05 (d, 4H, 3J = 8.56 Hz, AA’BB’), 7.19-7.33 (m, 
20H, Ph); RP-HPLC (220 nm, system 1): 91 % (tR = 20.8 min, k = 6.4); HRMS: (MALDI): m/z 
calcd. for [C74H95N12O12 + H]+ 1343.7192, found: 1343.7211; C74H94N12O12 × C4H2F6O4 (1571.7) 
 
(R,R)-8,8'-Bis({[4-diphenylacetamido-4-(4-hydroxybenzylaminocarbonyl)butyl]amino-
(amino)methylene}amino)-8,8'-dioxo-N,N'-(ethylenedioxydiethylenediyl)dioctanamide 
((R,R)-3.25). White solid; 14 % (8 mg); mp 78-80 °C; 1H-NMR (300 MHz, MeOH-d4):  (ppm) 
1.28-1.44 (m, 8H, CO-CH2-CH2-CH2-CH2-CH2-CH2-CO), 1.49-1.9 (bm, 16H, CH-CH2-CH2, CO-
CH2-CH2-CH2-CH2-CH2-CH2-CO), 2.19 (t, 4H, 3J = 7.12 Hz, CH2-CO), 2.44 (t, 4H, 3J = 7.23 Hz, 
CH2-CO), 3.26 (m, 4H, CH2-CH2-CH2-NH), 3.34 (t, 4H, 3J = 5.72 Hz, CH2 from O-CH2-CH2-NH), 
3.53 (t, 4H, 3J = 5.49 Hz, CH2 from O-CH2-CH2-NH), 3.6 (s, 4H, O-CH2-CH2-O), 4.21 (d, 2H, 2J = 
14.34 Hz, CH2-ArOH), 4.27 (d, 2H, 2J = 14.38 Hz, CH2-ArOH), 4.42 (m, 2H, CH), 5.07 (s, 2H, 
CH-(Ph)2), 6.7 (d, 4H, 3J = 8.57 Hz, AA’BB’), 7.05 (d, 4H, 3J = 8.56 Hz, AA’BB’), 7.2-7.35 (m, 
20H, Ph); RP-HPLC (220 nm, system 1): 93 % (tR = 23.2 min, k = 7.2); HRMS: (MALDI): m/z 
calcd. for [C76H99N12O12 + H]+ 1371.7505, found: 1371.7502; C76H98N12O12 × C4H2F6O4 (1599.7) 
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(S,S)-8,8'-Bis({[4-diphenylacetamido-4-(4-hydroxybenzylaminocarbonyl)butyl]amino-
(amino)methylene}amino)-8,8'-dioxo-N,N'-(ethylenedioxydiethylenediyl)dioctanamide 
((S,S)-3.25). White solid; 19 % (12.5 mg); mp 78-80 °C; 1H-NMR (300 MHz, MeOH-d4):  (ppm) 
1.27-1.44 (m, 8H, CO-CH2-CH2-CH2-CH2-CH2-CH2-CO), 1.47-1.9 (bm, 16H, CH-CH2-CH2, CO-
CH2-CH2-CH2-CH2-CH2-CH2-CO), 2.19 (t, 4H, 3J = 7.44 Hz, CH2-CO), 2.44 (t, 4H, 3J = 7.36 Hz, 
CH2-CO), 3.25 (m, 4H, CH2-CH2-CH2-NH), 3.34 (t, 4H, 3J = 5.60 Hz, CH2 from O-CH2-CH2-NH), 
3.52 (t, 4H, 3J = 5.53 Hz, CH2 from O-CH2-CH2-NH), 3.59 (s, 4H, O-CH2-CH2-O), 4.20 (d, 2H, 2J 
= 14.56 Hz, CH2-ArOH), 4.27 (d, 2H, 2J = 14.58 Hz, CH2-ArOH), 4.42 (m, 2H, CH), 5.07 (s, 2H, 
CH-(Ph)2), 6.7 (d, 4H, 3J = 8.56 Hz, AA’BB’), 7.05 (d, 4H, 3J = 8.55 Hz, AA’BB’), 7.19-7.33 (m, 
20H, Ph); RP-HPLC (220 nm, system 2): 90 % (tR = 20.6 min, k = 6.0); HRMS: (MALDI): m/z 
calcd. for [C76H99N12O12 + H]+ 1371.7505, found: 1371.7519; C76H98N12O12 × C4H2F6O4 (1599.7) 
 
N-tert-butoxycarbonyl-3,6-dioxa-octane-1,8-diamine (3.26). A solution of di-tert-butyl 
dicarbonate (12 g, 55 mmol, 1 eq) in CH2Cl2 (100 mL) was added dropwise to a solution of 3,6-
dioxa-octane-1,8-diamine (15.2 g, 102.7 mmol, 1.9 eq) and diisopropylethylamine (7.1 g, 55 
mmol, 1 eq) in CH2Cl2 (400 mL) over a period of 60 min. The mixture was stirred for another 2 h, 
the solvent was removed under reduced pressure and the product was isolated by column 
chromatography (CH2Cl2/MeOH/NH4OH). 48 % (6.5 g, 26.2 mmol); 1H-NMR (300 MHz, CDCl3): 
 (ppm) 1.39 (s, 9H, t-Bu), 2.44 (s, 2H, NH2), 2.85 (t, 2H, 3J = 5.08 Hz, O-CH2-CH2-NH2), 3.26 
(m, 2H, CH2), 3.49 (m, 4H, 2 × CH2), 3.57 (m, 4H, 2 × CH2); MS (CI, NH3): m/z 249 [M + H]+; 
C11H24N2O4 (248.3) 
 
N-(4-(Benzyloxycarbonyl)butanoyl)-3,6-dioxa-octane-1,8-diamine (3.27). 3.9 (1 g, 4.5 mmol, 
1 eq) and 3.26 (1.1 g, 4.5 mmol, 1 eq) were dissolved in CH2Cl2. EDAC (1 g, 5.4 mmol, 1.2 eq) 
was added and the mixture was kept under stirring at rt for 20 h. The intermediate was purified 
by column chromatography (EtOAc/MeOH) prior to deprotection with CH2Cl2/TFA 1/1 (v/v). 55 
% (1.15 g, 2.48 mmol); 1H-NMR (300 MHz, CDCl3):  (ppm) 1.95 (m, 2H, CH2-CH2-CH2), 2.23 (t, 
2H, 3J = 7.35 Hz, CH2-CO), 2.41 (t, 2H, 3J = 7.32 Hz, CH2-CO), 2.95 (t, 2H, 3J = 4.64 Hz, O-
CH2-CH2-NH2), 3.4 (m, 2H, CH2-NH), 3.47-3.64 (m, 8H, CH2-O-CH2-CH2-O-CH2), 5.09 (s, 2H, 
CH2-Ph), 7.28-7.36 (m, 5H, Ph); MS (CI, NH3): m/z 353 [M + H]+; C18H28N2O5 × C2HF3O2 (466.4) 
 
N,N'-Bis(N-(4-carboxybutanoyl)-8-amino-3,6-dioxa-octyl)-terephthalamide (3.28). 3.27 (0.9 
g, 1.93 mmol, 2 eq) was dissolved in CH2Cl2. NEt3 (98 mg, 134 µL, 0.97 mmol, 1 eq) and 
therephthaloyl dichloride (0.2 g, 0.965 mmol, 1 eq) were added and the mixture was allowed to 
stand at rt overnight. The intermediate was purified by column chromatography (EtOAc/MeOH) 
prior to hydrogenation at rt and atmospheric pressure in MeOH using hydrogen and a 10 % 
Pd/C catalyst. 84 % (0.53 g, 0.81 mmol); 1H-NMR (300 MHz, MeOH-d4):  (ppm) 1.86 (m, 4H, 
CH2-CH2-CH2), 2.22 (t, 4H, 3J = 7.44 Hz, CH2-CO), 2.30 (t, 4H, 3J = 7.41 Hz, CH2-CO), 3.34 (m, 
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4H, CH2 from O-CH2-CH2-NH), 3.53 (t, 4H, 3J = 5.53 Hz, CH2 from O-CH2-CH2-NH), 3.56-3.71 
(m, 16H, CH2 from O-CH2-CH2-NH, O-CH2-CH2-O), 7.91 (s, 4H, CO-C6H4-CO); C30H46N4O12 
(654.7) 
 
(R,R)-N,N'-Bis(N-{5-[4-diphenylacetamido-4-(4-hydroxybenzylaminocarbonyl)butyl]amino-
(amino)methyleneamino-5-oxopentanoyl}-8-amino-3,6-dioxa-octyl)-terephthalamide 
(3.29). A solution of 3.28 (21.5 mg, 33 µmol, 1 eq) and CDI (13.3 mg, 82.4 µmol, 2.5 eq) in DMF 
was stirred for 30 min. (R)-3.6 (52 mg, 82.4 µmol, 2.5 eq) was added and the mixture was kept 
under stirring at rt for 20 h. DMF was evaporated (45 °C, 5-10 mbar), CH2Cl2/TFA 1/1 (v/v, 2 
mL) as well as water (2 drops) were added, and the mixture was allowed to stand for 2.5 h. The 
mixture was concentrated under reduced pressure and CH2Cl2 was added three times, each 
time followed by evaporation under reduced pressure. The product was purified using 
preparative HPLC. White solid; 21 % (12.4 mg, 6.92 µmol); mp 85-87 °C; 1H-NMR (300 MHz, 
MeOH-d4):  (ppm) 1.48-1.96 (bm, 12H, CH-CH2-CH2, CO-CH2-CH2-CH2-CO), 2.24 (t, 4H, 3J = 
7.32 Hz, CH2-CO), 2.46 (t, 4H, 3J = 7.27 Hz, CH2-CO), 3.26 (m, 4H, CH2-CH2-CH2-NH), 3.32 (t, 
4H, 3J = 5.55 Hz, CH2 from O-CH2-CH2-NH), 3.52 (t, 4H, 3J = 5.56 Hz, CH2 from O-CH2-CH2-
NH), 3.55-3.68 (m, 16H, CH2 from O-CH2-CH2-NH, O-CH2-CH2-O), 4.21 (d, 2H, 2J = 14.56 Hz, 
CH2-ArOH), 4.27 (d, 2H, 2J = 14.68 Hz, CH2-ArOH), 4.42 (m, 2H, CH), 5.06 (s, 2H, CH-(Ph)2), 
6.7 (d, 4H, 3J = 8.57 Hz, AA’BB’), 7.05 (d, 4H, 3J = 8.58 Hz, AA’BB’), 7.2-7.33 (m, 20H, Ph), 
7.89 (s, 4H, CO-C6H4-CO); RP-HPLC (220 nm, system 2): 91 % (tR = 16.3 min, k = 4.6); HRMS: 
(MALDI): m/z calcd. for [C84H105N14O16 + H]+ 1565.7833, found: 1565.7824; C84H104N14O16 × 
C4H2F6O4 (1793.9) 
 
N,N-Bis(2-aminoethyl)-N’-Boc-ethane-1,2-diamine (3.30). A solution of di-tert-butyl 
dicarbonate (1.49 g, 6.8 mmol, 1 eq) in CH2Cl2 (300 mL) was added dropwise to a cooled (-78 
°C) solution of N,N-bis(2-aminoethyl)-ethane-1,2-diamine (10 g, 68.3 mmol, 10 eq) in CH2Cl2 
(1000 mL) over a period of 2 h. The mixture was allowed to warm up to rt and stirring was 
continued at rt overnight. The solvent was removed under reduced pressure and the product 
was isolated by column chromatography (CH2Cl2/MeOH/NH4OH). Jellowish oil; 82 % (1.38 g, 
5.6 mmol); 1H-NMR (300 MHz, CDCl3):  (ppm) 1.44 (s, 9H, t-Bu), 2.53 (m, 6H, N-CH2-CH2-
NHCO), 2.76 (t, 4H, 3J = 5.98, CH2-NH2), 3.18 (m, 2H, CH2-NHBoc); MS (CI, NH3): m/z 247 [M + 
H]+; C11H26N4O2 (246.35) 
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General procedure for the synthesis of linkers 3.31 - 3.33 
 
3.9, 3.10 or 3.12 (2 eq) and 3.30 (1 eq) were dissolved in CH2Cl2. EDAC (2.2 eq) was added 
and the mixture was kept under stirring at rt for 20 h. The intermediate was purified by column 
chromatography (EtOAc/MeOH) prior to hydrogenation at rt and atmospheric pressure in MeOH 
using hydrogen and a 10 % Pd/C catalyst.  
 
N,N-Bis(N-(4-carboxybutanoyl)-2-aminoethyl)-N’-Boc-ethane-1,2-diamine (3.31). 72 % (150 
mg); 1H-NMR (300 MHz, MeOH-d4):  (ppm) 1.44 (s, 9H, t-Bu), 1.90 (m, 4H, CH2-CH2-CH2), 2.3 
(m, 8H, CH2-CO), 2.7 (m, 6H, N-CH2-CH2-NHCO), 3.14 (t, 2H, 3J = 6.22 Hz, CH2-NHBoc), 3.29 
(t, 4H, 3J = 6.34, CH2-NHCO); MS (ES, CH2Cl2/MeOH + 10 mM NH4OAc): m/z 475 [M + H]+; 
C21H38N4O8 (474.55) 
 
N,N-Bis(N-(5-carboxypentanoyl)-2-aminoethyl)-N’-Boc-ethane-1,2-diamine (3.32). 75 % 
(165 mg); 1H-NMR (300 MHz, MeOH-d4):  (ppm) 1.46 (s, 9H, t-Bu), 1.63 (m, 8H, CH2-CH2-CH2-
CH2), 2.3 (m, 8H, CH2-CO), 3.4 (m, 8H, CH2 from N-CH2-CH2-NH), 3.53 (m, 4H, CH2 from N-
CH2-CH2-NH); MS (ES, CH2Cl2/MeOH + 10 mM NH4OAc): m/z 503 [M + H]+; C23H42N4O8 (502.6) 
 
N,N-Bis(N-(7-carboxyheptanoyl)-2-aminoethyl)-N’-Boc-ethane-1,2-diamine (3.33). 58 % 90 
mg); 1H-NMR (300 MHz, MeOH-d4):  (ppm) 1.36 (m, 8H, CH2-CH2-CH2-CH2-CH2-CH2), 1.44 (s, 
9H, t-Bu), 1.61 (m, 8H, CH2-CH2-CH2-CH2-CH2-CH2), 2.25 (m, 8H, CH2-CO), 2.67 (m, 6H, N-
CH2-CH2-NHCO), 3.12 (t, 2H, 3J = 6.18 Hz, CH2-NHBoc), 3.26 (t, 4H, 3J = 6.12 Hz, CH2-NHCO); 
MS (ES, CH2Cl2/MeOH + 10 mM NH4OAc): m/z 559 [M + H]+; C27H50N4O8 (558.7) 
 
N,N-Bis(N-(4-aminobutanoyl)-2-aminoethyl)-N’-Boc-ethane-1,2-diamine (3.34). 3.30 (0.28 g, 
1.16 mmol, 1 eq) and N-benzyloxycarbonyl--butyric acid (0.55 g, 2.3 mmol, 2 eq) were 
dissolved in CH2Cl2. EDAC (2.2 eq) was added and the mixture was kept under stirring at rt for 
20 h. The intermediate was purified by column chromatography (EtOAc/MeOH) prior to 
hydrogenation at rt and atmospheric pressure in MeOH using hydrogen and a 10 % Pd/C 
catalyst. 89 % (0.37 g, 0.43 mmol); 1H-NMR (300 MHz, CDCl3):  (ppm) 1.43 (s, 9H, t-Bu), 1.8 
(m, 4H, CH2-CH2-CH2), 2.34 (t, 4H, 3J = 7.0, CH2-CO), 2.53 (m, 6H, N-CH2-CH2-NHCO), 2.76 (t, 
4H, 3J = 6.55, CH2-NH2), 3.12 (m, 2H, CH2-NHBoc), 3.28 (m, 4H, CH2-NHCO); MS (ES, MeOH 
+ 10 mM NH4OAc): m/z 417 [M + H]+; C19H40N6O4 (416.6) 
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General procedure for the synthesis of linkers 3.35 - 3.36 
 
3.9 or 3.10 (2 eq) and 3.34 (1 eq) were dissolved in CH2Cl2. EDAC (2.2 eq) was added and the 
mixture was kept under stirring at rt for 20 h. The intermediate was purified by column 
chromatography (EtOAc/MeOH) prior to hydrogenation at rt and atmospheric pressure in MeOH 
using hydrogen and a 10 % Pd/C catalyst.  
 
N,N-Bis(N-(N-(4-carboxybutanoyl)-4-aminobutanoyl)-2-aminoethyl)-N’-Boc-ethane-1,2-
diamine (3.35). 60 % (220 mg); 1H-NMR (300 MHz, MeOH-d4):  (ppm) 1.43 (s, 9H, t-Bu), 1.73-
1.94 (m, 8H, CH2-CH2-CH2), 2.2-2.36 (m, 12H, CH2-CO), 2.69 (m, 6H, N-CH2-CH2-NHCO), 3.13 
(t, 2H, 3J = 6.23 Hz, CH2-NHBoc), 3.20 (t, 4H, 3J = 6.93 Hz, CH2-NHCO), 3.29 (t, 4H, 3J = 6.24 
Hz, CH2-NHCO); MS (ES, CH2Cl2/MeOH + 10 mM NH4OAc): m/z 645 [M + H]+; C29H52N6O10 
(644.8) 
 
N,N-Bis(N-(N-(5-carboxypentanoyl)-4-aminobutanoyl)-2-aminoethyl)-N’-Boc-ethane-1,2-
diamine (3.36). 53 % (95 mg); 1H-NMR (300 MHz, CDCl3):  (ppm) 1.37 (s, 9H, t-Bu), 1.58 (m, 
8H, CH2-CH2-CH2-CH2), 1.75 (m, 4H, CO-CH2-CH2-CH2-NH), 2.14-2.34 (m, 12H, CH2-CO), 3.15 
(m, 6H, N-CH2-CH2-NHCO), 3.33 (m, 4H, CH2-NHCO), 3.43 (m, 2H, CH2-NHBoc), 3.54 (m, 4H, 
CH2-NHCO); MS (ES, MeOH + 10 mM NH4OAc): m/z 673 [M + H]+; C31H56N6O10 (672.8)  
 
General procedure for the synthesis of bivalent ligands 3.37 - 3.41 
 
A solution of 3.31, 3.32, 3.33, 3.35 or 3.36 (1 eq) and CDI (2.2 eq) in DMF was stirred for 30-40 
min. (R)-3.6 (2.2 eq) was added and the mixture was kept under stirring at rt for 20 h. DMF was 
evaporated (45 °C, 5-10 mbar), CH2Cl2/TFA 1/1 (2 mL) as well as water (2-3 drops) were 
added, and the mixture was allowed to stand for 2.5 h. The mixture was concentrated under 
reduced pressure and CH2Cl2 was added three times, each time followed by evaporation under 
reduced pressure. The product was purified using preparative HPLC. 
 
(R,R)-N,N-Bis(N-{5-[4-diphenylacetamido-4-(4-hydroxybenzylaminocarbonyl)butyl]amino-
(amino)methyleneamino-5-oxopentanoyl}-2-aminoethyl)-ethane-1,2-diamine (3.37). White 
solid; 37 % (30 mg); mp 102-104 °C; 1H-NMR (300 MHz, MeOH-d4):  (ppm) 1.47-2.0 (bm, 12H, 
CH-CH2-CH2, CO-CH2-CH2-CH2-CO), 2.29 (t, 4H, 3J = 7.38 Hz, CH2-CO), 2.51 (t, 4H, 3J = 7.28 
Hz, CH2-CO), 2.69 (t, 4H, 3J = 6.08, N-CH2-CH2-NHCO), 2.85 (t, 2H, 3J = 5.61, CH2 from N-CH2-
CH2-NH2), 3.03 (t, 2H, 3J = 5.46, CH2 from N-CH2-CH2-NH2), 3.26 (m, 8H, CH2-CH2-CH2-NH, N-
CH2-CH2-NHCO), 4.20 (d, 2H, 2J = 14.64 Hz, CH2-ArOH), 4.26 (d, 2H, 2J = 14.57 Hz, CH2-
ArOH), 4.42 (m, 2H, CH), 5.07 (s, 2H, CH-(Ph)2), 6.7 (d, 4H, 3J = 8.54 Hz, AA’BB’), 7.04 (d, 4H, 
3J = 8.53 Hz, AA’BB’), 7.19-7.32 (m, 20H, Ph); RP-HPLC (220 nm, system 1): 98 % (tR = 18.4 
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min, k = 5.5); HRMS: (MALDI): m/z calcd. for [C70H89N14O10 + H]+ 1285.6886, found: 1285.6867; 
C70H88N14O10 × C8H4F12O8 (1741.6) 
 
(R,R)-N,N-Bis(N-{6-[4-diphenylacetamido-4-(4-hydroxybenzylaminocarbonyl)butyl]amino-
(amino)methyleneamino-6-oxohexanoyl}-2-aminoethyl)-ethane-1,2-diamine (3.38). White 
solid; 34 % (36 mg); mp 116-118 °C; 1H-NMR (300 MHz, MeOH-d4):  (ppm) 1.48-1.9 (bm, 16H, 
CH-CH2-CH2, CH2-CH2-CH2-CH2), 2.23 (t, 4H, 3J = 6.44 Hz, CH2-CO), 2.48 (t, 4H, 3J = 6.53 Hz, 
CH2-CO), 2.64 (t, 4H, 3J = 6.35, N-CH2-CH2-NHCO), 2.79 (t, 2H, 3J = 5.65, CH2 from N-CH2-
CH2-NH2), 2.99 (t, 2H, 3J = 5.50, CH2 from N-CH2-CH2-NH2), 3.25 (m, 8H, CH2-CH2-CH2-NH, N-
CH2-CH2-NHCO), 4.20 (d, 2H, 2J = 15.16 Hz, CH2-ArOH), 4.27 (d, 2H, 2J = 15.08 Hz, CH2-
ArOH), 4.42 (m, 2H, CH), 5.07 (s, 2H, CH-(Ph)2), 6.7 (d, 4H, 3J = 8.57 Hz, AA’BB’), 7.05 (d, 4H, 
3J = 8.54 Hz, AA’BB’), 7.2-7.32 (m, 20H, Ph); RP-HPLC (220 nm, system 1): 97 % (tR = 18.7 
min, k = 5.6); HRMS: (MALDI): m/z calcd. for [C72H93N14O10 + H]+ 1313.7199, found: 1313.7201; 
C72H92N14O10 × C8H4F12O8 (1769.7) 
 
(R,R)-N,N-Bis(N-{8-[4-diphenylacetamido-4-(4-hydroxybenzylaminocarbonyl)butyl]amino-
(amino)methyleneamino-8-oxo-octanoyl}-2-aminoethyl)-ethane-1,2-diamine (3.39). White 
solid; 24 % (16 mg); mp 104-105 °C; 1H-NMR (300 MHz, MeOH-d4):  (ppm) 1.28-1.43 (m, 8H, 
CH2-CH2-CH2-CH2-CH2-CH2),1.48-1.9 (bm, 16H, CH-CH2-CH2, CH2-CH2-CH2-CH2-CH2-CH2), 
2.20 (t, 4H, 3J = 7.44 Hz, CH2-CO), 2.45 (t, 4H, 3J = 7.29 Hz, CH2-CO), 2.63 (t, 4H, 3J = 6.67, N-
CH2-CH2-NHCO), 2.78 (t, 2H, 3J = 5.97, CH2 from N-CH2-CH2-NH2), 2.99 (t, 2H, 3J = 5.82, CH2 
from N-CH2-CH2-NH2), 3.25 (m, 8H, CH2-CH2-CH2-NH, N-CH2-CH2-NHCO), 4.21 (d, 2H, 2J = 
14.33 Hz, CH2-ArOH), 4.27 (d, 2H, 2J = 14.55 Hz, CH2-ArOH), 4.42 (m, 2H, CH), 5.07 (s, 2H, 
CH-(Ph)2), 6.7 (d, 4H, 3J = 8.55 Hz, AA’BB’), 7.05 (d, 4H, 3J = 8.53 Hz, AA’BB’), 7.18-7.33 (m, 
20H, Ph); RP-HPLC (220 nm, system 1): 92 % (tR = 18.8 min, k = 5.7); HRMS: (MALDI): m/z 
calcd. for [C76H101N14O10 + H]+ 1369.7825, found: 1369.7808; C76H100N14O10 × C8H4F12O8 
(1825.8) 
 
(R,R)-N,N-Bis[N-(N-{5-[4-diphenylacetamido-4-(4-hydroxybenzylaminocarbonyl)butyl]-
amino(amino)methyleneamino-5-oxopentanoyl}-4-aminobutanoyl)-2-aminoethyl]-ethane-
1,2-diamine (3.40). White solid; 35 % (114 mg); mp 100-102 °C; 1H-NMR (300 MHz, MeOH-d4): 
 (ppm) 1.48-2.0 (bm, 16H, CH-CH2-CH2, CO-CH2-CH2-CH2-CO, CO-CH2-CH2-CH2-NH), 2.23 
(m, 8H, CH2-CO), 2.50 (t, 4H, 3J = 7.25 Hz, CH2-CO), 2.65 (t, 4H, 3J = 5.76, N-CH2-CH2-NHCO), 
2.81 (t, 2H, 3J = 5.86, CH2 from N-CH2-CH2-NH2), 2.99 (t, 2H, 3J = 5.71, CH2 from N-CH2-CH2-
NH2), 3.17 (t, 4H, 3J = 7.15, CH2-NHCO), 3.26 (m, 8H, CH2-CH2-CH2-NH, CH2-NHCO), 4.21 (d, 
2H, 2J = 14.55 Hz, CH2-ArOH), 4.27 (d, 2H, 2J = 14.57 Hz, CH2-ArOH), 4.42 (m, 2H, CH), 5.07 
(s, 2H, CH-(Ph)2), 6.7 (d, 4H, 3J = 8.49 Hz, AA’BB’), 7.05 (d, 4H, 3J = 8.47 Hz, AA’BB’), 7.2-7.32 
(m, 20H, Ph); RP-HPLC (220 nm, system 1): 95 % (tR = 17.8 min, k = 5.3); HRMS: (MALDI): m/z 
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calcd. for [C78H103N16O12 + H]+ 1455.7941, found: 1455.7950; C78H102N16O12 × C8H4F12O8 
(1911.8) 
 
(R,R)-N,N-Bis[N-(N-{6-[4-diphenylacetamido-4-(4-hydroxybenzylaminocarbonyl)butyl]-
amino(amino)methyleneamino-6-oxohexanoyl}-4-aminobutanoyl)-2-aminoethyl]-ethane-
1,2-diamine (3.41). White solid; 12 % (5.7 mg); mp 71-73 °C; 1H-NMR (300 MHz, MeOH-d4):  
(ppm) 1.48-1.9 (bm, 20H, CH-CH2-CH2, CH2-CH2-CH2-CH2, CO-CH2-CH2-CH2-NH), 2.22 (m, 
8H, CH2-CO), 2.48 (t, 4H, 3J = 6.37 Hz, CH2-CO), 2.72 (t, 4H, 3J = 6.63, N-CH2-CH2-NHCO), 
2.89 (m, 2H, CH2 from N-CH2-CH2-NH2), 3.05 (t, 2H, CH2 from N-CH2-CH2-NH2), 3.18 (t, 4H, 3J 
= 7.07, CH2-NHCO), 3.27 (m, 8H, CH2-CH2-CH2-NH, CH2-NHCO), 4.21 (d, 2H, 2J = 14.75 Hz, 
CH2-ArOH), 4.27 (d, 2H, 2J = 14.58 Hz, CH2-ArOH), 4.42 (m, 2H, CH), 5.07 (s, 2H, CH-(Ph)2), 
6.7 (d, 4H, 3J = 8.58 Hz, AA’BB’), 7.05 (d, 4H, 3J = 8.59 Hz, AA’BB’), 7.18-7.33 (m, 20H, Ph); 
RP-HPLC (220 nm, system 1): 90 % (tR = 18.7 min, k = 5.6); HRMS: (MALDI): m/z calcd. for 
[C80H107N16O12 + H]+ 1483.8254, found: 1483.8251; C80H106N16O12 × C8H4F12O8 (1939.9) 
  
General procedure for the synthesis of bivalent ligands 3.42 - 3.44 
 
The precursor 3.38 or 3.40 (1.05 eq) was dissolved in DMF (200 µL) and NEt3 (5 eq) as well as 
the NHS ester of the pertinent acid (1 eq) in DMF (20 µL) were added. After an incubation 
period of 3 h at rt, 10 % aq. TFA (corresponding to 5 eq. of TFA) was added. The mixture was 
diluted with acetonitrile and water to give an injectable solution for purification with preparative 
HPLC. 
 
(R,R)-N,N-Bis(N-{6-[4-diphenylacetamido-4-(4-hydroxybenzylaminocarbonyl)butyl]amino-
(amino)methyleneamino-6-oxohexanoyl}-2-aminoethyl)-N’-propanoyl-ethane-1,2-diamine 
(3.42). From 3.38 and propionic acid succinimidyl ester; 68 % (9.9 mg); mp 115-118 °C; 1H-
NMR (600 MHz, DMSO-d6, COSY):  (ppm) 0.98 (t, 3H, 3J = 7.58 Hz, CH3), 1.36-1.47 (m, 4H, 
CH-CH2-CH2-CH2), 1.52 (m, 10H, CH-CH2-CH2, CH2-CH2-CH2-CH2), 1.67 (m, 2H, CH-CH2-CH2), 
2.12 (m, 6H, CH2-CO), 2.41 (t, 4H, 3J = 6.44 Hz, CH2-CO), 3.22 (m, 10H, CH2-CH2-CH2-NH, N-
CH2-CH2-NH), 3.38 (s, 6H, N-CH2-CH2-NH), 4.13 (dd, 2H, 2J = 14.79 Hz, 3J = 5.65 Hz, CH2-
ArOH), 4.17 (dd, 2H, 2J = 14.67 Hz, 3J = 5.91 Hz, CH2-ArOH), 4.33 (m, 2H, CH), 5.11 (s, 2H, 
CH-(Ph)2), 6.66 (d, 4H, 3J = 8.49 Hz, AA’BB’), 6.99 (d, 4H, 3J = 8.50 Hz, AA’BB’), 7.21 (m, 4H, 
Ph), 7.27 (m, 16H, Ph), 8.12 (m, 3H, NH, NHCO-CH2-CH3), 8.33 (t, 2H, 3J = 5.84 Hz, CO-NH-
CH2), 8.45 (d, 2H, 3J = 8.11 Hz, CO-NH-CH), 8.59 (s, 4H, NH2), 8.94 (s, 2H, NH), 9.26 (s, 2H, 
NH), 9.58 (s, 1H, NH+), 11.41 (s, 2H, ArOH); RP-HPLC (210 nm, system 3): 99 % (tR = 13.8 
min, k = 4.1); HRMS: (MALDI): m/z calcd. for [C75H97N14O11 + H]+ 1369.7461, found: 1369.7481; 
C75H96N14O11 × C6H3F9O6 (1711.7)    
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(R,R)-N,N-Bis[N-(N-{5-[4-diphenylacetamido-4-(4-hydroxybenzylaminocarbonyl)butyl]-
amino(amino)methyleneamino-5-oxopentanoyl}-4-aminobutanoyl)-2-aminoethyl]-N’-
propanoyl-ethane-1,2-diamine (3.43). From 3.40 and propionic acid succinimidyl ester; 62 % 
(12.6 mg); mp > 96 °C (decomp.); 1H-NMR (600 MHz, DMSO-d6, COSY):  (ppm) 0.99 (t, 3H, 3J 
= 7.58 Hz, CH3), 1.36-1.48 (m, 4H, CH-CH2-CH2-CH2), 1.53 (m, 2H, CH-CH2-CH2), 1.6 (m, 4H, 
CO-CH2-CH2-CH2-NH), 1.67 (m, 2H, CH-CH2-CH2), 1.76 (m, 4H, CO-CH2-CH2-CH2-CO), 2.11 
(m, 10H, CH2-CO), 2.41 (t, 4H, 3J = 7.36 Hz, CH2-CO), 3.01 (m, 4H, CO-CH2-CH2-CH2-NH), 
3.22 (m, 10H, CH2-CH2-CH2-NH, N-CH2-CH2-NH), 3.38 (s, 6H, N-CH2-CH2-NH), 4.1 (dd, 2H, 2J 
= 14.76 Hz, 3J = 5.61 Hz, CH2-ArOH), 4.17 (dd, 2H, 2J = 14.78 Hz, 3J = 5.86 Hz, CH2-ArOH), 
4.33 (m, 2H, CH), 5.11 (s, 2H, CH-(Ph)2), 6.66 (d, 4H, 3J = 8.49 Hz, AA’BB’), 6.99 (d, 4H, 3J = 
8.52 Hz, AA’BB’), 7.22 (m, 4H, Ph), 7.27 (m, 16H, Ph), 7.83 (t, 2H, 3J = 5.51 Hz, CO-CH2-CH2-
CH2-NH), 8.12 (s, 3H, NH, NHCO-CH2-CH3), 8.33 (t, 2H, 3J = 5.83 Hz, CO-NH-CH2), 8.45 (d, 
2H, 3J = 8.11 Hz, CO-NH-CH), 8.54 (bs, 4H, NH2), 8.86 (s, 2H, NH), 9.26 (s, 2H, NH), 9.51 (s, 
1H, NH+), 11.29 (s, 2H, ArOH); RP-HPLC (210 nm, system 3): 99 % (tR = 13.2 min, k = 3.9); 
HRMS: (MALDI): m/z calcd. for [C81H107N16O13 + H]+ 1511.8204, found: 1511.8210; 
C81H106N16O13 × C6H3F9O6 (1853.9) 
 
(R,R)-N,N-Bis[N-(N-{5-[4-diphenylacetamido-4-(4-hydroxybenzylaminocarbonyl)butyl]-
amino(amino)methyleneamino-5-oxopentanoyl}-4-aminobutanoyl)-2-aminoethyl]-N’-(4-
fluorobenzoyl)-ethane-1,2-diamine (3.44). From 3.40 and 4-fluorobenzoic acid succinimidyl 
ester; 55 % (8.75 mg); mp 117-118 °C; 1H-NMR (600 MHz, DMSO-d6, COSY):  (ppm) 1.36-
1.48 (m, 4H, CH-CH2-CH2-CH2), 1.49-1.62 (m, 6H, CH-CH2-CH2, CO-CH2-CH2-CH2-NH), 1.66 
(m, 2H, CH-CH2-CH2), 1.76 (m, 4H, CO-CH2-CH2-CH2-CO), 2.1 (m, 8H, CH2-CO), 2.41 (t, 4H, 3J 
= 7.38 Hz, CH2-CO), 2.99 (m, 4H, CO-CH2-CH2-CH2-NH), 3.21 (m, 4H, CH-CH2-CH2-CH2-NH), 
3.3 (s, 4H, N-CH2-CH2-NH), 3.41 (s, 6H, N-CH2-CH2-NH, N-CH2-CH2-NH), 3.61 (s, 2H, N-CH2-
CH2-NH), 4.1 (dd, 2H, 2J = 14.79 Hz, 3J = 5.64 Hz, CH2-ArOH), 4.17 (dd, 2H, 2J = 14.78 Hz, 3J = 
5.89 Hz, CH2-ArOH), 4.33 (m, 2H, CH), 5.11 (s, 2H, CH-(Ph)2), 6.66 (d, 4H, 3J = 8.49 Hz, 
AA’BB’), 6.99 (d, 4H, 3J = 8.49 Hz, AA’BB’), 7.22 (m, 4H, Ph), 7.25-7.34 (m, 18H, Ph, 4-F-Ph), 
7.82 (t, 2H, 3J = 5.52 Hz, CO-CH2-CH2-CH2-NH), 7.9 (dd, 2H, 3J = 8.65 Hz, 3J = 5.55 Hz, 4-F-
Ph), 8.15 (s, 2H, NH), 8.33 (t, 2H, 3J = 5.84 Hz, CO-NH-CH2), 8.45 (d, 2H, 3J = 8.12 Hz, CO-NH-
CH), 8.54 (bs, 4H, NH2), 8.74 (s, 1H, NHCO-Ar-F), 8.86 (s, 2H, NH), 9.26 (s, 2H, NH), 9.54 (s, 
1H, NH+), 11.29 (s, 2H, ArOH); RP-HPLC (210 nm, system 3): 100 % (tR = 13.9 min, k = 4.1); 
HRMS: (MALDI): m/z calcd. for [C85H106FN16O13 + H]+ 1577.8109, found: 1577.8107; 
C85H105FN16O13 × C6H3F9O6 (1919.9)       
 
(S)-N-(2,2-Diphenylacetyl)-N-(4-hydroxybenzyl)argininamide (3.45). TFA (50 % v/v) and 
water (0.5-1 % v/v) were added to a solution of (S)-3.6 in CH2Cl2. The mixture was allowed to 
stand for 3 hours at rt, CH2Cl2 (500 % v/v) was added and the mixture was concentrated under 
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reduced pressure. CH2Cl2 was added two times, each time followed by evaporation under 
reduced pressure. The product was purified using preparative HPLC. 91 % (35 mg); mp > 65 °C 
(decomp.); 1H-NMR (300 MHz, DMSO-d6):  (ppm) 1.38 (m, 2H, CH2-CH2-CH2), 1.51 (m, 1H, 
CH-CH2), 1.66 (m, 1H, CH-CH2), 3.05 (m, 2H, CH2-CH2-NH), 4.11 (dd, 1H, 2J = 14.86 Hz, 3J = 
5.81 Hz, CH2-C6H4-OH), 4.18 (dd, 1H, 2J = 15.16 Hz, 3J = 5.85 Hz, CH2-C6H4-OH), 4.32 (m, 1H, 
CH), 5.13 (s, 1H, CH-(Ph)2), 6.67 (d, 2H, 3J = 8.51 Hz, AA’BB’), 7.0 (d, 2H, 3J = 8.43 Hz, 
AA’BB’), 7.19-7.34 (m, 10H, Ph), 7.44 (t, 1H, 3J = 5.69, guanidine), 8.39 (t, 1H, 3J = 5.91 Hz, 
CO-NH-CH2), 8.50 (d, 1H, 3J = 8.08, CO-NH-CH), 9.31 (s, 1H, guanidine); MS (ES, 
CH2Cl2/MeOH + 10 mM NH4OAc): m/z 474 [M + H]+; C27H31N5O3 × C2H1F3O2 (587.6) 
 
 
3.3.3 Analysis of the Enantiomeric Purity of BIBP 3226 and BIBP 3435 (3.45) with 
Capillary Electrophoresis (CE) 
 
CE was performed on a BioFocusTM 3000 capillary electrophoresis system (BioRad, Hercules, 
CA, USA) using an uncoated fused silica capillary (75 / 70.4 cm × 50 µm i.d.) and a sodium 
phosphate buffer (125 mM, pH 2.5) enriched with -cyclodextrin (0.1 M) and urea (5 M). The 
capillary temperature was set to 30 °C and the voltage to 20.0 kV. UV-detection was performed 
at 210 nm. An equimolar mixture of BIBP 3435 and BIBP 3226 (racemic mixture) was analyzed 
followed by the analysis of BIBP 3435 and BIBP 3435 spiked with the racemic mixture. The 
difference in migration times of BIBP 3226 and BIBP 3435 was about 2 min Absolute migration 
times varied between 80 and 90 min. The enantiomeric purity of BIBP 3435 was determined to 
amount to an ee of 97.2 % (2.7 % were identified as the active stereoisomer BIBP 3226). The 
enantiomeric purity of BIBP 3226 (obtained through deprotection of building block 2.7 with TFA, 
cf. chapter 2) was similarly determined to be 99.3 % ee.  
 
 
3.3.4 Pharmacology: Cell Culture, Fura-2 Assay and Competition Binding Assay 
 
Cell culture. HEL and SK-N-MC cells were cultured as described elsewhere.31, 32 HEL cells 
were subcultured by 1:6-dilution with fresh culture medium 24 h prior to the Fura Ca2+-assay. 
MCF-7-Y1 cellsa were maintained in MEM (Sigma, Deisenhofen, Germany), supplemented with 
5 % FCS (Biochrom AG, Berlin, Germany). 
aThis cell line was subcloned from MCF-7 cells in passage 157th and shows a higher Y1R 
expression (by a factor 2 -3 higher than that of the MCF-7 cells (ATCC number HTB 22)).  
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Fura-2 assay on HEL cells. The Fura assay was performed with HEL cells as previously 
described28 using a Perkin-Elmer LS50 B spectrofluorimeter (Perkin Elmer, Überlingen, 
Germany).  
 
Radioligand competition binding assay. The procedure performed in the radioligand binding 
assay was deduced from a previously described protocol31 and [3H]-UR-MK114 (2.8b, cf. 
chapter 2) was used instead [3H]-propionyl-pNPY. Radioligand concentration was set to 1.5 nM 
for SK-N-MC cells (KD = 1.2 nM) and 2 nM for MCF-7 cells (KD = 2.9 nM). Cells were seeded in 
24-well plates 2 or 3 days prior to the experiment. MCF-7-Y1a cells were seeded in culture 
medium with 1 % -Estradiol in order to up-regulate the Y1 receptor. On the day of the 
experiment confluency of the cells was at least 70 %. The culture medium was sucked off, cells 
were washed once with buffer (500 µL) and covered with binding buffer (200 µL for SK-N-MC, 
400 µL for MCF-7 cells). Binding buffer (25/50 µL) and binding buffer (25/50 µL) with radioligand 
(ten fold concentrated) was added for total binding. For non-specific binding and competition of 
test compounds with radioligand binding buffer (25/50 µL) with the competing agent (pNPY or 
test substance, ten fold concentrated) and binding buffer (25/50 µL) with radioligand (ten fold 
concentrated) was added. During incubation at room temperature (22 – 25 °C) the plates were 
gently shaken. After incubation (20 min for SK-N-MC, 30 min for MCF-7-Y1 cells) the binding 
buffer was removed, the cells were washed twice with buffer (500 µL, 4 °C, ≤ 30 s) and covered 
with lysis solution (200 µL). The plates were gently shaken for at least 30 min. The lysis solution 
was transferred into 6-mL scintillation vials filled with scintillator (3 mL) and the dishes were 
washed once with lysis solution (100 µL). Assays were performed in triplicate or duplicate.  
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 Chapter 4 
 
Fluorescently Labeled Y1 Receptor Antagonists 
 
 
4.1  Introduction 
 
Fluorescence-based techniques offer highly attractive alternatives to radiometric assays for the 
investigation of ligand-receptor interactions. Consequently, there is a growing demand for 
appropriate fluorescent probes, and many fluorescent ligands have become available in the last 
decade.1 Fluorescence-labeled compounds are preferred over radioligands in terms of safety 
precautions and waste disposal, and in contrast to radiotracers, fluorescent ligands are 
applicable to fluorescence microscopy and flow cytometry, powerful techniques, which have 
become routine in many laboratories. For instance, by combination of fluorescent dyes emitting 
at distinct wavelengths, multiparametric assays become possible.2, 3 Compared to radioligands, 
however, a major challenge in the preparation of fluorescent ligands is to retain the binding 
affinity, particularly when small ligands are labeled with bulky fluorophores. A straightforward 
and frequently successful approach for investigations on peptidergic G-protein coupled 
receptors (GPCRs) consists in fluorescence labeling of the peptide. In the case of peptides, the 
decrease in affinity is often only moderate, although a factor of ten or higher compared to the 
parent peptide is not exceptional.4 Many fluorescent peptide ligands have been reported up to 
now, e.g. derivatives of formyl peptide,5 insulin,6 epidermal growth factor7, 8 or neuropeptide Y 
(NPY) analogs.9 The synthesis of non-peptidic receptor subtype selective fluorescent 
antagonists is more challenging, particularly in the field of aminergic GPCRs, although a 
growing number of low molecular weight fluorescent GPCR ligands with adequate binding 
affinity is reported in the literature.1, 10-14  
For the detection and investigation of only one receptor subtype on cells and in tissues selective 
potent fluorescent ligands are required. High affinity low molecular weight antagonists are 
superior to peptides concerning selectivity, kinetics, stability and mode of action. In most cases 
peptidic ligands are receptor agonists and can cause receptor desensitization and 
internalization, which may hamper the determination of binding kinetics and lead to a high non-
specific fluorescence background in binding assays. In addition, peptides often need a long 
period of time to reach binding equilibrium, and they can be (rapidly) degraded by enzymes.  
The lack of a selective low molecular weight fluorescent probe for the NPY Y1 receptor 
stimulated us to search for fluorescent ligands starting from the (R)-argininamide BIBP 3226, a 
potent and selective NPY Y1R antagonist.15 Previous investigations on N-substituted analogs 
of this argininamide in our laboratory revealed a preference for electron-withdrawing 
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substituents (alkanoyl, carbamoyl) in terms of retaining or even increasing the Y1R affinity over 
the parent compound.16, 17 This guanidine-acylguanidine bioisosterism, also found in the NPY 
Y2R18 as well as in the histamine H2R field19, enables the preparation of highly potent 
radioligands (cf. chapter 2) as well as fluorescent ligands as described below. 
 
 
 
4.2  Results and Discussion 
 
4.2.1  Chemistry 
 
With respect to potential use in cellular assays red fluorescent dyes (emission wavelength > 590 
nm) were selected to reduce the background fluorescence and thus to improve the signal-to-
noise ratio. Preferably, we used the new class of pyrylium dyes20, 21 (Py-1, Py-5 and Py-6), as 
well as the Cy5-related cyanine dye S0436 and the dye Dy-635 with an unsymmetrical 
hemicyanine structure consisting of an indol and a benzopyrane moiety (Figure 1). In addition, 
two fluorescent ligands were prepared by labeling with the benzothiazole derivative DE99 
(Figure 1), a dye derived from reported push-pull conjugated benzothiazolium compounds22. 
DE99 was synthesized by Daniela Erdmann in our research group as part of her dissertation 
project (to be reported elsewhere).  
The fluorescent dyes S0436, Dy-635 and DE99 are excitable at 635 nm with a red diode laser, 
used as light source in commercial flow cytometers. Fluorescence emission can be detected 
around 660 nm. The pyrylium dyes Py-1, Py-5 and Py-6 belong to the new class of “chameleon 
labels”, which has been developed for the staining and quantification of picomolar 
concentrations of proteins.21 These dyes as well as the benzothiazole derivative DE99 are 
relatively low molecular weight compounds (about 300 - 400 g/mol), and are therefore 
anticipated to be well suited for coupling to small molecules. An additional advantage of 
pyrylium labeled fluorescent probes consists in their excitability with the widely used 488 nm 
laser, a standard component of flow cytometers and confocal microscopes.  
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Figure 1. Structures of the dyes which were used for the preparation of the fluorescent Y1R antagonists 
(4.28 - 4.47). 
 
The dyes S0436, Dy-635 and DE99 contain a carboxylated side chain, which enables coupling 
to amines. S0436 and Dy-635 were purchased as succinimidyl esters, and DE99 was coupled 
as NHS ester or with the aid of coupling reagents (CDI, EDAC) (Scheme 7). Pyrylium dyes react 
very rapidly with primary amines at pH 8-9 at room temperature to form positively charged N-
substituted pyridinium adducts.23 The ring transformation is accompanied by a hypsochromic 
shift of the absorption maximum by more than 100 nm. Thus, the coupling reaction can be 
followed visually due to a change in color from blue to red.  
 
All synthesized fluorescent ligands, except 4.32, are derivatives of the (R)-argininamide BIBP 
3226 (Schemes 6 – 8). 4.32 represents a derivative of the (R)-argininamide BIBO 3304 (6.6, cf. 
chapter 6), another highly potent and selective Y1R antagonist.24 The synthesis of the BIBP 
3226 building block 2.7 is described in chapter 2. The BIBO 3304 moiety (building block 4.6) 
was built up straight forward using standard protecting group chemistry (Scheme 1). The urea 
entity was obtained from mono Boc-protected 1,4-bis(aminomethyl)benzene (4.7) and 
potassium cyanate, a common route for the synthesis of N-substituted ureas25-28 (Scheme 2). 
When the urea moiety was integrated (compound 4.2) subsequent synthesis of building block 
4.6 was hampered by solubility problems. Intermediate 4.4 (Scheme 1) exhibited lowest 
solubility, i. e. the compound was only slightly soluble in MeOH (under heating) and insoluble in 
methylene chloride, acetonitrile, 1,2-dimethoxyethane, THF, 1,4-dioxane, propan-2-ol, ethanol 
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and in mixtures of water with water-miscible solvents. Nevertheless, building block 4.6 was 
obtained in good yield (Scheme 1).  
The previously described synthesis of BIBO 3304 started with N-nitro protected D-arginine, 
which was first treated with diphenylacetyl choride and then amidated with N-(4-aminomethyl-
benzyl)urea (4.8) using TBTU as coupling reagent.29 Final cleavage of the N-nitro group (Pd, 
H2 at 5 bar, 80 % aq. acetic acid, 40 °C) yielded the argininamide BIBO 3304. 
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Scheme 1. Synthesis of NG-Boc-protected BIBO 3304 (4.6). 
Reagents and conditions: (a) K2CO3, di-tert-butyl dicarbonate, 1,4-dioxane, H2O, rt, 20 h, 92 %; (b) CDI, 
NEt3, DMAP, DMF, 0 °C/45 °C/rt, 20 h, 85 %; (c) AcCl, MeOH, rt, 2 h, 100 %; (d) NEt3, DMAP, DMF, rt, 
20 h, 83 %; (e) Pd/C, H2, CH3COOH, MeOH, 45 °C, 2.5 h, 88 %; (f) (1) NEt3, MeOH, CH2Cl2, rt, 20 h; (2) 
Pd/C, H2, CH3COOH, MeOH, rt, 6.5 h, 70 %. 
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Scheme 2. Synthesis of N-(4-aminomethyl-benzyl)urea (4.8). 
Reagents and conditions: (a) di-tert-butyl dicarbonate, 1 M aq. NaOH, 1,4-dioxane, 0 °C/rt, 20 h, 42 %; 
(b) (1) potassium cyanate, H2O, EtOH, 1 M aq. HCl, reflux, 2 h; (2) AcCl, MeOH, rt, 2.5 h, 88 %. 
 
The fluorophores were linked to the guanidine group of the argininamides via ω-aminoalkanoyl 
or ω-aminoalkylcarbamoyl spacers (Schemes 6 – 8) with a length of 6 – 17 atoms. ω-
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Aminoalkanoyl linkers containing glycol ether moieties or amide groups were used in order to 
retain a certain water solubility of the compounds. The linkers 4.10, 4.11, 4.16 and 4.17 were 
not commercially available; the synthesis is depicted in Schemes 3 and 6. 
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Scheme 3. Synthesis of the carboxylic acids 4.10 and 4.11. 
Reagents and conditions: (a) di-tert-butyl dicarbonate, CHCl3, -15 °C/rt, 20 h, 97 %; (b) CH2Cl2, rt, 60 min, 
97 %. 
 
Except for compounds 4.26, 4.27 and the bivalent amino precursors 3.38 – 3.40 (cf. chapter 3), 
all amino precursors (4.18 – 4.25) were prepared via direct attachment of the N-protected (Boc, 
Cbz) -aminocarboxylic acids to N-Boc, O-tert-butyl protected BIBP 3226 (2.7, cf. chapter 2) 
and NG-Boc protected BIBO 3304 (4.6) respectively (Scheme 6). The labeling precursor N-6-
aminohexanoyl-BIBP 3226 (4.21) proved to be sufficiently stable under basic conditions in 
contrast to its lower homolog, the N-5-aminopentanoyl derivative, which is cleaved by intra-
molecular aminolysis into BIBP 3226 and valerolactam. This decomposition takes place within 
seconds as demonstrated by kinetic investigations on aminopentanoyl-guanidine as a model 
compound.30 By contrast, the formation of a seven-membered ring, namely -lactam, by 
cleavage of 4.21 is considerably less favored.  
Amino precursor 4.26 was prepared from the N-(7-carboxyheptanoyl), N’-Boc, O-tert-butyl 
protected argininamide 3.16 (cf. chapter 3) as shown in Scheme 6. The N-carbamoylated 
amine precursor 4.27 was initially prepared from N-Boc-protected butane-1,4-diamine and the 
building block 2.7 (Scheme 4) following a reported protocol for the transformation of amines into 
isocyanates with the aid of triphosgene.31 Unfortunately, this procedure preferentially gave the 
N-substituted compound (4.27-Ni) instead of the desired N-substituted argininamide 
derivative (Scheme 4, Figure 2). This is presumably facilitated by the small size of the 
isocyanate entity (acting as electrophile), but other factors such as different nucleophilicity of the 
-nitrogen and the -nitrogen, seem to play a role as well. Therefore, the precursor 4.27 was 
prepared from the guanidinylating reagent 4.13 and amine 2.6 (cf. chapter 2) as depicted in 
Schemes 5 and 6. S-methyl-isothiourea (4.12) was prepared according to the methods 
described by A. Brennauer.18 
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Scheme 4. Synthesis of the amine precursor 4.27 via direct carbamoylation of N-Boc, O-tert-butyl 
protected BIBP 3226 (2.7). 
Reagents and conditions: (a) (1) triphosgene, DIEA, CH2Cl2, rt, 2.5 h; (2) CH2Cl2/TFA 1/1, rt, 1.5 h, total 
yield: 50 %. 4.27 and 4.27-Ni differ in the 1H-NMR signal of the -CH2 group (4.27:  = 3.19 ppm, 4.27-
Ni:  = 3.57 ppm).   
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Figure 2. HPLC control of the reaction mixture (after deprotection) of the synthesis of amino precursor 
4.27 from N-Boc-protected butane-1,4-diamine and the BIBP 3226 building block 2.7 (Scheme 4). 
Conditions: column: Eurospher-100 C18 (250 × 4 mm, 5 µm), eluent: mixtures of acetonitrile (A) and 0.05 
% aq. TFA (B), gradient: 0 to 30 min: A/B 20/80 to 95/5, 30 to 40 min: 95/5, flow rate: 0.8 mL/min, UV-
detection: 210 nm. I: 4.27-Ni (tR = 9.8 min), II: 4.27 (tR = 10.5 min), III: BIBP 3226 (tR = 12.3 min). 
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Scheme 5. Synthesis of the guanidinylation reagent 4.13. Reagents and conditions: (a) triphosgene, 
DIEA, CH2Cl2, rt, 3 h, 75 %. 
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Scheme 6. Synthesis of the amine precursors 4.18 – 4.27. 
Reagents and conditions: (a) (1) Cbz-Cl, NEt3, CH2Cl2, 0 °C/rt, 2.5 h; (2) CH2Cl2/TFA 4/1, rt, 3 h, 88 %; 
(b) (1) EDAC, CH2Cl2, rt, 20 h; (2) Pd/C, H2, MeOH, rt, 63-66 %; (c) (1) CDI, NEt3, acetonitrile, 35 °C, 20 
h; (2) acetonitrile/TFA, 50 °C, 1.5 h, 36 %; (d) (1) CDI, NEt3, CH2Cl2, rt, 20 h; (2) Pd/C, H2, MeOH, rt; (3) 
CH2Cl2/TFA 10/1, rt, 20 h, 36 %; (e) (1) CDI, NEt3, CH2Cl2, rt, 20 h; (2) CH2Cl2/TFA/H2O 18/6/1, rt, 3 h, 
64-94 %; (f) (1) CDI, NEt3, CH2Cl2, rt, 20 h; (2) CH2Cl2/TFA, rt, 2.5-4 h, 44-64 %; (g) (1) EDAC, CH2Cl2, rt, 
20 h; (2) CH2Cl2/TFA, rt, 2 h, 43 %; (h) (1) HgCl2, DIEA, DMF, rt, 20 h; (2) CH2Cl2/TFA 1/1, rt, 2 h, 74 %.  
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Except for 4.29, all fluorescent Y1R antagonists were prepared by coupling the fluorophores with 
completely deprotected amine precursors 4.18 – 4.27 (Scheme 6 – 8) and 3.38 – 4.40 (Scheme 
9). The synthesis of the bivalent Y1R antagonists 3.38 – 3.40 is described in chapter 3. Labeling 
of these bivalent amine precursors with Py-1 afforded the fluorescence labeled bivalent ligands 
in satisfactory yields, but labeling of the precursor 3.40 with DE99 or DE99-NHS failed totally 
(Scheme 9). This was also observed for the higher homolog 3.41 (cf. chapter 3, Scheme 5).  
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Scheme 7. Synthesis of the fluorescent Y1R ligands 4.28 – 4.31. 
Reagents and conditions: (a) NEt3, acetonitrile, rt, 3.5 h, 23 %; (b) (1) NEt3, acetonitrile, rt, 20 h; (2) 
acetonitrile/TFA 1/1, rt, 2 h, 20 % (isomer 1 (4.29-i1): 11 %, isomer 2 (4.29-i2): 9 %, cf. Figure 3); (c) CDI 
or EDAC, NEt3, DMF, rt, 2.5 - 7 h, 23 % for 4.30, 0.3 % for 4.31; (d) NEt3, DMF, rt, 3 h, 24 %. 
 
 
Activation of DE99 with carbonyldiimidazole in dimethylformamide and subsequent treatment 
with amine precursor 4.22 in the presence of triethylamine (Scheme 7) gave the fluorescent 
ligand 4.30 in satisfactory yield (23 %), whereas the synthesis of 4.31 from the carbamoyl 
precursor 4.27 nearly failed under the same conditions (yield: 0.3 %). Using EDAC instead of 
carbonyldiimidazole led to the same unsactisfactory result (Scheme 7). This can be explained 
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by the decomposition of precursor 4.27 into BIBP 3226 in the presence of carbonyldiimidazole 
or EDAC (Scheme 7) as analyzed by HPLC. By contrast labeling of amine 4.27 with DE99-NHS 
afforded 4.31 in 24 % yield (Scheme 7).  
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Scheme 8. Synthesis of the fluorescent Y1R ligands 4.32 – 4.44. 
Reagents and conditions: (a) NEt3, acetonitrile, H2O, rt, 2 h, 33 %; (b) NEt3, acetonitrile, DMF, rt, 1-2 h; 
13-56 %. 
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Scheme 9. Synthesis of the fluorescent Y1R ligands 4.45 – 4.47 and failed labeling of 3.40 with DE99. 
Reagents and conditions: (a) NEt3, acetonitrile, DMF, rt, 1-2 h; 26-28 %; (b) DE99 activated in DMF with 
CDI (30 min) followed by the addition of amino precursor and NEt3, rt; or: DE99-NHS, DMF, NEt3, rt. 
 
For the preparation of compound 4.29 the succinimidyl ester of the fluorescent dye S0436 was 
coupled with N-Boc, O-tert-butyl protected BIBP 3226 (2.7, cf. chapter 2) followed by a 
deprotection step (acetonitrile, TFA; Scheme 7). Interestingly, two different products were 
isolated. Both samples exhibited the expected molecular mass in MS analysis. Presumably, an 
isomerization of the fluorescent entity in S0436 (Figure 1) was induced under the acidic 
deprotection conditions. The isomers were referred to as 4.29-i1 (exhibits the lower retention 
time when analyzed with reversed-phase chromatography, Figure 3) and 4.29-i2 (exhibits a 
higher retention time, Figure 3). An acylation of the -nitrogen of the building block 2.7 is not 
very likely, since acylation of 2.7 with succinimidyl propionate (chapter 2) as well as acylation 
with carboxylic acids using CDI (preparation of amino precursors 4.19 – 4.23, Scheme 6) gave 
no remarkable amounts of N-acylated side products.  
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Figure 3. HPLC purity control of the fluorescent Y1R ligands 4.29-i1 and 4.29-i2. Conditions: column: 
Nucleodur 100-5 C18 (250 × 4 mm, 5 µm), eluent: mixtures of acetonitrile (A) and 0.05 % aq. TFA (B), 
gradient: 0 to 30 min: A/B 20/80 to 75/25, 30 to 31 min: 75/25 to 95/5, 31 to 38 min: 95/5, flow rate: 0.8 
mL/min, UV-detection: 210 nm. tR (4.29-i1) = 21.9 min; tR (4.29-i2) = 23.3 min. 
 
 
4.2.2  Y1 Receptor Antagonism, Affinity and Selectivity 
 
The fluorescent Y1R antagonists as well as the amino precursors 4.21 and 4.27 were 
investigated for Y1R antagonism in a spectrofluorimetric Ca2+-assay (Fura-2 assay) on human 
erythroleukemia (HEL) cells32 and in a radioligand binding assay on SK-N-MC neuroblastoma 
cells using [3H]-UR-MK114 (cf. chapter 2) as radioligand (Table 1). Y1R binding of the DE99 
labeled ligand 4.30 and the Py-1 labeled antagonist 4.34 was additionally determined on MCF-
7-Y1 breast cancer cells. All fluorescent ligands were able to antagonize the effect of the agonist 
pNPY on HEL cells in the lower and middle nanomolar range except the S0436 labeled ligand 
(4.29) with an IC50-value of about 1 µM and a corresponding Kb value of about 150 nM for both 
isomers (Table 1). Radioligand competition experiments on SK-N-MC cells revealed that most 
of the fluorescent Y1R antagonists are potent Y1R ligands with dissociation binding constants in 
the two-digit nanomolar range (Table 1). The lowest affinity showed the Dy-635 labeled ligand 
4.28 with a Ki value of 570 nM. Compound 4.34 proved to be the most potent ligand on SK-M-
MC cells (Ki = 13 nM), but binds on MCF-7-Y1 cells with the same affinity as fluorescent ligand 
4.30 (Ki = 52 nM and 57 nM, resp.). The lower affinity (factor 2 – 3) at Y1 receptors expressed 
on MCF-7 cells over Y1 receptors on SK-N-MC cells is a general phenomenon which was also 
observed for the radioligand [3H]-UR-MK114 (KD = 1.2 nM and 2.9 nM, resp.), for potential PET 
ligands described in chapter 5 as well as for a large number of bivalent Y1R antagonists 
(chapter 3).  
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Table 1. Structures, Y1 receptor antagonism and binding data of BIBP 3226, BIBO 3304 (6.6), amine
precursors 4.21, 4.27 and fluorescent ligands 4.28 - 4.47. 
(R)
H
N N
H
O
R'O
= R1 if R' = OH
= R2 if R' = CH2-NHCONH2
NH
NH2N
N
H3C
H3C TFA
R''
R'': depends on type of the Py-dye 
      (cf. Figure 1)
Py-1/5/6*  =
 
Compd. Structure IC50 (Kb) [nM]a Kib (Kic) [nM] 
BIBP 
3226 R
1-H 10±1 (1.5) 1.3±0.2 
6.6 R2-H (BIBO 3304) 4.6±1 (0.7) 0.25±0.01 
4.21 R1-CO-(CH2)5-NH2 620±130 (95) 19±5 
4.27 R1-CONH-(CH2)4-NH2 110±3 (16) 4.3±0.5 
4.27-Ni confer Scheme 4 3300±790 (510) 38±3 
4.28 R1-CO-(CH2)5-NH-Dy-635 110±11 (18) 570±270 
4.29-i1 R1-S0436 950±300 (150) 144±56 
4.29-i2 R1-S0436 990±270 (153) 40±7 
4.30 R1-CO-(CH2)3-CONH-(CH2)2-NH-DE99 16±1 (2.4) 42±5 (57±15) 
4.31 R1-CONH-(CH2)4-NH-DE99 4.6±1 (0.7) 26±2 
4.32 R2-CO-(CH2)5-Py-1 79±2 (12) 23±3 
4.33 R1-CO-(CH2-CH2-O)3-CH2-CH2-Py-1 27±2 (4.1) 97±6 
4.34 R1-CO-CH2-(O-CH2-CH2)2-Py-1 170±35 (26) 13±4 (52±7) 
4.35 R1-CO-CH2-(O-CH2-CH2)2-Py-5 74±5 (11) 24±3 
4.36 R1-CO-(CH2)5-Py-1 7.0±2 (1.1) 30±2 
4.37 R1-CO-(CH2)5-Py-5 24±4 (3,7) 50±4 
4.38 R1-CO-(CH2)3-CONH-(CH2)2-Py-1 39±2 (6.0) 22±5 
4.39 R1-CO-(CH2)3-CONH-(CH2)3-Py-1 73±3 (11) 38±2 
4.40 R1-CO-(CH2)3-CONH-(CH2-CH2-O)2-(CH2)2-Py-6 44±8 (6.8) 96±16 
4.41 R1-CO-(CH2)4-CONH-(CH2-CH2-O)2-(CH2)2-Py-6 52±6 (8.0) 130±40 
4.42 R1-CO-(CH2)6-CONH-(CH2-CH2-O)2-(CH2)2-Py-6 50±17 (7.8) 130±27 
4.43 R1-CONH-(CH2)4-Py-1 47±8 (7.2) 140±10 
4.44 R1-CONH-(CH2)4-Py-5 49±4 (7.6) 150±15 
X N
H
NH N
H
O
Y
O
Py-1
TFAO
R1
O
R1
 
4.45 X = Y = CH2-CH2 7.7±1 (1.2) 61±8 
4.46 X = Y = CH2-CH2-CH2-CH2 3.6±1 (0.6) 100±10 
4.47 X = CH2-CH2-CONH-CH2-CH2 Y = CH2-CH2-NHCO-CH2-CH2 
6.5±2 (1.0) 56±4 
The fluorescent dyes Dy-635, S0436 and DE99 are bound via the carboxylic groups. For structures of
dyes see Figure 1. aInhibition of 10 nM pNPY induced [Ca2+]i mobilization in HEL cells; mean values ± 
SEM from two independent experiments. b,cDissociation constant determined from the displacement of
[3H]-UR-MK114 (SK-N-MC cells: KD = 1.2 nM, MCF-7-Y1 cells: KD = 2.9 nM) on bSK-N-MC and 
cMCF-7-Y1 cells; mean values ± SEM from two independent experiments performed in triplicate. *In this 
Table “Py” designates the pyridinium adducts of the pyrylium dyes. 
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Interestingly, the BIBO 3304 derivative 4.32 and the BIBP 3326 derivative 4.36, differing only in 
their pharmacophoric moiety, exhibited nearly identical affinities (Ki = 23 nM and 30 nM, resp., 
Table 1) even though, comparing the parent compounds, BIBO 3304 is superior to BIBP 3226 
by a factor of about five. As described in chapter 6, the potential radioligand NG-propionyl-BIBO 
3304 (6.7) (Ki = 7.8 nM, cf. chapter 6) has even lower Y1R affinity than [3H]-N-propionyl-BIBP 
(2.8b) (KD = 1.2 nM, cf. chapter 2). Therefore, BIBO 3304 seems to interact with the Y1 receptor 
in a manner that N-substitution is less tolerated compared to BIBP 3226.   
The amino precursor 4.27, the carbamoyl analog of precursor 4.21, is more potent than 4.21 by 
a factor of about four (Ki = 4.3 nM and 19 nM, resp.). The same was found for N-
ethylaminocarbonyl-BIBP 322616 which has about four times higher Y1R affinity than the 
corresponding alkanoyl analog, N-butanoyl-BIBP 3226 (6.2, cf. chapter 6) (Ki values: 0.17 nM 
and 0.74 nM, resp.). However, this does not allow the conclusion that N-carbamoylation of 
BIBP 3226 is generally superior to N-acylation. For instance, the fluorescent ligands 4.43 and 
4.44 (Ki = 140 nM and 150 nM, Table 1) have markedly lower affinity than compound 4.36 (Ki = 
30 nM), the “carba analogue” of 4.43. Therefore it is possible that the presence of the 
carbamoyl NH-group implicates a different orientation of the N-substituent which is less 
compatible with the attachment of bulky entities such as fluorophores.       
The Ki and Kb values from binding and functional assays, respectively, are not identical. There 
are diverse possible reasons for these discrepancies. First, the Fura-2 Ca2+-assay is performed 
in a time window (a few minutes) in which the antagonists, exhibiting a high on- and off-rate 
(compare association and dissociation kinetics of [3H]-UR-MK114 (2.8b) in chapter 2), can 
nearly reach equilibrium conditions, whereas the agonist pNPY is characterized by slow binding 
kinetics.33 Moreover, also the structure of the compounds seems to play a role: The Kb value of 
most BIBP 3226 derived fluorescent ligands is significantly lower than the Ki value, but a good 
correlation between Kb and Ki value was found e.g. for BIBP 3226, BIBO 3304 and the BIBO 
3304 derived ligand 4.32. In case of amine precursors 4.21, 4.27 and 4.27-Ni the Kb value was 
even higher than the Ki value. 
 
The Y1 receptor selectivity was exemplary confirmed for compound 4.36 and 4.38 in flow 
cytometric binding studies using Cy5, Dy-635 and S0486 labeled peptides (Cy5-pNPY, Dy-635-
pNPY, S0586-[K4]hPP, Cy5-[K4]hPP) and cells expressing human Y1, Y2, Y4 and Y5 receptors 
(Table 2). It is not possible to determine selectivity data for the Dy-635, S0436 as well as DE99 
labeled ligands using these assays due to the excitability of Dy-635, S0436 and DE99 with the 
red diode laser (635 nm). For these compounds radiolabeled pNPY or PP analogs have to be 
used. 
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Table 2. NPY receptor subtype selectivity of the fluorescent ligands 4.36 and 4.38. 
Comp. Y1 Ki [nM]a Y1 Ki [nM]b Y2 Ki [nM]c Y4 Ki [nM]d Y5 Ki [nM]c 
4.36 30 7 > 1,500 > 500 > 1,000 
4.38 22 -- > 3,000 > 2,000 > 5,000 
aKi values from radioligand competition assay with [3H]-UR-MK114 (c = 1.5 nM) on SK-N-MC 
neuroblastoma cells. bFlow cytometric binding assay on HEL using Cy5-pNPY as labelled 
ligand. cFlow cytometric binding assay on CHO-Y2 and HEC-1B-Y5 cells using Dy-635-pNPY 
or Cy5-pNPY as labeled ligands (10 nM). dFlow cytometric binding assay on CHO-Y4 cells 
with S0586-[K4]-hPP (10 nM for 4.36) or Cy5-[K4]-hPP (5 nM for 4.38) as fluorescent ligand. 
 
 
4.2.3  Fluorescence Properties of the Fluorescently Labeled Y1R Antagonists 
 
The fluorescence properties of the labeled Y1R antagonists are summarized in Table 3. The 
fluorescence quantum yields were determined (reference: cresyl violet perchlorate) in 
phosphate buffered saline (PBS) at pH 7.0 and in PBS with 1 % bovine serum albumin (BSA) to 
simulate assay conditions and to study the influence of proteins on the fluorescence properties. 
Additionally, the quantum yield of most compounds was also determined in ethanol to examine 
the influence of the polarity of the solvent. 
 
Table 3. Spectroscopic properties of the fluorescent Y1R antagonists 4.28 - 4.47: Influence of the 
polarity of the solvent (PBS pH 7 vs. ethanol) and protein (BSA) on the quantum yield  (reference: 
cresyl violet perchlorate) as well as excitation/emission maxima.  
 PBS PBS + 1 % BSA EtOH 
Compd. Dye ex / em  [%] ex / em  [%] ex / em  [%]
4.28 Dy-635 505,643 / 668 0.4 505,659 / 673 36 -- -- 
4.29-i1 S0436 644 / 662 2.1 667 / 676 59 -- -- 
4.29-i2 S0436 646 / 663 7.5 608 / 676 62 -- -- 
4.30 DE99 583 / 704 1.8 600 / 680 25 595 / 706 6.6 
4.31 DE99 580 / 705 1.1 608 / 676 29 595 / 705 6.9 
4.32 Py-1 509 / 646 0.6 527 / 614 21 -- -- 
4.33 Py-1 508 / 640 1.1 525 / 613 45 521 / 633 2.5 
4.34 Py-1 506 / 640 1.4 518 / 610 50 519 / 633 2.3 
4.35 Py-5 470 / 708 4.6 488 / 643 38 509 / 708 20 
4.36 Py-1 508 / 647 0.7 540 / 614 56 -- -- 
4.37 Py-5 458 / 709 2.0 488 / 644 34 504 / 706 21 
4.38 Py-1 514 / 643 1.6 524 / 610 48 520 / 633 2.4 
4.39 Py-1 505 / 642 0.8 526 / 612 49 522 / 632 2.1 
4.40 Py-6 533 / 607 7.6 543 / 596 48 541 / 609 23 
4.41 Py-6 534 / 607 7.7 541 / 596 47 542 / 609 21 
4.42 Py-6 534 / 607 4.9 542 / 596 48 540 / 609 23 
4.43 Py-1 504 / 640 0.5 517 / 604 52 517 /630 2.4 
4.44 Py-5 456 / 707 2.4 489 / 643 34 497 / 705 24 
4.45 Py-1 545 / 644 0.7 527 / 612 37 525 / 634 2.8 
4.46 Py-1 540 / 644 0.6 526 / 610 23 525 / 635 2.7 
4.47 Py-1 543 / 642 0.5 526 / 611 50 524 / 633 3.0 
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Generally, the pharmacophoric entity (BIBP 3226 or BIBO 3304) and the chemical structure of 
the linkers, connecting pharmacophore and fluorophore, have almost no effect on the 
fluorescence properties. Only the bivalent ligands show a significant bathochromic shift of the 
excitation maximum in PBS (≈ 543 nm) compared to the monovalent fluorescent ligands labeled 
with Py-1 (ex ≈ 507 nm). 
 
All fluorescent ligands hold the highest quantum yield in PBS with 1 % BSA (up to ≈ 60 % for 
S0436 and ≈ 50 % quantum yield for Py-1 and Py-6 labeled compounds) and a very low 
quantum yield in pure PBS (< 8 %). In some cases the quantum yield increased by a factor 
higher than 50 after addition of BSA. Reasons for this phenomenon have to be intermolecular 
interactions, particularly hydrophobic and electrostatic interactions, of the fluorophores with the 
protein. Moreover, binding of the fluorescent ligands to proteins can be regarded as a kind of 
rigidization, which generally leads to an increase in quantum yield. Therefore, when BSA free 
buffers are used for binding assays with these fluorescent ligands, the fluorescence could 
increase in the receptor bound state. However, an increase in fluorescence intensity could also 
result form non-specific interactions of the ligand with other proteins or with the cell membrane. 
It is noticeable that the high quantum yields in ethanol are quite high (≈ 22 %) for the Py-5 and 
Py-6 labeled ligands in relation to the quantum yields of these compounds in PBS with 1 % BSA 
(Table 3) and compared to the compounds labeled with other fluorescent dyes. Obviously, 
ligands labeled with Py-5 or Py-6 are more sensitive to hydrophobic interactions than those 
labeled with Py-1 or DE99 (quantum yield in ethanol < 7 %). The two isomers of the fluorescent 
ligand 4.29 (cf. 4.2.1) do not differ significantly in their fluorescence properties. 
 
The excitation and corrected emission spectra of various fluorescence labeled antagonists in 
PBS containing 1 % of BSA are depicted in Figure 4. The largest Stoke’s shift show the Py-5 
labeled compounds followed by Py-1 and DE99 labeled ligands. S0436, Dy-635 and DE99 
labeled fluorescent ligands can be excited with the red diode laser at 635 nm. DE99 is 
additionally excitable at 488 nm (argon laser), but with lower efficiency. Py-1, Py-5 and Py-6 
labeled compounds can be excited at 488 nm (highest efficiency for Py-5).  
Thus, the fluorescence properties of all synthesized fluorescent ligands enable an application to 
flow cytometric equilibrium binding studies and confocal microscopy. 
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Figure 4. Excitation and corrected emission spectra in PBS + 1 % BSA of a Dy-635, S0436, DE99, Py-1, 
Py-5 and Py-6 labeled Y1R antagonist (recorded at 22 °C).    
 
 
 
 
 
 
 
 
Fluorescently Labeled Y1 Receptor Antagonists 95
4.2.4 Application of the Fluorescent Y1R Antagonists to Confocal Microscopy and Flow 
Cytometry  
 
For binding studies with confocal microscopy and flow cytometry only fluorescent Y1R 
antagonists with Ki values of 50 nM and lower (SK-N-MC cells) were used. In view of the 
potential diagnostic value of fluorescent GPCR ligands in microscopy, steroid hormone-
sensitive MCF-7 breast cancer cells were selected as a model, since these cells were reported 
to express the Y1R.34, 35 As a MCF-7 subclone showing higher Y1 receptor expression than the 
wild-type MCF-7 cells (ATCC number HTB 22) was recently established in our laboratory, this 
cell line (designated MCF-7-Y1) was used for confocal microscopy experiments. As shown in 
Figures 5 and 6, a clear difference between total and non-specific binding was obtained for the 
Py-1 labeled Y1R antagonists 4.36, 4.38, 4.34, 4.32, 4.45 and 4.47 as well as for the Py-5 
labeled ligand 4.35 and the DE99 labeled compounds 4.30 and 4.31. Non-specific binding was 
determined in the presence of the non-fluorescent Y1R antagonist BIBP 3226. The amount of 
specifically bound fluorescent ligand varies between low (4.32, Fig. 5, panel D) to very high 
(4.34, Fig. 5, panel C; 4.47, Fig. 6, panel I). In principle, this could be due to differing binding 
constants on Y1R expressed on MCF-7-Y1 cells (only determined for 4.30 and 4.34, Table 1) or 
fluctuations in the receptor density. Generally, the monovalent ligands were significantly 
enriched intracellularly after incubation periods longer than 15 min, as exemplary shown in 
Figure 6 (panel F) for the DE99 labeled Y1R antagonist 4.30. Penetration into the cell nuclei 
(apparent as dark areas) was not observed. By contrast, the bivalent fluorescent ligands 4.45 
and 4.47 were not detected inside the cells under the same conditions, as becomes obvious 
from Figure 6 (panels H and I) (images acquired after an incubation period of 23 min). 
Binding experiments with the S0436 labeled ligand 4.29-i2 (isomer with the higher affinity, cf. 
Table 1) revealed no clear difference between total and non-specific binding (Figure 7), 
presumably due low affinity for Y1 receptors expressed on MCF-7-Y1 cells (not determined) or to 
unusually high non-specific binding. 
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Figure 5. Binding of the fluorescent ligands 4.36 (panel A), 4.38 (panel B), 4.34 (panel C), 4.32 (panel D) 
and 4.35 (panel E) to Y1R constitutively expressed in the cell membrane of MCF-7-Y1 tumor cells, 
visualized by confocal microscopy. 1 designates total binding, 2 non-specific binding (in the presence of 
BIBP 3226 at 70-160 fold higher concentrations than the fluorescent ligands), 3 autofluorescence. A: 4.36 
(60 nM, 6 min), B: 4.38 (40 nM, 9 min), C: 4.34 (60 nM, 6 min), D: 4.32 (60 nM, 9 min), E: 4.35 (30 nM, 15 
min). Cells were incubated with the fluorescent ligands at room temperature in Leibowitz L15 culture 
medium. All images were acquired with a Zeiss Axiovert 200 M microscope.       
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Figure 6. Binding of the fluorescent ligands 4.30 (panel F), 4.31 (panel G), 4.45 (panel H) and 4.47 (panel 
I) to Y1R constitutively expressed in the cell membrane of MCF-7-Y1 tumor cancer cells, visualized by 
confocal microscopy. 1 designates total binding, 2 non-specific binding (in the presence of BIBP 3226, 
70-125 fold concentrated), 3 autofluorescence. F: 4.30 (70 nM, 1a: 10 min, 1b: 20 min), G: 4.31 (70 nM, 7 
min), H: 4.45 (80 nM, 23 min), I: 4.47 (80 nM, 23 min). Cells were incubated with the fluorescent ligands 
at room temperature in Leibowitz L15 culture medium. All images were acquired with a Zeiss Axiovert 200 
M microscope.       
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Figure 7. Binding of the fluorescent ligand 4.29-i2 to Y1R expressing MCF-7-Y1 tumor cells, visualized by 
confocal microscopy. J1: total binding (60 nM, 7 min), J2: non-specific binding (60 nM, 9 min) in the 
presence of BIBP 3226 (5 µM), J3: autofluorescence. All images were acquired with a Zeiss Axiovert 200 
M microscope after 7-9 min of incubation time at room temperature in Leibowitz L15 culture medium.       
 
 
With respect to the application of the fluorescent ligands in flow cytometric binding studies HEL 
cells, which are constitutively expressing Y1 receptors and can be easily grown in suspension 
culture, as well as MCF-7-Y1 cells were used. Displacement curves of the Py-1 labeled Y1R 
antagonist 4.36 with BIBP 3226 are shown in Figure 8. From the data recorded in the 
fluorescence channels Fl-2 (585 ± 21 nm, Figure 8A) and Fl-3 (> 670 nm, Figure 8B) Ki values 
of 3.5 nM and 4.6 nM were calculated. Thus, in principle both fluorescence channels are suited 
for binding studies with Y1R antagonist 4.36. The apparent Ki value of compound 4.36 (Ki = 7 
nM, Table 2) from the flow cytometric selectivity assay (Table 2) was used for the calculation of 
the Ki values for the model compound BIBP 3226. 
As shown in Figure 9A, flow cytometric saturation binding experiments with fluorescent ligand 
4.31 using MCF-7-Y1 breast cancer cells yielded saturation curves with low non-specific binding 
and a KD value of 5.3 ± 0.7 nM (mean value ± SEM, two independent experiments performed in 
duplicate). Displacement of the fluorescent ligand 4.31 with BIBP 3226 yielded a Ki value of 2.2 
nM calculated with the determined KD value of 5.3 nM.   
These data determined for the model compound BIBP 3226 (Ki = 3.5 nM and 4.6 nM, resp., as 
well as 2.2 nM) are in good accordance with the value (Ki = 1.3 nM) determined with [3H]-UR-
MK114 (chapter 2) as well as with previously reported Ki values of 7 nM and 5.1 nM, determined 
in radioligand competition studies.15, 36 
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Figure 8. Flow cytometric Y1R binding assay with antagonist 4.36 at human erythroleukemia cells (HEL 
cells). The geometrical mean values of fluorescence intensities obtained from the competition assay were 
converted to percentage inhibition according to the procedure described in detail previously.2, 3 
Displacement of 4.36 (10 nM) by increasing concentrations of BIBP 3226 was registered in fluorescence 
channels Fl-2 (585 ± 21 nm, Figure 4A) and Fl-3 (> 670 nm, Figure 4B), respectively. Samples were 
incubated at room temperature for 15 min. Calculated Ki values: 3.5 nM (A) and 4.6 nM (B). (mean values 
± SEM, n = 3) 
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Figure 9. A: Flow cytometric saturation binding experiment with fluorescent ligand 4.31 at human MCF-7-
Y1 breast cancer cellls. Unspecific binding was determined in the presence of BIBP 3226 (500-fold 
excess). Determined KD value: 5.0 ± 0.6 nM. B: Flow cytometric Y1R competition assay with 4.31 (10 nM) 
and BIBP 3226 using MCF-7-Y1 cells. The geometrical mean values of fluorescence intensities 
(fluorescence channel Fl-4) obtained from the competition assay were converted to percentage inhibition 
values according to the procedure described in detail previously.2, 3 Samples were incubated for 15 min at 
room temperature. Calculated Ki value: 2.2 nM. (mean values ± SEM, A: n = 2, B: n = 3) 
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4.2.5  Summary and Conclusion 
 
The design of fluorescent Y1R ligands was based on the application of the guanidine-
acylguanidine bioisosteric approach to the argininamide-type Y1R antagonists BIBP 3226 and 
BIBO 3304. The guanidine group was linked to fluorophores via -aminoacyl spacers of 
different lengths and chemical nature. Such derivatives proved to be potent and selective 
fluorescence labeled Y1R antagonists, although - depending on the fluorescent dye - a more or 
less pronounced decrease in activity compared to the parent argininamide was noticed.  
The low molecular weight pyrylium dyes, the smallest red-fluorescent fluorophores known, 
turned out to be well suited for the fluorescence labeling of Y1R antagonists. In some cases the 
decrease in affinity compared to the parent compound BIBP 3226 was less than a factor of 10 - 
20 (4.31, 4.34, 4.35 and 4.38, Table 1) which is a very good result for fluorescence labeling of a 
small ligand. Functionalization of amine precursors 4.22 and 4.27 with the benzothiazolium 
derivative DE99 (Figure 1) yielded fluorescent probes (4.30 and 4.31) for the Y1 receptor with 
favorable characteristics comparable to those of the pyrylium dye labeled compounds. The 
coupling of the dyes Py-1 and Py-5 (Figure 1) to amine precursor 4.20 (Scheme 6) provided the 
most potent fluorescent ligands (4.34 and 4.35, Table 1). With respect to future work, this result 
suggests labeling of the precursor 4.20 with DE99, as this dye proved to be superior to Py-1 
and Py-5 in terms of retaining the binding affinity (cf. compounds 4.31, 4.43 and 4.44, Table 1). 
The attachment of DE99 to precursor 4.20 will probably result in a high affinity fluorescent 
ligand with decreased lipophilicity and consequently lower membrane binding and cell 
penetration. 
The majority of the most potent fluorescent Y1R antagonists (Ki = 10 – 50 nM) was successfully 
applied in confocal microscopy and flow cytometric equilibrium binding studies. Such 
fluorescent antagonists are anticipated to enable more detailed investigations of association 
kinetics at the NPY Y1R with - compared to agonists - less interference with receptor 
desensitization and internalization processes. Therefore, these fluorescent probes pave the way 
to optical detection of NPY Y1 receptors on cells, in tissues and organs, as demonstrated on 
MCF-7-Y1 breast cancer cells in Figures 5 and 6. 
 
 
 
 
 
 
 
 
 
Fluorescently Labeled Y1 Receptor Antagonists 101
4.3  Experimental Section 
 
4.3.1 General Experimental Conditions 
 
Unless otherwise noted, chemicals and solvents were purchased from commercial suppliers 
and used without further purification. The glycol-derived spacers 12-amino-4,7,10-trioxa-
dodecanoic acid tert-butylester and N-Boc-8-amino-3,6-dioxa-octanoic acid dicyclohexylamine 
salt were purchased from Fluka (Sigma-Aldrich Chemie GmbH, Munich, Germany). D-Ornithine 
hydrochloride was obtained from Iris Biotech GmbH (Marktredwitz, Germany). Bovine serum 
albumin (BSA) was from Serva (Heidelberg, Germany). The tetrafluoroborate salts of the 
pyrylium dyes Py-1, Py-5 and Py-6 were synthesized in the Institute of Analytical Chemistry, 
Chemo- and Biosensors at the University of Regensburg20, 21 (note: these dyes are 
commercially available from Active Motif Chromeon, www.activemotif.com). The activated (NHS 
ester) fluorescent dyes S0536 (S0436-NHS) and Dy-635-NHS were obtained from FEW 
Chemicals (Bitterfeld-Wolfen, Germany) and Dyomics (Jena, Germany), respectively. Dy-635-
pNPY and Cy5-pNPY were synthesized as described previously.3 [K4]-hPP was synthesized in 
the laboratory of Prof. Beck-Sickinger (University of Leipzig, Germany) and labeled with the 
cyanine dyes Cy5 and S0586 (FEW chemicals (Bitterfeld-Wolfen, Germany) in our laboratory.37 
Porcine NPY (pNPY) was prepared in-house in the laboratory of Dr. C. Cabrele. The fura-2 AM 
(Calbiochem/Merck Biosciences, Beeston, UK) stock solution (1 mM) was prepared in DMSO. 
Pluronic F-127 (Calbiochem/Merck Biosciences, Beeston, UK) was dissolved in DMSO to obtain 
a concentration of 20 %. 
Millipore water was used throughout for the preparation of buffers and HPLC eluents. Petroleum 
ether (40-60 °C) was distilled before use. DMF was stored over a molecular sieve (3 Å). 
Anhydrous reactions were run under an atmosphere of dry nitrogen or argon. 
Thin layer chromatography was performed on Merck silica gel 60 F254 TLC aluminum plates. For 
column chromatography silica gel Geduran 60 (Merck, 0.063-0.200 mm) was used. NMR 
spectra were recorded on a Bruker Avance 300 (1H: 300 MHz) and a Bruker Avance 600 (1H: 
600 MHz, 13C: 150.9 MHz) (Bruker, Karlsruhe, Germany) with TMS as external standard. Mass 
spectrometry analysis (MS) was performed in-house on a Finnigan ThermoQuest TSQ 7000 
(ES-MS) and a Finnigan SSQ 710A (EI-MS 70 eV, CI-MS). Lyophilization was done with a 
Christ alpha 2-4 LD equipped with a vacuubrand RZ 6 rotary vane vacuum pump.  
Preparative HPLC was performed with a system from Knauer (Berlin, Germany) consisting of 
two K-1800 pumps and a K-2001 detector. A Nucleodur 100-5 C18 (20 × 21 mm, 5 µm; 
Macherey-Nagel, Germany) and a Eurospher-100 C18 (250 × 32 mm, 5 µm; Knauer, Germany) 
served as RP-columns at flow rates of 24 and 38 mL/min, respectively. Mixtures of acetonitrile 
and 0.1 % aq. TFA were used as mobile phase. Acetonitrile was removed from the eluates 
under reduced pressure (final pressure: 60 mbar) at 40 °C prior to lyophilization. Analytical 
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HPLC analysis was performed on a system from Thermo Separation Products (composed of a 
SN400 controller, a P4000 pump, a degasser (Degassex DG-4400, phenomenex), an AS3000 
autosampler and a Spectra Focus UV-VIS detector). An Eurospher-100 C18 (250 × 4 mm, 5 
µm, Knauer, Germany) or a Nucleodur 100-5 C18 ec (250 × 4 mm, 5 µm, Macherey-Nagel, 
Germany) served as RP-columns. Mixtures of acetonitrile (A) and 0.05 % aq. TFA (B) were 
used as mobile phase. Helium degassing, an oven temperature of 30 °C and a flow rate of 0.8 
mL/min were used throughout. Solutions for injection (concentrations in the two-digit µM range) 
were prepared in a mixture of A and B corresponding to the mixture at the beginning of the 
gradient. The following gradients were applied for analytical HPLC analysis:  
Gradient 1: 0 to 30 min: A/B 20/80 to 75/25, 30 to 31 min: 75/25 to 95/5, 31 to 35 min: 95/5 
Gradient 2: 0 to 30 min: A/B 20/80 to 60/40, 30 to 32 min: 60/40 to 95/5, 32 to 36 min: 95/5 
Gradient 3: 0 to 30 min: A/B 20/80 to 95/5, 30 to 40 min: 95/5 
The preparation of the buffer and the lysis solution for Y1R binding studies on SK-N-MC cells 
and MCF-7 cells as well as the loading buffer for the determination of the mobilization of 
intracellular Ca2+ in HEL cells are described in chapter 3. 
 
 
4.3.2 Chemistry: Experimental Protocols and Analytical Data 
 
(R)-N-Benzyloxycarbonyl-N-(tert-butoxycarbonyl)ornithine (4.1).38 Compound 2.1 (22 g, 
82.6 mmol, 1 eq; cf. chapter 2) was dissolved/suspended in an aqueous solution (250 mL) of 
potassium carbonate (12.56 g, 90.9 mmol, 1.1 eq) and 1,4-dioxane (100 mL) was added. Di-
tert-butyl dicarbonate (18.93 g, 86.75 mmol, 1.05 eq) was added dropwise in 1,4-dioxane (200 
mL) over a period of 60 min. The mixture was stirred at rt overnight, then concentrated under 
reduced pressure to a volume of about 150 mL. Water (50 mL) was added and the pH was 
adjusted to 2-3 by the addition of 1 M aq. hydrochloric acid (about 150 mL). The product was 
extracted with ethyl acetate (400 mL and 3 × 300 mL) and the combined organic phases were 
treated with 10 mM aq. hydrochloric acid (100 mL), saturated aq. NH4Cl (200 mL), water (100 
mL) as well as brine (250 mL) prior to drying over sodium sulfate. Filtration and evaporation of 
the solvent yielded a yellowish oil which turned into a foam that hardened to a solid during 
drying in vacuo (27.8 g, 75.9 mmol, 92 %). 1H-NMR (300 MHz, DMSO-d6):  (ppm) 1.38 (s, 9H, 
tert-butyl), 1.4-1.59 (m, 3H, CH-CH2-CH2), 1.65 (m, 1H, CH-CH2-CH2), 2.98 (m, 2H, CH2-NH), 
3.83 (m, 1H, CH), 5.0 (s, 2H, CH2-Ph), 7.07 (d, 1H, 3J = 7.98 Hz, CO-NH-CH), 7.25 (t, 1H, 3J = 
5.49 Hz, CO-NH-CH2), 7.34 (m, 5H, Ph), 12.42 (s, 1H, COOH); C18H28N2O6 (366.4) 
 
(R)-N-Benzyloxycarbonyl-N-tert-butoxycarbonyl-N-(4-ureidomethylbenzyl)ornithinamide 
(4.2). Compound 4.1 (7.93 g, 21.65 mmol, 1 eq) was activated with carbonyldiimidazole (3.86 g, 
23.8 mmol, 1.1 eq) in DMF (80 mL) at 0 °C for 60 min. NEt3 (3.3 g, 32.5 mmol, 1.5 eq), DMAP 
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(1.3 g, 10.8 mmol, 0.5 eq) and 4.8 (4.67 g, 21.65 mmol, 1 eq) were added in DMF (250 mL) as 
suspension. The mixture was slowly warmed up to 45 °C yielding an almost clear solution. 
Warming was finished after 30 min and the mixture was stirred at rt overnight. Glacial acetic 
acid (2 mL, about 1.5 eq) was added and DMF was removed under reduced pressure at 45 °C 
yielding an oily residue which was dried in vacuo. Purification by column chromatography 
yielded the product as a yellowish hard solid (9.75 g, 18.48 mmol, 85 %). 1H-NMR (300 MHz, 
MeOH-d4):  (ppm) 1.43 (s, 9H, tert-butyl), 1.46-1.66 (m, 3H, CH-CH2-CH2), 1.74 (m, 1H, CH-
CH2-CH2), 3.11 (m, 2H, CH2-CH2-NH), 4.04 (m, 1H, CH), 4.25 (s, 2H, CH2-NH-CO-NH2), 4.33 
(m, 2H, NH-CH2-Ar), 5.04 (s, 2H, CH2-Ph), 7.22 (m, 4H, CH2-C6H4-CH2), 7.28-7.35 (m, 5H, Ph); 
MS (ES, MeOH + 10 mM NH4OAc): m/z 528 [M + H]+; C27H37N5O6 (527.6) 
 
(R)-N-Benzyloxycarbonyl-N-(4-ureidomethyl-benzyl)ornithinamide (4.3). Compound 4.2 (9 
g, 17.1 mmol) was dissolved in MeOH (250 mL) and acetyl chloride (30 mL) was added 
dropwise under water cooling (20 °C) over a period of 1.5 h. Stirring was continued for 30 min, 
volatiles were removed under reduced pressure and the residue was suspended in water (100 
mL). Lyophilization afforded the product as a white solid (7.9 g, 17.1 mmol, 100 %); Solubility 
checked for DMF (+), MeOH (+), acetonitrile (-), THF (-), ethyl acetate (-), dimethoxyethane (-) 
and CH2Cl2 (-); 1H-NMR (300 MHz, MeOH-d4):  (ppm) 1.57 (m, 2H, CH-CH2-CH2), 1.72-2.04 
(bm, 2H, CH-CH2-CH2), 2.98 (m, 1H, CH), 3.14 (m, 2H, CH2-CH2-NH), 4.34-4.42 (m, 4H, CH2-
Ar-CH2), 5.05 (s, 2H, CH2-Ph), 7.26-7.36 (m, 9H, Ph, CH2-C6H4-CH2); MS (ES, MeOH + 10 mM 
NH4OAc): m/z 428 [M + H]+; C22H29N5O4 × HCl (464.0) 
 
(R)-N-Benzyloxycarbonyl-N-(2,2-diphenylacetyl)-N-(4-ureidomethylbenzyl)ornithinamide 
(4.4).29 Compound 4.3 (7.8 g, 16.8 mmol, 1 eq) was dissolved in anhydrous DMF (100 mL). 
NEt3 (2.6 g, 3.5 mL, 25.2 mmol, 1.5 eq), DMAP (1 g, 8.4 mmol, 0.5 eq) and 2.10 (6.2 g, 20.2 
mmol, 1.2 eq, cf. chapter 2) were added and the mixture was kept under stirring for 20 h at rt. 
Glacial acetic acid (3 mL) was added and DMF was removed under reduced pressure at 45 °C 
yielding a light yellow-brown solid which was dried in vacuo. The solid was insoluble or poorly 
soluble in MeOH, CH2Cl2, acetonitrile, dimethoxyethane, THF, 1,4-dioxane, propan-2-ol, ethanol 
and in mixtures with water of the water-miscible solvents. Therefore the solid material was 
mechanically crushed to small pellets and suspended in acetonitrile (2500 mL). The solid turned 
into a white fluffy solid during heating (70 °C) and treatment with ultrasound (30 min). 
Separation by filtration and intensive washing with acetonitrile (2 × 250 mL) and water (3 × 150 
mL) yielded the product as a white solid (8.7 g, 14 mmol, 83 %). Solubility: insoluble or poorly 
soluble in above listed solvents; 1H-NMR (300 MHz, DMSO-d6):  (ppm) 1.37 (m, 2H, CH-CH2-
CH2), 1.44-1.72 (bm, 2H, CH-CH2-CH2), 2.95 (m, 2H, CH2-CH2-NH), 4.1-4.26 (m, 4H, CH2-Ar-
CH2), 4.31 (m, 1H, CH), 5.0 (s, 2H, CH2-Ph), 5.12 (s, 1H, CH-(Ph)2), 5.52 (bs, 2H, NH2), 6.38 (t, 
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1H, NH-CO), 7.15 (m, 4H, CH2-C6H4-CH2), 7.18-7.38 (m, 16H, Ph, NH-CO), 8.44 (m, 2H, 2 × 
NH-CO); MS (ES, acetonitrile/TFA): m/z 622 [M + H]+; C36H39N5O5 (621.7) 
 
(R)-N-(2,2-Diphenylacetyl)-N-(4-ureidomethyl-benzyl)ornithinamide (4.5).29 Compound 4.4 
(2.7 g, 4.3 mmol) was suspended in MeOH (300 mL). The amount of solid could be reduced by 
heating the suspension to 60 °C. Glacial acetic acid (1.2 mL) and a 10 % Pd/C catalyst (430 
mg) were added and hydrogen was lead through the vigorously stirred mixture at 45 °C for 2.5 
h. At this time the white solid had disappeared. After 3 h the catalyst was removed by filtration, 
volatiles were removed under reduced pressure and the residue was suspended in water (50 
mL) at 40 °C. Lyophilization afforded the product as a white solid (2.1 g, 3.8 mmol, 88 %); 1H-
NMR (300 MHz, DMSO-d6):  (ppm) 1.4-1.63 (m, 3H, CH-CH2-CH2), 1.63-1.78 (m, 1H, CH-CH2-
CH2), 2.76 (m, 2H, CH2-NH2), 4.1-4.29 (m, 4H, CH2-Ar-CH2), 4.35 (m, 1H, CH), 5.13 (s, 1H, 
CH-(Ph)2), 5.54 (bs, 2H, NH2), 6.45 (t, 1H, NH-CO), 7.15 (m, 4H, CH2-C6H4-CH2), 7.2-7.35 (m, 
10H, Ph), 7.74 (bs, 3H, NH3+), 8.51 (t, 1H, NH-CO), 8.58 (d, 1H, CO-NH-CH); MS (ES, 
acetonitrile/TFA): m/z 488 [M + H]+; C28H33N5O3 × C2H4O2 (547.6) 
 
(R)-N-tert-Butoxycarbonyl-N-(2,2-diphenylacetyl)-N-(4-ureidomethylbenzyl)argininamide 
(4.6). Compound 4.5 (2.05 g, 3.74 mmol, 1 eq) was suspended in MeOH (30 mL). NEt3 (0.57 g, 
0.78 mL, 5.6 mmol, 1.5 eq) and 2.13 (1.55 g, 4.5 mmol, 1.5 eq, cf. chapter 2) were added in 
CH2Cl2 (10 mL) and the mixture was kept under stirring at rt for 20 h. The suspension turned 
into a cloudy solution during the first 30 min of the reaction. Volatiles were removed under 
reduced pressure and purification of the intermediate with column chromatography 
(CH2Cl2/MeOH 100/1 to 10/1) yielded a white solid which was dried in vacuo and dissolved in 
MeOH (180 mL). Glacial acetic acid (0.25 mL) and a 10 % Pd/C catalyst (400 mg) were added 
and hydrogen was lead through the vigorously stirred mixture for 6.5 h. The catalyst was 
removed by filtration, volatiles were removed under reduced pressure and the residue was 
suspended in water (60 mL). Lyophilization afforded the product as a white solid (1.8 g, 2.6 
mmol, 70 %); 1H-NMR (300 MHz, DMSO-d6):  (ppm) 1.27-1.45 (m, 11H, CH-CH2-CH2, tert-
butyl), 1.45-1.72 (bm, 2H, CH-CH2-CH2), 3.05 (m, 2H, CH2-CH2-NH), 4.13 (d, 2H, 3J = 5.99 Hz, 
CH2-Ar), 4.23 (d, 2H, 3J = 5.79 Hz, CH2-Ar), 4.35 (m, 1H, CH), 5.12 (s, 1H, CH-(Ph)2), 5.52 (s, 
2H, NH2), 6.38 (t, 1H, NH-CH2), 7.15 (m, 4H, CH2-C6H4-CH2), 7.2-7.34 (m, 10H, Ph), 8.48 (m, 
2H, 2 × NH); MS (ES, CH2Cl2/MeOH + 10 mM NH4OAc): m/z 630 [M + H]+; C34H43N7O5 × 
C2H4O2 (689.7) 
 
N-tert-Butoxycarbonyl-1,4-bis(aminomethyl)benzene (4.7).39 1,4-Bis(aminomethyl)benzene 
(30 g, 220.3 mmol, 1 eq) was dissolved/suspended in 1 M aq. NaOH (220 mL, 220.3 mmol, 1 
eq). 1,4-dioxane was added (250 mL) and the slolution was cooled in an ice-water bath. Di-tert-
butyl dicarbonate (48.1 g, 220.3 mmol, 1 eq) was added dropwise in 1,4-dioxane (150 mL) over 
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a period of 2 h. The ice-water bath was removed and the mixture was allowed to stand at rt 
overnight. The volume was reduced to about 250 mL under reduced pressure. The white solid 
was separated by filtration, washed twice with ice-cold water (2 × 100 mL) and dried in vacuo. 
White solid (47.6 g of a mixture of 4.7 and di-Boc-protected 1,4-bis(aminomethyl)benzene (≈ 
55:45), 22 g (93.1 mmol, 42 %) related to 4.7); 1H-NMR (300 MHz, MeOH-d4):  (ppm) 1.44 (s, 
24H, tert-butyl, 4.7 and “di-Boc”), 3.84 (s, 2H, CH2-NH2), 4.19 (s, 3.3H, CH2-NH, “di-Boc”), 4.20 
(s, 2H, CH2-NH, 4.7), 7.2 (s, 3.3H, CHAr, “di-Boc”), 7.29 (m, 4H, CHAr, 4.7); MS (CI, NH3): m/z 
254 [M + NH4]+, 354 [“di-Boc” + NH4]+; C13H20N2O2 (236.2) 
     
N-(4-Aminomethylbenzyl)urea (4.8).29 Compound 4.6 (19.6 g, 83.1 mmol, 1 eq; 42.5 g of a 
mixture with di-Boc-protected 1,4-bis(aminomethyl)benzene) was suspended in water (500 mL) 
and ethanol (400 mL). The suspension was heated to 60 °C and 1 M aq. hydrochloric acid (100 
mL) was added yielding a pH of about 3. Potassium cyanate (7 g, 86.3 mmol, 1.04 eq) was 
added and the mixture was refluxed for 75 min. 1 M aq. hydrochloric acid (8 mL) was added to 
adjust the pH to 7, followed by the addition of 4.67 g potassium cyanate (4.67 g, 57.6 mmol, 0.7 
eq). Reflux was continued for 2 h, then the mixture was stirred at rt overnight (final pH: ≈ 8) and 
concentrated under reduced pressure to a volume of about 200 mL. The white solid was 
separated by filtration, washed twice with water (2 × 150 mL) and dried in vacuo. A suspension 
was prepared in a mixture of MeOH and CH2Cl2 1/10 (2000 mL) and subjected to column 
chromatography (CH2Cl2/MeOH 20/1 to 7.5/1). The isolated Boc-protected intermediate (well 
soluble in MeOH, poorly soluble in water, acetonitrile, ethyl acetate and CH2Cl2) was dissolved 
in MeOH (300 mL) under moderate warming. Acetyl chloride (30 mL) was added dropwise over 
a period of 2 h and stirring was continued for 30 min. Volatiles were removed under reduced 
pressure and the residue was suspended in water (150 mL). Lyophilization afforded the product 
as a white solid (15.8 g, 73.3 mmol, 88 %). 1H-NMR (300 MHz, MeOH-d4/D2O 80/20):  (ppm) 
4.06 (s, 2H, CH2-NH2), 4.26 (s, 2H, CH2-NH), 7.34 (m, 4H, CHAr); MS (CI, NH3): m/z 197 [M + 
NH4]+, 180 [M + H]+; C14H21N3O3 × HCl (215.8) 
 
N-tert-Butoxycarbonyl-ethane-1,2-diamine (4.9).40 Ethane-1,2-diamine (36.1 g, 0.6 mol, 12 
eq) was dissolved in chloroform (450 mL) and the solution was cooled to -15 °C. A solution of 
di-tert-butyl dicarbonate (10.9 g, 50 mmol, 1eq) was added dropwise over a period of 4 h. 
Stirring was continued overnight and the mixture was allowed to slowly warm up to rt. The 
solution was washed three times with alkalified brine (3 × 130 mL of brine + 5 mL of 1 M aq. 
NaOH), then with brine (130 mL) and water (100 mL). Drying over sodium sulfate, filtration and 
removal of the solvent under reduced pressure yielded the product as yellow oil (7.82 g, 48.8 
mmol, 97 %). 1H-NMR (300 MHz, CDCl3):  (ppm) 1.42 (s, 9H, tert-Bu), 2.77 (t, 2H, 3J = 5.91 
Hz, CH2), 3.14 (m, 2H, CH2); C7H16N2O2 (160.2)   
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4-(2-tert-Butoxycarbonylaminoethyl)aminocarbonylbutanoic acid (4.10).41 Glutaric 
anhydride (2.28 g, 20 mmol, 1 eq) was added to a solution of amine 4.9 (3.5 g, 22 mmol, 1.1 eq) 
in CH2Cl2 (20 mL) and the mixture was stirred at rt for 60 min. CH2Cl2 (150 mL) was added prior 
to washing with aq. NH4Cl solution (two times 30 mL of a saturated solution + 10 mL of water) 
and brine (40 mL). Drying over sodium sulfate, filtration and removal of the solvent under 
reduced pressure yielded the product as highly viscous yellowish oil (5.4 g, 19.6 mmol, 98 %). 
1H-NMR (300 MHz, MeOH-d4):  (ppm) 1.43 (s, 9H, tert-Bu), 1.88 (p, 2H, 3J = 7.24 Hz, CH2-
CH2-CH2), 2.24 (t, 2H, 3J = 7.46 Hz, CH2-CO), 2.32 (t, 2H, 3J = 7.38 Hz, CH2-CO), 3.14 (m, 2H, 
CH2-NH), 3.24 (m, 2H, CH2-NH); MS (ES, CH2Cl2/MeOH + 10 mM NH4OAc): m/z 273 [M - H]-; 
C12H22N2O5 (274.3)   
 
4-(3-tert-Butoxycarbonylaminopropyl)aminocarbonylbutanoic acid (4.11).41 Glutaric 
anhydride (0.31 g, 2.73 mmol, 1 eq) in CH2Cl2 (5 mL) was added dropwise to a solution of N-
Boc-propane-1,3-diamine (0.5 g, 2.87 mmol, 1.05 eq) in CH2Cl2 (1.5 mL) over a period of 5 min. 
The mixture was stirred at rt for 60 min. Chloroform (40 mL) was added prior to washing with aq. 
NH4Cl solution (two times 8 mL of a saturated solution + 2 mL of water) and brine (10 mL). 
Drying over sodium sulfate, filtration and removal of the solvent under reduced pressure yielded 
the product as highly viscous yellowish oil (0.8 g, 2.78 mmol, 97 %). 1H-NMR (300 MHz, 
MeOH-d4):  (ppm) 1.43 (s, 9H, tert-Bu), 1.63 (p, 2H, 3J = 6.79 Hz, NH-CH2-CH2-CH2-NH), 1.88 
(p, 2H, 3J = 7.22 Hz, CO-CH2-CH2-CH2-CO), 2.24 (t, 2H, 3J = 7.47 Hz, CH2-CO), 2.32 (t, 2H, 3J 
= 7.37 Hz, CH2-CO), 3.06 (t, 2H, 3J = 6.78 Hz, CH2-NH), 3.19 (t, 2H, 3J = 6.87 Hz, CH2-NH); MS 
(ES, CH2Cl2/MeOH + 10 mM NH4OAc): m/z 287 [M - H]-; C13H24N2O5 (288.3)   
 
N-tert-Butoxycarbonyl-N’-[N-(4-tert-butoxycarbonylaminobutyl)aminocarbonyl]-S-
methylisothiourea (4.13). The reaction was carried out in an argon purged 50 mL two-necked 
round bottom flask equipped with a pressure equalizing addition funnel. The flask and the funnel 
were baked out in a nitrogen atmosphere prior to the reaction. A solution of N-Boc-butane-1,4-
diamine (250 mg, 1.33 mmol, 1 eq) and diisopropylethylamine (480 mg, 3.7 mmol, 2.8 eq) in 
anhydrous CH2Cl2 (10 mL) was added dropwise to a solution of triphosgene (197 mg, 0.66 
mmol, 0.5 eq) in anhydrous CH2Cl2 (5 mL) over a period of 30 min. N-Boc-S-methylisothiourea 
(505 mg, 2.66 mmol, 2 eq) was added and stirring was continued for 2.5 h. The volume was 
reduced under reduced pressure to about 3 mL and the mixture was directly subjected to 
column chromatography (CH2Cl2/EtOAc 50/1 to 5/1). The separation of the product from the 
excess of the urea was quite difficult due to nearly identical TLC Rf-values (CH2Cl2/EtOAc 5/1). 
Therefore the use of 1 eq of N-Boc-S-methylisothiourea is recommended. Highly viscous 
yellowish oil (403 mg, 1 mmol, 75 %). 1H-NMR (300 MHz, DMSO-d6):  (ppm) 1.27-1.53 (m, 
22H, 2 × tert-Bu, CH2-CH2-CH2-CH2), 2.28 (s, 3H, CH3), 2.89 (m, 2H, CH2-NH), 3.01 (m, 2H, 
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CH2-NH), 6.80 (t, 1H, 3J = 5.17 Hz, CH2-NH), 7.79 (t, 1H, 3J = 5.79 Hz, CH2-NH), 12.44 (s, 1H, 
NH); MS (ES, CH2Cl2/MeOH + 10 mM NH4OAc): m/z 405 [M + H]+; C17H34N4O5S (406.5)   
 
12-(Benzyloxycarbonylamino)-4,7,10-trioxadodecanoic acid (4.15). 12-Amino-4,7,10-
trioxadodecanoic acid tert-butylester (1 g, 3.6 mmol, 1 eq) was dissolved in CH2Cl2 (10 mL). 
NEt3 (0.73 g, 1 mL, 7.2 mmol, 2 eq) was added and the solution was cooled to 0 °C. Benzyl 
chloroformate (0.68 g, 3.97 mmol, 1.1 eq) was added dropwise in CH2Cl2 (10 mL) over a period 
of 30 min. The ice-water bath was removed and the mixture was allowed to stand at rt for 2 h. 
The intermediate was purified by column chromatography prior to ester cleavage in CH2Cl2/TFA 
4/1 (v/v, 25 mL) for 3 h. CH2Cl2 (20 mL) was added three times, each time followed by 
evaporation under reduced pressure. Drying in vacuo yielded the product as reddish oil (1.13 g, 
3.17 mmol, 88 %). 1H-NMR (300 MHz, DMSO-d6):  (ppm) 2.43 (t, 2H, 3J = 6.35 Hz, CH2-CH2-
COOH), 3.14 (m, 2H, CH2-NH), 3.41 (t, 2H, 3J = 5.94 Hz, O-CH2-CH2-NH), 3.48 (m, 8H, O-CH2-
CH2-O), 3.59 (t, 2H, 3J = 6.35 Hz, CH2-CH2-COOH), 5.01 (s, 2H, CH2-Ar), 7.27 (m, 1H, NH), 7.3-
7.4 (m, 5H, Ph); MS (ES, CH2Cl2/MeOH + 10 mM NH4OAc): m/z 356 [M + H]+, 354 [M - H]-; 
C17H25NO7 (355.4) 
 
General procedure for the synthesis of acids 4.16 and 4.17. 
 
N-Boc-3,6-dioxaoctane-1,8-diamine (1 eq, cf. chapter 3) and the pertinent alkanedioic acid 
monobenzylester (1 eq) were dissolved in dry CH2Cl2. EDAC (1.2 eq) was added and the 
mixture was kept under stirring at rt for 20 h. The intermediate was purified by column 
chromatography (EtOAc/MeOH) prior to hydrogenation at rt and atmospheric pressure in MeOH 
using hydrogen and a 10 % Pd/C catalyst.  
 
4-(8-tert-Butoxycarbonylamino-3,6-dioxaoctyl)aminocarbonylbutanoic acid (4.16). From 
glutaric acid monobenzylester 3.9 (cf. chapter 3); 63 % (460 mg); 1H-NMR (300 MHz, CDCl3):  
(ppm) 1.43 (s, 9H, t-Bu), 1.94 (m, 2H, CH2-CH2-CH2), 2.31 (t, 2H, CH2-CO), 2.39 (t, 2H, CH2-
CO), 3.31 (m, 2H, CH2 from O-CH2-CH2-NH), 3.47 (m, 2H, CH2 from O-CH2-CH2-NH), 3.51-3.63 
(m, 8H, CH2 from O-CH2-CH2-NH, O-CH2-CH2-O); MS (ES, CH2Cl2/MeOH + 10 mM NH4OAc): 
m/z 363 [M + H]+; C16H30N2O7 (362.4) 
 
5-(8-tert-Butoxycarbonylamino-3,6-dioxaoctyl)aminocarbonylpentanoic acid (4.17). From 
adipic acid monobenzylester 3.10 (cf. chapter 3); 66 % (260 mg); 1H-NMR (300 MHz, CDCl3):  
(ppm) 1.36 (s, 9H, t-Bu), 1.6 (m, 4H, CH2-CH2-CH2-CH2), 2.17 (t, 2H, CH2-CO), 2.28 (t, 2H, CH2-
CO), 3.25 (m, 2H, CH2 from O-CH2-CH2-NH), 3.39 (m, 2H, CH2 from O-CH2-CH2-NH), 3.45-3.63 
(m, 8H, CH2 from O-CH2-CH2-NH, O-CH2-CH2-O); MS (ES, CH2Cl2/MeOH + 10 mM NH4OAc): 
m/z 377 [M + H]+; C17H32N2O7 (376.5) 
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(R)-N-(6-Aminohexanoyl)-N-(2,2-diphenylacetyl)-N-(4-ureidomethylbenzyl)argininamide 
(4.18). Carbonyldiimidazole (56 mg, 0.35 mmol, 2.8 eq) was added to a solution of 6-
aminohexanoic acid (71.3 mg, 0.31 mmol, 2.5 eq) in anhydrous acetonitrile (2 mL). The mixture 
was stirred for 40 min at rt and then added to a suspension of 4.6 (85 mg, 0.12 mmol, 1 eq) and 
NEt3 (62.3 mg, 0.62 mmol, 5 eq) in acetonitrile (10 mL). The precipitate almost disappeared 
completely during heating to 40 °C for 2 h. The mixture was stirred at 35 °C overnight, then TFA 
(10 mL) was added and the mixture was allowed to stand at 50 °C for 1.5 h. MeOH (20 mL) was 
added three times each time followed by evaporation under reduced pressure. Purification with 
preparative HPLC afforded the product as a white fluffy solid (39 mg, 45 µmol, 36 %). 1H-NMR 
(300 MHz, MeOH-d4):  (ppm) 1.44 (m, 2H, CH2-CH2-CH2-CH2-CH2), 1.5-1.77 (bm, 7H, CH2-
CH2-CH2-CH2-CH2, CH-CH2-CH2), 1.84 (m, 1H, CH-CH2-CH2), 2.5 (t, 2H, 3J = 7.34 Hz, CH2-
CO), 2.91 (t, 2H, 3J = 7.59 Hz, CH2-NH2), 3.25 (m, 2H, CH2-CH2-NH), 4.26 (s, 2H, CH2-NH-CO-
NH2), 4.32 (m, 2H, CH-CO-NH-CH2-Ar), 4.42 (m, 1H, CH), 5.08 (s, 1H, CH-(Ph)2), 7.15-7.34 
(m, 14H, Ar); MS (ES, TFA/acetonitrile): m/z 322 [M + 2H]2+, 643 [M + H]+; C35H46N8O4 × 
C4H2F6O4 (870.8)  
 
(R)-N-(12-Amino-4,7,10-trioxadodecanoyl)-N-(2,2-diphenylacetyl)-N-(4-hydroxybenzyl)-
argininamide (4.19). A solution of 4.15 (300 mg, 0.84 mmol, 1.05 eq) and CDI (156 mg, 0.96 
mmol, 1.2 eq) in CH2Cl2 (10 mL) was stirred for 30 min. 2.7 (506 mg, 0.8 mmol, 1 eq) and NEt3 
(40.7 mg, 56 µL, 0.4 mmol, 0.5 eq) were added and the mixture was kept under stirring at rt for 
20 h. Volatiles were removed under reduced pressure and the intermediate was purified by 
column chromatography (CH2Cl2/MeOH 50/1 to 10/1) prior to hydrogenation at rt and 
atmospheric pressure in MeOH (20 mL) using hydrogen and a 10 % Pd/C catalyst (120 mg). 
The catalyst was removed by filtration and removal of the solvent in vacuo yielded a highly 
viscous colorless oil which was dissolved in CH2Cl2/TFA 10/1 (v/v). The mixture was allowed to 
stand at rt overnight and was subsequently concentrated under reduced pressure. Purification 
with preparative HPLC afforded the product as a white fluffy solid (264 mg, 0.29 µmol, 36 %). 
1H-NMR (300 MHz, DMSO-d6):  (ppm) 1.32-1.6 (m, 3H, CH-CH2-CH2), 1.66 (m, 1H, CH-CH2-
CH2), 2.68 (t, 2H, 3J = 5.94 Hz, CH2-CO), 2.96 (m, 2H, CH2-NH2), 3.24 (m, 2H, CH2-CH2-NH), 
3.54 (m, 10H, O-CH2-CH2-O, O-CH2-CH2-NH2), 3.68 (t, 2H, 3J = 6.04 Hz, CH2-CH2-CO), 4.1 (dd, 
1H, 2J = 15.17 Hz, 3J = 5.92 Hz, CH2-ArOH), 4.19 (dd, 1H, 2J = 15.09 Hz, 3J = 5.81 Hz, CH2-
ArOH), 4.34 (m, 1H, CH), 5.12 (s, 1H, CH-(Ph)2), 6.67 (d, 2H, 3J = 8.50 Hz, AA’BB’), 7.0 (d, 2H, 
3J = 8.46 Hz, AA’BB’), 7.18-7.35 (m, 10H, Ph), 7.75 (bs, 3H, NH3+), 8.38 (t, 1H, 3J = 5.67 Hz, 
CO-NH-CH2), 8.50 (d, 1H, 3J = 8.08 Hz, CO-NH-CH), 8.68 (s, 2H, NH2), 9.07 (m, 1H, NH), 9.3 
(s, 1H, NH), 11.63 (s, 1H, ArOH); MS (ES, CH2Cl2/MeOH + 10 mM NH4OAc): m/z 677 [M + H]+, 
339 [M + 2H]2+; C36H48N6O7 × C4H2F6O4 (904.8) 
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(R)-N-(8-Amino-3,6-dioxaoctanoyl)-N-(2,2-diphenylacetyl)-N-(4-hydroxybenzyl)arginin-
amide (4.20). N-Boc-8-amino-3,6-dioxaoctanoic acid × dicyclohexylamine (300 mg) was 
dissolved in dimethoxyethane (10 mL). The amine was precipitated by the addition of 37 % 
hydrochloric acid (≈ 60 µL) and removed by filtration. Removal of the solvent in vacuo yielded a 
yellow oil (200 mg, 0.76 mmol, 1 eq) which was dissolved in anhydrous CH2Cl2 (3 mL). 
Carbonyldiimidazole (148 mg, 0.91 mmol, 1.2 eq) was added and the mixture was allowed to 
stand at rt for 30 min. CH2Cl2 (15 mL), 2.7 (478 mg, 0.76 mmol, 1 eq) and NEt3 (77 mg, 105 µL, 
0.76 mmol, 1 eq) were added and the mixture was kept under stirring at rt for 20 h. TFA (10 mL) 
was added, the mixture was allowed to stand at rt for 4 h and then it was concentrated under 
reduced pressure. MeOH (20 mL) was added twice each time followed by evaporation under 
reduced pressure. Purification with preparative HPLC afforded the product as a white fluffy solid 
(300 mg, 0.35 mmol, 47 %). 1H-NMR (300 MHz, DMSO-d6):  (ppm) 1.32-1.61 (m, 3H, CH-CH2-
CH2), 1.68 (m, 1H, CH-CH2-CH2), 2.98 (m, 2H, CH2-NH2), 3.25 (m, 2H, CH2-CH2-NH), 3.61 (m, 
4H, O-CH2-CH2-O), 3.71 (m, 2H, O-CH2-CH2-NH2), 4.1 (dd, 1H, 2J = 15.35 Hz, 3J = 6.10 Hz, 
CH2-ArOH), 4.18 (dd, 1H, 2J = 15.36 Hz, 3J = 6.19 Hz, CH2-ArOH), 4.23 (s, 2H, O-CH2-CO), 
4.33 (m, 1H, CH), 5.13 (s, 1H, CH-(Ph)2), 6.67 (d, 2H, 3J = 8.51 Hz, AA’BB’), 7.0 (d, 2H, 3J = 
8.52 Hz, AA’BB’), 7.18-7.33 (m, 10H, Ph), 7.8 (bs, 3H, NH3+), 8.39 (t, 1H, 3J = 5.83 Hz, CO-NH-
CH2), 8.51 (d, 1H, 3J = 8.05 Hz, CO-NH-CH), 8.81 (s, 2H, NH2), 9.12 (m, 1H, NH), 9.32 (s, 1H, 
NH), 10.98 (s, 1H, ArOH); MS (ES, acetonitrile/TFA): m/z 310 [M + 2H]2+, 619 [M + H]+; 
C33H42N6O6 × C4H2F6O4 (846.8) 
 
General procedure for the synthesis of amines 4.21 to 4.23 
 
Carbonyldiimidazole (1.6 eq) was added to a solution of the pertinent carboxcylic acid (1.5 eq) 
in CH2Cl2 (2-3 mL) and the mixture was allowed to stand at rt for 30-40 min. 2.7 (1 eq) and NEt3 
(0.3 eq) were added and the mixture was kept under stirring at rt for 20 h. The intermediate was 
purified by column chromatography (4.21: CH2Cl2/EtOAc 5/1 to 1/1, 4.22 and 4.23: 
CH2Cl2/EtOAc 2/1 to EtOAc/MeOH 50/1) prior to deprotection with CH2Cl2/TFA/water 18/6/1 
(12.5 mL) for 3 h. CH2Cl2 (20 mL) was added three times each time followed by evaporation 
under reduced pressure. The oily residue was dissolved in water (20 mL) and lyophilized to 
afford the product as a white fluffy solid. 
 
(R)-N-(6-Aminohexanoyl)-N-(2,2-diphenylacetyl)-N-(4-hydroxybenzyl)argininamide 
(4.21).18 From 6-aminohexanoic acid (4.14); 94 % (490 mg); 1H-NMR (300 MHz, DMSO-d6):  
(ppm) 1.32 (m, 2H, CH2-CH2-CH2-NH2), 1.37-1.6 (m, 7H, CH-CH2-CH2, CH2-CH2-CH2-CH2-NH2), 
1.67 (m, 1H, CH-CH2-CH2), 2.42 (t, 2H, 3J = 7.33 Hz, CH2-CO), 2.76 (m, 2H, CH2-NH2), 3.24 (m, 
2H, CH2-CH2-NH), 4.1 (dd, 1H, 2J = 15.20 Hz, 3J = 5.93 Hz, CH2-ArOH), 4.18 (dd, 1H, 2J = 
15.08 Hz, 3J = 6.12 Hz, CH2-ArOH), 4.33 (m, 1H, CH), 5.13 (s, 1H, CH-(Ph)2), 6.67 (d, 2H, 3J = 
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8.51 Hz, AA’BB’), 7.0 (d, 2H, 3J = 8.50 Hz, AA’BB’), 7.18-7.33 (m, 10H, Ph), 7.63 (bs, 3H, NH3+), 
8.38 (t, 1H, 3J = 5.84 Hz, CO-NH-CH2), 8.5 (d, 1H, 3J = 8.05 Hz, CO-NH-CH), 8.6 (s, 2H, NH2), 
8.95 (m, 1H, NH), 9.3 (s, 1H, NH), 11.4 (s, 1H, ArOH); MS (ES, CH2Cl2/MeOH + 10 mM 
NH4OAc): m/z 587 [M + H]+, 294 [M + 2H]2+; C33H42N6O4 × C4H2F6O4 (814.7)          
 
(R)-N-[4-(2-Aminoethyl)aminocarbonylbutanoyl]-N-(2,2-diphenylacetyl)-N-(4-hydroxy-
benzyl)argininamide (4.22). From 4.10; 71 % (320 mg); 1H-NMR (300 MHz, DMSO-d6):  
(ppm) 1.32-1.6 (m, 3H, CH-CH2-CH2), 1.67 (m, 1H, CH-CH2-CH2), 1.78 (m, 2H, CO-CH2-CH2-
CH2-CO), 2.16 (t, 2H, 3J = 7.43 Hz, CH2-CO), 2.44 (t, 2H, 3J = 6.85 Hz, CH2-CO), 2.83 (m, 2H, 
CH2-NH2), 3.25 (m, 4H, NH-CH2-CH2-NH2, CH2-CH2-CH2-NH), 4.1 (dd, 1H, 2J = 15.17 Hz, 3J = 
6.22 Hz, CH2-ArOH), 4.18 (dd, 1H, 2J = 14.89 Hz, 3J = 6.02 Hz, CH2-ArOH), 4.34 (m, 1H, CH), 
5.13 (s, 1H, CH-(Ph)2), 6.67 (d, 2H, 3J = 8.55 Hz, AA’BB’), 7.0 (d, 2H, 3J = 8.51 Hz, AA’BB’), 
7.18-7.33 (m, 10H, Ph), 7.69 (bs, 3H, NH3+), 8.0 (t, 1H, 3J = 5.7 Hz, CO-NH-CH2), 8.38 (t, 1H, 3J 
= 6.15 Hz, CO-NH-CH2), 8.52 (m, 3H, CO-NH-CH, NH2), 8.85 (m, 1H, NH), 9.3 (s, 1H, NH), 
11.28 (s, 1H, ArOH); MS (ES, acetonitrile/TFA): m/z 315.5 [M + 2H]2+, 630 [M + H]+; C34H43N7O5 
× C4H2F6O4 (857.7)         
 
(R)-N-[4-(3-Aminopropyl)aminocarbonylbutanoyl]-N-(2,2-diphenylacetyl)-N-(4-hydroxy-
benzyl)argininamide (4.23). From 4.11; 64 % (310 mg); 1H-NMR (300 MHz, DMSO-d6):  
(ppm) 1.32-1.6 (m, 3H, CH-CH2-CH2), 1.65 (m, 3H, CH-CH2-CH2, CH2-CH2-NH2), 1.77 (m, 2H, 
CO-CH2-CH2-CH2-CO), 2.14 (t, 2H, 3J = 7.36 Hz, CH2-CO), 2.43 (t, 2H, 3J = 7.0 Hz, CH2-CO), 
2.76 (m, 2H, CH2-NH2), 3.1 (m, 2H, NH-CH2-CH2-CH2-NH2, 3.24 (m, 2H, CH-CH2-CH2-CH2-NH), 
4.1 (dd, 1H, 2J = 15.19 Hz, 3J = 6.0 Hz, CH2-ArOH), 4.18 (dd, 1H, 2J = 15.12 Hz, 3J = 5.90 Hz, 
CH2-ArOH), 4.34 (m, 1H, CH), 5.12 (s, 1H, CH-(Ph)2), 6.67 (d, 2H, 3J = 8.49 Hz, AA’BB’), 7.0 
(d, 2H, 3J = 8.49 Hz, AA’BB’), 7.18-7.33 (m, 10H, Ph), 7.65 (bs, 3H, NH3+), 7.98 (t, 1H, 3J = 5.5 
Hz, CO-NH-CH2), 8.38 (t, 1H, 3J = 5.69 Hz, CO-NH-CH2), 8.5 (d, 1H, CO-NH-CH), 8.56 (s, 2H, 
NH2), 8.85 (m, 1H, NH), 9.3 (s, 1H, NH), 11.32 (s, 1H, ArOH); MS (ES, acetonitrile/TFA): m/z 
322.5 [M + 2H]2+, 644 [M + H]+; C35H45N7O5 × C4H2F6O4 (871.7)  
  
General procedure for the synthesis of amines 4.24 and 4.25 
 
Carbonyldiimidazole (1.2 eq) was added to a solution of acid 4.16 or 4.17 (1 eq) in CH2Cl2 and 
the mixture was stirred for 30 min at rt. Compound 2.7 (1eq, cf chapter 2) was added and 
stirring was continued at rt overnight. The intermediate was purified by column chromatography 
(CH2Cl2/EtOAc) prior to deprotection with CH2Cl2/TFA 1/1 (v/v) for 2.5 h. CH2Cl2 (5 vol. parts) 
was added three times, each time followed by evaporation in vacuo. The product was purified 
using preparative HPLC. 
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(R)-N-[4-(8-Amino-3,6-dioxaoctyl)aminocarbonylbutanoyl]-N-(2,2-diphenylacetyl)-N-(4-
hydroxybenzyl)argininamide (4.24). From 4.16; white solid; 64 % (192 mg); 1H-NMR (300 
MHz, DMSO-d6):  (ppm) 1.34-1.6 (bm, 3H, CH-CH2-CH2), 1.66 (m, 1H, CH-CH2-CH2), 1.76 (p, 
2H, CO-CH2-CH2-CH2-CO, 3J = 7.26 Hz), 2.13 (t, 2H, 3J = 7.28 Hz, CH2-CO), 2.42 (t, 2H, 3J = 
7.29 Hz, CH2-CO), 2.97 (m, 2H, CH2-NH2), 3.21 (m, 4H, CH2-CH2-CH2-NH, NH-CH2-CH2-O), 3.4 
(t, 2H, 3J = 6.09 Hz, O-CH2-CH2-NH2), 3.5-3.61 (m, 6H, CH2-O-CH2-CH2-O), 4.14 (m, 2H, CH2-
ArOH), 4.33 (m, 1H, CH), 5.12 (s, 1H, CH-(Ph)2), 6.67 (d, 2H, 3J = 8.45 Hz, AA’BB’), 7.0 (d, 2H, 
3J = 8.44 Hz, AA’BB’), 7.18-7.33 (m, 10H, Ph), 7.77 (bs, 2H, NH2), 7.92 (t, 1H, 3J = 5.62 Hz, CO-
NH-CH2), 8.39 (t, 1H, 3J = 5.89 Hz, CO-NH-CH2), 8.5 (d, 1H, 3J = 8.01 Hz, CO-NH-CH), 8.64 (s, 
2H, NH2), 9.03 (s, 1H, NH), 9.31 (s, 1H, NH), 11.54 (s, 1H, ArOH); MS (ES, CH2Cl2/MeOH + 10 
mM NH4OAc): m/z 718 [M + H]+, 359.5 [M + 2H]2+; C38H51N7O7 × C4H2F6O4 (945.9) 
 
(R)-N-[5-(8-Amino-3,6-dioxaoctyl)aminocarbonylpentanoyl]-N-(2,2-diphenylacetyl)-N-(4-
hydroxybenzyl)argininamide (4.25). From 4.17; white solid; 44 % (135 mg); 1H-NMR (300 
MHz, DMSO-d6):  (ppm) 1.34-1.6 (bm, 7H, CH-CH2-CH2, CH2-CH2-CH2-CH2), 1.66 (m, 1H, CH-
CH2-CH2), 2.08 (t, 2H, 3J = 6.20 Hz, CH2-CO), 2.42 (t, 2H, 3J = 6.14 Hz, CH2-CO), 2.97 (m, 2H, 
CH2-NH2), 3.2 (m, 4H, CH2-CH2-CH2-NH, NH-CH2-CH2-O), 3.39 (t, 2H, 3J = 6.06 Hz, O-CH2-
CH2-NH2), 3.5-3.62 (m, 6H, CH2-O-CH2-CH2-O), 4.14 (m, 2H, CH2-ArOH), 4.33 (m, 1H, CH), 
5.12 (s, 1H, CH-(Ph)2), 6.67 (d, 2H, 3J = 8.47 Hz, AA’BB’), 7.0 (d, 2H, 3J = 8.47 Hz, AA’BB’), 
7.18-7.33 (m, 10H, Ph), 7.77 (bs, 2H, NH2), 7.88 (t, 1H, 3J = 5.51 Hz, CO-NH-CH2), 8.38 (t, 1H, 
3J = 5.85 Hz, CO-NH-CH2), 8.5 (d, 1H, 3J = 7.96 Hz, CO-NH-CH), 8.66 (s, 2H, NH2), 9.08 (s, 1H, 
NH), 9.31 (s, 1H, NH), 11.6 (s, 1H, ArOH); MS (ES, CH2Cl2/MeOH + 10 mM NH4OAc): m/z 732 
[M + H]+, 366.5 [M + 2H]2+; C39H53N7O7 × C4H2F6O4 (959.9) 
 
(R)-N-[7-(8-Amino-3,6-dioxaoctyl)aminocarbonylheptanoyl-N-(2,2-diphenylacetyl)-N-(4-
hydroxybenzyl)argininamide (4.26). The carboxylic acid 3.16 (370 mg, 0.47 mmol, 1 eq; cf. 
chapter 3) and amine 3.26 (140 mg, 0.56 mmol, 1.2 eq; cf. chapter 3) were dissolved in CH2Cl2 
(5 mL). EDAC (108 mg, 0.56 mmol, 1.2 eq) was added and the mixture was kept under stirring 
at rt for 20 h. TFA (4 mL) was added and stirring was continued for 2.5 h. CH2Cl2 (30 mL) was 
added three times, each time followed by evaporation under reduced pressure. The product 
was purified using preparative HPLC. Light brown resin; 43 % (200 mg, 0.2 mmol); 1H-NMR 
(300 MHz, DMSO-d6):  (ppm) 1.25 (m, 4H, CH2-CH2-CH2-CH2-CH2-CH2), 1.35-1.6 (m, 7H, CH-
CH2-CH2, CH2-CH2-CH2-CH2-CH2-CH2), 1.66 (m, 1H, CH-CH2-CH2), 2.05 (t, 2H, 3J = 7.38 Hz, 
CH2-CO), 2.4 (t, 2H, 3J = 7.34 Hz, CH2-CO), 2.97 (m, 2H, CH2-NH2), 3.2 (m, 4H, CH2-CH2-CH2-
NH, NH-CH2-CH2-O), 3.39 (t, 2H, 3J = 6.06 Hz, O-CH2-CH2-NH2), 3.5-3.61 (m, 6H, CH2-O-CH2-
CH2-O), 4.14 (m, 2H, CH2-ArOH), 4.33 (m, 1H, CH), 5.12 (s, 1H, CH-(Ph)2), 6.67 (d, 2H, 3J = 
8.44 Hz, AA’BB’), 7.0 (d, 2H, 3J = 8.45 Hz, AA’BB’), 7.18-7.34 (m, 10H, Ph), 7.76 (bs, 2H, NH2), 
7.84 (t, 1H, 3J = 5.49 Hz, CO-NH-CH2), 8.39 (t, 1H, 3J = 5.80 Hz, CO-NH-CH2), 8.5 (d, 1H, 3J = 
Chapter 4 112 
7.92 Hz, CO-NH-CH), 8.62 (s, 2H, NH2), 8.99 (s, 1H, NH), 9.31 (s, 1H, NH), 11.45 (s, 1H, 
ArOH); MS (ES, CH2Cl2/MeOH + 10 mM NH4OAc): m/z 380.5 [M + 2H]2+, 760 [M + H]+; 
C41H57N7O7 × C4H2F6O4 (988.0)           
 
(R)-N-[(4-Aminobutyl)aminocarbonyl]-N-(2,2-diphenylacetyl)-N-(4-hydroxybenzyl)-
argininamide (4.27). 4.13 (178 mg, 0.44 mmol, 1 eq) and 2.6 (215 mg, 0.44 mmol, 1 eq) were 
dissolved in anhydrous DMF (10 mL). HgCl2 (197 mg, 0.66 mmol, 1.5 eq) and 
diisopropylethylamine (114 mg, 0.88 mmol, 2 eq) were added, the mixture was stirred at rt 
overnight and then concentrated under reduced pressure (final pressure: 1 mbar) at 43 °C. The 
intermediate was purified by column chromatography (CH2Cl2/EtOAc 4/1 to 1/2) prior to 
deprotection with CH2Cl2/TFA 1/1 (4 mL) and three drops of water (2 h). CH2Cl2 (20 mL) was 
added three times, each time followed by evaporation under reduced pressure. Uptake of the 
oily residue in water (20 mL) and lyophilization afforded the product as a white fluffy solid (266 
mg, 0.33 mmol, 74 %). 1H-NMR (600 MHz, DMSO-d6, COSY):  (ppm) 1.34-1.56 (m, 7H, CH-
CH2-CH2, CH2-CH2-CH2-NH2), 1.66 (m, 1H, CH-CH2-CH2), 2.78 (m, 2H, CH2-NH2), 3.11 (m, 2H, 
NH-CH2-CH2-CH2-CH2), 3.19 (m, 2H, CH-CH2-CH2-CH2-NH), 4.11 (dd, 1H, 2J = 14.78 Hz, 3J = 
5.57 Hz, CH2-ArOH), 4.17 (dd, 1H, 2J = 14.76 Hz, 3J = 5.78 Hz, CH2-ArOH), 4.33 (m, 1H, CH), 
5.11 (s, 1H, CH-(Ph)2), 6.66 (d, 2H, 3J = 8.4 Hz, AA’BB’), 6.99 (d, 2H, 3J = 8.4 Hz, AA’BB’), 7.21 
(m, 2H, Ph), 7.28 (m, 8H, Ph), 7.54 (m, 1H, CO-NH-CH2), 7.66 (bs, 3H, NH3+), 8.35 (m, 1H, CO-
NH-CH2), 8.4 (bs, 2H, NH2), 8.47 (d, 1H, 3J = 8.08 Hz, CO-NH-CH), 8.9 (s, 1H, NH), 9.27 (s, 1H, 
NH), 9.96 (s, 1H, ArOH); MS (ES, acetonitrile/TFA): m/z 294.5 [M + 2H]2+, 588 [M + H]+; 
C32H41N7O4 × C4H2F6O4 (815.7)          
 
Compound 4.21 labeled with Dy-635 (4.28). A solution of Dy-635-NHS (1 mg, 1.32 µmol, 1 
eq) in acetonitrile (200 µL) was added to a solution of 4.21 (2.16 mg, 2.65 µmol, 2 eq) and NEt3 
(1.1 mg, 1.5 µL, 10.6 µmol, 8 eq) in acetonitrile (300 µL). The reaction was stopped by addition 
of 10 % aq. TFA (10 µL) after 3.5 h of incubation at room temperature and the solvent was 
evaporated. The residue was dissolved in a mixture of acetonitrile (300 µL) and 0.05 % aqueous 
TFA (300 µL) and the product was purified by analytical HPLC (column: Nucleodur 250 × 4 mm, 
7 injections). Yield: 23 % (0.44 mg, 0.304 µmol); RP-HPLC (Nucleodur 250 × 4 mm, 210 nm, 
gradient 1): 94 % (tR = 25.1 min, k = 9.9); MS (ES, H2O/acetonitrile): m/z 1227.9 M+, 614.5 [M+ + 
H]2+; C71H87N8O9S × C4H1F6O4 (1455.6)           
 
N-S0436-labeled BIBP 3226 (4.29). A solution of S0436-NHS (S0536) (5.4 mg, 7.69 µmol, 1 
eq) in acetonitrile (1 mL) was added to a solution of 2.7 (9.6 mg, 15.24 µmol, 2 eq) and NEt3 
(6.2 mg, 8.5 µL, 61.6 µmol, 8 eq) in acetonitrile (2 mL). The mixture was incubated for 20 h at 
room temperature. TFA (3 mL) and water (0.1 mL) were added and the mixture was allowed to 
stand for 2 h at room temperature prior to concentration to a volume of about 1 mL. Acetonitrile 
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(800 µL) and water (800 µL) was added and the product (both isomers) was isolated with 
preparative HPLC (column: Nucleodur 250 × 21 mm, 3 injections). Yield: 20 % (total: 1.8 mg, 
1.54 µmol; 0.8 mg of isomer 1, 1 mg of isomer 2); RP-HPLC (Nucleodur 250 × 4 mm, 210 nm, 
gradient 1): isomer 1: 95 % (tR = 21.9 min, k = 8.5), isomer 2: 99 % (tR = 23.3 min, k = 9.1); MS 
(ES, H2O/acetonitrile): isomer 1 (4.29-i1): m/z 1060.7 M+, 531.0 [M+ + H]2+, isomer 2 (4.29-i2): 
m/z 531.0 [M+ + H]2+, 1060.7 M+; C62H74N7O7S × C4H1F6O4 (1288.4)           
 
Compound 4.22 labeled with DE99 (4.30). Carbonyldiimidazole (1.1 mg, 6.6 µmol, 1.3 eq) 
was added to a solution of 4.22 (6.5 mg, 7.6 µmol, 1.5 eq) in anhydrous DMF (500 µL) and the 
mixture was stirred for 40 min at rt. DE99 (2 mg, 5.1 µmol, 1eq) and NEt3 (1.8 mg, 2.5 µL, 17.8 
µmol, 3.5 eq) were added and stirring was continued at rt for 6.5 h. The reaction was stopped 
by addition of 10 % aq. TFA (corresponding to 10 eq of TFA) and the product was purified with 
preparative HPLC (Eurospher, 250 × 32 mm). Yield: 23 % (1.43 mg, 1.16 µmol); RP-HPLC 
(Eurospher 250 × 4 mm, 210 nm, gradient 3): 95 % (tR = 16.9 min, k = 5.3); MS (ES, 
acetonitrile/TFA): m/z 502.9 [M+ + H]2+, 1004.6 M+; C57H66N9O6S × C4H1F6O4 (1232.3) 
 
Compound 4.27 labeled with DE99 (4.31). 4.27 (5.6 mg, 6.9 µmol, 1.6 eq) and DE99-NHS × 
CF3COO- (2.6 mg, 4.3 µmol, 1 eq) were dissolved in anhydrous DMF (150 µL). NEt3 (1.7 mg, 
2.4 µL, 17.2 µmol, 4 eq) was added and the mixture was stirred for 3 h at rt. The reaction was 
stopped by addition of 10 % aq. TFA (corresponding to 4 eq of TFA) and the product was 
purified with preparative HPLC (Eurospher, 250 × 32 mm). Yield: 24 % (1.23 mg, 1.03 µmol); 
RP-HPLC (Eurospher 250 × 4 mm, 220 nm, gradient 3): 94 % (tR = 18.5 min, k = 5.9); MS (ES, 
acetonitrile/TFA): m/z 481.5 [M+ + H]2+, 962 M+; C55H64N9O5S × C4H1F6O4 (1190.2)         
 
Compound 4.18 labeled with Py-1 (4.32). 4.18 (9.3 mg, 10.7 µmol, 2.1 eq) and NEt3 (5.1 mg, 
7.1 µL, 50.9 µmol, 10 eq) were dissolved in a mixture of acetonitrile (1 mL) and water (100 µL) 
followed by the addition of Py-1 × 1 BF4- (2 mg, 5.1 µmol, 1 eq) in acetonitrile (200 µL). The 
reaction was stopped by addition of 10 % aq. TFA (corresponding to 10 eq TFA) after an 
incubation period of 2 h at rt. The product was purified with preparative HPLC (column: 
Eurospher-100 C18 250 × 32 mm), Yield: 33 % (1.75 mg, 1.7 µmol); RP-HPLC (Eurospher 250 
× 4 mm, 210 nm, gradient 3): 82 % (tR = 19.7 min, k = 6.3); MS (ES, CH2Cl2/MeOH + 10 mM 
NH4OAc): m/z 465.5 [M+ + H]2+, 930 M+; C56H68N9O4 × C4H1F6O4 (1158.2)           
 
General procedure for the synthesis of fluorescent ligands 4.33 - 4.47 
 
The pertinent amine precursor (2-3 eq) and NEt3 (6-10 eq) was dissolved in a mixture of 
acetonitrile and DMF (≈ 10-20 % DMF v/v, total volume: 300-600 µL) followed by the addition of 
the pyrylium dye × 1 BF4- (1 eq) in DMF (≈ 25-50 µL). The reaction was stopped by addition of 
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10 % aq. TFA (corresponding to 6-10 eq TFA) after an incubation period of 1-2 h at rt. The 
product was purified with preparative HPLC (column: Eurospher, 250 × 32 mm, except for 4.36).  
 
Compound 4.19 labeled with Py-1 (4.33). Yield: 47 % (2.84 mg); RP-HPLC (Eurospher 250 × 
4 mm, 210 nm, gradient 3): 92 % (tR = 21.7 min, k = 7.0); MS (ES, CH2Cl2/MeOH + 10 mM 
NH4OAc): m/z 482.5 [M+ + H]2+, 964 M+; C57H70N7O7 × C4H1F6O4 (1192.2)           
 
Compound 4.20 labeled with Py-1 (4.34). Yield: 56 % (1.63 mg); RP-HPLC (Eurospher 250 × 
4 mm, 210 nm, gradient 3): 97 % (tR = 19.4 min, k = 6.2); MS (ES, TFA/acetonitrile): m/z 453.5 
[M+ + H]2+, 906 M+; C54H64N7O6 × C4H1F6O4 (1134.1)           
 
Compound 4.20 labeled with Py-5 (4.35). Yield: 23 % (1.58 mg); RP-HPLC (Eurospher 250 × 
4 mm, 210 nm, gradient 3): 96 % (tR = 16.8 min, k = 5.2); MS (ES, CH2Cl2/MeOH + 10 mM 
NH4OAc): m/z 440.5 [M+ + H]2+, 880 M+; C52H62N7O6 × C4H1F6O4 (1108.1)           
 
Compound 4.21 labeled with Py-1 (4.36). Purification with preparative HPLC: Nucleodur 250 × 
21 mm; Yield: 42 % (5.2 mg); RP-HPLC (Nucleodur 250 × 4 mm, 210 nm, gradient 2): 99 % (tR 
= 25.2 min, k = 10.0); MS (ES, H2O/acetonitrile): m/z 437.5 [M+ + H]2+, 874 M+; C54H64N7O4 × 
C4H1F6O4 (1102.1)           
 
Compound 4.21 labeled with Py-5 (4.37). Yield: 15 % (1.3 mg); RP-HPLC (Eurospher 250 × 4 
mm, 210 nm, gradient 3): 96 % (tR = 18.1 min, k = 5.7); MS (ES, H2O/acetonitrile/MeOH + 10 
mM NH4OAc): m/z 424.5 [M+ + H]2+, 848 M+; C52H62N7O4 × C4H1F6O4 (1076.1)           
 
Compound 4.22 labeled with Py-1 (4.38). Yield: 53 % (3.07 mg); RP-HPLC (Eurospher 250 × 
4 mm, 210 nm, gradient 3): 96 % (tR = 18.5 min, k = 5.9); MS (ES, CH2Cl2/MeOH + 10 mM 
NH4OAc): m/z 459 [M+ + H]2+, 917 M+; C55H65N8O5 × C4H1F6O4 (1145.2)           
 
Compound 4.23 labeled with Py-1 (4.39). Yield: 36 % (2.15 mg); RP-HPLC (Eurospher 250 × 
4 mm, 210 nm, gradient 3): 96 % (tR = 18.9 min, k = 6.0); MS (ES, CH2Cl2/MeOH + 10 mM 
NH4OAc): m/z 466 [M+ + H]2+, 931 M+; C56H67N8O5 × C4H1F6O4 (1159.2)           
 
Compound 4.24 labeled with Py-6 (4.40). Yield: 15 % (1.51 mg); RP-HPLC (Eurospher 250 × 
4 mm, 210 nm, gradient 3): 97 % (tR = 21.3 min, k = 6.9); MS (ES, CH2Cl2/MeOH + 10 mM 
NH4OAc): m/z 528.5 [M+ + H]2+, 1055.6 M+; C63H75N8O7 × C4H1F6O4 (1283.3)          
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Compound 4.25 labeled with Py-6 (4.41). Yield: 16 % (1.68 mg); RP-HPLC (Eurospher 250 × 
4 mm, 210 nm, gradient 3): 96 % (tR = 21.5 min, k = 7.0); MS (ES, CH2Cl2/MeOH + 10 mM 
NH4OAc): m/z 535.5 [M+ + H]2+, 1069.7 M+; C64H77N8O7 × C4H1F6O4 (1297.3)          
 
Compound 4.26 labeled with Py-6 (4.42). Yield: 13 % (1.43 mg); RP-HPLC (Eurospher 250 × 
4 mm, 210 nm, gradient 3): 89 % (tR = 21.7 min, k = 7.0); MS (ES, CH2Cl2/MeOH + 10 mM 
NH4OAc): m/z 549.5 [M+ + H]2+, 1097.7 M+; C66H81N8O7 × C4H1F6O4 (1325.4)          
 
Compound 4.27 labeled with Py-1 (4.43). Yield: 26 % (1.94 mg); RP-HPLC (Eurospher 250 × 
4 mm, 210 nm, gradient 3): 97 % (tR = 20.3 min, k = 6.5); MS (ES, TFA/acetonitrile): m/z 438 
[M+ + H]2+, 875 M+; C53H63N8O4 × C4H1F6O4 (1103.1)          
 
Compound 4.27 labeled with Py-5 (4.44). Yield: 23 % (0.94 mg); RP-HPLC (Eurospher 250 × 
4 mm, 210 nm, gradient 3): 99 % (tR = 17.4 min, k = 5.4); MS (ES, TFA/acetonitrile): m/z 425 
[M+ + H]2+, 849 M+; C51H61N8O4 × C4H1F6O4 (1077.1)          
 
Compound 3.38 labeled with Py-1 (4.45). Yield: 26 % (1.32 mg); RP-HPLC (Eurospher 250 × 
4 mm, 210 nm, gradient 3): 98 % (tR = 18.0 min, k = 5.7); MS (ES, TFA/acetonitrile): m/z 801.1 
[M+ + H]2+, 543.5 [M+ + 2H]3+; C93H114N15O10 × C8H4F12O8 (2057.1)           
 
Compound 3.39 labeled with Py-1 (4.46). Yield: 28 % (1.54 mg); RP-HPLC (Eurospher 250 × 
4 mm, 210 nm, gradient 3): 90 % (tR = 18.8 min, k = 6.0); MS (ES, TFA/acetonitrile): m/z 553.2 
[M+ + 2H]3+, 829.2 [M+ + H]2+; C97H122N15O10 × C8H4F12O8 (2113.2)           
 
Compound 3.40 labeled with Py-1 (4.47). Yield: 28 % (1.53 mg); RP-HPLC (Eurospher 250 × 
4 mm, 210 nm, gradient 3): 93 % (tR = 16.7 min, k = 5.2); MS (ES, TFA/acetonitrile): m/z 872.2 
[M+ + H]2+, 581.9 [M+ + 2H]3+; C99H124N17O12 × C8H4F12O8 (2199.3)           
 
 
4.3.3 Fluorescence Spectroscopy and Determination of Quantum Yields 
 
Determination of quantum yields was performed with a Cary Eclipse spectrofluorimeter and 
Cary 100 UV/VIS photometer (Varian Inc., Mulgrave, Victoria, Australia). The photomultiplier 
voltage of the Cary Eclipse spectrofluorimeter was set to 400 V throughout. Recording of 
excitation spectra was performed with an excitation slit of 5 nm and an emission slit of 10 nm. 
Emission spectra depicted in Figure 4 were recorded with an excitation slit of 10 nm and an 
emission slit of 5 nm.  
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For the determination of quantum yields cresyl violet perchlorate (Acros Organics, Geel, 
Belgium) was used as a red fluorescent standard, for which a quantum yield of 54 % in ethanol 
was reported in the literature42. It is important to use the perchlorate, because only this salt is 
provided with sufficiently high purity. 
Spectra were recorded in glass cuvettes (Hellma, 100-OS, 10 × 10 mm) or in acryl cuvettes (10 
× 10 mm, Ref. 67.755, Sarstedt, Nümbrecht, Germany). The use of the latter was less time 
consuming due to the one-way use and solutions had not to be transferred into another cuvette 
between recording of fluorescence and absorption spectra. Quantum yields proved to be nearly 
unaffected by the material of the cuvette (glass/acryl). First of all, the concentrations of the 
fluorescent ligands for the determination of the quantum yield was determined. For this purpose 
an absorption spectrum was recorded with a concentration in the range of 2-6 µM. For the 
determination of quantum yields solutions with absorbances between 0.1 and 0.2 at the 
excitation wavelength were used. The excitation wavelength was chosen as close to the 
absorption maximum as possible or at a plateau of the absorption spectrum (e.g. S0436 labeled 
compounds). It was strictly avoided to excite the fluorescent compounds in flank of the 
excitation spectrum.    
Solutions of the fluorescent ligands in PBS, PBS + 1 % BSA or ethanol were freshly prepared 
from 1 or 2 mM stock solutions (DMSO) of the compounds and immediately protected from light. 
Fluorescence spectra were recorded at three different slit adjustments (excitation/emission): 5/5 
nm, 10/5 nm and 10/10 nm. Spectra of the cresyl violet standard were only recorded in ethanol. 
For the determination of reference spectra, the pure solvents with the same DMSO content, but 
without fluorescent compound, were used. The solutions were always maintained in the dark. 
The emission spectra were recorded within 15 - 20 min at a temperature of 22 °C using the 
medium scan rate. The filter settings were “auto” for the excitation and “open” for the emission 
filter. The emission starting point was set 10 nm above the excitation wavelength for the slit 
adjustments 5/5 nm and 10/5 nm as well as 15 nm above the excitation wavelength for the slit 
combination 10/10 nm. From every emission spectrum the corresponding reference spectrum 
was subtracted, yielding the net spectra, which were multiplied with the corresponding lamp 
correction spectra. The resulting corrected net spectra were integrated up to 850 nm.  
The absorbance at the excitation wavelength was determined by recording absorption spectra 
immediatly after the recording of the emission spectra (within 30 min after preparation of test 
solutions). Baselines were stored using reference solutions and subtracted from the raw 
spectra. The quantum yield was calculated according to the following equation:  
ΦF(X) = (As/Ax) (Fx/Fs) (nx/ns)2 ΦF(S) 
where As is the absorbance and Fs the integral of the corrected emission spectrum of the cresyl 
violet standard solution. Ax and Fx stand for the absorbance and the integral of the corrected 
emission spectrum of the fluorescent ligand. The refraction indices of the solvents for the 
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fluorescent ligands and the cresyl violet standard are denoted nx and ns, respectively. ΦF(S) is 
the reported quantum yield of cresyl violet, in this case 54 %. 
 
 
4.3.4 Pharmacology: Cell Culture, Fura-2 Assay and Competition Binding Assay 
 
Cell culture. HEL and SK-N-MC cells were cultured as described elsewhere.43, 44 HEL cells 
were subcultured by 1:6-dilution with fresh culture medium 24 h prior to the fura Ca2+-assay. 
MCF-7-Y1a cells were maintained in MEM (Sigma), supplemented with 5 % FCS (Biochrom AG, 
Berlin, Germany). The CHO cells, transfected with the human Y2R, Gqi5 and aequorin, were 
cultured as previously described.3 CHO cells, transfected with the human Y4R, Gqi5 and 
aequorin, were cultured under the same conditions. HEC-1B cells, transfected with the human 
Y5R, were cultured as previously described.45  
aThis cell line was established from MCF-7 cells (ATCC number HTB 22) in the 157th passage 
and shows 2 - 3-fold higher Y1R expression than the original MCF-7 cells. 
 
Fura-2 assay on HEL cells and radioligand competition binding assay. The Fura assay 
was performed with HEL cells as previously described32 using a Perkin-Elmer LS50 B 
spectrofluorimeter (Perkin Elmer, Überlingen, Germany). Radioligand competition experiments 
with [3H]-UR-MK114 (cf. chapter 2) were performed as described in chapter 3. 
 
 
4.3.5 Pharmacology: Flow Cytometric Binding Experiments 
 
All flow cytometric assays were performed with a FACSCaliburTM flow cytometer (Becton 
Dickinson, Heidelberg, Germany), equipped with an argon laser (488 nm) and a red diode laser 
(635 nm).  
 
Selectivity assay with fluorescent ligand 4.36. The selectivity assay was essentially 
performed as previously described3 with the following modifications: due to the interfering 
fluorescence emission of compound 4.36 in channel Fl-3 of the flow cytometer, the indicator dye 
fura red was not used for cell labeling. Therefore, only two cell types were mixed. One mixture 
contained fluo-4 loaded HEL cells (constitutively expressing the Y1R) and unloaded CHO cells 
(transfected with the Y2R, Gqi5 and aequorin). The other mixture consisted of fluo-4 loaded 
HEL cells and unloaded Y5R transfected HEC-1B cells. Fluo-4 loading of the HEL cells was 
essentially performed as previously described for fura-243, but with a fluo-4 concentration of 0.75 
µM. The cell density in the final mixture was 106 cells/mL for the HEL cells, 0.7·106 cells/mL for 
the CHO cells and 0.6·106 cells/mL for the HEC-1B cells. Every cell suspension contained 
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bacitracin (0.1 g/l) in order to inhibit protease activity. 490 µL of cell suspension were added to 
the reaction vessels containing 5 µL of the respective 100-fold concentrated stock solutions 
(cy5-pNPY in 10 mM HCl + 0.1 % BSA and compound 4.36 in DMSO). Compound 4.36 was 
used in the range between 0.1 nM and 10 µM, cy5-pNPY at a concentration of 10 nM. All 
samples were prepared in triplicates. After incubation at room temperature for 60-90 min, the 
samples were measured at the highest flow rate until 20,000 gated events were counted. 
 
Flow cytometric binding studies with 4.38 at the Y2R and Y5R. Flow cytometric binding 
studies with 4.38 at the Y2R (CHO cells, transfected with the Y2R, Gqi5 and aequorin)46, and at 
the Y5R (expressed by HEC-1B cells transfected with the Y5R)3, 47 were performed as previously 
described. The cell density in loading buffer was 106 cells/mL (Y2R) or 0.5·106 cells/mL (Y5R). 
For Y2R binding studies Dy-635-pNPY (10 nM) was used instead of Cy5-pNPY (10 nM).  
 
Flow cytometric binding studies at the Y4R. For the determination of the Y4R affinity of 
compound 4.36 and 4.38, a confluent culture of CHO cells transfected with the Y4R, Gqi5 and 
aequorin was trypsinized and resuspended in loading buffer containing 1 % BSA. After 
centrifugation at 1,000 rpm for 5 min, the cells were suspended in loading buffer + 1% BSA to a 
density of 2.5·105 cells/mL (4.36) or 106 cells/mL (4.38). Bacitracin was added (0.1 g/l) in order 
to prevent protease-mediated degradation of the peptide ligands. Compound 4.36 was tested at 
the same concentrations as in the aforementioned selectivity assay, compound 4.38 at a 
concentration of 1 and 10 µM. In both cases 100-fold concentrated stock solutions in DMSO 
were used. An S0586-labeled derivative of the human pancreatic polypeptide (S0586-[K4]-hPP) 
was used as fluorescent ligand (10 nM) to determine the affinity of 4.36, and Cy5-[K4]-hPP37 (5 
nM) was used to determine the affinity of 4.38. Stock solutions (S0586-[K4]-hPP: 1 µM, Cy5-
[K4]-hPP: 0.5 µM) were prepared in 10 mM HCl + 0.1 % BSA. 490 µL of the cell suspension 
were added to the reaction vessels containing 5 µL of the respective stock solutions of S0586-
[K4]-hPP or Cy5-[K4]-hPP and the test compounds. Non-specific binding was determined in the 
presence of hPP (100 nM). All samples were prepared in triplicates. The samples were 
incubated for 90 min at room temperature and measured at the highest flow rate (4.36: 1 min, 
4.38: until 20,000 gated events were counted), detecting the S0586-[K4]-hPP or Cy5-[K4]-hPP 
fluorescence emission in the Fl-4 channel. 
 
Displacement of fluorescent ligand 4.36 by BIBP 3226. The displacement of antagonist 4.36 
by BIBP 3226 (Figure 8) was determined on HEL cells in loading buffer without BSA using a cell 
density of 2.5·105 cells/mL. The non-fluorescent antagonist BIBP 3226 was used at final 
concentrations between 0.1 nM and 1 µM. For the determination of non-specific binding BIBP 
3226 (10 µM) was added. Compound 4.36 (5 µL of a 1 µM solution in 50 % DMSO) and the 
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respective 100-fold concentrated BIBP 3226 solution (5 µL) were premixed in 1.5 mL Eppendorf 
reaction vessels. Incubation of the cells was started by addition of cell suspension (490 µL) to 
the tubes to yield a final volume of 500 µL containing 10 nM of compound 4.36 and the 
respective concentration of BIBP 3226. After 15 min of incubation at room temperature the 
samples were measured by flow cytometry, recording the fluorescence signals in channels Fl-2 
(585 ± 21 nm) and Fl-3 (> 670 nm) using an excitation wavelength of 488 nm (argon laser). 
From every sample 15,000 – 18,000 cells were gated. 
 
Saturation binding experiment with 4.31 and displacement of 4.31 by BIBP 3226. MCF-7-
Y1 cellsa were seeded in a 175-cm2 culture flask 5-6 days prior to the experiment. 17--Estradiol 
(1 nM) was added 3 days prior to the experiment using a 1 µM solution in ethanol. Cells were 
treated with trypsin, suspended in culture medium and centrifuged. The cell pellet was re-
suspended in buffer (see general experimental conditions), cells were centrifuged and re-
suspended in buffer to a density of 0.5·106 - 1·106 cells/mL. 4.31 was used at final 
concentrations between 1 and 50 nM for saturation binding experiments. Non-specific binding 
was determined in the presence of BIBP 3226 (500-fold concentrated). The fluorescent ligand 
(4.31) was used at a concentration of 10 nM for displacement with BIBP 3226 (final 
concentrations: 0.03 – 3,000 nM).  
For total binding 50 % DMSO in water (5 µL) and 50 % DMSO in water (5 µL) with 4.31 (100-
fold concentrated) was added to the cell suspension (490 µL). For displacement of 4.31 with 
BIBP 3226 50 % DMSO in water (5 µL) with 4.31 (100-fold concentrated) and 50 % DMSO in 
water (5 µL) with BIBP 3226 (100-fold concentrated) was added to the cell suspension (490 µL).  
After 15 min of incubation in darkness at room temperature the samples were measured by flow 
cytometry using an excitation wavelength of 633 nm (red diode laser) and recording the 
fluorescence signals in channel Fl-4 (661 ± 18 nm). Measurements were stopped when 20,000 
gated events had been counted (highest flow rate).  
 
 
4.3.6 Confocal Microscopy 
 
Two days prior to the experiment MCF-7-Y1 cells (between 175th and 190th passage) were 
trypsinized and seeded in Nunc LabTekTM II chambered coverglasses with 8 chambers (Nunc, 
Wiesbaden, Germany) in MEM containing 1 nM 17-estradiol and 5 % FCS. On the day of the 
experiment confluency of the cells was 30 - 60 %. The culture medium was removed, the cells 
were washed twice with Leibowitz L15 culture medium (400 µL) and covered with L15 medium 
(240 µL). L15 medium (80 µL) and L15 medium (80 µL) with the fluorescent probe (five fold 
concentrated) was added for total binding. For non-specific binding L15 medium (80 µL) with the 
competing agent BIBP 3226 (five fold concentrated) and L15 medium (80 µL) with the 
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fluorescent probe (five fold concentrated) was added. Images of total and non-specific binding 
were acquired after an incubation period of 6 -24 min.  
Confocal microscopy was performed with a Zeiss Axiovert 200 M microscope, equipped with the 
LSM 510 laser scanner. The objective was a Plan-Apochromat 63x/1.4 with oil immersion. 
Table 4 shows the most important settings for the detection of the investigated fluorescent 
ligands. 
Table 4. Conditions for the detection of the fluorescent ligands 4.36, 4.38, 4.34, 4.32, 
4.35, 4.30, 4.31, 4.45, 4.47 and 4.29-i2 with the Zeiss Axiovert 200 M microscope.  
Compd. Excitation (laser transmission) Filter Pinhole [µm] 
4.36 488 nm (5.1 %) LP 505 71 
4.38 488 nm (5.1 %) LP 505 71 
4.34 488 nm (5.1 %) LP 505 71 
4.32 488 nm (5.1 %) LP 505 71 
4.35 488 nm (5.1 %) LP 560 396 
4.30 488 nm (5.1 %) LP 650 896 
4.31 488 nm (5.1 %) LP 650 896 
4.45 488 nm (5.1 %) LP 560 240 
4.47 488 nm (5.1 %) LP 505 71 
4.29-i2 633 nm (5.1 %) LP 650 80 
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Chapter 5 
 
Y1 Receptor Antagonistic PET Ligands 
 
 
5.1 Introduction 
 
Positron emission tomography (PET) and single-photon emission computed tomography 
(SPECT) are powerful medical (molecular) imaging techniques in diagnosis. Whereas SPECT 
uses gamma ray emitting radionuclides such as 99mTc (decay: isomeric transition) or 123I (decay: 
electron capture), PET is based on the use of positron emitting isotopes such as 18F (t1/2 = 109.7 
min), 11C (t1/2 = 20.4 min), 64Cu (t1/2 = 12.7 h) or 124I (t1/2 = 4.18 d). During positron decay a 
proton is transmuted to a neutron, and a positron as well as a neutrino are emitted. Depending 
on the kinetic energy of the positron it can travel up to a few millimeters in water or tissue. When 
the positron decelerates it combines with an electron in the surrounding medium. Annihilation 
results in the back-to-back emission of a pair of photons (gamma, 511 keV) which are captured 
by the detector. This means, not the source of positron emission but the location of positron 
annihilation is detected. Thus, resolution in PET imaging depends not only on the quality of the 
detector but is also limited by the energy of the emitted positrons. For instance, 18F, the most 
frequently used radionuclide in PET applications, emits low energy positrons (compared to other 
positron emitters) which travel in water a distance of less than 1 mm before annihilation. The 
interaction of the 511-keV gamma photons with tissue, and the implicated scattering, is less 
pronounced compared to gamma photons (energy: 100 - 200 keV) emitted by nuclides used for 
SPECT. Radioactive decay is detected in PET by coincidence registration of the gamma 
quanta, when they reach a scintillator material in a scanning device. For the detection of the 
511-keV gamma photons, scintillation crystals are used, which are read out by photomultiplier 
tubes. Bismuth germanate (BGO) has been the most commonly used crystals in PET, but 
gadolinium oxyorthosilicate (GSO) and lutetium oxyorthosilicate (LSO) crystals are increasingly 
applied for the assembly of PET cameras. Compared to SPECT, positron emission tomography 
provides a higher resolution of acquired 3D images. The clinical adoption of PET imaging was 
extensively promoted in the last decade with the introduction of integrated PET/CT scanners as 
the combination of PET and CT shortens the duration of the scan and provides additional 
valuable diagnostic information for improved accuracy. 
The important radionuclide 18F is typically produced by proton bombardment (10 - 20 MeV) of an 
18O enriched water target through the 18O(p,n)18F nuclear reaction. It is recovered as an 
aqueous solution of fluoride-18 and can be easily extracted by ion exchange chromatography. 
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Today, PET is an important technique in nuclear medicine for diagnoses in the field of oncology, 
neurology and cardiology. Several powerful imaging probes are already established in clinical 
routine, and the development of new tracers is on-going. Most efforts were spent in the 
development of PET and SPECT tracers for tumor imaging. For instance, 2-[18F]fluoro-2-deoxy-
D-glucose ([18F]FDG) constitutes a large part of the success story of PET and is extensively 
used for diagnosis and therapy control of cancer. [18F]FDG is a substrate for glucose 
transporters and hexokinase and allows the measurement of glucose consumption. A number of 
biological characteristics of tumors such as high proliferation, angiogenesis, apoptosis, 
metastasis and hypoxia have been tried to be exploited by the application of appropriate nuclear 
probes1. Since a variety of receptors such as epidermal growth factor receptor2 and receptors 
for regulatory peptides (e.g. somatostatin, gastrin, bombesin, gastrin-releasing peptide, 
neurotensin, neuropeptide Y)3 are overexpressed on tumors, radiolabeled selective high-affinity 
ligands for these receptors are regarded as promising tools for cancer diagnosis. The success 
of these nuclear probes strictly depends on its pharmacokinetic properties, which are 
determined by the physicochemical profile (size, chemical structure, polarity, etc.) of the 
radiotracers. Rapid clearance from blood and non-target tissues, a high tumor-to-background 
ratio, high tumor penetration, penetration across the blood brain barrier (if required), metabolic 
stability and low immunogenicity are characteristics of an ideal nuclear probe. Generally, 
macromolecules such as proteins as well as compounds with logP values > 0 cannot fulfill these 
criteria. Proteins show a slow clearance from blood and non-target organs and consequently a 
low tumor-to-background ratio. Furthermore, they can be easily degraded by proteases / 
peptidases, and their immunogenic potential is high. The development of low molecular weight 
(< 1000 Da) PET tracers is mainly challenged by the difficulty to find the balance between 
required physicochemical properties (logP < 0) and sufficiently high affinity (Ki < 10 nM). 
Therefore, the development of adequate radiotracers for in vivo imaging is a highly 
interdisciplinary and challenging process. A straight forward method is the optimization of 
endogenous compounds (small receptor ligands, enzyme substrates, peptides, antibodies) with 
respect to their in vivo stability, affinity, high specificity of binding, low unspecific uptake, fast 
renal excretion, etc.. Toxicity of radiotracers is often a minor problem due to the very low 
dosage of radiopharmaceuticals. Another issue, which has to be addressed, is the type of action 
of radioligands used for PET imaging. While receptor agonists induce internalization of the 
receptor-agonist complex, receptor antagonists are supposed to lack this ability and have not 
been regarded as promising tracers in oncology. However, very recently a high tumor uptake 
was reported for radiolabeled peptidic somatostatin receptor antagonists.4 In vitro investigations 
revealed that the antagonists labeled a higher number of binding sites than the agonists tested.  
 
Recently, the neuropeptide Y Y1 receptor gained new interest since it has been reported to be 
expressed in different malignancies such as breast cancer5, prostate cancer6 and adrenal 
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tumors7, and therefore proposed as a potential tumor marker.8 Previous studies on N-
substituted derivatives of the Y1R antagonist BIBP 3226 revealed a preference for electron-
withdrawing substituents in terms of retaining or even increasing the binding affinity9. These 
findings gave reason to prepare Y1R antagonistic, fluorinated potential PET ligands, which can, 
labeled with 18F, potentially serve as tools for in vivo imaging of Y1 receptors. Since 4-
nitrophenyl 2-[18F]fluoropropanoate ([18F]NPFP) and N-succinimidyl 4-[18F]fluorobenzoate 
([18F]SFB) are standard reagents for a 18F-labeling, -amino functionalized acyl and carbamoyl 
linkers were introduced into the N-position of the (R)-argininamide BIBP 3226, the first highly 
potent and selective NPY Y1 receptor antagonist.10 These amine precursors were amidated with 
2-fluoropropionic acid and 4-fluorobenzoic acid to obtain the potential Y1R antagonistic PET 
ligands, which were evaluated in terms of Y1R antagonistic activity and affinity. Since the 
basicity of acylguanidines (pKa ≈ 7 – 8) is decreased by 4 - 5 orders of magnitude compared to 
guanidines (pKa ≈ 12.5) these compounds are anticipated to penetrate across the blood brain 
barrier as a considerable fraction remains uncharged under physiological conditions. This could 
be shown for arpromidine-derived histamine H2 receptor agonists which include an 
acylguanidine moiety.11 
A first set of six BIBP 3226-derived Y1R antagonistic potential PET ligands (“cold” form), was 
prepared by A. Brennauer.12 In continuation of this project, further potential PET ligands with 
varying structures of the linkers as well as two compounds labeled with 18F are presented here. 
 
 
 
5.2  Results and Discussion 
 
5.2.1  Chemistry 
 
The Y1R antagonistic potential PET ligands were prepared through 4-fluorobenzoylation and 2-
fluoropropionylation of amine precursors consisting of BIBP 3226 and N-attached amino-
functionalized acyl or carbamoyl linkers (Scheme 3). The synthesis of the amine precursors, 
except precursor 5.7, is described in chapter 4. Amine precursor 5.7 was prepared by analogy 
with the procedure described for compound 4.27 via attachment of the N-Boc protected linker to 
S-methylisothiourea and subsequent guanidinylation of amine 2.6 (Scheme 2). In the potential 
PET ligand 5.8 a linker between the guanidine group and the fluorinated carboxylic acid was 
omitted. Instead, the latter was directly attached to the guanidine of N-Boc, O-tert-butyl 
protected BIBP 3226 (Scheme 3). 2-Fluoropropionic acid was prepared from 2-bromopropionic 
acid following cited protocols13, 14 and was activated as 4-nitrophenyl ester15 (Scheme 1). 
4-Fluorobenzoic acid was activated as succinimidyl ester (Scheme 1). As an exception the 
potential PET ligand 5.21 was prepared via monoamidation of octanedioic acid with 4-
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fluorobenzylamine and coupling of the resulting carboxylic acid (5.20) to the guanidine group of 
the argininamide derivative 2.7 (Scheme 4). 
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Scheme 1. Synthesis of active esters 5.4 and 5.5. 
Reagents and conditions: (a) EtOH, toluene, reflux, 5.5 h, 76 %; (b) potassium fluoride, acetamide, 125 
°C, 3 h, 36 %; (c) NaOH, H2O, EtOH, reflux, 60 min, 91 %; (d) 4-nitrophenol, dicyclohexylcarbodiimide, 
THF, 0 °C to rt, 20 h, 27 %; (e) N-hydroxysuccinimide, dicyclohexylcarbodiimide, THF, 0 °C to rt, 20 h, 92 
%. 
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Scheme 2. Synthesis of amine precursor 5.7. 
Reagents and conditions: (a) triphosgene, diisopropylethylamine, CH2Cl2, rt, 2 h, 75 %; (b) (1) HgCl2, 
diisopropylethylamine, DMF, rt, 20 h; (2) CH2Cl2/TFA/H2O 10/10/1, rt, 2 h, 50 %. 
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Scheme 3. Synthesis of potential PET ligands 5.8 – 5.19. 
Reagents and conditions: (a) (1) NEt3, acetonitrile, rt, 16 h, (2) acetonitrile/TFA 1/1, 50 °C, 60 min, 84 %; 
(b) (1) NEt3, acetonitrile, rt, 1 - 5 h, 48 – 81 %; (c) (1) NEt3, CH2Cl2, rt, 5 h; (2) CH2Cl2, TFA, rt, 2 h, 50 %; 
(d) NEt3, DMF, rt, 1 - 2 h, 67 – 91 %. 
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Scheme 4. Synthesis of the potential PET ligand 5.21. 
Reagents and conditions: (a) 4-fluorobenzylamine, NEt3, CH2Cl2, rt, 6 h, 16 %; (b) (1) NEt3, CH2Cl2, rt, 20 
h, (2) CH2Cl2/TFA 1/1, rt, 2.5 h, 71 %. 
 
The 18F-labeled compounds 5.8-F18 and 5.9-F18 were prepared in the laboratory of Prof. Dr. 
H.J. Wester (Nuclear Medicine Department of the Klinikum rechts der Isar, TU München) from 
4-nitrophenyl 2-[18F]fluoropropionate as well as N-Boc, O-tert-butyl protected BIBP 3226 (2.7) 
and amine precursor 4.21, respectively (Scheme 5). 4-Nitrophenyl-2-[18F]fluoropropionate was 
synthesized as described elsewhere16 from bis-(4-nitrophenyl) carbonate and 2-fluoropropionic 
acid. The latter was obtained through hydrolysis of 9-anthrylmethyl 2-[18F]fluoropropionate which 
was prepared by the treatment of 9-anthrylmethyl 2-bromopropionate with the cryptate 
([K/2.2.2]+/18F- in acetonitrile at 95 °C for 5 min. After its production via the 18O(p,n)18F nuclear 
reaction using a cyclotron, fluoride-18 was purified by ion exchange chromatography and 
recovered as potassium cryptate salt to enable the nucleophilic substitution in an organic 
solvent (acetonitrile). 
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Scheme 5. Synthesis of PET ligands 5.8-F18 and 5.9-F18. 
Reagents and conditions: (a) (1) NEt3, acetonitrile, 65 °C, 20 min, (2) acetonitrile/TFA 1/1, 70 °C, 40 min, 
70 %; (b) NEt3, acetonitrile, DMSO, 50 °C, 15 min, 60 %. 
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While amidation of 2-fluoropropionic acid with primary amines results in stable compounds, the 
2-fluoropropionyl-guanidine entity, which is present in compound 5.8, turned out to be 
chemically unstable. At pH 7.4 and 40 °C this molecule is degraded to BIBP 3226 with a half-life 
of about 100 min (Scheme 6, Figure 1). The decomposition takes also place in acidic media but 
at a considerable lower rate (Figure 1). 
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Scheme 6. Degradation of 5.8 to BIBP 3226. The half-life at pH 7.4 and 40 °C is about 100 min. 
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Figure 1. Degradation of compound 5.8 (II) to BIBP 3226 (I) at pH 2.2 (0.05 % aq. TFA) and pH 7.4 
(phosphate buffer) at 40 °C monitored by HPLC analysis (column: Nucleodur 100-5 C18, 250 × 4 mm, 5 
µm; detection: 210 nm). Depicted are the chromatograms for time points t = 0 min (t0) and t = 240 min 
(t240). The presence of about 6 % of BIBP 3226 at the beginning is due to a partial degradation during the 
work-up of 5.8. The decomposition under acidic conditions is considerably slower compared to neutral 
conditions. The half-life in phosphate buffer (pH 7.4) was determined to be about 100 min (40 °C). The 
identity of BIBP 3226 was determined by analysis of a spiked sample. 
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5.2.2 Y1 Receptor Antagonism, Affinity and Selectivity 
 
All potential Y1R antagonistic PET ligands antagonized the NPY induced intracellular Ca2+-
mobilization in human erythroleukemia (HEL) cells in the nanomolar range (Table 1). Binding 
constants were determined by displacement of [3H]-UR-MK114 (cf. chapter 2) on SK-N-MC 
neuroblastoma cells as well as for the three most potent compounds (5.10, 5.16, 5.17) on MCF-
7 breast cancer cells. Affinities of less than 10 nM, commonly regarded as prerequisite for a 
successful PET imaging, were not be achieved by 4-fluorobenzoylation and 2-
fluoropropionylation of various -aminoacylated BIBP 3226 derivatives (Table 1). 
The comparison of Y1R binding data of N-butanoylated BIBP 3226 (6.2) with its “aza analog”, 
N-ethylaminocarbonyl BIBP 32269 (Figure 1), gave reason to introduce -aminocarbamoyl 
linkers which finally paved the way to a potential PET ligand with an affinity of about 1 nM (5.16, 
Table 1). Compound 5.16 differs from 5.9 only in the -position of the spacer (Figure 2). The 
exchange of the -methylene group by “NH” results in an increase in affinity by a factor of about 
20, suggesting a binding enhancing effect of the “carbamoyl-NH”. Unfortunately, the gain in 
affinity is mitigated with increasing size of the residues attached to the carbamoyl nitrogen as 
becomes obvious from compounds 5.17 – 5.19 (Table 1). 
The chemically unstable Y1R antagonist 5.8 had to be analyzed in the presence of about 8 % 
BIBP 3226 due to a partial degradation during the preparative work-up. Therefore, the real 
binding constant of N-2-fluoropropionylated BIBP 3226 (5.8) is probably above the value (Ki = 
10 nM) determined in the presence of the high affinity ligand BIBP 3226 (Ki = 1.3 nM, Table 1). 
Nevertheless, comparing the fluoropropionyl derivative 5.8 and the corresponding non-
fluorinated analog 2.8 (KD = 1.2 nM, cf. chapter 2) the decrease in affinity induced by fluorination 
is remarkable. A plausible reason for this phenomenon is the lower basicity of the 2-fluoro-
propionyl-guanidine moiety compared to a propionylated guanidine (calculated (ACDLABS 9.0) 
pKa values: 8.1 and 6.6, resp.). Therefore the degree of protonation of compound 5.8 at 
physiological pH is considerably decreased and results in an attenuated key interaction of the 
guanidine function with Asp287 of the receptor protein17. 
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Table 1. Structures, Y1 receptor antagonism and binding data of BIBP 3226, amine precursors 4.21 and
4.27 as well as of potential PET ligands 5.8 - 5.19 and 5.21. 
(R)
H
N N
H
O
OHO
NH
NH2N
R =
O
F
CH3
O
F
2FP =
4FB =
 
Compd. Structure IC50 (Kb) [nM]a Kib (Kic) [nM] 
BIBP 3226 R-H 10±1 (1.5) 1.3±0.2 
4.21 R-CO-(CH2)5-NH2 620±130 (95) 19±5 
4.27 R-CONH-(CH2)4-NH2 110±3 (16) 4.3±0.5 
5.8 R-2FP 75±11* (12) 10±3* 
5.9 R-CO-(CH2)5-NH-2FP 53±7 (8) 25±4 
5.10 R-CO-CH2-(O-CH2-CH2)2-NH-2FP 510±51 (79) 15±1 (31±11) 
5.11 R-CO-(CH2)3-CONH-(CH2)2-(O-CH2-CH2)2-NH-4FB 930±330 (140) 37±10 
5.12 R-CO-(CH2)6-CONH-(CH2)2-(O-CH2-CH2)2-NH-4FB 190±10 (30) 51±11 
5.13 R-CO-(CH2)3-CONH-(CH2)2-4FB 230±24 (35) 24±2 
5.14 R-CO-(CH2)3-CONH-(CH2)3-4FB 220±14 (34) 64±3 
5.15 R-CO-(CH2-CH2-O)3-CH2-CH2-NH-4FB 140±5 (22) 51±5 
5.16 R-CONH-(CH2)4-NH-2FP 4.3±0.2 (0.7) 1.3±0.4 (3.3±0.1)
5.17 R-CONH-(CH2)4-NH-4FB 3±0.1 (0.5) 7±2 (6.8±0.5) 
5.18 R-CONH-(CH2)2-(O-CH2-CH2)2-NH-2FP 130±18 (19) 19±4 
5.19 R-CONH-(CH2)2-(O-CH2-CH2)2-NH-4FB 23±1 (3.5) 16±5 
5.21 R-CO-(CH2)6-CONH-(4-fluorobenzyl) 46±3 (7.1) 30±5 
aInhibition of 10 nM NPY induced [Ca2+]i mobilization in HEL cells; mean values ± SEM from two
independent experiments. b/cDissociation constant determined from the displacement of [3H]-UR-MK114
(SK-N-MC cells: KD = 1.2 nM, MCF-7 cells: KD = 2.9 nM) on bSK-N-MC and cMCF-7-Y1 cells; mean values
± SEM from two independent experiments performed in duplicate or triplicate. *Determined in the
presence of about 8 % BIBP 3226 (analyzed by HPLC).  
 
The potential PET ligand 5.21 was prepared in dependence on the N-(7-methoxycarbonyl-
heptanoyl)-substituted argininamide 6.4 (Figure 2, cf. also chapter 6), a highly potent Y1R 
antagonist (Ki = 0.9 nM) suggesting an affinity-enhancing effect of the methoxycarbonyl group. 
With respect to the preparation of a PET ligand the methoxy group in 6.4 was replaced by 4-
fluorobenzylamine which is also a standard reagent for the introduction of 18F. Unfortunately, 
this structural variation (5.21) resulted in a remarkable decrease in affinity by a factor of about 
30 (Figure 2). It might be possible that the 4-fluorobenzyl entity hampers an interaction 
(hydrogen bonding) of the carbonyl oxygen with the receptor protein as it could be the case for 
6.4.  
The Kb (functional assay) and Ki (binding assay) values for the Y1R antagonists in Table 1 are 
generally in better accordance than the data for the series of fluorescent Y1R ligands presented 
in chapter 4. Possible reasons for discrepancies between Kb and Ki values were discussed in 
chapter 4. 
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Figure 2. Structures and Y1R affinities (SK-N-MC cells) of a selection of Y1R antagonists derived from 
BIBP 3226. aDissociation constant determinded with [3H]-UR-MK114 as radioligand (c = 1.5 nM). 
  
 
The Y1 receptor selectivity was exemplary confirmed for antagonists 5.16 and 5.17, the most 
potent potential PET ligands, using established flow cytometric binding assays based on 
fluorescence labeled pNPY and PP (Table 2). 
  
Table 2. NPY receptor subtype selectivity of the potential PET ligands 5.16 and 5.17. 
Compd. Y1 Ki [nM]a Y2 Ki [nM]b Y4 Ki [nM]c Y5 Ki [nM]b 
5.16 1.3 > 2,000 > 10,000 > 5,000 
5.17 7 > 2,000 > 5,000 > 5,000 
aDissociation constant from radioligand competition assay with [3H]-UR-MK114 (c = 
1.5 nM) on SK-N-MC neuroblastoma cells. bFlow cytometric binding assay on CHO-Y2
and HEC-1B-Y5 cells using Dy-635-pNPY as labeled ligand (10 nM). cFlow cytometric 
binding assay on CHO-Y4 cells with Cy5-[K4]-hPP (5 nM) as fluorescent ligand. 
 
 
 
5.2.3  PET and Biodistribution Experiments 
 
Fluorine-18 labeling of precursors 2.7 and 4.21 to obtain the Y1R antagonistic PET ligands 5.8-
F18 and 5.9-F18 (Scheme 5) was performed in the laboratory of Prof. Dr. H.J. Wester at the 
Nuclear Medicine Department of the Klinikum rechts der Isar, TU München. Both PET ligands 
were administered intravenously to male NMRI (nu/nu) mice with SK-N-MC xenografts in the 
flank to perform biodistribution experiments as well as 60-min PET scans with small animal PET 
cameras. The chemical instability of compound 5.8 (Scheme 6, Figure 1) was known at the time 
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of the preparation of the hot analog 5.8-F18, but an alternative PET ligand was not yet 
available, when this proof-of-concept study was started. 
After injection of PET ligand 5.8-F18 most of the radioactivity was detected over the whole scan 
(60 min) in a part of the intestines, probably the cecum (Figure 3, A + B). 
 
 
Figure 3. PET images (color table: NIH + white) of a male NMRI (nu/nu) mouse bearing a subcutanous 
SK-N-MC xenograft in the right flank after intravenous (tail vein) injection of the 18F-labeled Y1R 
antagonist 5.8-F18. The PET scan was started 5 min after injection and images were acquired as six 5-
min frames and three 10-min frames. Sets of corresponding coronal, sagittal and transaxial sections 
(planes are indicated by red arrows) are shown for the first (A) and last (B + C) frame of the scan. Already 
5 min after injection most radioactivity was detected in a part of the gastrointestinal tract, probably in the 
cecum, where it was retained for more than 60 min. An accumulation of radioactivity in the brain was 
clearly detectable in the last frame (55 – 65 min after injection) (C, image depicted with lower threshold). 
An accumulation of radioactivity in the SK-N-MC xenograft in the right flank was not observed. 
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Figure 4. Biodistribution of 5.8-F18 in NMRI (nu/nu) mice bearing subcutaneous SK-N-MC xenografts 30 
min after injection of the PET ligand (n = 3). 
 
 
Compound 5.9-F18 and potential metabolites, respectively, were excreted either to the gall and 
urinary bladder as becomes obvious from Figure 5A and Figure 6. In both cases the 
administration of the PET ligand resulted in a moderate accumulation of radioactivity in the brain 
(examplary shown for 5.8-F18 in Figure 1C). 
 
 
Figure 5. PET images (color table: NIH + white) of a male NMRI (nu/nu) mouse bearing a subcutanous 
SK-N-MC xenograft in the left flank after intravenous (tail vein) injection of the 18F-labeled Y1R antagonist 
5.9-F18. A 60-min PET scan was started 10 min after injection and images were acquired as 5-min 
frames. A1: Coronal PET image of frame 2 (15 – 20 min after injection). A2: Coronal PET image of frame 
12 (65 – 70 min after injection). B1: Coronal PET image of frame 2 at lower threshold; B2: Corresponding 
transaxial image (planes are indicated by red arrows). The biliary and renal excretion of 5.9-F18 and 
metabolites, respectively, becomes obvious from images A1 and A2 (highest intensity in the gall and 
urinary bladder). The SK-N-MC tumor (open arrow) could be visualized only in the first three frames (B1 
and B2 show images of frame 2). 
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Figure 6. Biodistribution of 5.9-F18 in NMRI (nu/nu) mice with and without subcutaneous SK-N-MC 
xenografts 90 min after injection of the PET ligand (n = 4, *n = 2). 
 
 
Whereas imaging of the Y1R expressing SK-N-MC tumor was sucessful in the early phase of 
the PET scan after injection of 5.9-F18 (Figure 5B), the xenograft could not be detected after 
administration of 5.8-F18. 
While biodistribution data correlate well with the PET images in case of the experiments with 
PET ligand 5.9-F18 (Figure 6), the amount of radioactivity in the intestine after administration of 
5.8-F18 appears to be too low compared to the PET images (Figures 3 and 4). Unfortunately, 
the radioactivity was determined in the whole gastrointestinal (GI) tract and not in individual 
organ segments. As the activity was normalized by the weight of the sample, potential local 
enrichment of activity inside the GI tract was not resolved in biodistribution studies with 5.8-F18 
(Figure 4). 
 
As already mentioned in the introduction, most PET ligands, which enable tumor imaging, have 
logP values < 0. Calculated logP values of the presented potential PET ligands are in the range 
of 1 - 4 indicating a too low water solubility of these compounds (Table 3). 4-Fluorobenzoylation 
leads to a considerable higher lipophilicity compared to 2-fluoropropionylation as becomes 
obvious from the logP values computed for compounds which differ only in the fluorinated acyl 
moiety (5.16 and 5.17 as well as 5.18 and 5.19, Table 3). 
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Table 3. Structures and computed logP values of BIBP 3226 and the potential PET ligands
5.8 - 5.19 as well as 5.21 for the depicted tautomeric forms. 
(R)
H
N N
H
O
OHO
NH
NH2N
R =
O
F
CH3
O
F
2FP =
4FB =
 
Comp. Structure clogPa logPb 
BIBP 
3226 R-H 1.3 1.9±0.9 
5.8 R-2FP 1.8 2.8±0.8 
5.9 R-CO-(CH2)5-NH-2FP 2.1 2.5±0.9 
5.10 R-CO-CH2-(O-CH2-CH2)2-NH-2FP 1.6 1.6±1 
5.11 R-CO-(CH2)3-CONH-(CH2)2-(O-CH2-CH2)2-NH-4FB -- 3.1±1 
5.12 R-CO-(CH2)6-CONH-(CH2)2-(O-CH2-CH2)2-NH-4FB -- 4.2±1 
5.13 R-CO-(CH2)3-CONH-(CH2)2-4FB -- 3.3±0.9 
5.14 R-CO-(CH2)3-CONH-(CH2)3-4FB -- 3.5±0.9 
5.15 R-CO-(CH2-CH2-O)3-CH2-CH2-NH-4FB -- 3.3±1 
5.16 R-CONH-(CH2)4-NH-2FP 1.4 2.0±0.9 
5.17 R-CONH-(CH2)4-NH-4FB 3.0 4.4±0.9 
5.18 R-CONH-(CH2)2-(O-CH2-CH2)2-NH-2FP -- 1.3±1 
5.19 R-CONH-(CH2)2-(O-CH2-CH2)2-NH-4FB -- 3.5±0.9 
5.21 R-CO-(CH2)6-CONH-(4-fluorobenzyl) -- 4.5±0.8 
acalculated with ChemDraw Ultra 11.0; bcalculated with ACDLABS 9.0; no entry:
calculation was not possible with the respective software  
 
Protonation of the basic guanidine group under physiological conditions leads to an increase in 
water solubility, but this is insufficient to prevent a biliary excretion of the compounds presented 
in this chapter. The partial renal excretion of PET ligand 5.9-F18 can be attributed to a partial 
metabolic conversion of this compound, which should be investigated e.g. by thin layer 
chromatography analysis of the urine of the mouse in future studies. 
As these PET and biodistribution experiments are preliminary studies, co-administration of a 
non-labeled Y1R antagonist to prevent specific binding of the tracer was not performed. This 
kind of experiment was envisaged in the case of successful tumor imaging. Therefore, it is not 
possible to state that the accumulation in the brain (Figure 3C) or the visualization of the tumor 
(Figure 5B) was Y1 receptor mediated.  
The 18F-labeled analog of compound 5.17 (Ki = 7 nM) was synthesized as the third PET ligand 
of this series in the research laboratories of Bayer Schering Pharma AG (Department of 
Oncology Imaging Research, Berlin) by acylation of amine precursor 4.27 with N-succinimidyl 4-
[18F]fluorobenzoate. Unfortunately, the preparation of the hot analog of the 2-fluoropropionylated 
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high affinity ligand 5.16 (Ki = 1.3 nM) was impossible since 4-nitrophenyl-2-[18F]fluoropropionate 
is only routinely used in Munich. PET ligand 5.17-F18 was prepared and administered 
intravenously to estrogen substituted nude mice with subcutaneous Y1R-expressing MCF-7-Y1 
tumors (for tumor induction same MCF-7-Y1 cells as used in previous studies in our laboratory 
were provided, cf. chapter 2). The experiment revealed a strong hepatobiliary excretion pattern 
of this compound, and an accumulation in the tumor was not observed (20-min PET scans were 
started 40 min after injection, n = 3). This can be explained by the unfavorable physicochemical 
properties of this compound, which is even more lipophilic than the PET ligand 5.9-F18 
(ACDLABS 9.0 computed logP values: 2.5 and 4.4, resp.). 
 
 
5.2.4  Summary and Outlook 
 
Based on the (R)-argininamide BIBP 3226 a series of potential antagonistic Y1R PET ligands 
with affinities in the lower nanomolar range was synthesized (“cold ligands”). Two compounds 
were prepared as prototype 18F-labeled PET ligands (Scheme 5) and administered 
intravenously to nude mice bearing SK-N-MC xenografts in the flank. One of these PET ligands 
(5.9-F18) with an affinity of 25 nM enabled the imaging of the subcutaneous SK-N-MC tumor 
(Figure 5B) in the early stage (up to 25 min) after administration, but a persistent tumor uptake 
enabling a late imaging after systemic clearance of the tracer was not observed. 
A major drawback of the presented potential PET ligands is the low water solubility (calculated 
logP values in the range of 1 – 4, cf. Table 3) which is the reason for a rapid biliary excretion in-
vivo. Compound 5.16 is the most promising potential PET ligand. The Y1R affinity of 5.16 is 
about 15 times higher and the compound is moderately more polar compared to PET ligand 5.9-
F18, which already enabled a tumor imaging in a preliminary PET experiment (Figure 5B).  
Using MCF-7 breast cancer cells instead of SK-N-MC xenografts, a refinened tumor model for 
Y1R PET imaging, was developed. MCF-7 cells show a higher Y1 receptor expression than SK-
N-MC cells (cf. chapter 2). Subcutaneous MCF-7 xenografts can be established in estrogen 
substituted NMRI (nu/nu) mice (cf. appendix). In addition to these achievements in terms of an 
appropriate in vivo model, PET ligands with improved pharmacokinetic properties are required 
with respect to the continuation of this project. As such compounds should be more polar than 
those used in the preliminary studies, the incorporation of hydroxyl groups, sugar moieties, or 
basic centers (e.g. secondary amines) into the linker seems a promising strategy, whereby the 
latter structural variation may be best to retain receptor affinity (cf. chapter 6). Such potential 
PET ligands with improved physicochemical properties and retained affinity (single-digit nM 
range) will be useful molecular tools – in particular to answer the question if GPCR antagonists 
in general can serve as PET ligands for an (improved) tumor imaging. 
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5.3  Experimental Section 
 
5.3.1  General Experimental Conditions 
 
Unless otherwise noted, chemicals and solvents were purchased from commercial suppliers 
and used without further purification. Dy-635-pNPY was synthesized as described previously.18 
[K4]-hPP was synthesized in the laboratory of Prof. Beck-Sickinger (University of Leipzig, 
Germany) and labeled with the cyanine dye Cy5 (FEW chemicals (Bitterfeld-Wolfen, Germany) 
in our laboratory.19 Porcine NPY (pNPY) was prepared in-house in the laboratory of Dr. C. 
Cabrele. Millipore water was used throughout for the preparation of buffers and HPLC eluents. 
Petroleum ether (40-60 °C) was distilled before use. DMF was stored over molecular sieves (3 
Å). Anhydrous reactions were run under an atmosphere of dry nitrogen or argon. 
Thin layer chromatography was performed on Merck silica gel 60 F254 TLC aluminum plates. For 
column chromatography silica gel Geduran 60 (Merck, 0.063-0.200 mm) was used. NMR 
spectra were recorded on a Bruker Avance 300 (1H: 300 MHz), a Bruker Avance 600 (1H: 600 
MHz) and a Bruker Avance III 600 with cryogenic probehead (1H: 600 MHz) (Bruker, Karlsruhe, 
Germany) with TMS as external standard. Mass spectrometry analysis (MS) was performed in-
house on a Finnigan ThermoQuest TSQ 7000 (ES-MS), a Finnigan SSQ 710A (EI-MS 70 eV, 
CI-MS) and a Finnigan MAT 95 (LSIMS, HRMS). Melting points were determined with a Büchi 
510 melting point apparatus and are uncorrected. Lyophilization was done with a Christ alpha 2-
4 LD equipped with a vacuubrand RZ 6 rotary vane vacuum pump. 
Preparative HPLC was performed with a system from Knauer (Berlin, Germany) consisting of 
two K-1800 pumps and a K-2001 detector. A Nucleodur 100-5 C18 (20 × 21 mm, 5 µm; 
Macherey-Nagel, Germany) and a Eurospher-100 C18 (250 × 32 mm, 5 µm; Knauer, Germany) 
served as RP-columns at flow rates of 24 and 38 mL/min, respectively. Mixtures of acetonitrile 
and 0.1 % aq. TFA were used as mobile phase. Acetonitrile was removed from the eluates 
under reduced pressure (final pressure: 60 mbar) at 40 °C prior to lyophilization. Analytical 
HPLC analysis was performed on a system from Thermo Separation Products (composed of a 
SN400 controller, a P4000 pump, a degasser (Degassex DG-4400, phenomenex), an AS3000 
autosampler and a Spectra Focus UV-VIS detector). An Eurospher-100 C18 (250 × 4 mm, 5 
µm, Knauer, Germany) or a Nucleodur 100-5 C18 ec (250 × 4 mm, 5 µm, Macherey-Nagel, 
Germany) served as RP-columns. Mixtures of acetonitrile (A) and 0.05 % aq. TFA (B) were 
used as mobile phase. Helium degassing, an oven temperature of 30 °C and a flow rate of 0.8 
mL/min were used throughout. Solutions for injection (concentrations in the two-digit µM range) 
were prepared in a mixture of A and B corresponding to the composition at the beginning of the 
gradient. The following gradients were applied for analytical HPLC analysis: 
Gradient 1: 0 to 25 min: A/B 25/75 to 65/35, 25 to 27 min: 65/35 to 95/5, 27 to 31 min: 95/5 
Gradient 2: 0 to 30 min: A/B 20/80 to 95/5, 30 to 40 min: 95/5 
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Purification and purity controls of F-18 labeled compounds was done on a HPLC system from 
Sykam GmbH (Gilching, Germany) consisting of a gradient pump S 1021, a mixer S 8111 and a 
controller S 2000. UV detection was performed with a UVIS detector 200 photometer (Linear 
TM. Instruments Corporation, Reno, USA) and radiometric detection was done with a Wallac 
EGG Ortec Ace Mate 925-Scint. Data were analyzed with Winnie-Software (Raytest, 
Straubenhardt, Germany). 
 
The preparation of the buffer and the lysis solution for Y1R binding studies on SK-N-MC cells 
and MCF-7 cells as well as the loading buffer for the determination of the mobilization of 
intracellular Ca2+ in HEL cells are described in chapter 3. 
5 mM stock solutions for HPLC purity controls were prepared in acetonitrile with an additive (5 
or 10 %) of 0.1 % aq. TFA. Stock solutions for pharmacological studies were prepared in DMSO 
at concentrations of 10 mM and stored at –78 °C. Tritium Counting was done in 3 mL of a liquid 
scintillator (RothiszintTM eco plus) with a Beckman LS 6500 beta-counter. 
 
 
5.3.2 Chemistry: Experimental Protocols and Analytical Data 
 
Ethyl 2-bromo-propanoate (5.1).13 2-Bromopropanoic acid (28.9 g, 17 mL, 189 mmol) and 2.5 
g of a cation exchanger (Dowex 50 X8, Fluka) were added to a mixture of toluene (100 mL) and 
ethanol (25 mL). Azeotropic esterification was performed under reflux using a Dean-Stark 
distilling trap. After 1 h of reflux about 10 mL of the lower layer were removed from the trap. 
Reflux was continued for 1 h and cation exchanger (2.5 g) and ethanol (25 mL) were added. 
After 1.5 h of reflux again 10 mL of the lower layer were drained off. The reaction was finished 
after 5.5 h (total time) of reflux. The ion exchanger was removed by filtration and the volume of 
the filtrate was reduced to about 30 mL under reduced pressure. The product was isolated as a 
colorless liquid (bp 66 °C, 30 mbar) using vacuum distillation (26.1 g, 144 mmol, 76 %). 1H-NMR 
(300 MHz, CDCl3):  (ppm) 1.3 (t, 3H, 3J = 7.13 Hz, CH3-CH2), 1.82 (d, 3H, 3J = 6.94 Hz, CH3-
CHBr), 4.23 (dq, 2H, 3J = 7.11 Hz, 2J = 1.01 Hz, CH3-CH2), 4.35 (q, 1H, 3J = 6.84 Hz, CHBr); 
C5H9BrO2 (181.0) 
 
Ethyl 2-fluoropropanoate (5.2).20 Dry potassium fluoride (45 g) and dry acetamide (40 g) were 
mixed in a 250-mL three necked round bottom flask equipped with a mechanical stirrer. The 
mixture was warmed up to 125 °C (bath temperature), 5.1 (25 g, 138 mmol) was added and 
stirring was continued at 125 °C for 3 h. The mixture was cooled down to room temperature and 
water (75 mL) was added yielding a suspension (consisting of 2 liquid phases) which was 
treated with ultrasound. The liquids were separated from the solid by decantation and the solid 
was washed with water (25 mL). The washing was combined with the liquid phases and the 
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product was extracted with ethyl ether (4 × 50 mL). The extracts were pooled, dried over sodium 
sulfate and filtered. Ethyl ether was removed under reduced pressure prior to vacuum distillation 
which afforded the product (bp 57 °C at 100 mbar) as a colorless liquid (6 g, 50 mmol, 36 %). 
1H-NMR (300 MHz, CDCl3):  (ppm) 1.31 (t, 3H, 3J = 7.14 Hz, CH3-CH2), 1.57 (dd, 3H, 3J = 
23.62 Hz, 3J = 6.87 Hz, CH3-CHF), 4.25 (q, 2H, 3J = 7.14 Hz, CH3-CH2), 4.99 (dq, 1H, 2J = 46.68 
Hz, 3J = 6.87 Hz, CHF); C5H9FO2 (120.1) 
 
2-Fluoropropanoic acid (5.3).14, 21 Sodium hydroxide (4.5 g, 112.5 mmol, 2.3 eq) was 
dissolved in water (13 mL) and 5.2 (5.9 g, 49.1 mmol, 1 eq) was added together with ethanol 
(13 mL). The mixture was heated under reflux for 60 min, cooled down to room temperature, 
and concentrated to a volume of about 10 mL under reduced pressure. Water (4.5 mL) and 
concentrated hydrochloric acid (9 mL) were added and the product was extracted with ethyl 
ether (6 × 15 mL). The extracts were pooled, dried over sodium sulfate and filtered. Ethyl ether 
was removed under reduced pressure prior to vacuum distillation which afforded the product (bp 
86 °C at 40 mbar) as a colorless liquid (4.1 g, 44.5 mmol, 91 %). 1H-NMR (300 MHz, CDCl3):  
(ppm) 1.64 (dd, 3H, 3J = 23.45 Hz, 3J = 6.96 Hz, CH3), 5.07 (dq, 1H, 2J = 48.51 Hz, 3J = 6.96 Hz, 
CHF); C3H5FO2 (92.1) 
 
4-Nitrophenyl 2-fluoropropanoate (5.4).22 DCC (2.3 g, 10.8 mmol, 1 eq) was added to a 
stirred ice-cold solution of 5.3 (1 g, 10.8 mmol, 1 eq) and 4-nitrophenol (1.65 g, 11.9 mmol, 1.1 
eq) in anhydrous THF (40 mL). The ice-bath was removed after 30 min and stirring was 
continued at rt overnight. The white solid (DCU) was removed by filtration and the solvent was 
removed under reduced pressure. Purification with column chromatography (eluent: PE/EtOAc 
9/1 to 3/1) and subsequent crystallization from ethanol yielded the product as a pale yellow 
crystalline solid (0.62 g, 2.9 mmol, 27 %). 1H-NMR (300 MHz, CDCl3):  (ppm) 1.78 (dd, 3H, 3J = 
23.41 Hz, 3J = 6.91 Hz, CH3), 5.28 (dq, 1H, 2J = 48.12 Hz, 3J = 6.91 Hz, CHF), 7.39 (m, 2H, Ar), 
8.31 (m, 2H, Ar); MS (EI): m/z 213 (M·+); C9H8FNO4 (213.2) 
 
Succinimidyl 4-fluorobenzoate (5.5).23 DCC (4.54 g, 22 mmol, 1.1 eq) was added to a stirred 
ice-cold solution of 4-fluorobenzoic acid (2.8 g, 20 mmol, 1 eq) and N-hydroxysuccinimide (2.53 
g, 22 mmol, 1.1 eq) in anhydrous THF (60 mL). The ice-bath was removed after 60 min and 
stirring was continued at rt overnight. The white solid (DCU) was removed by filtration and the 
solvent was removed under reduced pressure. Purification with column chromatography (eluent: 
PE/EtOAc 5/1 to 1/1) yielded the product as white solid (4.37 g, 18.4 mmol, 92 %). 1H-NMR 
(300 MHz, CDCl3):  (ppm) 2.9 (s, 4H, CH2), 7.19 (m, 2H, Ar), 8.16 (m, 2H, Ar); MS (EI): m/z 
237 (M·+); C11H8FNO4 (237.2) 
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N-tert-Butoxycarbonyl-N’-[8-(tert-butoxycarbonylamino)-3,6-dioxaoctyl]aminocarbonyl-S-
methylisothiourea (5.6). The reaction was carried out in an argon purged 50 mL two-necked 
round bottom flask equipped with a pressure equalizing addition funnel. The flask and the funnel 
were baked out in a nitrogen atmosphere prior to the reaction. A solution of N-Boc-3,6-dioxa-
octyl-1,8-diamine (500 mg, 2.01 mmol, 1 eq) and diisopropylethylamine (729 mg, 5.64 mmol, 
2.8 eq) in anhydrous CH2Cl2 (10 mL) was added dropwise to a solution of triphosgene (299 mg, 
1.0 mmol, 0.5 eq) in anhydrous CH2Cl2 (10 mL) over a period of 30 min. N-Boc-S-methylisothio-
urea (575 mg, 3.02 mmol, 1.5 eq) was added and stirring was continued for 1.5 h. The volume 
was reduced under reduced pressure to about 6 mL and the mixture was directly subjected to 
column chromatography (CH2Cl2/EtOAc 10/1 to 3/1). Highly viscous yellow oil (671 mg, 1.44 
mmol, 72 %); 1H-NMR (300 MHz, DMSO-d6):  (ppm) 1.36 (m, 9H, tert-Bu, 1.44 (m, 9H, tert-
Bu), 2.28 (s, 3H, CH3), 3.04 (m, 2H, CH2-NH), 3.19 (m, 2H, CH2-NH), 3.36 (t, 2H, 3J = 6.91 Hz, 
O-CH2-CH2-NH), 3.44 (t, 2H, 3J = 5.95 Hz, O-CH2-CH2-NH), 3.49 (s, 4H, O-CH2-CH2-O), 6.76 (t, 
1H, 3J = 5.42 Hz, CH2-NH), 7.77 (t, 1H, 3J = 5.86 Hz, CH2-NH), 12.34 (s, 1H, NH); MS (ES, 
CH2Cl2/MeOH + 10 mM NH4OAc): m/z 465 [M + H]+; C19H36N4O7S (464.6) 
 
(R)-N-(8-Amino-3,6-dioxaoctyl)aminocarbonyl-N-(2,2-diphenylacetyl)-N-(4-hydroxy-
benzyl)argininamide (5.6). Compound 5.5 (250 mg, 0.54 mmol, 1.1 eq) and 2.6 (239 mg, 0.49 
mmol, 1 eq, cf. chapter 2) were dissolved in anhydrous DMF (12 mL). HgCl2 (200 mg, 0.73 
mmol, 1.5 eq) and diisopropylethylamine (127 mg, 0.98 mmol, 2 eq) were added and the 
mixture was stirred at rt overnight. The solvent was removed under reduced pressure as far as 
possible (final pressure: 1 mbar, 43 °C) and the intermediate was purified by column 
chromatography (CH2Cl2/EtOAc 2/1 to 1/2) prior to deprotection with CH2Cl2/TFA/H2O 10/10/1 
(4 mL) for 2 h. CH2Cl2 (20 mL) was added three times, each time followed by evaporation under 
reduced pressure. Uptake of the green oily residue in water (20 mL) and lyophilization afforded 
the product as a heterogeneously colored (white/green) fluffy solid which turned into a green oil 
about 1 min after contact with air. The product was purified with preparative HPLC yielding a 
white fluffy solid (212 mg, 0.24 mmol, 50 %). 1H-NMR (300 MHz, DMSO-d6):  (ppm) 1.32-1.6 
(m, 3H, CH-CH2-CH2), 1.67 (m, 1H, CH-CH2-CH2), 2.97 (m, 2H, CH2-NH2), 3.2 (m, 2H, CH2-
NH), 3.28 (m, 2H, CH2-NH), 3.48 (t, 2H, 3J = 5.55 Hz, O-CH2-CH2-NH), 3.57 (m, 6H, CH2-O-
CH2-CH2-O), 4.15 (m, 2H, CH2-ArOH), 4.33 (m, 1H, CH), 5.13 (s, 1H, CH-(Ph)2), 6.66 (d, 2H, 3J 
= 8.51 Hz, AA’BB’), 7.0 (d, 2H, 3J = 8.52 Hz, AA’BB’), 7.18-7.33 (m, 10H, Ph), 7.51 (t, 1H, 3J = 
5.31 Hz, CO-NH-CH2), 7.79 (bs, 3H, NH3+), 8.38 (t, 1H, 3J = 5.77 Hz, CO-NH-CH2), 8.43 (bs, 
1H, NH), 8.5 (d, 1H, 3J = 8.08 Hz, CO-NH-CH), 8.96 (s, 1H, NH), 9.31 (s, 1H, NH), 10.15 (s, 1H, 
ArOH); MS (ES, MeOH + 10 mM NH4OAc): m/z 648 [M + H]+, 324.5 [M + 2H]2+; C34H45N7O6 × 
C4H2F6O4 (875.8) 
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(R)-N-(2,2-Diphenylacetyl)-N-(2-fluoropropanoyl)-N-(4-hydroxybenzyl)argininamide (5.8). 
Compound 2.7 (90 mg, 143 µmol, 1.05 eq, cf. chapter 2) was added to a solution of 5.4 (29 mg, 
136 µmol, 1 eq) in dry acetonitrile (3 mL). NEt3 (29.2 mg, 40 µL, 290 µmol, 2 eq) was added and 
the mixture was stirred at rt for 16 h. TFA (3 mL) was added and stirring was continued at 50 °C 
for 1 h. MeOH (5 mL) was added twice, each time followed by evaporation under reduced 
pressure. Purification with preparative HPLC (column: Nucleodur 250 × 21 mm) and 
lyophilization afforded the product as a white fluffy solid (75.6 mg, 114 µmol, 84 %). Mp 126-128 
°C; 1H-NMR (600 MHz, DMSO-d6):  (ppm) 1.34-1.61 (m, 3H, CH-CH2-CH2), 1.53 (dd, 3H, 3J = 
24.7 Hz, 3J = 6.74 Hz, CH3), 1.68 (m, 1H, CH-CH2-CH2), 3.25 (m, 2H, CH2-CH2-NH), 4.12 (dd, 
1H, 2J = 14.96 Hz, 3J = 5.73 Hz, CH2-ArOH), 4.18 (dd, 1H, 2J = 15.17 Hz, 3J = 5.79 Hz, CH2-
ArOH), 4.34 (m, 1H, CH), 5.13 (s, 1H, CH-(Ph)2), 5.33 (m, 1H, CHF), 6.67 (d, 2H, 3J = 8.53 Hz, 
AA’BB’), 7.01 (d, 2H, 3J = 8.5 Hz, AA’BB’), 7.24 (m, 2H, Ph), 7.28 (m, 8H, Ph), 8.4 (t, 1H, 3J = 
5.69 Hz, CH-CO-NH-CH2), 8.51 (d, 1H, 3J = 8.18 Hz, CO-NH-CH), 8.58 (bs, 1H, NH), 8.84 (bs, 
2H, NH2), 9.3 (s, 1H, NH), 10.98 (s, 1H, ArOH); RP-HPLC (Nucleodur 250 × 4 mm, 210 nm, 
gradient 1): 95 % (tR = 11.8 min, k = 4.1); HRMS: (FAB+, CH2Cl2/n-butylamine): m/z calcd. for 
[C30H34FN5O4 + H]+ 548.2673, found: 548.2684; C30H34FN5O4 × C2HF3O2 (661.6) 
 
(R)-N-(2,2-Diphenylacetyl)-N-[6-(2-fluoropropanoylamino)hexanoyl]-N-(4-hydroxy-
benzyl)argininamide (5.9). Amine precursor 4.21 (78 mg, 95.7 µmol, 1.3 eq; cf. chapter 4) was 
dissolved in acetonitrile (5 mL). NEt3 (18.6 mg, 25.5 µL, 184 µmol, 2.5 eq) and active ester 5.4 
(15.7 mg, 73.6 µmol, 1 eq) were added and the mixture was stirred at rt for 2 h prior to the 
addition of a few drops of TFA. Purification with preparative HPLC (column: Nucleodur 250 × 21 
mm) and lyophilization afforded the product as a white fluffy solid (30.4 mg, 39.2 µmol, 53 %). 
Mp > 86 °C (decomp.); 1H-NMR (600 MHz, DMSO-d6, COSY):  (ppm) 1.27 (m, 2H, CH2-CH2-
CH2-CH2-CH2), 1.4 (dd, 3H, 3J = 24.49 Hz, 3J = 6.69 Hz, CH3), 1.4-1.49 (m, 4H, 2 × CH2-CH2-
NH), 1.56 (m, 3H, CH-CH2, CO-CH2-CH2), 1.68 (m, 1H, CH-CH2), 2.41 (t, 2H, 3J = 7.30 Hz, CO-
CH2), 3.08 (m, 2H, CH2-NH-CO-CHF), 3.23 (m, 2H, CH-CH2-CH2-CH2-NH), 4.12 (dd, 1H, 2J = 
14.79 Hz, 3J = 5.71 Hz, CH2-ArOH), 4.17 (dd, 1H, 2J = 14.79 Hz, 3J = 5.84 Hz, CH2-ArOH), 4.34 
(m, 1H, CH), 4.96 (dq, 1H, 2J = 49.0 Hz, 3J = 6.69 Hz, CHF), 5.13 (s, 1H, CH-(Ph)2), 6.67 (d, 
2H, 3J = 8.5 Hz, AA’BB’), 7.0 (d, 2H, 3J = 8.5 Hz, AA’BB’), 7.22 (m, 2H, Ph), 7.29 (m, 8H, Ph), 
8.11 (t, 1H, 3J = 5.01 Hz, NH-CO-CHF), 8.35 (t, 1H, 3J = 5.8 Hz, CH-CO-NH-CH2), 8.47 (d, 1H, 
3J = 8.09 Hz, CO-NH-CH), 8.7 (bs, 2H, NH2), 9.17 (t, 1H, 3J = 5.01 Hz, CH-CH2-CH2-CH2-NH), 
9.29 (s, 1H, NH), 11.73 (s, 1H, ArOH); RP-HPLC (Nucleodur 250 × 4 mm, 210 nm, gradient 1): 
> 99 % (tR = 12.8 min, k = 4.6); HRMS: (FAB+, MeOH/glycerin): m/z calcd. for [C36H45FN6O5 + 
H]+ 661.3514, found: 661.3496; C36H45FN6O5 × C2HF3O2 (774.8)  
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(R)-N-(2,2-Diphenylacetyl)-N-[8-(2-fluoropropanoylamino)-3,6-dioxaoctanoyl]-N-(4-
hydroxybenzyl)argininamide (5.10). Amine precursor 4.20 (110 mg, 130 µmol, 1 eq; cf. 
chapter 4) was dissolved in acetonitrile (8 mL). NEt3 (32.9 mg, 45 µL, 325 µmol, 2.5 eq) and 
active ester 5.4 (27.7 mg, 130 µmol, 1 eq) were added and the mixture was stirred at rt for 1 h 
prior to the addition of a few drops of TFA. Purification with preparative HPLC (column: 
Eurospher 250 × 32 mm) and lyophilization afforded the product as a yellowish fluffy solid which 
turned into a resin after contact with air (79.1 mg, 98 µmol, 75 %). 1H-NMR (300 MHz, CD3OD): 
 (ppm) 1.49 (dd, 3H, 3J = 24.33 Hz, 3J = 6.77 Hz, CH3), 1.51-1.78 (bm, 3H, CH-CH2-CH2), 1.85 
(m, 1H, CH-CH2-CH2), 3.26 (m, 2H, CH2-CH2-CH2-NH), 3.43 (m, 2H, O-CH2-CH2-NH), 3.58 (t, 
2H, 3J = 5.51 Hz, O-CH2-CH2-NH), 3.72 (m, 4H, O-CH2-CH2-O), 4.22 (d, 1H, 2J = 14.79 Hz, 
CH2-ArOH), 4.23 (s, 2H, CH2-CO), 4.28 (d, 1H, 2J = 14.79 Hz, CH2-ArOH), 4.43 (m, 1H, CH), 
4.97 (dq, 1H, 2J = 48.84 Hz, 3J = 6.83 Hz, CHF), 5.06 (s, 1H, CH-(Ph)2), 6.7 (d, 2H, 3J = 8.57 
Hz, AA’BB’), 7.06 (d, 2H, 3J = 8.58 Hz, AA’BB’), 7.21-7.33 (m, 10H, Ph); RP-HPLC (Eurospher 
250 × 4 mm, 210 nm, gradient 2): 98 % (tR = 13.9 min, k = 4.1); HRMS: (FAB+, MeOH/glycerin): 
m/z calcd. for [C36H45FN6O7 + H]+ 693.3412, found: 693.3395; C36H45FN6O7 × C2HF3O2 (806.8)  
 
(R)-N-(2,2-Diphenylacetyl)-N-{5-[8-(4-fluorobenzoylamino)-3,6-dioxaoctyl]amino-5-oxo-
pentanoyl}-N-(4-hydroxybenzyl)argininamide (5.11). Amine precursor 4.24 (62 mg, 65.5 
µmol, 1 eq; cf. chapter 4) was dissolved in acetonitrile (6 mL). NEt3 (16.6 mg, 23 µL, 164 µmol, 
2.5 eq) and active ester 5.5 (15.5 mg, 65.5 µmol, 1 eq) were added and the mixture was stirred 
at rt for 5 h prior to the addition of 10 % aq. TFA (corresponding to 2.5 eq of TFA). Purification 
with preparative HPLC (column: Eurospher 250 × 32 mm) and lyophilization afforded the 
product as a white fluffy solid (50.8 mg, 53.2 µmol, 81 %). Mp 52-54 °C; 1H-NMR (600 MHz, 
DMSO-d6, COSY):  (ppm) 1.42 (m, 2H, CH2-CH2-CH2-NH), 1.53 (m, 1H, CH-CH2), 1.66 (m, 1H, 
CH-CH2), 1.75 (p, 2H, 3J = 7.38 Hz, CO-CH2-CH2-CH2-CO), 2.12 (t, 2H, 3J = 7.29 Hz, CO-CH2), 
2.41 (t, 2H, 3J = 7.39 Hz, CO-CH2), 3.17 (m, 2H, O-CH2-CH2-NH), 3.22 (m, 2H, CH2-CH2-CH2-
NH), 3.39 (m, 4H, CH2-O-CH2-CH2-O, O-CH2-CH2-NH), 3.51 (m, 6H, CH2-O-CH2-CH2-O), 4.1 
(dd, 1H, 2J = 14.78 Hz, 3J = 5.65 Hz, CH2-ArOH), 4.16 (dd, 1H, 2J = 14.78 Hz, 3J = 5.86 Hz, 
CH2-ArOH), 4.33 (m, 1H, CH), 5.11 (s, 1H, CH-(Ph)2), 6.66 (d, 2H, 3J = 8.5 Hz, AA’BB’ (Ar-
OH)), 6.99 (d, 2H, 3J = 8.5 Hz, AA’BB’ (Ar-OH)), 7.21 (m, 2H, Ph), 7.28 (m, 10H, Ph, CC’DD’ 
(Ar-F)), 7.86 (t, 1H, 3J = 5.59 Hz, O-CH2-CH2-NH), 7.9 (m, 2H, CC’DD’ (Ar-F)), 8.33 (t, 1H, 3J = 
5.83 Hz, CH-CO-NH-CH2), 8.45 (d, 1H, 3J = 8.11 Hz, CO-NH-CH), 8.51 (t, 1H, 3J = 5.51 Hz, O-
CH2-CH2-NH), 8.53 (bs, 2H, NH2), 8.85 (s, 1H, CH2-CH2-CH2-NH), 9.26 (s, 1H, NH), 11.26 (s, 
1H, ArOH); RP-HPLC (Eurospher 250 × 4 mm, 210 nm, gradient 2): > 99 % (tR = 14.7 min, k = 
4.4); HRMS: (FAB+, MeOH/glycerin): m/z calcd. for [C45H54FN7O8 + H]+ 840.4069, found: 
840.4087; C45H54FN7O8 × C2HF3O2 (954.0) 
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(R)-N-(2,2-Diphenylacetyl)-N-{8-[8-(4-fluorobenzoylamino)-3,6-dioxaoctyl]amino-8-oxo-
octanoyl}-N-(4-hydroxybenzyl)argininamide (5.12). Amine precursor 4.26 (40 mg, 40.5 µmol, 
1.1 eq; cf. chapter 4) was dissolved in acetonitrile (3 mL). NEt3 (10.2 mg, 14 µL, 101 µmol, 2.5 
eq) and active ester 5.5 (8.6 mg, 36.4 µmol, 1 eq) were added and the mixture was stirred at rt 
for 4 h prior to the addition of 10 % aq. TFA (corresponding to 2.5 eq of TFA) Purification with 
preparative HPLC (column: Eurospher 250 × 32 mm) and lyophilization afforded the product as 
a white fluffy solid which turned into a resin after contact with air (17.6 mg, 17.6 µmol, 48 %). 
1H-NMR (600 MHz, DMSO-d6, COSY):  (ppm) 1.24 (m, 4H, CH2-CH2-CH2-CH2-CH2-CH2), 1.35-
1.48 (m, 4H, CH2-CH2-CH2-NH, CO-CH2-CH2), 1.53 (m, 3H, CH-CH2, CO-CH2-CH2), 1.66 (m, 
1H, CH-CH2), 2.03 (t, 2H, 3J = 7.41 Hz, CO-CH2), 2.38 (t, 2H, 3J = 7.3 Hz, CO-CH2), 3.16 (m, 
2H, O-CH2-CH2-NH), 3.22 (m, 2H, CH2-CH2-CH2-NH), 3.38 (m, 4H, CH2-O-CH2-CH2-O, O-CH2-
CH2-NH), 3.51 (m, 6H, CH2-O-CH2-CH2-O), 4.1 (dd, 1H, 2J = 14.77 Hz, 3J = 5.67 Hz, CH2-
ArOH), 4.16 (dd, 1H, 2J = 14.75 Hz, 3J = 5.84 Hz, CH2-ArOH), 4.33 (m, 1H, CH), 5.11 (s, 1H, 
CH-(Ph)2), 6.66 (d, 2H, 3J = 8.49 Hz, AA’BB’ (Ar-OH)), 6.99 (d, 2H, 3J = 8.49 Hz, AA’BB’ (Ar-
OH)), 7.22 (m, 2H, Ph), 7.28 (m, 10H, Ph, CC’DD’ (Ar-F)), 7.77 (t, 1H, 3J = 5.59 Hz, O-CH2-CH2-
NH), 7.9 (m, 2H, CC’DD’ (Ar-F)), 8.33 (t, 1H, 3J = 5.83 Hz, CH-CO-NH-CH2), 8.45 (d, 1H, 3J = 
8.1 Hz, CO-NH-CH), 8.48 (bs, 2H, NH2), 8.51 (t, 1H, 3J = 5.52 Hz, O-CH2-CH2-NH), 8.77 (s, 1H, 
CH2-CH2-CH2-NH), 9.25 (s, 1H, NH), 11.08 (s, 1H, ArOH); RP-HPLC (Eurospher 250 × 4 mm, 
210 nm, gradient 2): 90 % (tR = 15.9 min, k = 4.9); HRMS: (FAB+, MeOH/glycerin): m/z calcd. for 
[C48H60FN7O8 + H]+ 882.4566, found: 882.4558; C48H60FN7O8 × C2HF3O2 (996.1)  
 
General procedure for the synthesis of the potential PET-ligands 5.13 and 5.14 
 
Amine precursor 4.22 or 4.23 (1 eq; cf. chapter 4) was dissolved in acetonitrile (4 - 6 mL). NEt3 
(2.5 eq) and active ester 5.5 (1 eq) were added and the mixture was stirred at rt for 5 h prior to 
the addition of 10 % aq. TFA (corresponding to 2.5 eq of TFA). Purification with preparative 
HPLC (column: Eurospher 250 × 32 mm) and lyophilization afforded the product as a white fluffy 
solid. 
 
(R)-N-(2,2-Diphenylacetyl)-N-{5-[2-(4-fluorobenzoylamino)ethyl]amino-5-oxopentanoyl}-
N-(4-hydroxybenzyl)argininamide (5.13). Yield: 52 % (52.9 mg); mp 201-203 °C; 1H-NMR 
(600 MHz, DMSO-d6, COSY):  (ppm) 1.42 (m, 2H, CH2-CH2-CH2-NH), 1.53 (m, 1H, CH-CH2), 
1.66 (m, 1H, CH-CH2), 1.77 (p, 2H, 3J = 7.35 Hz, CO-CH2-CH2-CH2-CO), 2.12 (t, 2H, 3J = 7.28 
Hz, CO-CH2), 2.42 (t, 2H, 3J = 7.33 Hz, CO-CH2), 3.21 (m, 4H, NH-CH2-CH2-NH, CH2-CH2-CH2-
NH), 3.3 (m, 2H, NH-CH2-CH2-NH), 4.1 (dd, 1H, 2J = 14.78 Hz, 3J = 5.64 Hz, CH2-ArOH), 4.16 
(dd, 1H, 2J = 14.78 Hz, 3J = 5.86 Hz, CH2-ArOH), 4.33 (m, 1H, CH), 5.11 (s, 1H, CH-(Ph)2), 
6.66 (d, 2H, 3J = 8.46 Hz, AA’BB’ (Ar-OH)), 6.99 (d, 2H, 3J = 8.45 Hz, AA’BB’ (Ar-OH)), 7.21 (m, 
2H, Ph), 7.28 (m, 10H, Ph, CC’DD’ (Ar-F)), 7.89 (m, 2H, CC’DD’ (Ar-F)), 7.95 (t, 1H, 3J = 5.71 
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Hz, NH-CH2-CH2-NH), 8.33 (t, 1H, 3J = 5.81 Hz, CH-CO-NH-CH2), 8.45 (d, 1H, 3J = 8.1 Hz, CO-
NH-CH), 8.49 (t, 1H, 3J = 5.55 Hz, NH-CH2-CH2-NH), 8.52 (bs, 2H, NH2), 8.83 (s, 1H, CH2-CH2-
CH2-NH), 9.26 (s, 1H, NH), 11.22 (s, 1H, ArOH); RP-HPLC (Eurospher 250 × 4 mm, 210 nm, 
gradient 2): 92 % (tR = 14.4 min, k = 5.9); HRMS: (FAB+, MeOH/glycerin): m/z calcd. for 
[C41H46FN7O6 + H]+ 752.3572, found: 752.3552; C41H46FN7O6 × C2HF3O2 (865.9) 
 
(R)-N-(2,2-Diphenylacetyl)-N-{5-[3-(4-fluorobenzoylamino)propyl]amino-5-oxo-
pentanoyl}-N-(4-hydroxybenzyl)argininamide (5.14). Yield: 65 % (66.2 mg); mp > 86 °C 
(decomp.); 1H-NMR (600 MHz, DMSO-d6, COSY):  (ppm) 1.36-1.48 (m, 2H, CH-CH2-CH2), 
1.53 (m, 1H, CH-CH2), 1.64 (m, 3H, CH-CH2, NH-CH2-CH2-CH2-NH), 1.77 (p, 2H, 3J = 7.37 Hz, 
CO-CH2-CH2-CH2-CO), 2.12 (t, 2H, 3J = 7.28 Hz, CO-CH2), 2.42 (t, 2H, 3J = 7.36 Hz, CO-CH2), 
3.09 (m, 2H, NH-CH2-CH2-CH2-NH), 3.23 (m, 4H, NH-CH2-CH2-CH2-NH, CH-CH2-CH2-CH2-NH), 
4.1 (dd, 1H, 2J = 14.78 Hz, 3J = 5.68 Hz, CH2-ArOH), 4.16 (dd, 1H, 2J = 14.77 Hz, 3J = 5.87 Hz, 
CH2-ArOH), 4.33 (m, 1H, CH), 5.11 (s, 1H, CH-(Ph)2), 6.66 (d, 2H, 3J = 8.52 Hz, AA’BB’ (Ar-
OH)), 6.99 (d, 2H, 3J = 8.53 Hz, AA’BB’ (Ar-OH)), 7.21 (m, 2H, Ph), 7.28 (m, 10H, Ph, CC’DD’ 
(Ar-F)), 7.85 (t, 1H, 3J = 5.65 Hz, NH-CH2-CH2-CH2-NH), 7.89 (m, 2H, CC’DD’ (Ar-F)), 8.33 (t, 
1H, 3J = 5.82 Hz, CH-CO-NH-CH2), 8.45 (m, 2H, CO-NH-CH, NH-CH2-CH2-CH2-NH), 8.53 (bs, 
2H, NH2), 8.85 (s, 1H, CH-CH2-CH2-CH2-NH), 9.25 (bs, 1H, NH), 11.25 (s, 1H, ArOH); RP-
HPLC (Eurospher 250 × 4 mm, 210 nm, gradient 2): 97 % (tR = 14.8 min, k = 4.5); HRMS: 
(FAB+, MeOH/glycerin): m/z calcd. for [C42H48FN7O6 + H]+ 766.3728, found: 766.3733; 
C42H48FN7O6 × C2HF3O2 (879.9) 
 
(R)-N-(2,2-Diphenylacetyl)-N-[N-(4-fluorobenzoyl)-12-Amino-4,7,10-trioxa-dodecanoyl]-
N-(4-hydroxybenzyl)argininamide (5.15). This compound was prepared from N-Boc, O-t-
butyl protected amine precursor 4.19 (170 mg, 190.4 µmol, 1 eq; cf. chapter 4) which was 
dissolved in CH2Cl2 (3 mL) followed by the addition of NEt3 (58 mg, 79 µL, 571 µmol, 3 eq) and 
active ester 5.5 (50 mg, 209.4 µmol, 1.1 eq). The mixture was stirred at rt for 5 h. TFA (2.5 mL) 
was added and stirring was continued for 2 h. CH2Cl2 (25 mL) was added three times, each time 
followed by evaporation under reduced pressure. Purification with preparative HPLC (column: 
Eurospher 250 × 32 mm) and lyophilization afforded the product as a white fluffy solid which 
turned into a resin after contact with air (86.9 mg, 95.2 µmol, 50 %). 1H-NMR (600 MHz, 
DMSO-d6, COSY):  (ppm) 1.42 (m, 2H, CH-CH2-CH2), 1.53 (m, 1H, CH-CH2), 1.66 (m, 1H, CH-
CH2), 2.64 (t, 2H, 3J = 5.92 Hz, CH2-CO), 3.22 (m, 2H, CH2-CH2-CH2-NH), 3.4 (m, 2H, O-CH2-
CH2-NH), 3.5 (m, 10H, O-CH2-CH2-O, O-CH2-CH2-NH), 3.65 (t, 2H, 3J = 6.02 Hz, CH2-CH2-CO), 
4.1 (dd, 1H, 2J = 14.78 Hz, 3J = 5.65 Hz, CH2-ArOH), 4.16 (dd, 1H, 2J = 14.77 Hz, 3J = 5.86 Hz, 
CH2-ArOH), 4.33 (m, 1H, CH), 5.11 (s, 1H, CH-(Ph)2), 6.66 (d, 2H, 3J = 8.49 Hz, AA’BB’ (Ar-
OH)), 6.99 (d, 2H, 3J = 8.49 Hz, AA’BB’ (Ar-OH)), 7.21 (m, 2H, Ph), 7.27 (m, 10H, Ph, CC’DD’ 
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(Ar-F)), 7.9 (m, 2H, CC’DD’ (Ar-F)), 8.33 (t, 1H, 3J = 5.82 Hz, CH-CO-NH-CH2), 8.45 (d, 1H, 3J = 
8.12 Hz, CO-NH-CH), 8.5 (t, 1H, 3J = 5.48 Hz, O-CH2-CH2-NH), 8.58 (bs, 2H, NH2), 8.91 (s, 1H, 
CH2-CH2-CH2-NH), 9.26 (s, 1H, NH), 11.34 (s, 1H, ArOH); RP-HPLC (Eurospher 250 × 4 mm, 
210 nm, gradient 2): 91 % (tR = 15.9 min, k = 4.9); HRMS: (FAB+, MeOH/glycerin): m/z calcd. for 
[C43H51FN6O8 + H]+ 799.3831, found: 799.3835; C43H51FN6O8 × C2HF3O2 (912.9) 
 
General procedure for the synthesis of the potential PET-ligands 5.16 - 5.19 
 
The pertinent amine precursor (1.05 eq) and NEt3 (3 eq) were dissolved in DMF (ca. 15 
µmol/100 µL) followed by the addition of active ester 5.4 or 5.5 (1 eq) in DMF (ca. 100 µL/15 
µmol). The reaction was stopped by addition of 10 % aq. TFA (corresponding to 2 - 3 eq of TFA) 
after an incubation period of 1-2 h at rt. Purification with preparative HPLC (column: Eurospher 
250 × 32 mm) and lyophilization afforded the products as white fluffy solids. 
 
(R)-N-(2,2-Diphenylacetyl)-N-[4-(2-fluoropropanoylamino)butyl]aminocarbonyl-N-(4-
hydroxybenzyl)argininamide (5.16). From 4.27 and 5.4; yield: 76 % (10.9 mg); mp > 65 °C 
(decomp.); 1H-NMR (600 MHz, DMSO-d6, COSY):  (ppm) 1.4 (dd, 3H, 3J = 24.52 Hz, 3J = 6.7 
Hz, CH3), 1.43 (m, 6H, CH2-CH2-CH2-CH2, CH-CH2-CH2), 1.53 (m, 1H, CH-CH2), 1.66 (m, 1H, 
CH-CH2), 3.09 (m, 4H, 2 × CH2-CH2-NH), 3.18 (m, 2H, CH2-CH2-NH), 4.1 (dd, 1H, 2J = 14.78 
Hz, 3J = 5.63 Hz, CH2-ArOH), 4.16 (dd, 1H, 2J = 14.76 Hz, 3J = 5.86 Hz, CH2-ArOH), 4.33 (m, 
1H, CH), 4.95 (dq, 1H, 2J = 48.98 Hz, 3J = 6.69 Hz, CHF), 5.11 (s, 1H, CH-(Ph)2), 6.66 (d, 2H, 
3J = 8.49 Hz, AA’BB’), 6.99 (d, 2H, 3J = 8.49 Hz, AA’BB’), 7.22 (m, 2H, Ph), 7.28 (m, 8H, Ph), 
7.46 (s, 1H, CH2-CH2-NH), 8.12 (t, 1H, 3J = 5.16 Hz, CH2-CH2-NH), 8.34 (t, 1H, 3J = 5.82 Hz, 
CH-CO-NH-CH2), 8.36 (bs, 2H, NH2), 8.45 (d, 1H, 3J = 8.13 Hz, CO-NH-CH), 8.86 (s, 1H, CH2-
CH2-NH), 9.25 (s, 1H, NH), 9.51 (s, 1H, ArOH); RP-HPLC (Eurospher 250 × 4 mm, 210 nm, 
gradient 2): 97 % (tR = 13.9 min, k = 4.1); HRMS: (FAB+, MeOH/glycerin): m/z calcd. for 
[C35H44FN7O5 + H]+ 662.3466, found: 662.3472; C35H44FN7O5 × C2HF3O2 (775.8) 
 
(R)-N-(2,2-Diphenylacetyl)-N-[4-(4-fluorobenzoylamino)butyl]aminocarbonyl-N-(4-
hydroxybenzyl)argininamide (5.17). From 4.27 and 5.5; yield: 91 % (34.9 mg); mp > 66 °C 
(decomp.); 1H-NMR (600 MHz, DMSO-d6, COSY):  (ppm) 1.41 (m, 2H, CH-CH2-CH2), 1.51 (m, 
5H, CH2-CH2-CH2-CH2, CH-CH2), 1.66 (m, 1H, CH-CH2), 3.12 (m, 2H, CH2-CH2-CH2-CH2-NH), 
3.18 (m, 2H, CH-CH2-CH2-CH2-NH), 3.26 (m, 2H, CH2-CH2-CH2-CH2-NH), 4.1 (dd, 1H, 2J = 
14.78 Hz, 3J = 5.67 Hz, CH2-ArOH), 4.16 (dd, 1H, 2J = 14.78 Hz, 3J = 5.88 Hz, CH2-ArOH), 4.33 
(m, 1H, CH), 5.11 (s, 1H, CH-(Ph)2), 6.66 (d, 2H, 3J = 8.5 Hz, AA’BB’ (Ar-OH)), 6.99 (d, 2H, 3J 
= 8.51 Hz, AA’BB’ (Ar-OH)), 7.22 (m, 2H, Ph), 7.28 (m, 10H, Ph, CC’DD’ (Ar-F)), 7.48 (s, 1H, 
CH2-CH2-CH2-CH2-NH), 7.89 (m, 2H, CC’DD’ (Ar-F)), 8.33 (t, 1H, 3J = 5.82 Hz, CH-CO-NH-
CH2), 8.36 (bs, 2H, NH2), 8.45 (d, 1H, 3J = 8.17 Hz, CO-NH-CH), 8.47 (t, 1H, 3J = 5.7 Hz, CH2-
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CH2-CH2-CH2-NH), 8.85 (s, 1H, CH-CH2-CH2-CH2-NH), 9.25 (s, 1H, NH), 9.51 (s, 1H, ArOH); 
RP-HPLC (Eurospher 250 × 4 mm, 210 nm, gradient 2): 98 % (tR = 16.0 min, k = 4.9); HRMS: 
(FAB+, MeOH/glycerin): m/z calcd. for [C39H44FN7O5 + H]+ 710.3466, found: 710.3460; 
C39H44FN7O5 × C2HF3O2 (823.8) 
 
(R)-N-(2,2-Diphenylacetyl)-N-[8-(2-fluoropropanoyl)amino-3,6-dioxaoctyl]amino-
carbonyl-N-(4-hydroxybenzyl)argininamide (5.18). From 5.7 and 5.4; yield: 67 % (12.1 mg); 
mp > 44 °C (decomp.); 1H-NMR (600 MHz, DMSO-d6, COSY):  (ppm) 1.4 (dd, 3H, 3J = 24.54 
Hz, 3J = 6.7 Hz, CH3), 1.43 (m, 2H, CH-CH2-CH2), 1.54 (m, 1H, CH-CH2), 1.67 (m, 1H, CH-CH2), 
3.19 (m, 2H, CH2-CH2-CH2-NH), 3.27 (m, 4H, 2 × O-CH2-CH2-NH), 3.44 (t, 2H, 3J = 6.13 Hz, O-
CH2-CH2-NH), 3.48 (t, 2H, 3J = 5.47 Hz, O-CH2-CH2-NH), 3.53 (s, 4H, O-CH2-CH2-O), 4.12 (dd, 
1H, 2J = 14.79 Hz, 3J = 5.65 Hz, CH2-ArOH), 4.17 (dd, 1H, 2J = 14.78 Hz, 3J = 5.84 Hz, CH2-
ArOH), 4.34 (m, 1H, CH), 4.98 (dq, 1H, 2J = 48.93 Hz, 3J = 6.69 Hz, CHF), 5.12 (s, 1H, CH-
(Ph)2), 6.67 (d, 2H, 3J = 8.49 Hz, AA’BB’), 7.0 (d, 2H, 3J = 8.49 Hz, AA’BB’), 7.23 (m, 2H, Ph), 
7.29 (m, 8H, Ph), 7.51 (s, 1H, O-CH2-CH2-NH), 8.07 (s, 1H, O-CH2-CH2-NH), 8.34 (t, 1H, 3J = 
5.82 Hz, CH-CO-NH-CH2), 8.39 (bs, 2H, NH2), 8.46 (d, 1H, 3J = 8.12 Hz, CO-NH-CH), 8.89 (s, 
1H, CH2-CH2-CH2-NH), 9.26 (s, 1H, NH), 9.67 (s, 1H, ArOH); RP-HPLC (Eurospher 250 × 4 
mm, 220 nm, gradient 2): 99 % (tR = 13.7 min, k = 4.1); HRMS: (FAB+, MeOH/glycerin): m/z 
calcd. for [C37H48FN7O7 + H]+ 722.3677, found: 722.3687; C37H48FN7O7 × C2HF3O2 (835.8) 
 
(R)-N-(2,2-Diphenylacetyl)-N-[8-(4-fluorobenzoylamino)-3,6-dioxaoctyl]aminocarbonyl-
N-(4-hydroxybenzyl)argininamide (5.19). From 5.7 and 5.5; yield: 73 % (14 mg); mp > 58 °C 
(decomp.); 1H-NMR (600 MHz, DMSO-d6, COSY):  (ppm) 1.41 (m, 2H, CH-CH2-CH2), 1.53 (m, 
1H, CH-CH2), 1.66 (m, 1H, CH-CH2), 3.18 (m, 2H, CH2-CH2-CH2-NH), 3.24 (m, 2H, O-CH2-CH2-
NH), 3.4 (m, 2H, O-CH2-CH2-NH), 3.46 (t, 2H, 3J = 5.46 Hz, O-CH2-CH2-NH), 3.53 (m, 6H, CH2-
O-CH2-CH2-O), 4.11 (dd, 1H, 2J = 14.78 Hz, 3J = 5.68 Hz, CH2-ArOH), 4.16 (dd, 1H, 2J = 14.78 
Hz, 3J = 5.89 Hz, CH2-ArOH), 4.33 (m, 1H, CH), 5.11 (s, 1H, CH-(Ph)2), 6.66 (d, 2H, 3J = 8.49 
Hz, AA’BB’ (Ar-OH)), 6.99 (d, 2H, 3J = 8.5 Hz, AA’BB’ (Ar-OH)), 7.21 (m, 2H, Ph), 7.27 (m, 10H, 
Ph, CC’DD’ (Ar-F)), 7.49 (s, 1H, O-CH2-CH2-NH), 7.9 (m, 2H, CC’DD’ (Ar-F)), 8.33 (t, 1H, 3J = 
5.82 Hz, CH-CO-NH-CH2), 8.38 (bs, 2H, NH2), 8.45 (d, 1H, 3J = 8.12 Hz, CO-NH-CH), 8.51 (t, 
1H, 3J = 5.54 Hz, O-CH2-CH2-NH), 8.87 (s, 1H, CH2-CH2-CH2-NH), 9.25 (s, 1H, NH), 9.59 (s, 
1H, ArOH); RP-HPLC (Eurospher 250 × 4 mm, 220 nm, gradient 2): 97 % (tR = 15.7 min, k = 
4.8); HRMS: (FAB+, MeOH/glycerin): m/z calcd. for [C41H48FN7O7 + H]+ 770.3677, found: 
770.3691; C41H48FN7O7 × C2HF3O2 (883.9)  
 
Succinimidyl 8-(4-fluorobenzylamino)-8-oxooctanoate (5.20).24 Octanedioic acid 
disuccinimidyl ester 3.7 (220 mg, 0.6 mmol, 1.4 eq; cf. chapter 3) and NEt3 (8.5 mg, 11.6 µl, 
83.6 µmol, 0.2 eq) were dissolved in CH2Cl2 (15 mL). 4-Fluorobenzylamine (52.3 mg, 47.5 µL, 
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0.42 mmol, 1 eq) in CH2Cl2 (5 mL) was added dropwise over a period of 2 h and stirring was 
continued for 4 h. Purification with column chromatography (CH2Cl2/EtOAc 3/1 to 1/2) afforded 
the product as crystalline solid (25 mg, 66.1 µmol, 16 %). 1H-NMR (300 MHz, CDCl3):  (ppm) 
1.4 (m, 4H, CH2-CH2-CH2-CH2-CH2-CH2), 1.73 (m, 4H, CH2-CH2-CH2-CH2-CH2-CH2), 2.23 (t, 
2H, 3J = 7.39 Hz, CO-CH2), 2.6 (t, 2H, 3J = 7.13 Hz, CO-CH2), 2.79 (s, 4H, CO-CH2-CH2-CO), 
4.4 (d, 2H, 3J = 5.7 Hz, CH2-Ar), 5.91 (bs, 1H, NH-CH2-Ar), 7.01 (pseudo-t, 2H, 3J = 8.71 Hz, 
Ar), 7.25 (m, 2H, Ar); MS (CI, NH3): m/z 379 [M + H]+; C19H23FN2O5 (378.4)  
 
(R)-N-(2,2-Diphenylacetyl)-N-[8-(4-fluorobenzylamino)-8-oxooctanoyl]-N-(4-hydroxy-
benzyl)argininamide (5.21). 5.20 (25 mg, 66.1 µmol, 1 eq) and 2.7 (104 mg, 165 µmol, 2.5 eq) 
were dissolved in CH2Cl2 (4 mL). NEt3 (6.7 mg, 9.2 µl, 66.1 µmol, 1 eq) was added and the 
mixture was kept under stirring at rt for 20 h. TFA (4 mL) was added and stirring was continued 
for 2.5 h. The solvent was removed under reduced pressure, and MeOH (25 mL) was added 
followed by evaporation under reduced pressure. Purification with preparative HPLC (column: 
Eurospher 250 × 32 mm) and lyophilization afforded the product as white solid (39.9 mg, 46.9 
µmol, 71 %). Mp 163-166 °C; 1H-NMR (600 MHz, CD3OD, COSY):  (ppm) 1.36 (m, 4H, CH2-
CH2-CH2-CH2-CH2-CH2), 1.49-1.74 (m, 7H, CH-CH2-CH2, CH2-CH2-CH2-CH2-CH2-CH2), 1.83 
(m, 1H, CH-CH2), 2.22 (t, 2H, 3J = 7.42 Hz, CO-CH2), 2.42 (t, 2H, 3J = 7.39 Hz, CO-CH2), 3.25 
(m, 2H, CH2-CH2-NH), 4.22 (d, 1H, 2J = 14.55 Hz, CH2-ArOH), 4.26 (d, 1H, 2J = 14.56 Hz, CH2-
ArOH), 4.32 (s, 2H, CH2-Ar-F), 4.42 (m, 1H, CH), 5.06 (s, 1H, CH-(Ph)2), 6.7 (d, 2H, 3J = 8.54 
Hz, AA’BB’ (ArOH)), 7.02 (pseudo-t, 2H, 3J = 8.8 Hz, CC’DD’ (Ar-F)), 7.05 (d, 2H, 3J = 8.54 Hz, 
AA’BB’ (ArOH)), 7.2-7.31 (m, 12H, Ph, CC’DD’ (Ar-F)); RP-HPLC (Eurospher 250 × 4 mm, 210 
nm, gradient 2): 99 % (tR = 18.0 min, k = 5.7); HRMS: (FAB+, MeOH/glycerin): m/z calcd. for 
[C42H49FN6O5 + H]+ 737.3827, found: 737.3839; C42H49FN6O5 × C2HF3O2 (850.9) 
 
4-Nitrophenyl 2-[18F]fluoropropanoate ([18F]NPFP). [18F]NPFP was synthesized at the 
Nuclear Medicine Department of the Klinikum rechts der Isar at TU München according to a 
previously described protocol16. 
 
(R)-N-(2,2-Diphenylacetyl)-N-(2-[18F]fluoropropanoyl)-N-(4-hydroxybenzyl)argininamide 
(5.8-F18). The synthesis was carried out in a 15-ml Falcone tube under an atmosphere of 
argon. 18 µL of a 1:9 mixture (v/v) of triethylamine (1.31 mg, 1.8 µL, 13 µmol) in anhydrous 
acetonitrile were added to a solution of 2.7 (3 mg, cf. chapter 2) in anhydrous acetonitrile (600 
µL). 250 µL of this solution (2.7: 1.21 mg, 1.9 µmol; NEt3: 0.53 mg, 5.2 µmol) were added to 
[18F]-NPFP (5.4-F18) (10.9 mCi at the time of addition, provided in a 15-ml Falcone tube) using 
a 1-mL-syringe. The mixture was briefly vortexed, then stirred (micro stirrer) at 65 °C for 20 min. 
TFA (250 µL, 3.25 mmol) was added and stirring was continued for 40 min at 70 °C. 5 M aq. 
NaOH (250 µL, 1.25 mmol) was added and a white precipitate occurred. Acetonitrile (150 µL) 
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was added prior to removal of the precipitate using a 4-mm syringe filter (0.2 µm). The activity 
retained in the filter was negligible. 0.1 % aq. TFA (50 µL) was added to the filtrate (ca. 900 µL) 
yielding the solution for injection into the HPLC system. The product was purified by reversed-
phase HPLC on a semi-preparative column (YMC RP 18 S, 4 µm, 80 Å, 150 x 20 mm; YMC 
Europe GmbH), using mixtures of 0.1 % TFA in acetonitrile (A) and 0.1 % aq. TFA (B) as eluent 
and a flow rate of 5 mL/min (gradient: 0-20 min: A/B 20/80 to 60/40). The eluate containing the 
product (tR ≈ 15 min) was transferred into a 20-mL-syringe, diluted with water (16 mL) and 
charged to a conditioned (MeOH, water) C18 SPE-cartridge. The passed liquid contained no 
measurable activity. The SPE cartridge was washed with water (5 mL) and the liquid was 
removed as far as possible by air flow. The product was eluted with ethanol (4 mL) into a 10-mL 
round bottom flask and the solvent was removed under reduced pressure at 35 °C (final 
pressure: 50 mbar). The residue (ca. 1.2 mL, 2.8 mCi, 2 h 40 min after start of synthesis) was 
transferred into a 2-mL Eppendorf reaction vessel and 20 µL (40 µCi) were mixed with 80 µL of 
0.1 % aq. TFA. 25 µL of this solution were analyzed by HPLC as purity control using a reversed-
phase column (Nucleosil 100 C18, 125 x 4 mm, 5 µm; CS - Chromatographie Service GmbH, 
Langerwehe, Germany) and a flow rate of 1 mL/min. Mixtures of 0.1 % TFA in acetonitrile (A) 
and 0.1 % aq. TFA (B) were used as eluent (gradient: 0-20 min: A/B 20/80 to 60/40). The purity 
was determined to be > 98 % (radiometric detection, tR = 14.8 min). A little impurity (tR = 15.8 
min) was detected at 220 nm. Decay corrected yield: 70 %. 
Preparation of injection solutions for in-vivo studies: 
DMSO (20 µL) was added to 1000 µL of the aqueous residue remained after evaporation of 
ethanol. To obtain the injection solution for biodistribution and PET studies 200 µL of this 
solution were diluted with 700 µL of PBS and 20 µL of 10-fold concentrated PBS, respectively. 
 
(R)-N-(2,2-Diphenylacetyl)-N-[6-(2-[18F]fluoropropanoylamino)hexanoyl]-N-(4-hydroxy-
benzyl)argininamide (5.9-F18). The synthesis was carried out in a 15-ml Falcone tube under 
an atmosphere of argon. DMSO (25 µL) and 17 µL of a 1:9 mixture (v/v) of triethylamine (1.24 
mg, 1.7 µL, 12.3 µmol) in anhydrous acetonitrile were added to a solution of 4.21 (1 mg, 1.23 
µmol, cf. chapter 4) in anhydrous acetonitrile (250 µL). This clear solution was added to [18F]-
NPFP 5.4-F18 (13.53 mCi at the time of addition, provided in a 15-ml Falcone tube) using a 1-
mL-syringe. The mixture was briefly vortexed, then stirred (micro stirrer) at 50 °C for 15 min and 
additionally 10 min at rt. 1.1 mL of acetonitrile/0.1 % aq. TFA (47/53 v/v) was added to acidify 
the mixture and to obtain a solution for injection into the HPLC system. The product was purified 
by reversed-phase HPLC on a semi-preparative column (YMC RP 18 S, 4 µm, 80 Å, 150 x 20 
mm; YMC Europe GmbH) using mixtures of 0.1 % TFA in acetonitrile (A) and 0.1 % aq. TFA (B) 
as eluent and a flow rate of 5 mL/min (gradient: 0-20 min: A/B 30/70 to 70/30). The eluate 
containing the product (tR ≈ 11 min, vol.: 4.5 – 5 mL) was transferred into a 20-mL-syringe, 
diluted with water (15 mL) and charged to a conditioned (MeOH, water) C18 SPE-cartridge. The 
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passed liquid contained no measurable activity. The SPE cartridge was washed with water (5 
mL) and the liquid was removed as far as possible by air flow. The product was eluted with 
ethanol (4 mL) into a 10-mL round bottom flask and the solvent was removed under reduced 
pressure at 40 °C (final pressure: 90 mbar). The residue (ca. 200 µL) was filtered with a 4-mm 
syringe filter (0.2 µm) and transferred into a 1.5-mL Eppendorf reaction vessel. The flask and 
the filter were washed with PBS (800 µL) and the filtrates were combined to give the injection 
solution for in-vivo PET and biodistribution experiments (3.84 mCi, 1h 56 min after start of 
synthesis). 10 µL (30 µCi) of this solution were analyzed by HPLC as purity control using a 
reversed-phase column (Nucleosil 100 C18, 125 x 4 mm, 5 µm; CS - Chromatographie Service 
GmbH, Langerwehe, Germany) and a flow rate of 1 mL/min. Mixtures of acetonitrile (A) and 0.1 
% aq. TFA (B) were used as eluent (gradient: 0-20 min: A/B 30/70 to 75/25). The purity was 
determined to be > 98 % (radiometric detection, tR = 9.8 min). Decay corrected yield: 60 %. 
 
 
5.3.3 Pharmacology: Cell Culture, Fura-2 Assay and Competition Binding Assay 
 
Cell culture. HEL and SK-N-MC cells were cultured as described elsewhere.25, 26 HEL cells 
were subcultured by 1:6-dilution with fresh culture medium 24 h prior to the fura Ca2+-assay. 
MCF-7-Y1a cells were maintained in MEM (Sigma), supplemented with 5 % FCS (Biochrom AG, 
Berlin, Germany). The CHO cells, transfected with the Y2R, Gqi5 and aequorin, were cultured as 
previously described.18 CHO cells, transfected with the Y4R, Gqi5 and aequorin, were cultured 
under the same conditions. HEC-1B cells, transfected with the Y5R, were cultured as previously 
described.27 
(aThis cell line was established by subcloning from MCF-7 cells (ATCC number HTB 22) in the 
157th passage and shows a 2 - 3-fold higher Y1R expression than the original MCF-7 cells.) 
 
Fura-2 assay on HEL cells and radioligand competition binding assay. The Fura assay 
was performed with HEL cells as previously described28 using a Perkin-Elmer LS50 B 
spectrofluorimeter (Perkin Elmer, Überlingen, Germany). The fura-2 AM (Calbiochem/Merck 
Biosciences, Beeston, UK) stock solution (1 mM) was prepared in anhydrous DMSO. Pluronic 
F-127 (Calbiochem/Merck Biosciences, Beeston, UK) was dissolved in DMSO to a 
concentration of 20 %. 
Radioligand competition experiments with [3H]-UR-MK114 (cf. chapter 2) were performed as 
described in chapter 3. 
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5.3.4 Pharmacology: Flow Cytometric Binding Experiments 
 
Flow cytometric binding studies at the Y2R (CHO cells transfected with the Y2R, Gqi5 and 
aequorin)29 and at the Y5R (expressed by HEC-1B cells transfected with the Y5R)18, 30 were 
performed as previously described. The cell density in loading buffer was 106 cells/mL (Y2R) or 
0.5·106 cells/mL (Y5R). For Y2R binding studies Dy-635-pNPY (10 nM) was used instead of Cy5-
pNPY (10 nM). 
Flow cytometric binding studies at the Y4R (expressed by CHO cells transfected with the Y4R, 
Gqi5 and aequorin)19 were performed as reported31 with the following variations: Cy5-[K4]-hPP19 
(5 nM) was used instead of S0586-[K4]-hPP (10 nM). The cell density in loading buffer was 106 
cells/mL. Non-specific binding was determined in the presence of hPP (100 nM). The stock 
solution of Cy5-[K4]-hPP was prepared in 10 mM HCl + 0.1 % BSA (500 nM). 
All flow cytometric assays were performed in triplicate on a FACSCaliburTM flow cytometer 
(Becton Dickinson, Heidelberg, Germany), equipped with an argon laser (488 nm) and a red 
diode laser (635 nm). 5.16 and 5.17 were tested at a concentration of 1 µM and 10 µM. No 
displacement of the fluorescent ligand by 5.16 and 5.17 (10 µM) was observed in case of the 
Y5R, and at the Y2R both compounds (10 µM) displaced around 50 % of the fluorescent ligand. 
Whereas no displacement of fluorescent ligand by 5.16 (10 µM) was found at the Y4R, 5.17 
displaced about 30 % of Cy5-[K4]-hPP (5 nM) at a concentration of 10 µM. 
 
 
5.3.5 Biodistribution and PET Experiments 
 
Biodistribution of the PET ligands 5.8-F18 and 5.9-F18 was investigated in NMRI (nu/nu) mice 
(male, 4 - 5 month) bearing subcutaneous SK-N-MC xenografts, which were established by 
subcutaneous injection of a cell suspension in culture medium without FCS (3·106 cells in 50 µL, 
between 50th and 60th in vitro passage) into the flank. At the day of experiment the size of the 
tumors ranged from 5 × 5 mm to 11 × 10 mm. 
 
Biodistribution studies with 5.8-F18. 45 – 65 µCi (180 – 200 µL of the above described 
injection solution) of the PET ligand 5.8-F18 were injected intravenously into the tail vein of SK-
N-MC tumor-bearing (right flank) NMRI (nu/nu) mice. The animals were killed (CO2) 30 min after 
injection and the radioactivity of weighted tissue or secretion samples as well as of a standard 
with known radioactivity was measured using a -counter. Results are expressed as the 
percentage injected dose per gram (%ID/g). 
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Biodistribution studies with 5.9-F18. 108 and 54 µCi (50 – 100 µL of the above described 
injection solution) of the PET ligand 5.9-F18 were injected intravenously into the tail vein of SK-
N-MC tumor-bearing (left flank) NMRI (nu/nu) mice, and 120 as well as 84 µCi (100 – 150 µL of 
the above described injection solution) of 5.9-F18 were injected intravenously into the tail vein 
of two NMRI (nu/nu) mice without SK-N-MC tumor. The animals were killed by cardiac puncture 
90 min after injection, and the radioactivity of weighted tissue or secretion samples as well as of 
a standard with known radioactivity was measured using a -counter. Results are expressed as 
the percentage injected dose per gram (%ID/g). 
 
PET imaging with 5.8-F18. For PET imaging with the PET ligand 5.8-F18, 280 µCi (ca. 200 µL 
of the above described injection solution) of the 18F-labeled compound was injected 
intravenously into the tail vein of a SK-N-MC tumor-bearing (right flank) NMRI (nu/nu) mouse. 5 
min after injection a dynamic PET scan (60 min, 6 5-min frames, 3 10-min frames) was 
performed using a Philips MOSAIC small animal PET scanner (Philips, Hamburg, Germany). 
The mouse was anesthetized using a combination of xylazine and ketamine. 
 
PET imaging with 5.9-F18. For PET imaging with the PET ligand 5.9-F18, a dynamic PET scan 
(60 min, 5-min frames) was performed with two NMRI (nu/nu) mice (anesthetized with 
isofluorane) of the biodistribution experiment (mice with 108 and 120 µCi injection dose) using a 
microPET Focus 120 small animal PET scanner (Siemens Healthcare, Erlangen, Germany). 
Scans were started 10 min after injection. 
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Chapter 6 
 
Miscellaneous Y1 Receptor Antagonists 
 
 
6.1  Introduction 
 
This chapter comprises BIBP 3226 or BIBO 3304 derived Y1R antagonists, which are neither 
bivalent Y1R ligands (chapter 3) nor fluorescent (chapter 4) nor potential PET ligands (chapter 
5). The Y1R antagonists, presented in this chapter, are either “non-functional” or represent 
potential monovalent tritiated Y1R ligands. Bivalent potential tritiated ligands for the Y1R were 
shown in chapter 3. Finally, proposals (in addition to suggestions given in chapters 4 and 5) are 
made for the preparation of other BIBP 3226 or BIBO 3304 analogs, which could not be realized 
anymore.      
 
6.2  Chemistry 
 
N-Butanoyl-BIBP 3226 (6.2) and N-pentanoyl-BIBP 3226 (6.3) were obtained through 
treatment of the argininamide building block 2.7 (cf. chapter 2) with succinimidyl butanoate (6.1) 
and pentanoic anhydride, respectively, followed by deprotection with TFA (Scheme 1). Y1R 
antagonist 6.4 was synthesized through the coupling of suberic acid monomethylester to 
building block 2.7 (Scheme 1). 
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Scheme 1. Synthesis of N-butanoyl-BIBP 3226 (6.2), N-pentanoyl-BIBP 3226 (6.3) and N-(8-methoxy-
8-oxooctanoyl)-BIBP 3226 (6.4). 
Reagents and conditions: (a) (1) NEt3, acetonitrile, rt, 20 h; (2) TFA, acetonitrile, 40 °C, 1.5 h, 55 %; (b) 
(1) pentanoic acid anhydride, NEt3, CH2Cl2, rt, 5 h; (2) TFA, CH2Cl2, rt, 2 h, 59 %; (c) (1) EDAC, DMAP, 
CH2Cl2, rt, 20 h; (2) TFA, CH2Cl2, rt, 4 h, 82 %. 
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The potential radioligand 6.5 was prepared from succinimidyl propanoate (2.11a, cf. chapter 2) 
and amine precursor 4.27 (synthesis see chapter 4) in very good yield (Scheme 2). 
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Scheme 2. Synthesis of the potential radioligand 6.5. 
Reagents and conditions: (a) (1) NEt3, DMF, rt, 2.5 h, 86 %. 
 
In an analogous way, the BIBO 3304 building block 4.6 (cf. chapter 4) was treated with 
succinimidyl propanoate (2.11a, cf. chapter 2) to obtain NG-propanoyl-BIBO 3304 (6.7). Non-
converted building block 4.6 was recovered as BIBO 3304 (6.6) after deprotection with TFA 
(Scheme 3). A major drawback of this reaction is the low solubility of building block 4.6 in a 
broad variety of solvents. When MeOH was used as solvent (4.6 is better soluble in MeOH than 
e.g. in acetonitrile and CH2Cl2), the yield of NG-propanoyl-BIBO 3304 (6.7) was very low (ca. 4 
%). As an alternative the synthesis of 6.7 was explored using a microwave synthesizer (Biotage 
Initiator 8): 300 mg of 4.6 could be dissolved in acetonitrile (3 mL) at temperatures > 80 °C. A 
reaction time of 10 min and a temperature of 120 °C as well as subsequent deprotection with 
TFA afforded compound 6.7 with 30 % yield.  
Since building block 4.6 is well soluble in DMF (30 mg in 1 mL of DMF at 20 °C), acylation at the 
guanidine group should be performed in DMF. The removal of the solvent (DMF) prior to the 
deprotection with TFA is considered an acceptable compromise. 
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Scheme 3. Synthesis of BIBO 3304 (6.6) and NG-propanoyl-BIBO 3304 (6.7). 
Reagents and conditions: (a) (1) NEt3, MeOH, rt/50 °C, 24 h; (2) TFA, MeOH, rt, 4 h, 66 % (6.6), 4 % 
(6.7); (b) (1) NEt3, acetonitrile, 120 °C, 10 min (microwave); (2) acetonitrile/TFA/H2O 10/1/1, 80 °C, 10 
min (microwave), 30 % (6.7).  
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6.3  Y1 Receptor Antagonism, Affinity and Selectivity 
 
The N-butanoyl (6.2) and the N-pentanoyl derivative of BIBP 3226 (6.3) were synthesized for 
comparison with the lower homologues N-propanoyl- (2.8) and N-acetyl-BIBP 32261 (6.8) 
(Table 1). While the extension of the acetyl residue to a propanoyl substituent leads to a 
considerable increase in Y1R affinity (from 12 nM to 1.0 nM, Table 1), the affinity remains almost 
unaffected by a further homologization to butanoyl (6.2) and pentanoyl (6.3) entities (Table 1).  
 
Table 1. Structures, Y1 receptor antagonism and binding data of BIBP 3226, Y1R antagonists 
6.2 – 6.7 and a selection of reported BIBP 3226 derivatives. 
(R)
H
N N
H
O
R'O
= R1 if R' = OH
= R2 if R' = CH2-NHCONH2
NH
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Compd. Structure IC50 (Kb) [nM]a Ki [nM] 
BIBP 3226 R1-H 10±1 (1.5) 1.3±0.2b 
6.8 
CH3
O
R1
 
141 (2.2) 121, c 
2.8a 
O
CH3R1  
2.3±0.7 (0.35) 1.0±0.1b 
6.2 
O
CH3R1  
0.44±0.01 (0.07) 0.74±0.01b 
6.3 
O
CH3R1  
1.0±0.02 (0.15) 1.6±0.3b 
6.4 
O
O
O
CH3R1
 
0.4±0.08 (0.06) 0.94±0.06b 
6.9 N
H
O
O
O
R1 CH3
 
0.641 (0.1) 0.721, c 
6.5 N
H
O H
N
O
CH3R1
 
3.8±0.2 (0.6) 1.2±0.2b 
6.6 (BIBO 3304) R2-H 4.6±1 (0.7) 0.25±0.01b 
6.7 
O
CH3R2  
230±4 (36) 7.8±2.6b 
aInhibition of 10 nM NPY induced [Ca2+]i mobilization in HEL cells, mean values ± SEM from 
two independent experiments. bDissociation constant determined from the displacement of [3H]-
UR-MK114 (KD = 1.2 nM, c = 1.5 nM) on SK-N-MC cells, mean values ± SEM from two 
independent experiments performed in triplicate. cDissociation constant determined from the 
displacement of ([2,3-3H]propionyl)-pNPY on SK-N-MC cells.1 
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The high affinity (Ki = 0.94 nM, Table 1) of N-(8-methoxy-8-oxo-octanoyl)-BIBP 3226 (6.4) 
suggests an affinity enhancing effect of the ester carbonyl group. However, the increase in 
binding could also arise from hydrophobic interactions of the alkyl chain as this is the case for 
compounds 2.8a, 6.2 and 6.3. Y1R ligand 6.4 was isolated serendipitously as a by-product 
during the work-up of bivalent ligand 3.8 (cf. chapter 3) which is composed of two BIBP 3226 
entities linked through octanedioic acid. As described in chapter 3 compound 3.8 was prepared 
from octanedioic acid disuccinimidylester (3.7) and BIBP 3226 building block 2.7 (for structure 
of 2.7 see Scheme 1). Since the formation of the bivalent ligand was incomplete, a part of the 
semi-reacted octandioic acid was esterified with MeOH at the carboxylic group to give 6.4 
during the removal of TFA (for Boc and O-tert-butyl deprotection) with the aid of MeOH. 
Compound 6.4 was isolated during the purification of bivalent ligand 3.8 with preparative HPLC 
and turned out to be an Y1 receptor antagonist with an affinity in the very low nanomolar range 
(Ki = 0.94, Table 1). NMR analysis enabled the elucidation of the structure and consequently the 
synthesis of compound 6.4. Interestingly, the N-carbamoylated BIBP 3226 derivative 6.9, 
bearing an ethylester group in the same distance from the guanidine as the methyl ester moiety 
in compound 6.4, was formerly reported to bind with a comparable high affinity (Ki = 0.74, 
Table 1).1, 2 
 
BIBO 3304 (6.6), reported to be about ten times more potent than BIBP 32263, was prepared 
with the intension to obtain functionalized (fluorescence and radiolabeled) Y1R ligands with 
increased affinities over analogous BIBP 3226 derivatives (described in chapters 4 and 5). 
Unfortunately NG-propanoyl-BIBO 3304 (6.7) proved to be about 30 times less potent than the 
parent compound (Ki = 7.8 and 0.25 nM, resp., Table 1), whereas N-propanoyl-BIBP 3226 (2.8) 
exhibits the same affinity as unsubstituted BIBP 3226 (Ki = 1.0 and 1.3 nM, resp., Table 1). This 
suggests different binding modes of these two argininamides in the binding pocket of the Y1 
receptor. Though the preparation of tritiated NG-propanoyl-BIBO 3304 (6.7) may be taken into 
account, the corresponding tritiated BIBP 3226 derivative, [3H]-UR-MK114 (2.8b, cf. chapter 2), 
is more attractive in terms of affinity and synthetic availability.  
A much more attractive alternative to [3H]-UR-MK114 (2.8b) is the potential radioligand 6.5 
(Table 1), which is as potent as 2.8b (Ki = 1.2 nM and KD = 1.2 nM, resp.) and can be easily 
prepared as a tritiated ligand from amine precursor 4.27 and succinimidyl [2,3-3H]propanoate 
(cf. Scheme 2). Since tritiated propanoic acid is attached to a primary amine in case of 6.5, and 
not to the guanidine group as in 2.8b, the labeling reaction is anticipated to be superior to the 
preparation of radioligand 2.8b with respect to yield, time and deprotection after radiolabeling. In 
contrast to the preparation of [3H]-UR-MK114 (2.8b) final deprotection is not required for a 
synthesis of the tritiated analog of 6.5. 
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The Ki and Kb values from binding and functional assays are in good accordance for Y1R 
antagonists such as BIBP 3226, BIBO 3304 (6.6) and compound 6.5. For other argininamide-
type Y1R antagonists there was a discrepancy between Ki and Kb value of about a factor of ten 
(Table 1), suggesting the correlation between Kb and Ki value to depend on the chemical 
structure of the Y1R antagonists. Further reasons for a misrepresentation of the observed 
antagonistic effect in the fura-2 Ca2+-assay were discussed in chapter 4 (4.2.2). 
The Y1 receptor subtype selectivity was confirmed for the potential radioligand 6.5, which is an 
attractive alternative to the tritium ligand [3H]-UR-MK114 (cf. chapter 2). Selectivity data are 
shown in Table 2. 
  
Table 2. NPY receptor subtype selectivity of the potential radioligand 6.5. 
Y1 Ki [nM]a Y2 Ki [nM]b Y4 Ki [nM]c Y5 Ki [nM]b 
1.3 > 2,000 > 5,000 > 5,000 
aDissociation constant from radioligand competition binding assay with [3H]-UR-
MK114 (cf. chapter 2, c = 1.5 nM) on SK-N-MC neuroblastoma cells. bFlow 
cytometric binding assay on CHO-Y2 and HEC-1B-Y5 cells using Dy-635-pNPY as 
labeled ligand (10 nM). cFlow cytometric binding assay on CHO-Y4 cells with Cy5-
[K4]-hPP (3 nM) as fluorescent ligand. 
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6.4 Perspectives 
 
As discussed in chapter 5, the lipophilicity of the potential PET ligands is a major drawback of 
these BIBP 3226 derivatives, probably being the reason for the failure to image Y1 receptors in 
vivo. The calculated logP values of most of the BIBP 3226 derived Y1R antagonists, presented 
in this thesis, are in the range of 1 - 5, for some fluorescent ligands (chapter 4) even higher. 
Although the actual lipophilicity of the compounds at pH 7.4 is lower due to one or more positive 
charges (guanidine, fluorophore), a further decrease in lipophilicity is preferable. Compared to 
the introduction of glycol ether moieties, which leads only to a moderate gain in polarity, the 
integration of secondary amines into the linker (Figure 1) should have a stronger impact on the 
polarity. Such a decrease in lipophilicity is supposed to reduce interferences with membrane 
binding and cell penetration. Acylation of such amine precursors at the primary amino group in 
terms of functionalization should give only a low portion of side products as the primary amine is 
sterically preferred, and an excess of the precursor can be used.  
   
(R)
H
N N
H
O
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NH2N X
O H
N
X = CH2, NH
N
HO
NH2n
 
Figure 1. N-Acylated BIBP 3226 derivatives with terminal amino group and secondary basic nitrogen. 
 
 
Different Y1 receptor binding modes for the (R)-argininamides BIBP 3226 and BIBO 3304 were 
concluded from the binding data of these Y1R antagonists and their NG-propionylated 
derivatives (discussed above, cf. Tabe 1). Additionally, N-acylated and N-carbamoylated BIBP 
3226 analogs seem to bind in slightly different modes (compare chapter 4). Therefore, the 
introduction of carbamoyl substituents into BIBO 3304 (cf. Figure 2) should be considered with 
respect to further investigation of the structure-activity relationships and binding modes of 
argininamide-type Y1R antagonists.  
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Figure 2. NG-Carbamoylated BIBO 3304 derivatives with terminal amino group. 
 
 
Assumed that the second polar moiety of BIBO 3304, the ureido group, is oriented to the 
extracellular space, an attachment of amino-functionalized linkers to the ureido function could 
be tolerated without a substantial loss of affinity (cf. Figure 3). The synthesis of such BIBO 3304 
derivatives seems feasible according to the synthetic strategy described in this thesis (cf. 
synthesis of 4.6 in chapter 4).   
 
(R)
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X = (CH2)n, O-CH2-CH2-O, CONH, HNCO, NH, etc.  
Figure 3. NU-Substituted BIBO 3304 derivatives with terminal amino group. 
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6.5  Experimental Section 
 
6.5.1  General Experimental Conditions 
 
Unless otherwise noted, chemicals and solvents were purchased from commercial suppliers 
and used without further purification. Dy-635-pNPY was synthesized as described previously.4 
[K4]-hPP was synthesized in the laboratory of Prof. Beck-Sickinger (University of Leipzig, 
Germany) and labeled with the cyanine dye Cy5 (FEW chemicals (Bitterfeld-Wolfen, Germany) 
in our laboratory.5 Porcine NPY (pNPY) was prepared in-house in the laboratory of Dr. C. 
Cabrele. Millipore water was used throughout for the preparation of buffers and HPLC eluents. 
Petroleum ether (40-60 °C) was distilled before use. DMF was stored over a molecular sieves (3 
Å). Anhydrous reactions were run under an atmosphere of dry nitrogen or argon. 
Thin layer chromatography was performed on Merck silica gel 60 F254 TLC aluminium plates. 
For column chromatography silica gel Geduran 60 (Merck, 0.063-0.200 mm) was used. NMR 
spectra were recorded on a Bruker Avance 300 (1H: 300 MHz), a Bruker Avance 600 (1H: 600 
MHz) and a Bruker Avance III 600 with cryogenic probehead (1H: 600 MHz) (Bruker, Karlsruhe, 
Germany) with TMS as external standard. Mass spectrometry analysis (MS) was performed in-
house on a Finnigan SSQ 710A (EI-MS 70 eV) and a Finnigan MAT 95 (LSIMS, HRMS). 
Melting points were determined with a Büchi 510 melting point apparatus and are uncorrected. 
 
Preparative HPLC was performed with a system from Knauer (Berlin, Germany) consisting of 
two K-1800 pumps and a K-2001 detector. A Eurospher-100 C18 (250 × 32 mm, 5 µm; Knauer, 
Germany) served as RP-column at a flow rate of 38 mL/min. Mixtures of acetonitrile (in case of 
6.2 MeOH) and 0.1 % aq. TFA were used as mobile phase. Acetonitrile or MeOH was removed 
from the eluates under reduced pressure (final pressure: 60 mbar) at 40 °C prior to 
lyophilization. Analytical HPLC analysis was performed on a system from Thermo Separation 
Products (composed of a SN400 controller, a P4000 pump, a degasser (Degassex DG-4400, 
phenomenex), an AS3000 autosampler and a Spectra Focus UV-VIS detector). An Eurospher-
100 C18 (250 × 4 mm, 5 µ, Knauer, Germany) or a Nucleodur 100-5 C18 ec (250 × 4 mm, 5 
µm, Macherey-Nagel, Germany) served as RP-columns. Acetonitrile (A) and 0.05 % aq. TFA 
(B) were used as mobile phase components. Helium degassing, an oven temperature of 30 °C 
and a flow rate of 0.8 mL/min were used throughout. Solutions for injection (concentrations in 
the two-digit µM range) were prepared in a mixture of A and B corresponding to the composition 
at the beginning of the gradient. The following gradients were applied for analytical HPLC 
analysis: 
Gradient 1: 0 to 25 min: A/B 25/75 to 65/35, 25 to 27 min: 65/35 to 95/5, 27 to 31 min: 95/5 
Gradient 2: 0 to 30 min: A/B 20/80 to 95/5, 30 to 40 min: 95/5 
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The preparation of the buffer and the lysis solution for Y1R binding studies on SK-N-MC cells as 
well as the loading buffer for the determination of intracellular Ca2+ mobilization in HEL cells are 
described in chapter 3. 
Stock solutions were prepared in DMSO at concentrations of 10 mM and stored at –78 °C. 
 
 
6.5.2 Chemistry: Experimental Protocols and Analytical Data 
 
Succinimidyl butanoate (6.1).6 Butyric chloride (1.02 g, 9.6 mmol, 1.2 eq) was added dropwise 
to a stirred ice-cold solution of N-hydroxysuccinimide (0.92 g, 8 mmol, 1 eq) and NEt3 (1.2 g, 1.7 
mL, 12 mmol, 1.5 eq) in anhydrous THF (40 mL) over a period of 5 min. The ice-bath was 
removed and stirring was continued at rt for 5 h. The white solid (triethylammonium chloride) 
was removed by filtration and the solvent was removed under reduced pressure. Purification 
with column chromatography (eluent: PE/EtOAc 2/1 to 1/1) yielded the product as white solid 
(1.41 g, 7.61 mmol, 95 %). 1H-NMR (300 MHz, CDCl3):  (ppm) 1.03 (t, 3H, 3J = 7.42 Hz, CH3), 
1.78 (m, 2H, CH2-CH3), 2.58 (t, 2H, 3J = 7.33 Hz, CO-CH2-CH2-CH3), 2.83 (s, 4H, CO-CH2-CH2-
CO); MS (EI): m/z 185 (M·+); C8H11NO4 (185.2) 
 
(R)-N-Butanoyl-N-(2,2-diphenylacetyl)-N-(4-hydroxybenzyl)argininamide (6.2). 2.7 (32.7 
mg, 51.9 µmol, 1 eq, cf. chapter 2) in dry acetonitrile (1.5 mL) was added to a solution of 6.1 
(9.6 mg, 51.9 µmol, 1 eq) in anhydrous acetonitrile (0.2 mL). NEt3 (5.3 g, 7.2 µL, 51.9 µmol, 1 
eq) was added and the mixture was stirred at rt for 20 h. TFA (2 mL) was added and stirring 
was continued at 40 °C for 1.5 h. MeOH (6 mL) was added followed by evaporation under 
reduced pressure. Purification with preparative HPLC (column: Eurospher 250 × 32 mm) and 
lyophilization afforded the product as a white fluffy solid (18.9 mg, 28.7 µmol, 55 %). Mp > 164 
°C (decomp.); 1H-NMR (300 MHz, DMSO-d6):  (ppm) 0.91 (t, 3H, 3J = 7.39 Hz, CH3), 1.44 (m, 
2H, CH-CH2-CH2), 1.5-1.74 (m, 4H, CH-CH2, CO-CH2-CH2), 2.39 (t, 2H, 3J = 7.23 Hz, CO-CH2), 
3.23 (m, 2H, CH2-CH2-NH), 4.14 (m, 2H, CH2-ArOH), 4.34 (m, 1H, CH), 5.12 (s, 1H, CH-(Ph)2), 
6.67 (d, 2H, 3J = 8.5 Hz, AA’BB’), 7.0 (d, 2H, 3J = 8.49 Hz, AA’BB’), 7.18-7.31 (m, 10H, Ph), 
8.38 (t, 1H, 3J = 5.72 Hz, CH-CO-NH-CH2), 8.49 (d, 1H, 3J = 8.07 Hz, CO-NH-CH), 8.56 (bs, 2H, 
NH2), 8.88 (s, 1H, NH), 9.29 (s, 1H, NH), 11.26 (s, 1H, ArOH); RP-HPLC (Nucleodur 250 × 4 
mm, 210 nm, gradient 1): > 99 % (tR = 13.3 min, k = 4.8); HRMS: (FAB+, MeOH/glycerin): m/z 
calcd. for [C31H37N5O4 + H]+ 544.2924, found: 544.2909; C31H37N5O4 × C2HF3O2 (657.7)  
 
(R)-N-(2,2-Diphenylacetyl)-N-(4-hydroxybenzyl)-N-pentanoylargininamide (6.3). 
Pentanoic anhydride (97.6 mg, 0.52 mmol, 1.1 eq) was added to a solution of 2.7 (300 mg, 0.48 
mmol, 1 eq, cf. chapter 2) and NEt3 (48 mg, 66 µL, 0.48 mmol, 1 eq) in CH2Cl2 (10 mL). The 
mixture was stirred at rt for 5 h. TFA (10 mL) was added and stirring was continued at rt for 2 h. 
Chapter 6 166 
MeOH (30 mL) was added followed by evaporation under reduced pressure. Purification with 
preparative HPLC (column: Eurospher 250 × 32 mm) and lyophilization afforded the product as 
a white fluffy solid (190 mg, 0.28 mmol, 59 %). Mp > 118 °C (decomp.); 1H-NMR (400 MHz, 
CD3OD, COSY):  (ppm) 0.93 (t, 3H, 3J = 7.35 Hz, CH3), 1.37 (m, 2H, CH2-CH3), 1.48-1.76 (bm, 
5H, CH-CH2-CH2, CH2-CH2-CH3), 1.83 (m, 1H, CH-CH2-CH2), 2.45 (t, 2H, 3J = 7.44 Hz, CH2-
CO), 3.23 (m, 2H, CH2-CH2-NH), 4.2 (d, 1H, 2J = 14.6 Hz, CH2-ArOH), 4.26 (d, 1H, 2J = 14.59 
Hz, CH2-ArOH), 4.43 (m, 1H, CH), 5.07 (s, 1H, CH-(Ph)2), 6.7 (d, 2H, 3J = 8.6 Hz, AA’BB’), 7.04 
(d, 2H, 3J = 8.62 Hz, AA’BB’), 7.16-7.31 (m, 10H, Ph); RP-HPLC (Eurospher 250 × 4 mm, 210 
nm, gradient 2): 99 % (tR = 16.6 min, k = 5.1); HRMS: (FAB+, MeOH/glycerin): m/z calcd. for 
[C32H39N5O4 + H]+ 558.3080, found: 558.3080; C32H39N5O4 × C2HF3O2 (671.7)      
 
(R)-N-(2,2-Diphenylacetyl)-N-(4-hydroxybenzyl)-N-(8-methoxy-8-oxooctanoyl)arginin-
amide (6.4). EDAC (21.3 mg, 111 µmol, 1.4 eq) was added to a solution of 2.7 (50 mg, 79 µmol, 
1 eq, cf. chapter 2), octanedioic acid monomethylester (18 mg, 95 µmol, 1.2 eq) and DMAP (3 
mg) in CH2Cl2 (2 mL). The mixture was stirred at rt overnight. TFA (1.5 mL) and two drops of 
water were added and stirring was continued at rt for 4 h. CH2Cl2 (20 mL) was added three 
times, each time followed by evaporation under reduced pressure. Purification with preparative 
HPLC (column: Eurospher 250 × 32 mm) and lyophilization afforded the product as a white fluffy 
solid (49.3 mg, 65 µmol, 82 %). Mp > 106 °C (decomp.); 1H-NMR (600 MHz, CD3OD, COSY):  
(ppm) 1.36 (m, 4H, CH2-CH2-CH2-CH2-CH2-CH2), 1.5-1.74 (m, 7H, CH-CH2-CH2, CH2-CH2-CH2-
CH2-CH2-CH2), 1.83 (m, 1H, CH-CH2-CH2), 2.32 (t, 2H, 3J = 7.39 Hz, CO-CH2), 2.44 (t, 2H, 3J = 
7.37 Hz, CO-CH2), 3.25 (m, 2H, CH2-CH2-NH), 3.64 (s, 3H, CH3), 4.22 (d, 1H, 2J = 14.56 Hz, 
CH2-ArOH), 4.26 (d, 1H, 2J = 14.56 Hz, CH2-ArOH), 4.42 (m, 1H, CH), 5.06 (s, 1H, CH-(Ph)2), 
6.7 (d, 2H, 3J = 8.56 Hz, AA’BB’), 7.05 (d, 2H, 3J = 8.57 Hz, AA’BB’), 7.21-7.32 (m, 10H, Ph); 
RP-HPLC (Eurospher 250 × 4 mm, 210 nm, gradient 2): 99 % (tR = 17.3 min, k = 5.4); HRMS: 
(FAB+, MeOH/glycerin): m/z calcd. for [C36H45N5O6 + H]+ 644.3448, found: 644.3432; 
C36H45N5O6 × C2HF3O2 (757.8)    
 
(R)-N-(2,2-Diphenylacetyl)-N-(4-hydroxybenzyl)-N-[4-(propanoylamino)butyl]amino-
carbonyl-argininamide (6.5). Amine precursor 4.27 (20 mg, 24.5 µmol, 1.05 eq) and NEt3 (7.1 
mg, 9.7 µL, 70 µmol, 3 eq) were dissolved in DMF (150 µL) followed by the addition of active 
ester 2.11a (4 mg, 23.4 µmol, 1 eq) in DMF (150 µL). The reaction was stopped by addition of 
10 % aq. TFA (corresponding to 2 - 3 eq of TFA) after an incubation period of 2.5 h at rt. 
Purification with preparative HPLC (column: Eurospher 250 × 32 mm) and lyophilization 
afforded the product as a white fluffy solid (15.2 mg, 20.1 µmol, 86 %). Mp > 65 °C (decomp.); 
1H-NMR (600 MHz, DMSO-d6, COSY):  (ppm) 0.97 (t, 3H, 3J = 7.61 Hz, CH3), 1.4 (m, 6H, CH2-
CH2-CH2-CH2, CH-CH2-CH2), 1.53 (m, 1H, CH-CH2), 1.66 (m, 1H, CH-CH2), 2.04 (q, 2H, 3J = 
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7.6 Hz, CO-CH2), 3.02 (m, 2H, CH2-CH2-CH2-CH2-NH), 3.09 (m, 2H, CH2-CH2-CH2-CH2-NH), 
3.18 (m, 2H, CH-CH2-CH2-CH2-NH), 4.11 (dd, 1H, 2J = 14.78 Hz, 3J = 5.69 Hz, CH2-ArOH), 4.16 
(dd, 1H, 2J = 14.79 Hz, 3J = 5.87 Hz, CH2-ArOH), 4.33 (m, 1H, CH), 5.11 (s, 1H, CH-(Ph)2), 
6.66 (d, 2H, 3J = 8.49 Hz, AA’BB’), 6.99 (d, 2H, 3J = 8.49 Hz, AA’BB’), 7.22 (m, 2H, Ph), 7.28 
(m, 8H, Ph), 7.47 (s, 1H, CH2-CH2-CH2-CH2-NH), 7.71 (t, 1H, 3J = 5.17 Hz, CH2-CH2-CH2-CH2-
NH), 8.34 (t, 1H, 3J = 5.82 Hz, CH-CO-NH-CH2), 8.37 (bs, 2H, NH2), 8.45 (d, 1H, 3J = 8.12 Hz, 
CO-NH-CH), 8.89 (s, 1H, CH-CH2-CH2-CH2-NH), 9.26 (s, 1H, NH), 9.68 (s, 1H, ArOH); RP-
HPLC (Eurospher 250 × 4 mm, 210 nm, gradient 2): 99 % (tR = 13.1 min, k = 3.9); HRMS: 
(FAB+, MeOH/glycerin): m/z calcd. for [C35H45N7O5 + H]+ 644.3555, found: 644.3572; 
C35H45N7O5 × C2HF3O2 (757.8) 
 
Synthesis of BIBO 3304 (6.6) and N-propanoyl-BIBO 3304 (6.7). Succinimidyl propanoate 
(2.11a, cf. chapter 2) (47.6 mg, 278 µmol, 0.8 eq) and NEt3 (141 mg, 193 µL, 139 µmol, 4 eq) 
were added to a cloudy solution of BIBO 3304 building block 4.6 (240 mg, 348 µmol, 1 eq, cf. 
chapter 4) in MeOH (5 mL). The mixture was stirred at rt overnight. HPLC analysis revealed that 
almost no product was formed. Therefore succinimidyl propanoate (95.2 mg, 556 µmol, 1.6 eq) 
and NEt3 (141 mg, 193 µL, 139 µmol, 4 eq) were added and stirring was continued at 50 °C for 
2.5 h. TFA (15 mL) was added and stirring was continued at rt for 4 h. MeOH (25 mL) was 
added three times, each time followed by evaporation under reduced pressure. Purification with 
preparative HPLC (column: Eurospher, 250 × 32 mm) and lyophilization afforded the products 
as white fluffy solids. 
 
(R)-N-(2,2-Diphenylacetyl)-N-(4-ureidomethylbenzyl)argininamide (6.6). 146.6 mg, 228 
µmol, 66 %; mp > 60 °C (decomp.); 1H-NMR (300 MHz, DMSO-d6):  (ppm) 1.4 (m, 2H, CH-
CH2-CH2), 1.53 (m, 1H, CH-CH2), 1.66 (m, 1H, CH-CH2), 3.06 (m, 2H, CH2-CH2-NH), 4.15 (s, 
2H, CH2-Ar), 4.23 (d, 2H, 3J = 5.71 Hz, CH2-Ar), 4.34 (m, 1H, CH), 5.13 (s, 1H, CH-(Ph)2), 6.47 
(s, 1H, NH), 7.05 (bs, 2H, NH2), 7.15 (m, 4H, AA’BB’), 7.26 (m, 10H, Ph), 7.59 (t, 1H, 3J = 5.63 
Hz, NH), 8.52 (m, 2H, 2 × NH); RP-HPLC (Eurospher 250 × 4 mm, 210 nm, gradient 2): > 99 % 
(tR = 10.8 min, k = 3.0); HRMS: (FAB+, MeOH/glycerin): m/z calcd. for [C29H35N7O3 + H]+ 
530.2880, found: 530.2867; C29H35N7O3 × C2HF3O2 (643.7) 
 
(R)-N-(2,2-Diphenylacetyl)-N-propanoyl-N-(4-ureidomethylbenzyl)argininamide (6.7). 9.4 
mg, 13.4 µmol, 4 %; mp > 192 °C (decomp.); 1H-NMR (600 MHz, DMSO-d6, COSY):  (ppm) 
1.04 (t, 3H, 3J = 7.41 Hz, CH3), 1.42 (m, 2H, CH-CH2-CH2), 1.54 (m, 1H, CH-CH2), 1.68 (m, 1H, 
CH-CH2), 2.46 (q, 2H, 3J = 7.39 Hz, CO-CH2), 3.22 (m, 2H, CH2-CH2-NH), 4.13 (d, 2H, 3J = 5.85 
Hz, CH2-Ar), 4.22 (m, 2H, CH2-Ar), 4.34 (m, 1H, CH), 5.11 (s, 1H, CH-(Ph)2), 5.5 (bs, 2H, NH2), 
6.37 (t, 1H, 3J = 5.95 Hz, NH-CH2-Ar), 7.12 (d, 2H, 3J = 8.48 Hz, AA’BB’), 7.14 (d, 2H, 3J = 8.46 
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Hz, AA’BB’), 7.22 (m, 2H, Ph), 7.28 (m, 8H, Ph), 8.45 (t, 1H, 3J = 5.96 Hz, NH-CH2-Ar), 8.48 (d, 
1H, 3J = 8.1 Hz, CO-NH-CH), 8.53 (bs, 2H, NH2), 8.87 (s, 1H, CH2-CH2-NH), 11.22 (s, 1H, NH); 
RP-HPLC (Eurospher 250 × 4 mm, 210 nm, gradient 2): 98 % (tR = 12.3 min, k = 3.6); HRMS: 
(FAB+, MeOH/glycerin): m/z calcd. for [C32H39N7O4 + H]+ 586.3142, found: 586.3100; 
C32H39N7O4 × C2HF3O2 (699.7) 
 
 
6.5.3 Pharmacology: Cell Culture, Fura-2 Assay and Competition Binding Assay 
 
Cell culture. HEL and SK-N-MC cells were cultured as described elsewhere.7, 8 HEL cells were 
subcultured by 1:6-dilution with fresh culture medium 24 h prior to the fura Ca2+-assay. The 
CHO cells transfected with the Y2R, Gqi5 and aequorin were cultured as previously described.4 
CHO cells transfected with the Y4R, Gqi5 and aequorin were cultured under the same 
conditions. HEC-1B cells were cultured as previously described.9 
 
Fura-2 assay on HEL cells and radioligand competition binding assay. The Fura assay 
was performed with HEL cells as previously described10 using a Perkin-Elmer LS50 B 
spectrofluorimeter (Perkin Elmer, Überlingen, Germany). The fura-2 AM (Calbiochem/Merck 
Biosciences, Beeston, UK) stock solution (1 mM) was prepared in anhydrous DMSO. Pluronic 
F-127 (Calbiochem/Merck Biosciences, Beeston, UK) was dissolved in DMSO to a 
concentration of 20 %. 
Radioligand competition experiments with [3H]-UR-MK114 (cf. Chapter 2) were performed as 
described in chapter 3. 
 
 
6.5.4 Pharmacology: Flow Cytometric Experiments with the Potential Radioligand 6.5 
 
Flow cytometric binding studies at the Y2R (CHO cells transfected with the Y2R, Gqi5 and 
aequorin)11 and at the Y5R (expressed by HEC-1B cells transfected with the Y5R)4, 12 were 
performed as previously described. The cell density in loading buffer was 106 cells/mL (Y2R) or 
0.5·106 cells/mL (Y5R). For Y2R binding studies Dy-635-pNPY (10 nM) was used instead of Cy5-
pNPY (10 nM). 
Flow cytometric binding studies at the Y4R (expressed by CHO cells transfected with the Y4R, 
Gqi5 and aequorin)5 were performed as reported13 with the following variations: Cy5-[K4]-hPP5 
(3 nM) was used instead of S0586-[K4]-hPP (10 nM). The cell density in loading buffer was 106 
cells/mL. Non-specific binding was determined in the presence of hPP (100 nM). The stock 
solution of Cy5-[K4]-hPP was prepared in 10 mM HCl + 0.1 % BSA (500 nM). 
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All flow cytometric assays were performed in triplicate on a FACSCaliburTM flow cytometer 
(Becton Dickinson, Heidelberg, Germany), equipped with an argon laser (488 nm) and a red 
diode laser (635 nm). 6.5 was tested at a concentration of 1 µM and 10 µM. Whereas no 
displacement of the fluorescent ligand by 6.5 (10 µM) was observed in case of the Y5R, 
displacement at the Y2R was around 50 % and at the Y4R around 30 %. 
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Chapter 7 
 
Functionalized Arginine Building Blocks 
 
 
7.1  Introduction 
 
Radio- and fluorescence labeled analogs of endogenous oligopeptides addressing membrane 
receptors (e.g. GPCRs) are valuable pharmacological tools for the identification and 
pharmacological characterization of these receptors and their ligands. Moreover, labeling of 
peptides is a promising strategy to develop radiopharmaceuticals. Since a wide range of peptide 
receptors is over-expressed on tumor cells or matrix components, chemical strategies have 
been developed that allow radiolabeling of the corresponding peptidic ligands in order to obtain 
tracers for in vivo imaging techniques such as PET and SPECT. 
As only a few natural amino acids (e.g. Lys, Tyr, Cys) enable fluorescence or radiolabeling of 
peptides, the introduction of such amino acids, i.e. structural variation of the amino acid 
sequence, is often required. Generally, such structural variations may be associated with a 
decrease in affinity. However, there are examples of retained affinity after replacement of amino 
acids with Lys for introduction of a label, for instance [Lys4]hPP as a Y4R agonist.1 
In contrast to labeling strategies targeting Lys, Tyr or Cys, structural modifications of arginine 
are not routine, since appropriate building blocks are not available. Moreover, it may be 
speculated that such derivatization approaches have little prospect of success since the label 
has to be attached to the guanidino group in Arg which is a key amino acid for receptor binding 
of many peptides. Thus, N-substitution in Arg can negatively affect receptor affinity. 
Recently, a successful guanidine-acylguanidine bioisosteric approach was reported by our 
research group for NPY Y1R2 (cf. also chapters 2, 4 - 6), Y2R3 and histamine H2 receptor4 
ligands. Acylation of the guanidine or alkyl-guanidine group leads to a decrease in the strong 
basicity of the guanidine (pKa = 12 – 13) to pKa values of about 8. On one hand such 
acylguanidines are still sufficiently basic to interact with acid key residues of the receptor 
protein, on the other hand the lower basicity leads to more favorable pharmacokinetics5. This 
bioisosteric approach proved to be of special value in the development of radio- and 
fluorescence labeled argininamide-type Y1R antagonists as described in chapters 2 – 6. 
The achievements in the NPY antagonist field prompted to prepare N-Fmoc-N-Boc-arginine 
bearing an appropriate N’-acyl residue as a versatile building block for solid phase synthesis of 
modified peptides. In principle, such arginine derivatives could be universally applied to prepare 
ligands for any peptidergic receptor. With respect to radio- and fluorescence labeling the N’-
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substituent should be functionalized, preferably with an -amino group (protected during 
peptide synthesis), to enable labeling. 
Target peptides for the integration of the modified arginine have to contain at least one arginine 
residue, preferably in the N-terminal region, and should not exceed 10 – 15 amino acids, since 
the presented arginine building blocks are less stable (discussed below) than the protected 
amino acids routinely used in solid phase synthesis. Some physiologically relevant peptides 
containing at least one arginine residue are listed in Table 1. As arginine-containing receptor 
ligands, such as the RGD peptides as well as neurotensin, bombesin, substance P (Table 1) 
and analogs thereof, are investigational diagnostic radiopharmaceuticals,6 the novel arginine 
building blocks described in this chapter could promote the development and broaden the 
spectrum of molecular imaging tools. 
 
Table 1. Sequences and targets of a selection of endogenous arginine-containing oligopeptides.  
Peptide Sequence Receptor 
RGD peptides small peptides containing the Arg-Gly-Asp motif V3 integrin 
angiotensin II Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-OH AT1 
bradykinin Arg–Pro–Pro–Gly–Phe–Ser–Pro–Phe–Arg-OH B1, B2 
neurotensin pyroGlu-Leu-Tyr-Glu-Asn-Lys-Pro-Arg-Arg-Pro-Tyr-Ile-Leu-OH NT receptors 
bombesin pyroGlu-Gln-Arg-Leu-Gly-Asn-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2 
GRPa, NMBb, 
BB3c 
substance P Arg−Pro−Lys−Pro−Gln−Gln−Phe−Phe−Gly−Leu−Met−NH2 NK1, NK2, NK3d 
agastrin releasing peptide, bneuromedin B, cbombesin subtype-3, dneurokinin 1, 2 and 3 
 
 
 
7.2  Results and Discussion 
 
7.2.1 Preparation of Modified Arginine Building Blocks 
 
The synthesis of N-Fmoc, N-Boc, N’-acylated arginine derivatives is impeded in terms of 
efficiency (yield), purification and stability of building blocks and target compounds. Guanidine 
moieties bearing two electron-withdrawing substituents (e.g. Cbz and Boc or acyl and 
carbamoyl residues) are less stable than the corresponding mono-substituted guanidines. This 
could be clearly demonstrated by the mono-Boc deprotection of arginine derivative 7.11 which 
contains a NG,NG’-diBoc protected guanidine entity. One of the Boc groups can be selectively 
removed at pH 2 – 3 (Scheme 3, Figure 2) resulting in a mono-Boc-substituted guanidine, which 
is more resistant under the same acidic conditions, i. e. the retained Boc group gains stability 
upon cleavage of the first one. Moreover, for NG-Boc, NG’-acylated guanidines the sensitivity of 
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the acyl residue was higher than that of the Boc group at pH > 5. The impact of the electron-
withdrawing groups on the stability of the linker has to be considered as long as the N-Boc (or 
Cbz) group is present: as soon as this protecting group is removed (e.g. after completion of the 
peptide synthesis), the N-acylated arginine derivatives turn into relatively stable chemical 
structures.  
Here some efforts are presented to cope with the aforementioned problems, to economically 
prepare a few arginine building blocks in mg scale (up to 200 mg) as well as to demonstrate that 
these building blocks can be used for solid phase peptide synthesis. In view of a proof of 
concept racemization (enantiomeric purities of the presented arginine building blocks) was not 
taken into account. 
 
Initial attempts to prepare the arginine building blocks 7.4 and 7.5 through guanidinylation of N-
Fmoc-L-ornithine (7.1) using S-methylisothiourea derivatives (7.2, 7.3) failed due to very low 
yields and numerous by-products (Scheme 1). The guanidinylating reagent 7.3 was synthesized 
by A. Brennauer in our research group3 and the analog 7.2 was synthesized using a similar 
protocol. N-Fmoc-L-ornithine (7.1) was obtained through Cbz-deprotection of N-Cbz-N-Fmoc-
L-ornithine 3.1 (cf. chapter 3). As the Fmoc group is cleaved to some extent during 
hydrogenolysis (Pd/C, H2, rt, atmospheric pressure), traces of ornithine had to be removed with 
preparative reversed-phase HPLC. 
a (< 20 %)
(S)
H
N OH
O
Fmoc
NH2
7.1
(S)
H
N OH
O
Fmoc
NH
7.4
N
H
N
SH3C
RBoc
7.2
NN
H
RBoc
× 1 TFA
O
O O
H
N Boc
7.3
O H
N Boc
R =
7.5R =
 
Scheme 1. Synthesis of the arginine building blocks 7.4 and 7.5 via guanidinylation of N-Fmoc-ornithine. 
Reagents and conditions: (a) HgCl2, NEt3, CH2Cl2/DMF, rt, 24-72 h, 10-20 %. 
 
Guanidinylation of N-Fmoc-L-ornithine (7.1) using the N,N’-diurethane-protected 1H-pyrazole-
1-carboxamidine 2.13 (cf. chapter 2) afforded the corresponding arginine derivative in good 
yield (Scheme 2) but the purification with preparative HPLC using acetonitrile and 0.02 % aq. 
TFA as eluent resulted in partial cleavage of the N-Boc group. This gave reason to prepare N-
Fmoc, N-Cbz protected L-arginine (7.6) instead of the N-Boc analog as a precursor for the 
introduction of -(Boc-amino)alkanoyl substituents at the guanidine group (Scheme 2). The 
coupling of 8-(Boc-amino)-3,6-dioxaoctanoic acid to 7.6 resulted in the N-Cbz protected 
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arginine building block 7.7 (Scheme 2). This compound was obtained with about 30 % yield 
after purification with preparative HPLC using acetonitrile and 0.05 % aq. TFA as eluent. A 
minor fraction was degraded to 7.6 during evaporation of acetonitrile at 37 °C (analyzed with 
ES-MS and HPLC, cf. Figure 1). 
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Scheme 2. Synthesis of the arginine building block 7.7. 
Reagents and conditions: (a) NEt3, CH2Cl2, acetonitrile, rt, 20 h, 70 %; (b) acetonitrile, 0.05 % aq. TFA, 40 
°C, 4 h, 99 %; (c) 8-(Boc-amino)-3,6-dioxaoctanoic acid, CDI, NEt3, CH2Cl2, rt, 20 h, 31 %. 
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Figure 1. HPLC purity control of the arginine building block 7.7. Conditions: column: Eurospher-100 C18 
(250 × 4 mm, 5 µm), eluent: mixtures of acetonitrile (A) and 0.025 % aq. TFA (B), gradient: 0 to 30 min: 
A/B 20/80 to 95/5, 30 to 40 min: 95/5, flow rate: 0.8 mL/min, UV-detection: 210 nm. 7.7: tR = 25.3 min, 89 
%; 7.6: tR = 18.9 min, 10 %. The partial degradation to building block 7.6 occurred during evaporation of 
acetonitrile at 37 °C from the eluate of preparative HPLC (eluent: acetonitrile and 0.05 % aq. TFA). 
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With the intension to introduce the N’-acyl substituent with higher efficiency N-Boc-N-Fmoc-
arginine benzyl ester (7.12) was prepared as a universal precursor for a direct attachment of 
various N'-acyl substituents (Scheme 3). The synthesis of compound 7.12 was accomplished 
with excellent yield starting from commercially available N-Boc-N-Fmoc-L-ornithine which was 
successively converted to the benzyl ester, Boc-deprotected and guanidinylated using diBoc-
protected 1H-pyrazole-carboxamidine 7.10 (provided by A. Brennauer3) to give the N,N'-diBoc 
protected arginine derivative 7.11 (Scheme 3).   
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Scheme 3. Synthesis of building block 7.12. 
Reagents and conditions: (a) DCC, DMAP, CH2Cl2, rt, 20 h, 94 %; (b) CH2Cl2/TFA (7.5/1), rt, 16 h, 99 %; 
(c) NEt3, CH2Cl2, rt, 1.5 h, 80 %; (d) acetonitrile/water (3/1, supplemented with ≈ 0.3 % TFA), 24-50 °C, 
4.5 h, 96 %. 
 
 
Building block 7.12 was obtained via mono-Boc-deprotection of compound 7.11 taking 
advantage of the above described phenomenon that guanidines bearing two electron-
withdrawing substituents (urethane, acyl, carbamoyl, etc.) are less stable than the 
corresponding mono-substituted analogs (Scheme 3, Figure 2) enabling selective mono-
deprotection. 
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Figure 2. HPLC monitoring of selective mono-deprotection of the guanidine group in 7.11 yielding 7.12 in 
acetonitrile/water (3/1, supplemented with about 0.3 % TFA) at  50 °C (cf. exp. section). HPLC 
conditions: column: Eurospher-100 C18 (250 × 4 mm, 5 µm), eluent: mixtures of acetonitrile (A) and 0.05 
% aq. TFA (B), gradient: 0 to 30 min: A/B 20/80 to 95/5, 30 to 40 min: 95/5, flow rate: 0.8 mL/min, UV-
detection: 210 nm. 7.11: tR = 30.5 min, 7.12: tR = 23.7 min, I: (S)-N-Fmoc-arginine benzyl ester, tR = 19.7 
min. 
 
In contrast to the efficient guanidinylation of N-Fmoc-L-ornithine benzyl ester (7.9) using 1H-
pyrazole-carboxamidine derivative 7.10 (Scheme 3) the reaction of 7.9 with the S-methyl-
isothiourea derivative 7.3 resulted in low amounts of product (7.5) and numerous by-products 
(Scheme 4) as also observed for the reaction of N-Fmoc-L-ornithine (7.1) with guanidinylating 
reagent 7.3 (Scheme 1). 
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Scheme 4. Synthesis of the arginine building block 7.5 via guanidinylation of amine 7.9 and subsequent 
hydrogenolysis. 
Reagents and conditions: (a) (1) HgCl2, NEt3, CH2Cl2, rt, 24 h; (2) 10 % Pd/C, H2, MeOH, rt, 45 min, 15-
20 %. 
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As intended, acylation of building block 7.12 with -(Boc-amino)alkanoic acids was efficiently 
achieved (≈ 70 %). A partial cleavage of the Fmoc group during subsequent hydrogenolysis of 
the benzyl ester was expected, but purification, i.e. separation from the N-terminally deprotected 
by-product and 9-methylene-9H-fluorene, turned out to be quite complicated. This resulted 
again in a considerable decrease in yield (Scheme 5). 
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Scheme 5. Synthesis of the arginine building blocks 7.5, 7.13 and 7.14 from building block 7.12. 
Reagents and conditions: (a) (1) CDI, NEt3, CH2Cl2, rt, 20 h; (2) 10 % Pd/C, H2, MeOH, rt, 15 min, 48 % 
(7.5), 30 % (7.13); (b) triphosgene, diisopropylethylamine, CH2Cl2, rt, 2.5 h; (2) 10 % Pd/C, H2, MeOH, rt, 
30 min, 20 % (7.14). *Raw yields. 
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Figure 3. Panel A: HPLC analysis of the crude product 7.5 obtained after cleavage of the benzyl ester 
(Scheme 5). Conditions: column: Eurospher-100 C18 (250 × 4 mm, 5 µm), eluent: acetonitrile (A) and 
water (B), gradient: 0 to 30 min: A/B 20/80 to 95/5, 30 to 40 min: 95/5, flow rate: 0.8 mL/min, UV-
detection: 220 nm (A1) and 254 nm (A2). 7.5: tR = 29.2 min, II: 9-methylene-9H-fluorene (Cleavage of N-
Fmoc!). B: HPLC analysis of 7.5 purified with preparative HPLC. Conditions: the same as in A, UV-
detection: 220 nm. 7.5: tR = 28.4 min, 97 %. C: HPLC analysis of Boc-deprotected 7.5 (7.5-B). Conditions: 
the same as in A, but with 0.05 % aq. TFA instead of water, UV-detection: 220 nm. 7.5-B: tR = 11.0 min, 
7.16 (N-Fmoc-arginine): tR = 13.1 min. 
 
 
An attempt to purify arginine building block 7.13 with column chromatography using methylene 
chloride and methanol as eluent (column packed with 1 % triethylamine) resulted in an 
extensive degradation of the compound. Therefore building blocks 7.5, 7.13 and 7.14 were 
isolated with preparative HPLC. Because of the carboxyl group an acidification of the mobile 
phase is advantageous to improve the separation, but under these conditions a significant 
cleavage of the N-Boc group occurred during removal of acetonitrile from the eluate under 
reduced pressure (35 °C). Consequently, acetonitrile and pure water were used as eluent 
components (pH ≈ 5 – 6) to purify compounds 7.5 and 7.13, although this led to broadening of 
the peaks, large volumes of product fractions and substantial increase in time necessary (> 60 
min) for removal of the organic solvent at 35 °C prior to lyophilization. Under these conditions 
the N-acyl substituents were cleaved off, as analyzed with electrospray mass spectrometry 
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(ES-MS) and confirmed by HPLC of the Boc-deprotected compounds (Figure 3C and 4B). To 
exclude fragmentation during MS analysis a small amount of pure product 7.13 (1 mL of the 
eluate from preparative HPLC) was treated under mild conditions to remove the solvent (temp. 
< 10 °C); ES-MS analysis of the residue revealed no degradation.  
Whereas degradation of compound 7.5 to N-Boc-N-Fmoc-arginine (7.17) during evaporation 
of acetonitrile at 35 °C was moderate (Figure 3B/C), about 40 % of the linker in 7.13 was 
cleaved off under the same conditions (Figure 4B). The mixture of arginine building block 7.13 
and its degradation product N-Boc-N-Fmoc-arginine (7.17) was not separated when analyzed 
with HPLC using acetonitrile and water (both compounds were “co-eluted” with a fronting; 
Figure 4A). By contrast the Boc-deprotected compounds were readily separated as shown in 
Figure 4B.  
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Figure 4. A: HPLC analysis of the arginine building block 7.13 purified with preparative HPLC. 
Conditions: column: Eurospher-100 C18 (250 × 4 mm, 5 µm), eluent: acetonitrile (A) and water (B), 
gradient: 0 to 30 min: A/B 20/80 to 95/5, 30 to 40 min: 95/5, flow rate: 0.8 mL/min, UV-detection: 210 nm. 
III: co-elution of 7.13 and its degradation product N-Boc-N-Fmoc-arginine 7.17, tR = 23.4 min (peak-
fronting). The coexistence of 7.13 and 7.17 becomes obvious from B and was confirmed with ES-MS. B: 
HPLC analysis of Boc-deprotected 7.13 (7.13-B). Conditions: the same as in A, but with 0.05 % aq. TFA 
instead of water, UV-detection: 220 nm. 7.13-B: tR = 10.5 min, 61 %; 7.16 (N-Fmoc-arginine): tR = 13.0 
min, 37 %. C: HPLC analysis of 7.14 purified with preparative HPLC. Conditions: the same as in A, UV-
detection: 220 nm. 7.14: tR = 25.8 min, 74 %. D: HPLC analysis of Boc-deprotected 7.14 (7.14-B). 
Conditions: the same as in B. 7.14-B: tR = 10.7 min. N-Fmoc-arginine (7.16) (tR ≈ 13 min) was not 
detected, i.e. the N-carbamoyl-substituent was not cleaved during the preparative work-up. 
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Carbamoylation of precursor 7.12 with the isocyanate generated from N-Boc-butane-1,4-
diamine gave a considerable amount of the N-substituted isomer of 7.14 (Scheme 5). This was 
also observed for the carbamoylation of N-Boc, O-t-butyl protected BIBP 3226 (2.7) using the 
same isocyanate (discussed in chapter 4). Purification of the arginine building block 7.14 with 
preparative HPLC using acetonitrile and 0.025 % aqueous TFA obviously resulted in fractional 
cleavage of the N-Boc group whereas the N-carbamoyl substituent was retained (Figure 
4C/D). 
 
Thus, the synthetic route using building block 7.12 (Scheme 3) is very efficient including the N-
acylation step, but subsequent hydrogenolytic debenzylation results in a fractional cleavage of 
the N-Fmoc group, and due to instability of the desired compounds the separation from by-
products is complicated. The N-Boc analog of the N-Cbz-protected compound 7.6 (Scheme 2) 
as a universal building block for the introduction of aminoalkanoyl substituents is considered a 
promising alternative, but preventing decomposition during purification of the products remains 
challenging anyway. Separation of the products from by-products formed by N-Fmoc cleavage 
during hydrogenolytic debenzylation under water free conditions taking advantage of different 
solubilities may be feasible.  
 
 
7.2.2 Application of the Modified Arginine Building Blocks in Peptide Synthesis 
 
The octapeptide angiotensin II (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-OH) was selected as a model 
compound to investigate the suitability of the arginine building blocks for solid phase peptide 
synthesis. Since the peptide chain is built from C-terminus to N-terminus in the case of 
angiotensin II only one additional amino acid (Asp) had to be coupled after the introduction of 
the modified arginine. In a first approach the N-Cbz protected building block 7.7 was 
introduced. Modified angiotensin II was obtained in acceptable yield after cleavage from the 
resin under neutral conditions. However, hydrogenolytic cleavage of Cbz in MeOH gave 
considerable amounts of C-terminal methyl ester, presumably due to catalysis by a small 
amount of acid (TFA, AcOH) in the reaction mixture. After Cbz-deprotection the acid sensitive 
protecting groups were removed. Unfortunately, purification of the target compound turned out 
to be too difficult because of nearly identical retention times of both the desired product and the 
C-terminally esterified peptide. When the peptide mixture was treated with lithium hydroxide 
extensive cleavage of the N-acyl linker occured. 
In a second attempt building block 7.5 was employed. For coupling 2.5 equivalents of 7.5 were 
used as well as 2.5 equivalents of HOBt/HBTU and 5 equivalents of DIPEA (single coupling, 8 
h). The resulting angiotensin II derivative 7.15 (Scheme 6) was cleaved from the trityl resin 
under acidic conditions. Since the N-Boc group was simultaneously removed in this step the 
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N-acyl substituent gained better stability (discussed in the beginning). HPLC-MS analysis 
revealed two main products, the designated one (7.15) and the heptapeptide lacking the 
arginine. Thus, coupling of the solid phase bound angiotensin 1 - 6 with arginine building block 
7.5 was incomplete although a Kaiser-test had been negative. Only a very small fraction of 
peptide was lacking the N-acyl linker. The angiotensin II derivative 7.15 was obtained with 95 
% purity (210 nm) after isolation with preparative HPLC (Figure 5A).  
The aminohexanoyl substituted angiotensin II (7.15) was allowed to react with the pyrylium dye 
Py-17, 8 (Scheme 6, cf. also chapter 4) to yield the fluorescence labeled peptide 7.5-Py1 with 
about 20 % yield and 94 % purity (220 nm, Figure 5B). 
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Scheme 6. Synthesis of the fluorescence labeled angiotensin II derivative 7.15-Py1. 
Reagents and conditions: (a) NEt3, acetonitrile, DMF, rt, 4.5 h, 19 %. 
 
 
 
With respect to broader application of these arginine building blocks in solid phase synthesis the 
required number of coupling steps after the integration of the modified arginine has to be taken 
into account since a fractional cleavage of the N-acyl substituent is anticipated. Therefore, N-
terminal position of the modified arginine residue is preferable.  
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Figure 5. HPLC purity control of the angiotensin II derivative 7.15 (A) and its Py-1 labeled analog 7.15-
Py1 (B). A: Conditions: column: Eurospher-100 C18 (250 × 4 mm, 5 µm), eluent: acetonitrile (A) and 0.05 
% aq. TFA (B), gradient: 0 to 25 min: A/B 10/90 to 35/65, 25 to 30 min: 35/65 to 90/10, 30 to 40 min: 
90/10, flow rate: 0.8 mL/min, UV-detection: 210 nm. 7.15: tR = 18.9 min, 95 %. B: Conditions: column, 
eluent and flow rate as in A, gradient: 0 to 27 min: A/B 15/85 to 50/50, 27 to 32 min: 50/50 to 90/10, 32 to 
40 min: 90/10, UV-detection: 220 nm. 7.15-Py1: tR = 25.4 min, 94 %.  
 
 
7.2.3  AT1 Receptor Agonism 
 
The angiotensin II derivatives 7.15 and 7.15-Py1 were investigated for AT1 receptor agonism in 
a fura-2 based Ca2+-assay on rat mesangial cells. As becomes obvious from Figure 6, 
compounds 7.15 and 7.15-Py1 (EC50 = 21 nM and 80 nM, resp.) were about as potent or only 
slightly less potent than angiotensin II (EC50 = 17 nM) and produced nearly maximal Ca2+-
response in rat mesangial cells. This result supports the working hypothesis that the guanidine-
acylguanidine bioisosteric approach is applicable to arginine residues in endogenous peptides.  
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Figure 6. Concentration-response curves (CRCs) of angiotensin II, 7.15 and 7.15-Py1 from a fura-2 
assay on rat mesangial cells expressing the AT1 receptor. EC50: 17 nM (Angiotensin II), 21 nM (7.15), ca. 
80 nM (7.15-Py1). Mean values ± SEM from two independent experiments (angiotensin II and 7.15). 
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Unfortunately, several trials to image AT1 receptor binding of 7.5-Py1 with confocal microscopy 
using rat mesangial cells were unsuccessful (Leibowitz L15 medium with (1 %) and without fetal 
calf serum; same settings as for the imaging of Y1 receptors with Py-1 labeled Y1R antagonists, 
cf. chapter 4).  
 
 
7.2.4  Conclusion 
 
The preparation of the arginine building blocks presented in this chapter was hampered by the 
fact that guanidines bearing two electron withdrawing substituents such as urethane (Boc, Cbz), 
acyl and carbamoyl exhibit a definite instability. Consequently, the synthetic protocols and 
purification procedures for the arginine building blocks need further optimization. Nevertheless, 
such a building block (7.5) was effectually integrated in the octapeptide angiotensin II using 
automated solid phase synthesis. The resulting angiotensin II derivative 7.15 was equipotent 
with the parent compound in a calcium assay on AT1 receptor expressing cells. The 
functionalized arginine building block used for the preparation of 7.15 may also be used for the 
derivatization of other arginine-containing peptides and pave the way to radio- or fluorescence 
labeled receptor ligands.  
 
 
 
7.3  Experimental Section 
 
7.3.1  General Experimental Conditions 
 
Unless otherwise noted, chemicals and solvents were purchased from commercial suppliers 
and used without further purification. Angiotensin II was obtained from Bachem (Weil am Rhein, 
Germany) The Py-1 pyrylium salt (Py-1) was synthesized in the Institute of Analytical Chemistry, 
Chemo- and Biosensors at the University of Regensburg.7, 8 Pyrylium dyes are commercially 
available from Active Motif Chromeon (www.activemotif.com). Millipore water was used 
throughout for the preparation of buffers and HPLC eluents. Petroleum ether (40-60 °C) was 
distilled before use. DMF was stored over a molecular sieves (3 Å). Anhydrous reactions were 
run under an atmosphere of dry nitrogen or argon. 
Thin layer chromatography was performed on Merck silica gel 60 F254 TLC aluminum plates. For 
column chromatography silica gel Geduran 60 (Merck, 0.063-0.200 mm) was used. NMR 
spectra were recorded on a Bruker Avance 300 (1H: 300 MHz) and a Bruker Avance 600 (1H: 
600 MHz) (Bruker, Karlsruhe, Germany) with TMS as external standard. Mass spectrometry 
analysis (MS) was performed in-house on a Finnigan ThermoQuest TSQ 7000 (ES-MS). 
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Lyophilization was done with a Christ alpha 2-4 LD equipped with a vacuubrand RZ 6 rotary 
vane vacuum pump.  
Preparative HPLC was performed with a system from Knauer (Berlin, Germany) consisting of 
two K-1800 pumps and a K-2001 detector. An Eurospher-100 C18 (250 × 32 mm, 5 µm; 
Knauer, Germany) served as RP-column at a flow rate of 38 mL/min. Analytical HPLC analysis 
was performed on a system from Thermo Separation Products (composed of a SN400 
controller, a P4000 pump, a degasser (Degassex DG-4400, phenomenex), an AS3000 
autosampler and a Spectra Focus UV-VIS detector). An Eurospher-100 C18 (250 × 4 mm, 5 
µm, Knauer, Germany) served as RP-column. Helium degassing, an oven temperature of 30 °C 
and a flow rate of 0.8 mL/min were used throughout. Solutions for injection (concentrations in 
the two-digit µM range) were prepared in mobile phase corresponding to the composition at the 
beginning of the gradient. The following gradients were applied for analytical HPLC analysis of 
7.12, 7.15 and 7.15-Py1 (mobile phase composed of acetonitrile (A) and 0.05 % aq. TFA (B):  
Gradient 1 (7.12): 0 to 30 min: A/B 20/80 to 95/5, 30 to 40 min: 95/5 
Gradient 2 (7.15): 0 to 25 min: A/B 10/90 to 35/65, 25 to 30 min: 35/65 to 90/10, 30 to 40 min: 
90/10 
Gradient 3 (7.15-Py1): 0 to 27 min: A/B 15/95 to 50/50, 27 to 32 min: 50/50 to 90/10, 32 to 40 
min: 90/10 
A stock solutions of 7.15 (ca. 5 mM) for HPLC purity control was prepared in acetonitrile/0.05 % 
aq. TFA (1/1). Stock solutions for pharmacological studies as well as for the purity control (7.15-
Py1) were prepared in DMSO (Angiotensin II: 1 mM, 7.15: 5 mM, 7.15-Py1: 1 mM) and stored 
at –78 °C.  
 
 
7.3.2 Chemistry: Experimental Protocols and Analytical Data 
 
(S)-N-(9-Fluorenylmethoxycarbonyl)ornithine (7.1). (S)-N-Benzyloxycarbonyl-N-(9-fluor-
enylmethoxycarbonyl)ornithine (2.2) (2.25 g, 4.61 mmol, 1 eq, cf. chapter 2) was dissolved in 
MeOH (110 mL) and a 10 % Pd/C catalyst (225 mg) was added under an atmosphere of 
nitrogen. Ammonium formate (5.8 g, 92.1 mmol, 20 eq) was added and the suspension was 
kept under vigorous stirring for 3 h. Glacial acetic acid (4.5 mL) was added and stirring was 
continued for 2 h. Glacial acetic acid (45 mL) was added prior to removal of the catalyst by 
filtration. Volatiles were removed under reduced pressure as far as possible (45 °C, 10 mbar 
final pressure), water (60 mL) was added twice, each time followed by lyophilization. Purification 
with preparative HPLC using mixtures of acetonitrile (32 %) and 0.1 % aq. TFA (68 %) as eluent 
afforded the product as a white solid (0.99 g, 2.11 mmol, 46 %); 1H-NMR (300 MHz, DMSO-d6): 
 (ppm) 1.63 (m, 3H, CH-CH2-CH2), 1.79 (m, 1H, CH-CH2-CH2), 2.79 (m, 2H, CH2-NH2), 3.96 
(m, 1H, CH), 4.18-4.36 (m, 3H, CH-CH2 Fmoc), 7.38 (m, 4H, Fmoc), 7.72 (m, 3H, Fmoc, NH), 
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7.81 (bs, 2H, NH2), 7.90 (d, 2H, 3J = 7.43 Hz, Fmoc), 12.79 (bs, 1H, COOH); MS (ES, 
CH2Cl2/MeOH + 10 mM NH4OAc): m/z 355 [M + H]+; C20H22N2O4 × C2HF3O2 (468.4) 
(S)-N-tert-Butoxycarbonyl-N’-(6-tert-butoxycarbonylaminohexanoyl)-N-(9-fluorenyl-
methoxycarbonyl)arginine (7.5). A solution of 6-tert-butoxycarbonylaminohexanoic acid (172 
mg, 0.74 mmol, 1.3 eq) and CDI (130 mg, 0.8 mmol, 1.4 eq) in CH2Cl2 (8 mL) was stirred at rt 
for 30 min. 7.12 (400 mg, 0.57 mmol, 1 eq) and NEt3 (116 mg, 158 µL, 1.14 mmol, 2 eq) were 
added and the mixture was kept under stirring at rt for 20 h. The volume of the mixture was 
reduced under reduced pressure to about 3 mL and the intermediate was purified by column 
chromatography (PE/EtOAc 3/1 to 1/1) prior to hydrogenation at rt and air pressure in MeOH 
(10 mL) using hydrogen and a 10 % Pd/C catalyst (60 mg). The flow of hydrogen was stopped 
after 15 min when starting material was no longer detectable by TLC. The catalyst was removed 
by filtration and removal of the solvent under reduced pressure yielded a highly viscous 
colorless oil which hardened to a solid during drying in vacuo. Purification with preparative 
HPLC using mixtures of acetonitrile (A) and water (B) as eluent (gradient: 0 – 25 min: A/B 30/70 
to 90/10, tR ≈ 19 – 25 min) afforded the product as a white fluffy solid (193 mg, 0.27 µmol, 48 
%). For HPLC and NMR analysis a small amount (6.8 mg) of 7.5 was Boc-deprotected through 
the treatment with acetonitrile/TFA (1:2, 300 µL) at 50 °C for 30 min. The mixture was analyzed 
by HPLC (Figure 3C) prior to the isolation of Boc-deprotected 7.5 (7.5-B) with preparative HPLC 
(eluent: mixtures of acetonitrile (A) and 0.05 % aq. TFA (B), gradient: 0 – 20 min: A/B 20/80 to 
60/40, tR ≈ 13 min). 1H-NMR (600 MHz, DMSO-d6, COSY) 7.5-B:  (ppm) 1.31 (m, 2H, CH2-
CH2-CH2-CH2-CH2), 1.47-1.65 (m, 7H, CH2-CH2-CH2-CH2-CH2, CH-CH2-CH2), 1.75 (m, 1H, CH-
CH2-CH2), 2.41 (t, 2H, 3J = 7.30 Hz, CO-CH2), 2.76 (m, 2H, CH2-NH2), 3.26 (m, 2H, CH2-NH), 
3.96 (m, 1H, CH), 4.22 (m, 1H, CH-CH2, Fmoc), 4.29 (m, 2H, CH-CH2, Fmoc), 7.32 (t, 2H, 3J = 
7.41 Hz, Fmoc), 7.41 (t, 2H, 3J = 7.45 Hz, Fmoc), 7.66 (m (bs + d), 3H, CH2-NH2, CH-NH), 7.71 
(m, 2H, Fmoc), 7.89 (d, 2H, 3J = 7.54 Hz, Fmoc), 8.77 (bs, 2H, NH2), 9.24 (s, 1H, CH2-NH), 11.8 
(s, 1H, NH), 12.65 (bs, 1H, COOH); MS (ES, CH2Cl2/MeOH + 10 mM NH4OAc) 7.5: m/z 710 [M 
+ H]+, 497 [M - (N-acyl substituent) + H]+; MS (ES, MeCN/TFA) 7.5-B: m/z 510 [M + H]+; 
C37H51N5O9 (709.8) 
 
(S)-N-Benzyloxycarbonyl-N-(9-fluorenylmethoxycarbonyl)arginine (7.6). 7.1 (500 mg, 
1.07 mmol, 1 eq) and 2.13 (551 mg, 1.6 mmol, 1.5 eq, cf. chapter 2) were dissolved in CH2Cl2 
(15 mL) yielding a clear solution which turned into a white, highly viscous suspension after 
addition of NEt3 (216 mg, 296 µL, 2.14 mmol, 0.5 eq). The viscosity of the suspension 
decreased with the addition of CH2Cl2 (20 mL) and acetonitrile (10 mL). The amount of the white 
precipitate decreased during stirring overnight at rt. Volatiles were removed under reduced 
pressure (40 °C) and the intermediate was isolated with preparative HPLC using mixtures of 
acetonitrile and 0.02 % aq. TFA as eluent. Removal of the acetonitrile (40 °C, ~ 1.5 h) from the 
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fraction containing the intermediate resulted already in a partial cleavage of the N-Boc group 
(30 – 50 %). Boc-deprotection was completed through the treatment of the white solid (obtained 
after lyophilization) with a mixture of acetonitrile and 0.05 % aq. TFA (1:1, 100 mL) at 40 °C for 
4 h. Removal of acetonitrile under reduced pressure and subsequent lyophilization afforded the 
product as a white solid (480 mg, 0.75 mmol, 70 %). 1H-NMR (300 MHz, DMSO-d6):  (ppm) 
1.59 (m, 3H, CH-CH2-CH2), 1.76 (m, 1H, CH-CH2-CH2), 3.28 (m, 2H, CH2-NH), 3.96 (m, 1H, 
CH), 4.18-4.34 (m, 3H, CH-CH2 Fmoc), 5.24 (s, 2H, CH2-Ph), 7.28-7.45 (m, 10H, Ph, Fmoc, 
NH), 7.66 (d, 1H, 3J = 8.05 Hz, CO-NH-CH), 7.72 (d, 2H, 3J = 7.41 Hz, Fmoc), 7.89 (d, 2H, 3J = 
7.40 Hz, Fmoc), 8.59 (bs, 2H, NH2), 8.8 (bs, 1H, NH) 12.15 (bd, 1H, COOH); MS (ES, 
MeCN/MeOH + 10 mM NH4OAc): m/z 531 [M + H]+; C29H30N4O6 × C2HF3O2 (644.6). 
 
(S)-N-Benzyloxycarbonyl-N’-(8-tert-butoxycarbonylamino-3,6-dioxaoctanoyl)-N-(9-
fluorenylmethoxycarbonyl)arginine (7.7). 8-tert-butoxycarbonylamino-3,6-dioxaoctanoic acid 
× dicyclohexylamine (160 mg) was dissolved in dimethoxyethane (10 mL). The amine was 
precipitated by the addition of 37 % hydrochloric acid (~ 60 µL) and removed by filtration. 
Removal of the solvent under reduced pressure and drying in vacuo yielded a yellow oil (105 
mg, 0.4 mmol, 1.3 eq) which was dissolved in anhydrous CH2Cl2 (3 mL). Carbonyldiimidazole 
(69.6 mg, 0.43 mmol, 1.4 eq) was added and the mixture was allowed to stand at rt for 40 min. 
7.6 (198 mg, 0.31 mmol, 1 eq) and NEt3 (62 mg, 85 µL, 0.6 mmol, 2 eq) were added and the 
mixture was kept under stirring at rt for 20 h. Volatiles were removed under reduced pressure 
and purification with preparative HPLC (eluent: mixtures of acetonitrile and 0.05 % aq. TFA) 
afforded the product as a white fluffy solid (74.4 mg, 0.096 mmol, 31 %). 1H-NMR (300 MHz, 
DMSO-d6):  (ppm) 1.35 (s, 9H, tert-butyl), 1.58 (m, 3H, CH-CH2-CH2), 1.72 (m, 1H, CH-CH2-
CH2), 3.07 (m, 2H, CH2-NH), 3.33 (m, 2H, CH2-NH), 3.39 (t, 2H, 3J = 6.05 Hz, CH2-CH2), 3.59 
(m, 2H, O-CH2), 3.67 (m, 2H, O-CH2), 3.96 (m, 1H, CH), 4.18 (s, 2H, CO-CH2-O), 4.26 (m, 3H, 
CH-CH2, Fmoc), 5.05 (s, 2H, CH2-Ph), 6.76 (t, 1H, 3J = 4.7 Hz, CH2-NH), 7.35 (m, 9H, Ph, 
Fmoc), 7.7 (m, 3H, Fmoc, NH), 7.89 (d, 2H, 3J = 7.43 Hz, Fmoc), 9.01 (t, 1H, 3J = 5.50 Hz, CH2-
NH), 12.54 (s, 1H, NH), 12.57 (bs, 1H, COOH); MS (ES, MeOH + 10 mM NH4OAc): m/z 776 [M 
+ H]+, 531 [M - (N-acyl substituent) + H]+; C40H49N5O11 (775.8) 
 
(S)-N-(9-Fluorenylmethoxycarbonyl)ornithine benzyl ester (7.9).9 (S)-N-Boc-N-Fmoc-orni-
thine (7.8) (5 g, 11 mmol, 1 eq) was suspended in CH2Cl2 (200 mL). Benzyl alcohol (1.55 g, 
14.3 mmol, 1.3 eq) was added resulting in a decrease of the amount of white precipitate. The 
mixture cleared up completely when dicyclohexylcarbodiimide (2.5 g, 12.1 mmol, 1.1 eq) was 
added. DMAP (40 mg, 0.33 mmol, 0.03 eq) was added and the mixture was stirred at rt for 20 h. 
The white solid (DCU) was removed by filtration and the solvent was removed under reduced 
pressure. The intermediate was purified with column chromatography (eluent: CH2Cl2 to 
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CH2Cl2/EtOAc 8/1) yielding a white solid (5.6 g, 94 %) which was dissolved in CH2Cl2 (150 mL). 
TFA (20 mL) was added, the mixture was stirred at rt for 16 h, and then it was concentrated 
under reduced pressure. CH2Cl2 (100 mL) was added and evaporated under reduced pressure. 
This was repeated twice. The residue, a yellow oil, was suspended in water (70 mL) and 
lyophilization afforded the product as a white solid (5.72 g, 10.24 mmol, 93 %). 1H-NMR (300 
MHz, CDCl3):  (ppm) 1.68 (bs, 3H, CH-CH2-CH2), 1.89 (bs, 1H, CH-CH2-CH2), 2.94 (bs, 2H), 
4.11 (m, 1H, CH), 4.29 (m, 3H, CH-CH2, Fmoc), 5.1 (s, 2H, CH2-Ph), 5.74 (m, 1H, NH), 7.24 
(m, 7H, Ph, Fmoc), 7.34 (m, 2H, Fmoc), 7.51 (m, 2H, Fmoc), 7.7 (d, 2H, 3J = 7.46 Hz, Fmoc), 
7.77 (bs, 3H, NH3+); MS (ES, CH2Cl2/MeOH + 10 mM NH4OAc): m/z 445 [M + H]+; C27H28N2O4 × 
C2HF3O2 (558.5) 
 
(S)-N,N’-Bis(tert-butoxycarbonyl)-N-(9-fluorenylmethoxycarbonyl)arginine benzyl ester 
(7.11). 7.9 (3.85 g, 6.89 mmol, 1 eq) and 7.10 (2.3 g, 8.6 mmol, 1.07 eq) were dissolved in 
CH2Cl2 (16 mL) and NEt3 (0.79 g, 1.08 mL, 7.8 mmol, 1.13 eq) was added. The reaction mixture 
was stirred at rt for 1.5 h and the product was isolated using column chromatography (eluent: 
PE/EE 5/1 to 3/1, column was packed with 0.5 % NEt3). The eluate containing the product was 
evaporated to dryness in vacuo yielding a hardened foam (3.8 g, 5.53 mmol, 80 %). 1H-NMR 
(300 MHz, DMSO-d6):  (ppm) 1.38 (s, 9H, tert-butyl), 1.47 (s, 9H, tert-butyl), 1.54 (m, 2H, CH-
CH2-CH2), 1.68 (bm, 2H, CH-CH2-CH2), 3.28 (m, 2H, CH2-NH), 4.12 (m, 1H, CH), 4.22 (m, 1H, 
CH), 4.31 (m, 2H, CH-CH2, Fmoc), 5.12 (s, 2H, CH2-Ph), 7.33 (m, 7H, Ph, Fmoc), 7.41 (m, 2H, 
Fmoc), 7.7 (d, 2H, 3J = 7.4 Hz, Fmoc), 7.88 (m, 3H, Fmoc, NH), 8.29 (t, 1H, 3J = 5.49 Hz, CH2-
NH), 11.51 (s, 1H, NH); C38H46N4O8 (686.8) 
 
(S)-N-tert-Butoxycarbonyl-N-(9-fluorenylmethoxycarbonyl)arginine benzyl ester (7.12). 
This reaction was monitored with analytical HPLC (cf. Figure 2). Sample drawing was performed 
at the following points: 0 min, 50 min, 1 h 35 min, 2 h 30 min, 3 h 20 min and 4 h 20 min. 7.11 
(3.75 g, 5.46 mmol) was dissolved in acetonitrile (100 mL). Water (30 mL) was added and a 
sample was drawn for HPLC analysis (point 0 min) prior to the addition of TFA (300 µL) and 
heating to 40 °C. The mixture was stirred at 40 °C for 1 h and 20 min. TFA (150 µL) was added 
and stirring was continued at 50 °C for 30 min. Then the following incubation periods and 
temperatures were applied: 1 h 30 min at 45 °C, 30 min at 24 °C, 30 min at 45 °C and 30 min at 
5 °C (total incubation time: 4 h and 50 min). The addition of water (200 mL) resulted in the 
formation of a suspension. Acetonitrile was removed under reduced pressure at 35 °C (40 mbar 
final pressure). Lyophilization afforded the product as a white solid (3.69 g, 5.27 mmol, 96 %). 
1H-NMR (300 MHz, DMSO-d6):  (ppm) 1.48 (s, 9H, tert-butyl), 1.55 (m, 2H, CH-CH2-CH2), 1.65 
(m, 1H, CH-CH2-CH2), 1.76 (m, 1H, CH-CH2-CH2), 3.25 (m, 2H, CH2-NH), 4.12 (m, 1H, CH), 
4.24 (m, 1H, CH), 4.33 (m, 2H, CH-CH2, Fmoc), 5.13 (s, 2H, CH2-Ph), 7.34 (m, 7H, Ph, Fmoc), 
7.42 (m, 2H, Fmoc), 7.7 (d, 2H, 3J = 7.7 Hz, Fmoc), 7.88 (m, 3H, Fmoc, NH), 8.41 (m, 3H, NH, 
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NH2), 10.84 (s, 1H, NH); reversed-phase HPLC (gradient 1, cf. Figure 2, tend): 92 % (tR = 23.6 
min, k = 7.7); MS (ES, CH2Cl2/MeOH + 10 mM NH4OAc): m/z 587 [M + H]+; C33H38N4O6 × 
C2HF3O2 (700.7) 
(S)-N-tert-Butoxycarbonyl-N’-[4-(2-tert-butoxycarbonylaminoethyl)aminocarbonyl-
butanoyl]-N-(9-fluorenylmethoxycarbonyl)arginine (7.13). A solution of 4-(2-tert-
butoxycarbonylaminoethyl)aminocarbonylbutanoic acid (4.10, cf. chapter 4) (141 mg, 0.51 
mmol, 1.2 eq) and CDI (90 mg, 0.56 mmol, 1.3 eq) in CH2Cl2 (2 mL) was stirred at rt for 30 min. 
7.12 (300 mg, 0.43 mmol, 1 eq) was added in CH2Cl2 (2 mL). NEt3 (56 mg, 77 µL, 0.56 mmol, 
1.3 eq) was added and the mixture was kept under stirring at rt for 20 h. Volatiles were removed 
under reduced pressure and the intermediate was purified with column chromatography (eluent: 
CH2Cl2/EtOAc 2/1 to EtOAc, column was packed with 0.5 % NEt3) yielding a highly viscous 
colorless oil (260 mg, 72 %) which was dissolved in MeOH (8 mL). A 10 % Pd/C catalyst (25 
mg) was added under an atmosphere of nitrogen and hydrogen was conducted through the 
vigorously stirred suspension. The flow of hydrogen was stopped after 15 min and no starting 
material could be detected with TLC analysis. The catalyst was removed by filtration and 
removal of the solvent under reduced pressure yielded a highly viscous colorless oil which 
hardened to a solid during drying in vacuo. Purification with preparative HPLC using mixtures of 
acetonitrile (A) and water (B) as eluent (gradient: 0 – 35 min: A/B 30/70 to 90/10, tR ≈ 20 – 27 
min) afforded the product as a white fluffy solid (96 mg, 0.13 mmol, 30 %). For HPLC and NMR 
analysis 6.2 mg of 7.13 were Boc-deprotected through the treatment with acetonitrile/TFA (1:2, 
300 µL) at 50 °C for 30 min. The mixture was analyzed by HPLC (Figure 4B) prior to the 
isolation of Boc-deprotected 7.13 (7.13-B) with preparative HPLC (eluent: mixtures of 
acetonitrile (A) and 0.05 % aq. TFA (B), gradient: 0 – 20 min: A/B 20/80 to 60/40, tR ≈ 13 min). 
1H-NMR (600 MHz, DMSO-d6, COSY) 7.13-B:  (ppm) 1.59 (m, 3H, CH-CH2-CH2), 1.77 (m, 3H, 
CH-CH2-CH2, CO-CH2-CH2-CH2-CO), 2.14 (t, 2H, 3J = 7.42 Hz, CO-CH2), 2.43 (t, 2H, 3J = 7.29 
Hz, CO-CH2), 2.83 (m, 2H, CH2-NH2), 3.26 (m, 4H, CH2-NH), 3.96 (m, 1H, CH), 4.22 (m, 1H, 
CH-CH2, Fmoc), 4.29 (m, 2H, CH-CH2, Fmoc), 7.32 (t, 2H, 3J = 7.42 Hz, Fmoc), 7.41 (t, 2H, 3J = 
7.45 Hz, Fmoc), 7.65 (d, 1H, 3J = 8.14 Hz, CH-NH), 7.71 (m, 4H, Fmoc, CH2-NH2), 7.89 (d, 2H, 
3J = 7.48 Hz, Fmoc), 7.99 (t, 1H, 3J = 5.54 Hz, CH2-NH), 8.66 (s, 2H, NH2), 9.04 (s, 1H, CH2-
NH), 11.51 (s, 1H, NH), 12.65 (bs, 1H, COOH); MS (ES, CH2Cl2/MeOH + 10 mM NH4OAc) 7.13: 
m/z 497 [M - (N-acyl substituent) + H]+, 753 [M + H]+; MS (ES, MeCN/TFA) 7.13-B: m/z 553 [M 
+ H]+; C38H52N6O10 (752.9) 
(S)-N-tert-Butoxycarbonyl-N’-[(4-tert-Butoxycarbonylaminobutyl)aminocarbonyl]-N-(9-
fluorenylmethoxycarbonyl)arginine (7.14). The reaction was carried out in an argon purged 
50 mL two-necked round bottom flask equipped with a pressure equalizing addition funnel. The 
flask and the funnel were baked out in a nitrogen atmosphere prior to the reaction. A solution of 
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N-Boc-butane-1,4-diamine (281 mg, 1.49 mmol, 1.1 eq) and diisopropylethylamine (491 mg, 3.8 
mmol, 2.8 eq) in anhydrous CH2Cl2 (8 mL) was added dropwise to a solution of triphosgene 
(221 mg, 0.75 mmol, 0.55 eq) in anhydrous CH2Cl2 (4 mL) over a period of 30 min. This 
solution, containing the isocyanate, was added dropwise to a solution of 7.12 (950 mg, 1.36 
mmol, 1 eq) over a period of 30 min and stirring was continued for 1.5 h. The volatiles were 
removed under reduced pressure and both intermediates (the N- as well as the N-
carbamoylated arginine derivative, cf. Scheme 5) were isolated using column chromatography 
(CH2Cl2/EtOAc 5/1 to 3/1, column was packed with 0.5 % NEt3). Each intermediate (yellowish 
oils, N-derivative: 282 mg, N-derivative: 359 mg) was dissolved in MeOH (10 mL). A 10 % 
Pd/C catalyst (45 mg and 55 mg, resp.) was added under an atmosphere of nitrogen and 
hydrogen was conducted through the vigorously stirred suspension. The flow of hydrogen was 
stopped after 30 min and depletion of starting material was nearly complete (TLC analysis). The 
catalyst was removed by filtration and removal of the solvent under reduced pressure yielded a 
highly viscous colorless oil which hardned to a solid during drying in vacuo. Purification with 
preparative HPLC (only N-derivative) using mixtures of acetonitrile (A) and 0.025 % aq. acetic 
acid (B) as eluent (gradient: 0 – 20 min: A/B 50/50 to 95/5, tR ≈ 18 – 22 min) afforded the 
product as a white fluffy solid (188 mg, 0.26 mmol, 19.5 %). For NMR analysis 7.5 mg of 7.14 
were Boc-deprotected through the treatment with acetonitrile/TFA (1:2, 300 µL) at 50 °C for 30 
min. The mixture was analyzed by HPLC (Figure 4D) prior to the isolation of Boc-deprotected 
7.14 (7.14-B) with preparative HPLC (eluent: mixtures of acetonitrile (A) and 0.05 % aq. TFA 
(B), gradient: 0 – 20 min: A/B 20/80 to 60/40, tR ≈ 13 min). 1H-NMR (600 MHz, DMSO-d6, 
COSY) 7.14-B:  (ppm) 1.43-1.65 (m, 7H, CH-CH2-CH2, CH2-CH2-CH2-CH2), 1.75 (m, 1H, CH-
CH2-CH2), 2.78 (m, 2H, CH2-NH2), 3.1 (m, 2H, CH2-NH), 3.23 (m, 2H, CH2-NH), 3.96 (m, 1H, 
CH), 4.22 (m, 1H, CH-CH2, Fmoc), 4.29 (m, 2H, CH-CH2, Fmoc), 7.32 (dt, 2H, 3J = 7.42 Hz, 4J 
= 0.83 Hz, Fmoc), 7.41 (t, 2H, 3J = 7.45 Hz, Fmoc), 7.56 (s, 1H, CH2-NH), 7.66 (d, 1H, 3J = 8.11 
Hz, CH-NH), 7.71 (m, 4H, Fmoc, CH2-NH2), 7.89 (d, 2H, 3J = 7.54 Hz, Fmoc), 8.46 (s, 2H, 
NH2), 8.97 (s, 1H, CH2-NH), 10.22 (s, 1H, NH), 12.67 (bs, 1H, COOH); MS (ES, CH2Cl2/MeOH + 
10 mM NH4OAc) 7.14: m/z 711 [M + H]+; MS (ES, MeCN/TFA) 7.14-B: m/z 511 [M + H]+; 
C36H50N6O9 (710.8) 
 
H2N-Asp-Arg(N-Ahx)-Val-Tyr-Ile-His-Pro-Phe-OH (7.15). The angiotensin II derivate 7.15, 
containing an Ahx-substituted arginine (derived from the arginine building block 7.5), was 
synthesized on a Fmoc-Phe-trityl resin (200-400 mesh; loading 0.6 mmol/g) using a standard 
Fmoc protocol for solid-phase peptide synthesis with N-hydroxybenzotriazole (HOBt) and 2-(1H-
benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU), respectively, as 
coupling reagents and N-diisopropylethylamine (DIPEA) as a base. The synthesis was 
performed in a mixture of DMF and N-methyl-2-pyrrolidon (NMP) (80/20). Natural Fmoc-
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protected amino acids were coupled using 5 eq. of the pertinent amino acid, 5 eq. of 
HOBt/HBTU and 10 eq. of DIPEA (double coupling, 2 × 40 min). For coupling of 7.5 2.5 eq. 
were used as well as 2.5 eq. of HOBt/HBTU and 5 eq. of DIPEA (single coupling, 8 h). 
Cleavage from the resin was achieved with CH2Cl2/hexafluoroisopropanol (3:1) and subsequent 
side-chain deprotection was performed using TFA/H2O/CH2Cl2 (5:1:4). The octapeptide was 
purified with preparative HPLC using mixtures of acetonitrile (A) and 0.1 % aq. TFA (B) as 
eluent (gradient: 0 – 30 min: A/B 10/90 to 35/65, tR ≈ 32.5 min). Acetonitrile was removed under 
reduced pressure at 37 °C (final pressure: 50 mbar) prior to lyophilization which afforded the 
product as a white fluffy solid (3.3 mg, 2.04 µmol). Reversed-phase HPLC (gradient 2, cf. Figure 
5A): 95 % (tR = 18.9 min, k = 6.0); MS (ES, CH2Cl2/MeOH + 10 mM NH4OAc): m/z 580.4 [M + 
2H]2+, 1159.8 [M + H]+; C56H82N14O13 × C8H4F12O8 (1615.4) 
 
Peptide 7.15 labaled with the fluorescent dye Py-1 (7.15-Py1). This reaction was monitored 
with analytical HPLC. Therefore the pyrylium dye Py-1 was added in dependence on the 
amount of starting material 7.15 detected with HPLC.  
H2N-Asp-Arg(N-Ahx)-Val-Tyr-Ile-His-Pro-Phe-OH (7.15) (0.8 mg, 0.53 µmol, 1 eq) and NEt3 
(1.08 mg, 1.4 µL, 10.6 µmol, 20 eq) were dissolved in a mixture of acetonitrile (50 µL) and DMF 
(75 µL) followed by the addition of the pyrylium dye Py-1 × 1 BF4- (0.21 mg, 0.53 µmol, 1 eq) in 
DMF (25 µL). The mixture was stirred at rt. Additional portions of Py-1 × 1 BF4- (each 0.21 mg, 
0.53 µmol, 1 eq) were added 70 min, 2 h, 3 h and 4 h after beginning of the reaction. The 
reaction was stopped by addition of 10 % aq. TFA (15 µL) after an incubation period of 4.5 h. 
The product was purified with preparative HPLC using mixtures of acetonitrile (A) and 0.1 % aq. 
TFA (B) as eluent (gradient: 0 – 30 min: A/B 15/85 to 52/48, tR = 28.7 min). Acetonitrile was 
removed under reduced pressure at 35 °C (final pressure: 50 mbar) and lyophilization afforded 
the product as a colored solid which was transferred into a 1.5-mL eppendorf reaction vessel 
(screw top) using mixtures of acetonitrile and 0.1 % aq. TFA. Evaporation in a vacuum 
concentrator and lyophilization yielded 0.19 mg (0.1 µmol, 19 %) of the product as fourfold TFA 
salt. Reversed-phase HPLC (gradient 3, cf. Figure 5B): 94 % (tR = 25.4 min, k = 8.4); MS (ES, 
CH2Cl2/MeOH + 10 mM NH4OAc): m/z 724.1 [M + 2H]2+, 483.1 [M + 3H]3+, 1447.1 [M + H]+; 
C77H104N15O13 × C8H3F12O8 (1902.8) 
 
 
7.3.3  Fura-2 Ca2+-Assay on Rat Mesangial Cells 
 
The rat mesangial cell line was kindly provided by Prof. Dr. A. Kurtz, Department of Physiology, 
University of Regensburg. Cells were maintained in antibiotic-free RPMI 1640 medium (Sigma, 
Deisenhofen, Germany) containing 10 % fetal calf serum (FCS) and 0.24 mg/L insulin in a water 
saturated atmosphere (95 % water, 5 % CO2) at 37 °C. 4 - 5 days before testing, cells from a 
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confluent 25-cm2 flask (Nunc GmbH & Co. KG, Langenselbold, Germany) were transferred to 
four 175-cm2 flasks (Nunc GmbH & Co. KG, Langenselbold, Germany). On the day of the 
experiment cells were trypsinized, suspended in medium and centrifuged for 7 min at 200 g and 
room temperature. Cells were resuspended in 40 mL of loading buffer (25 mM HEPES (Sigma, 
Deisenhofen, Germany), 120 mM NaCl, 5 mM KCl, 2 mM MgCl2, 1.5 mM CaCl2, 10 mM 
glucose), pH 7.4, and 30 µL of fura-2/AM (1 mM in DMSO, Calbiochem/Merck Biosciences, 
Beeston, UK), 37.5 µL of pluronic F-127 (20 % in DMSO, Calbiochem/Merck Biosciences, 
Beeston, UK) as well as BSA (200 mg) were added. The cell suspension was incubated in the 
dark at room temperature for 30 min and then centrifuged. Cells were resuspended in fresh 
loading buffer and allowed to stand for 60 min at room temperature in the dark. After two 
washing/centrifugation cycles (loading buffer, 200 g, 7 min) and resuspension in 25 mL of 
loading buffer, cells were incubated for at least 15 min at 20 °C in the dark. Measurements were 
performed as described for a fura-2 assay on human erythroleukemia (HEL) cells10 using a 
Perkin-Elmer LS 50 B Luminescence Spectrometer (Perkin Elmer, Überlingen, Germany). 
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Chapter 8 
 
Summary 
 
Neuropeptide Y (NPY) is one of the most abundant neuropeptides in the central and peripheral 
nervous system. This 36-amino acid peptide is involved in the regulation of numerous 
physiological functions such as food intake, blood pressure, stress, pain and hormone 
secretion. In humans, the action of NPY is mediated by four receptor subtypes (Y1, Y2, Y4 and 
Y5), members of the superfamily of G-protein coupled receptors (GPCRs). The Y1 receptor 
(Y1R) is expressed e.g. in vascular smooth muscle, adipose tissue, in the gastrointestinal tract 
and in distinct brain regions such as the cerebral cortex and the hypothalamus. Recently, the 
Y1R gained new interest as it was reported to be expressed in malignancies (e.g. breast and 
prostate cancer, ovarian and adrenal tumors). The first highly potent and selective Y1R 
antagonist was the (R)-argininamide BIBP 3226, a C-terminal mimic of NPY. N-Acylation of 
BIBP 3226 was demonstrated to retain or even increase the Y1R affinity, thereby improving the 
pharmacokinetic properties. Taking advantage of these phenomena led to selective radio- and 
fluorescence labeled argininamide-type Y1R antagonists described in this thesis. 
N-substitution with [2,3-3H]-propanoic acid yielded the easily accessible, highly potent and 
selective tritiated Y1R antagonist [3H]-UR-MK114 (KB: 0.8 nM, Ca2+-assay, HEL cells; KD, 
saturation: 1.2 nM, SK-N-MC cells), which was shown to be a useful pharmacological tool for 
the radiochemical determination of Y1R ligand affinities, the quantification of Y1R binding sites 
and for autoradiography. Another high affinity potential tritium ligand (Ki = 1.3 nM), containing an 
-aminocarbamoyl linker between the BIBP 3226 pharmacophore and tritiated propionic acid, 
was prepared and investigated pharmacologically. 
Aiming at molecular probes for in vivo imaging of Y1Rs, several potential Y1R antagonistic PET 
ligands were prepared and characterized. For this purpose, -aminocarboxylic acids of different 
length and chemical structure were attached to the guanidine of BIBP 3226, yielding amine 
precursors for coupling with small fluorinated carboxylic acids (2-fluoropropanoic and 4-
fluorobenzoic acid). Two Y1R antagonists with Ki values in the low two-digit nM range were 
prepared as prototype 18F-labeled PET ligands and administered intravenously to nude mice 
bearing Y1R expressing subcutaneous SK-N-MC xenografts. One of these PET ligands enabled 
the detection of the tumor during an early period (< 25 min) after administration, but late imaging 
of the tumor after systemic clearance of the tracer failed. The relatively high lipophilicity of the 
PET ligands (logP in the range of 1 – 4) led to rapid biliary excretion, requiring optimization of 
the physicochemical properties. 
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Diverse BIBP 3226 derived amine precursors were also used for the preparation of a series of 
Y1R selective fluorescent ligands. In terms of retaining affinity, low molecular weight pyrylium 
dyes as well as a newly prepared benzothiazolium derivative proved to be superior to cyanine 
dyes such as S0436. The majority of the most potent fluorescent Y1R antagonists (Ki = 10 - 50 
nM) was successfully applied in confocal microscopy and flow cytometric equilibrium binding 
studies. 
As bivalent ligands are considered as potential tools to study the dimerization of GPCRs, a 
series of bivalent Y1R antagonists was prepared through the connection of two BIBP 3226 
pharmacophoric entities by dicarboxylic acids of different chain length (8 – 36 atoms) and 
structure. To exploit the fact that the distomer of BIBP 3226, the (S)-enantiomer, is more than 
1000 times less potent, sets of (R,R)-, (R,S)- and (S,S)-configured bivalent ligands were 
synthesized. The most potent bivalent ligand (Ki = 9 nM), consisting of a 20 atom spacer, 
revealed a moderately lower Y1R affinity for the (R,S)-stereoisomer compared to the (R,R)-
enantiomer (factor of 5), which was not observed for other pairs of (R,R)- and (R,S)-configured 
bivalent ligands. Interestingly, among the (R,R)-configured ligands only minor differences in 
affinities (Ki values 9 - 63 nM), irrespective of spacer length and chemical diversity, were 
observed. A potential bivalent radioligand (Ki = 18 nM) is considered as a potential tool to 
perform investigations on the stoichiometry of binding sites in combination with monovalent 
radioligands. 
The achievements in the Y1R antagonists motivated the preparation of N-Boc-N-Fmoc-
arginine bearing an appropriate N’-acyl residue as a versatile building block for solid phase 
synthesis of modified peptides. The incorporation of such an arginine substitute into angiotensin 
II (AT) resulted in amino-functionalized and fluorescence-labeled AT derivatives with retained 
agonistic potency at the AT1 receptor (EC50: 21 and 80 nM, AT: 17 nM). As these arginine 
derivatives could be universally applied to prepare ligands for any peptidergic receptor, the 
proof of concept described in this thesis could promote the development and broaden the 
spectrum of molecular imaging tools. 
 
 
 
 
 Appendix 
 
 
A.1  Growth of Subcutaneous SK-N-MC and MCF-7-Y1 Tumors in Nude Mice 
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Figure 1. Growth of subcutaneous SK-N-MC tumors (0th passage) in male NMRI (nu/nu) mice after 
injection of 3 million cells (50th in vitro passage). Number of animals: 6, take rate: 6/6. 
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Figure 2. Growth of subcutaneous SK-N-MC tumors (1st passage) in male NMRI (nu/nu) mice after 
transplantation of freshly dissected pieces (ca. 2 × 2 mm) of a s.c. tumor (0th passage). Number of 
animals: 6, take rate: 4/6. 
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Figure 3. Growth of subcutaneous SK-N-MC tumors (2nd passage) in male NMRI (nu/nu) mice after 
transplantation of freshly dissected pieces (ca. 2 × 2 mm) of a s.c. tumor (1st passage). Number of 
animals: 4, take rate: 2/4. 
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Figure 4. Growth of subcutaneous MCF-7-Y1 tumors (0th passage) in female estrogen-substituted NMRI 
(nu/nu) mice after injection of 4 million cells (171st in vitro passage). Number of animals: 12, take rate: 
9/12. Subcutaneous estrogen depots were implanted 10 – 12 days prior to tumor implantation. 
 
 
 
Appendix 197
Time [d]
0 10 20 30 40 50
Tu
m
or
 A
re
a 
[m
m
2 ]
0
20
40
60
80
individual tumors
mean ± SEM
 
Figure 5. Growth of subcutaneous MCF-7-Y1 tumors (1st passage) in female estrogen-substituted NMRI 
(nu/nu) mice after transplantation of pieces (ca. 2 × 2 mm) of a s.c. tumor (0th passage), stored in liquid 
nitrogen in culture medium without FCS and supplemented with 10 % DMSO. Number of animals: 9, take 
rate: 4/9. Subcutaneous estrogen depots were implanted 10 – 12 days prior to tumor implantation. 
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Figure 6. Growth of subcutaneous MCF-7-Y1 tumors (2nd passage) in female estrogen-substituted NMRI 
(nu/nu) mice after transplantation of freshly dissected pieces (ca. 2 × 2 mm) of a s.c. tumor (1st passage). 
Number of animals: 12, take rate: 10/12. Subcutaneous estrogen depots were implanted 10 – 12 days 
prior to tumor implantation. 
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A.2 Data Processing 
 
All data to be fitted were processed with SigmaPlot 9.0. Data from radioligand competition 
experiments and concentration response curves (fura-2 assays) were analyzed by 4 parameter 
sigmoidal fits. IC50 values from radioligand competition studies were converted to Ki values 
according to the Cheng-Prusoff equation1 using the respective KD value of the radioligand. 
Three data points (between 20 and 80 % inhibition, from fura-2 assays) served for the 
calculation of IC50 values after logit-log transformation. IC50 values were converted to Kb values 
according to the Cheng-Prusoff equation1 using an EC50 value of 1.8 nM for pNPY (mean value 
from 4 independently determined concentration-effect curves on HEL cells).  
Data from saturation experiments (chapter 2 and 4) were evaluated by one-site saturation fits 
(KD, Bmax). Rate constants (kob, koff, chapter 2) were analyzed using linear plots and simple linear 
regressions. The association rate constant (kon) in chapter 2 was calculated from kob, koff and the 
radioligand concentration according to the correlation: kon = (kob – koff)/[radioligand]. For Schild 
analysis in chapter 2 log10(r - 1) was plotted against log10[antagonist] with r = 10pEC50. 
Raw data from flow cytometric experiments were processed with the aid of the WinMDI 2.7 
software. The confocal images were processed with the Carl Zeiss LSM image browser 4.2TM. 
The retention (capacity) factor was calculated according to k = (tR – t0)/t0. All error bars in the 
diagrams represent the standard errors of the means or errors calculated according to the law 
of error propagation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations 199
A.3 Abbreviations 
 
AA amino acid(s) 
Ahx 6-aminohexanoic acid (6-aminohexanoyl) 
aq. aqueous 
Ar aryl 
as specific activity 
BBB blood brain barrier 
Bmax maximum number of binding sites 
Boc tert-butoxycarbonyl 
Bq becquerel 
BRET bioluminescence resonance energy transfer 
bs broad singulet 
BSA bovine serum albumin 
tBu tert-butyl 
c concentration 
[Ca2+]i intracellular calcium ion concentration 
Cbz benzyloxycarbonyl 
CDI carbonyldiimidazole 
CH2Cl2 methylene chloride 
CHO cells chinese hamster ovary cells 
Ci curie 
CI chemical ionization 
CNS central nervous system 
COSY correlated spectroscopy 
d doublet 
 chemical shift 
DCC N,N’-dicyclohexylcarbodiimide 
DCU N,N’-dicyclohexylurea 
decomp. decomposition 
CDCl3 deuterated chloroform 
DIPEA N,N-diisopropyl-ethylamine 
DMAP 4-(dimethylamino)-pyridine 
DMF N,N-dimethylformamide 
DMSO dimethylsulfoxide 
DMSO-d6 per-deuterated dimethylsulfoxide 
EC50 agonist concentration which induces 50 % of the maximum response 
EtOAc ethyl acetate 
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EDAC N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide (hydrochloride) 
EI electron impact ionization 
eq. equivalent(s) 
FAB fast atom bombardment 
FACS fluorescence activated cell sorter 
FCS fetal calf serum 
Fmoc 9-fluorenylmethoxycarbonyl 
FmocOSu 9-fluorenylmethyl-N-succinimidylcarbonate 
FRET fluorescence resonance energy transfer 
GPCR G-protein coupled receptor 
h hour(s) 
HBTU 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate 
H&E hematoxylin and eosin 
HEK-1B cells human endometrial carcinoma cells 
HEL cells human erythroleukemia cells 
HEPES 2-(4-(2-hydroxyethyl)-1-piperazinyl)-ethanesulfonic acid 
HMBC heteronuclear multiple bond correlation 
hPP human pancreatic polypeptide 
HOBt 1-hydroxybenzotriazole (monohydrate) 
HR-MS high resolution mass spectrometry 
HSQC heteronuclear single quantum coherence 
IC50 inhibitor/antagonist concentration which suppresses 50 % of an agonist 
induced effect or displaces 50 % of a labeled ligand from the binding site 
nJ coupling constant for geminal (n = 2), vicinal (n = 3), etc. coupling 
k retention (capacity) factor 
Kb dissociation constant derived from a functional assay 
KD dissociation constant derived from a saturation experiment 
Ki dissociation constant derived from a competition binding assay 
LiAlH4 Lithiumaluminiumhydrid 
kob observed/macroscopic association rate constant 
koff dissociation rate constant 
kon association rate constant 
logP common logarithm of the n-octanol/water partition coefficient 
m multiplet 
M molar (mol/L) 
MCF-7 cells human breast adenocarcinoma cells 
MEM minimum essential medium eagle 
MeOH-d4 per-deuterated methanol 
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mol mole(s) 
mp melting point 
mRNA messenger RNA 
NEt3 triethylamine 
NG guanidine nitrogen (cp. N nomenclature for arginines) 
NHS N-hydroxysuccinimide 
NIH national (US) institutes of health 
PBS phosphate buffered saline 
PE petroleum ether 
PET positron emission tomography 
Ph phenyl 
pNPY porcine neuropeptide Y 
ppm parts per million 
q quartet 
RP reversed-phase 
rt room temperature 
s (1) singulet, (2) second(s) 
SEM standard error of the mean 
SK-N-MC cells human neuroblastoma cell line established from the supraorbital metastasis of 
a neuroblastoma of a 14-year old girl in 1971 
t (1) time, (2) triplet 
t0 hold-up time (also designated as tM) 
TFA trifluoroacetic acid 
THF tetrahydrofurane 
tR retention time 
UV ultraviolet 
Yn NPY receptor subtypes, n = 1, 2, 4, 5, 6, 7 
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